Cost analysis of patients undergoing allogeneic stem cell transplantation or chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma from a German healthcare payer perspective
Ahmadi P, Ghandili S, Jakobs F, Konnopka C, Morgner-Miehlke A, Kröger N, Ayuk F
BONE MARROW TRANSPL. 2024;59(4):572-574.

Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis
Akahoshi Y, Spyrou N, Hoepting M, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, Choe H, Eder M, Etra A, Grupp S, Hexner E, Hogan W, Kitko C, Kraus S, Al Malki M, Merli P, Qayed M, Reshef R, Schechter T, Ullrich E, Vasova I, Wölfl M, Zeiser R, Baez J, Beheshti R, Eng G, Gleich S, Kasikis S, Katsivelos N, Kowalyk S, Morales G, Young R, DeFilipp Z, Ferrara J, Levine J, Nakamura R
BLOOD ADV. 2024;8(8):2047-2057.

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD
Akahoshi Y, Spyrou N, Weber D, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, Choe H, Eder M, Etra A, Grupp S, Hexner E, Hogan W, Kitko C, Kraus S, Al Malki M, Merli P, Qayed M, Reshef R, Schechter T, Ullrich E, Vasova I, Wölfl M, Zeiser R, Baez J, Beheshti R, Eng G, Gleich S, Katsivelos N, Kowalyk S, Morales G, Young R, Chen Y, Nakamura R, Levine J, Ferrara J
BLOOD. 2024;144(9):1010-1021.

CARs come to AID
Ayuk F, Fehse B
MOL THER. 2024;32(4):861-862.

Methodological challenges in the development of endpoints for myelofibrosis clinical trials
Barosi G, Tefferi A, Gangat N, Szuber N, Rambaldi A, Odenike O, Kröger N, Gagelmann N, Talpaz M, Kantarjian H, Gale R
LANCET HAEMATOL. 2024;11(5):e383-e389.

Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study
Bazarbachi A, Labopin M, Moukalled N, Kröger N, Rautenberg C, Schetelig J, Finke J, Blau I, Blaise D, Stelljes M, Eder M, Platzbecker U, Dreger P, Bethge W, Tischer J, Burns D, Sengeloev H, Brissot E, Giebel S, Nagler A, Ciceri F, Mohty M
CLIN CANCER RES. 2024;30(9):1778-1787.

Enhancing drug therapy in ostomy patients: Best practice recommendations for medication management
Berger V, Reeh M, Scherer M, Härterich S, Möller S, Wansing E, van der Linde A, Langebrake C
PLOS ONE. 2024;19(6):e0305047.

Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease
Bonig H, Verbeek M, Herhaus P, Braitsch K, Beutel G, Schmid C, Müller N, Bug G, Döring M, von Stackelberg A, Tischer J, Ayuk F, Wulf G, Holtick U, Pfeffermann L, Jahrsdörfer B, Schrezenmeier H, Kuci S, Kuci Z, Zens A, Tribanek M, Zeiser R, Huenecke S, Bader P
J TRANSL MED. 2024;22(1):.

Exploring the therapeutic potential of autologous hematopoietic stem cell transplantation in progressive multiple sclerosis-a systematic review
Braun B, Fischbach F, Pfeffer L, Richter J, Janson D, Kröger N, Mariottini A, Heesen C, Häußler V
EUR J NEUROL. 2024 [Epub ahead of print];e16427.

Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: Sustained improvement in cognition and quality of life
Braun B, Fischbach F, Richter J, Pfeffer L, Fay H, Reinhardt S, Friese M, Stellmann J, Kröger N, Heesen C, Häußler V
MULT SCLER RELAT DIS. 2024;82:105414.

Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey
Comoli P, Pentheroudakis G, Ruggeri A, Koehl U, Lordick F, Mooyaart J, Hoogenboom J, Urbano-Ispizua A, Peters S, Kuball J, Kröger N, Sureda A, Chabannon C, Haanen J, Pedrazzoli P
ANN ONCOL. 2024;35(4):404-406.

The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
DeFilipp Z, Kim H, Spyrou N, Katsivelos N, Kowalyk S, Eng G, Kasikis S, Beheshti R, Baez J, Akahoshi Y, Ayuk F, Choe H, Etra A, Grupp S, Hexner E, Hogan W, Kitko C, Qayed M, Reshef R, Vasova I, Zeiser R, Young R, Holler E, Ferrara J, Nakamura R, Levine J, Chen Y
BLOOD ADV. 2024;8(13):3488-3496.

A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT)
Domingos V, Nezvalova-Henriksen K, Dadkhah A, Moreno-Martinez M, Ben Hassine K, Pires V, Kröger N, Bauters T, Hassan M, Duncan N, Kalwak K, Ansari M, Langebrake C, Admiraal R
BONE MARROW TRANSPL. 2024 [Epub ahead of print].

Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire
Eden T, Schaffrath A, Wesolowski J, Stähler T, Tode N, Richter N, Schäfer W, Hambach J, Hermans-Borgmeyer I, Woens J, Le Gall C, Wendler S, Linke-Winnebeck C, Stobbe M, Budnicki I, Wanney A, Heitz Y, Schimmelpfennig L, Schweitzer L, Zimmer D, Stahl E, Seyfried F, Gebhardt A, Dieckow L, Riecken K, Fehse B, Bannas P, Magnus T, Verdoes M, Figdor C, Hartlepp K, Schleer H, Füner J, Tomas N, Haag F, Rissiek B, Mann A, Menzel S, Koch-Nolte F
NAT COMMUN. 2024;15(1):4728.

Ikaros sets the threshold for negative B-cell selection by regulation of the signaling strength of the AKT pathway
Ehm P, Horn S, Hoffer K, Kriegs M, Horn M, Giehler S, Nalaskowski M, Rehbach C, Horstmann M, Jücker M
CELL COMMUN SIGNAL. 2024;22(1):360.

Barriers and facilitators in continuous medical education related to allogeneic stem cell transplantation - a qualitative study of physicians
Eickmann S, Wolff D, Kobbe G, Dreger P, Kröger N, Herrmann-Johns A
ONCOL RES TREAT. 2024;47(4):136-144.

Targeting T cell plasticity in kidney and gut inflammation by pooled single-cell CRISPR screening
Enk L, Hellmig M, Riecken K, Kilian C, Datlinger P, Jauch-Speer S, Neben T, Sultana Z, Sivayoganathan V, Borchers A, Paust H, Zhao Y, Asada N, Liu S, Agalioti T, Pelczar P, Wiech T, Bock C, Huber T, Huber S, Bonn S, Gagliani N, Fehse B, Panzer U, Krebs C
SCI IMMUNOL. 2024;9(96):eadd6774.

Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
Etra A, El Jurdi N, Katsivelos N, Kwon D, Gergoudis S, Morales G, Spyrou N, Kowalyk S, Aguayo-Hiraldo P, Akahoshi Y, Ayuk F, Baez J, Betts B, Chanswangphuwana C, Chen Y, Choe H, DeFilipp Z, Gleich S, Hexner E, Hogan W, Holler E, Kitko C, Kraus S, Al Malki M, MacMillan M, Pawarode A, Quagliarella F, Qayed M, Reshef R, Schechter T, Vasova I, Weisdorf D, Wölfl M, Young R, Nakamura R, Ferrara J, Levine J, Holtan S
BLOOD ADV. 2024;8(12):3284-3292.

Chimeric autoantibody receptor cell therapy for the treatment of membranous nephropathy: The authors reply
Fehse B, Tomas N
KIDNEY INT. 2024;105(6):1320-1321.

Systematic Evaluation of Donor-KIR/Recipient-HLA Interactions in HLA-matched Hematopoietic Cell Transplantation for AML
Fein J, Shouval R, Krieger E, Spellman S, Wang T, Baldauf H, Fleischhauer K, Kröger N, Horowitz M, Maiers M, Miller J, Mohty M, Nagler A, Weisdorf D, Malmberg K, Toor A, Schetelig J, Romee R, Koreth J
BLOOD ADV. 2024;8(3):581-590.

Salivary Gland Volume Predicts Malnutrition in Irradiated Head and Neck Cancer Patients: A Prospective Analysis
FINGER A, GREINERT F, GROHMANN M, SEYEDI N, ZOHRI R, KRÜLL A, PETERSEN C, ZEMKOVA O, ZIEMANN C, RAMKE K, WERNER E, DITZ C, LEPPERT J, HAHN L, RADES D, LÖSER A
IN VIVO. 2024;38(6):2795-2803.

Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study)
Finke J, Schmoor C, Ayuk F, Hasenkamp J, Verbeek M, Wagner E, Biersack H, Schäfer-Eckart K, Wolf D, Stuhler G, Reibke R, Schmid C, Kaufmann M, Eder M, Bertz H, Grishina O
BONE MARROW TRANSPL. 2024;59(7):936-941.

CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis
Fischbach F, Richter J, Pfeffer L, Fehse B, Berger S, Reinhardt S, Kuhle J, Badbaran A, Rathje K, Gagelmann N, Borie D, Seibel J, Ayuk F, Friese M, Heesen C, Kröger N
MED-CAMBRIDGE. 2024;5(6):550-558.e2.

Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B-cell lymphoma: a systematic review and meta-analysis
Gagelmann N, Bishop M, Ayuk F, Bethge W, Glass B, Sureda A, Pasquini M, Kröger N
TRANSPL CELL THER. 2024;30(6):584.e1-584.e13.

Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, Oliver-Caldés A, Stölzel F, Rathje K, Fischer L, Born P, Schäfer L, Albici A, Schub N, Kfir-Erenfeld S, Assayag M, Asherie N, Wulf G, Kharboutli S, Müller F, Shune L, Davis J, Anwer F, Vucinic V, Platzbecker U, Ayuk F, Kröger N, Khouri J, Gurnari C, McGuirk J, Stepensky P, Abdallah A, Fernández de Larrea C
J CLIN ONCOL. 2024;42(14):1665-1675.

Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis
Gagelmann N, Hobbs G, Campodonico E, Helbig G, Novak P, Schroeder T, Schneider A, Rautenberg C, Reinhardt H, Bosques L, Heuser M, Panagiota V, Thol F, Gurnari C, Maciejewski J, Ciceri F, Rathje K, Robin M, Pagliuca S, Rubio M, Rocha V, Funke V, Hamerschlak N, Salit R, Scott B, Duarte F, Mitrus I, Czerw T, Greco R, Kröger N
AM J HEMATOL. 2024;99(5):844-853.

The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party
Gjærde L, Ruutu T, Peczynski C, Boreland W, Kröger N, Blaise D, Schroeder T, Peffault de Latour R, Gedde-Dahl T, Kulagin A, Sengeløv H, Yakoub-Agha I, Finke J, Eder M, Basak G, Moiseev I, Schoemans H, Koenecke C, Penack O, Perić Z
BONE MARROW TRANSPL. 2024;59(2):255-263.

Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Guièze R, Eikema D, Koster L, Schetelig J, Sengeloev H, Passweg J, Finke J, Arat M, Broers A, Stölzel F, Byrne J, Castilla-Llorente C, Dreger P, Eder M, Gedde-Dahl T, Kröger N, Ribera Santasusana J, Richardson D, Rambaldi A, Yañez L, Van Gelder M, Drozd-Sokolowska J, Raj K, Yakoub-Agha I, Tournilhac O, McLornan D
BONE MARROW TRANSPL. 2024;59(7):950-956.

Comparison of ex vivo bioluminescence imaging, Alu-qPCR and histology for the quantification of spontaneous lung and bone metastases in subcutaneous xenograft mouse models
Haider M, Freytag V, Krause L, Spethmann T, Gosau T, Beine M, Knies C, Schröder-Schwarz J, Horn M, Riecken K, Lange T
CLIN EXP METASTAS. 2024;41(2):103-115.

Successful treatment of refractory checkpoint inhibitor-induced hepatitis with quadruple therapy including extracorporeal photopheresis and infliximab
Hansen I, Kött J, Heidenreich S, Ayuk F, Doll P, Abeck F, Booken N, Gebhardt C, Schneider S
Journal of the European Academy of Dermatology and Venerology Clinical Practice. 2024;3(1):317-320.

CD45-Directed CAR-T Cells with CD45 Knockout Efficiently Kill Myeloid Leukemia and Lymphoma Cells In Vitro Even after Extended Culture
Harfmann M, Schröder T, Głów D, Jung M, Uhde A, Kröger N, Horn S, Riecken K, Fehse B, Ayuk F
CANCERS. 2024;16(2):.

Wie sicher ist die Gentherapie? : Zweiter Todesfall nach Therapie der Duchenne-Muskeldystrophie
Horn S, Fehse B
INNERE MED. 2024;65(6):617-623.

Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis
Jacobson C, Munoz J, Sun F, Kanters S, Limbrick-Oldfield E, Spooner C, Mignone K, Ayuk F, Sanderson R, Whitmore J, Wang Y, Xu H, Dickinson M
TRANSPL CELL THER. 2024;30(1):77.e1-77.e15.

Multiple myeloma in the young: insights on prognosis, clinical features and treatment outcome derived from nationwide German registry data and a nested multicenter sample
Kamili A, Ahmadi P, Leypoldt L, Marquard F, Schaefers C, Kosch R, Peters F, Kusche H, Zamrik T, Hanoun C, Seib M, Shumilov E, Leitner T, Khandanpour C, Bokemeyer C, Weisel K, Ghandili S
HAEMATOLOGICA. 2024;109(11):3795-3799.

Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR
Klyuchnikov E, Badbaran A, Massoud R, Freiberger P, Wolschke C, Ayuk F, Fehse B, Bacher U, Kröger N
LEUKEMIA. 2024;38(2):386-388.

Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group
Kröger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, Gupta V, Hamad N, Harrison C, Hernandez-Boluda J, Koschmieder S, Jain T, Mascarenhas J, Mesa R, Popat U, Passamonti F, Polverelli N, Rambaldi A, Robin M, Salit R, Scott B, Tamari R, Tefferi A, Vannucchi A, McLornan D, Barosi G
LANCET HAEMATOL. 2024;11(1):e62-e74.

Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective phase II study
Kröger N, Wulf G, Hegenbart U, Burchert A, Stelljes M, Gagelmann N, Brecht A, Kaufmann M, Müller L, Ganser A, Wolf D, Bethge W, Bornhäuser M, Kiehl M, Wagner E, Schmid C, Reinhardt H, Kobbe G, Salwender H, Heinicke T, Kropff M, Heinzelmann M, Ayuk F, Trümper L, Neubauer A, Völp A, Kluychnikov E, Schönland S, Wolschke C
HAEMATOLOGICA. 2024;109(5):1469-1479.

Implementierung und operatives Management zugelassener CAR-T-Zelltherapien: Ein Leitfaden der GoCART Coalition Pharmacist Working Group
Langebrake C
Krankenhauspharmazie. 2024;45(2):50-52.

Stationäres Medikationsmanagement
Langebrake C, Baehr M
Pharmakon. 2024;12(5):391-396.

Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma
Locke F, Filosto S, Chou J, Vardhanabhuti S, Perbost R, Dreger P, Hill B, Lee C, Zinzani P, Kröger N, López-Guillermo A, Greinix H, Zhang W, Tiwari G, Budka J, Marincola F, To C, Mattie M, Schupp M, Cheng P, Bot A, Shen R, Bedognetti D, Miao H, Galon J
NAT MED. 2024;30(2):507-518.

Multidisciplinary survey on use of feeding tubes in head and neck cancer patients undergoing chemoradiotherapy in Germany-the SUFEETUBE project
Löser A, Fabian A, Rühle A, Thieme A, Baehr A, Käsmann L, Zwaan I, Kahle B, Soror T, Kunte A, Seyedi N, Kebenko M, Seidel C, Dierks F, Krause L, Bruchhage K, Rades D
STRAHLENTHER ONKOL. 2024;200(7):583-594.

Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries
Lübke J, Christen D, Schwaab J, Kaiser A, Naumann N, Shoumariyeh K, Jentzsch M, Sockel K, Schaffrath J, Ayuk F, Stelljes M, Hilgendorf I, Sala E, Kaivers J, Schönland S, Wittke C, Hertenstein B, Radsak M, Kaiser U, Brückl V, Kröger N, Brümmendorf T, Hofmann W, Klein S, Jost E, Reiter A, Panse J
LEUKEMIA. 2024;38(4):810-821.

Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Maffini E, Labopin M, Kröger N, Finke J, Stelljes M, Schroeder T, Einsele H, Tischer J, Bornhäuser M, Bethge W, Brecht A, Rösler W, Dreger P, Schäfer-Eckart K, Passweg J, Blau I, Nagler A, Ciceri F, Mohty M
BONE MARROW TRANSPL. 2024;59(7):983-990.

Allogeneic hematopoetic stem cell transplant for patients with refractory T-Cell lymphomas
Massoud R, Naim H, Klyuchnikov E, Janson D, Wolschke C, Ayuk F, Kröger N
EUR J HAEMATOL. 2024;112(2):276-285.

Protocol for differential multi-omic analyses of distinct cell types in the mouse cerebral cortex
Meka D, Richter M, Rücker T, Voss H, Rissiek A, Krisp C, Kumar N, Schwanke B, Fornasiero E, Schlüter H, Calderon de Anda F
STAR PROTOC. 2024;5(1):102793.

Generation and characterization of antagonistic anti-human CD39 nanobodies
Menzel S, Duan Y, Hambach J, Albrecht B, Wendt-Cousin D, Winzer R, Tolosa E, Rissiek A, Guse A, Haag F, Magnus T, Koch-Nolte F, Rissiek B
FRONT IMMUNOL. 2024;15:1328306.

Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1-mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party
Moukalled N, Labopin M, Versluis J, Socié G, Blaise D, Salmenniemi U, Rambaldi A, Gedde-Dahl T, Tholouli E, Kröger N, Bourhis J, Von Dem Borne P, Daguindau E, Forcade E, Nagler A, Esteve J, Ciceri F, Bazarbachi A, Mohty M
AM J HEMATOL. 2024;99(3):360-369.

Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study
Mussetti A, Rius-Sansalvador B, Moreno V, Peczynski C, Polge E, Galimard J, Kröger N, Blaise D, Peffault de Latour R, Kulagin A, Mousavi A, Stelljes M, Hamladji R, Middeke J, Salmenniemi U, Sengeloev H, Forcade E, Platzbecker U, Reményi P, Angelucci E, Chevallier P, Yakoub-Agha I, Craddock C, Ciceri F, Schroeder T, Aljurf M, Ch K, Moiseev I, Penack O, Schoemans H, Mohty M, Glass B, Sureda A, Basak G, Peric Z
BONE MARROW TRANSPL. 2024;59(2):232-238.

Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Nabergoj M, Eikema D, Koster L, Platzbecker U, Sockel K, Finke J, Kröger N, Forcade E, Nagler A, Eder M, Tischer J, Broers A, Kuball J, Wilson K, Hunault-Berger M, Collin M, Russo D, Corral L, Helbig G, Mussetti A, Scheid C, Gurnari C, Raj K, Drozd-Sokolowska J, Yakoub-Agha I, Robin M, McLornan D
BONE MARROW TRANSPL. 2024;59(3):395-402.

Hematopoietic cell transplantation (HCT) in MDS patients of older age
Niederwieser C, Kröger N
LEUKEMIA LYMPHOMA. 2024;65(5):570-584.

Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation
Oechsler S, Gagelmann N, Wolschke C, Janson D, Badbaran A, Klyuchnikov E, Massoud R, Rathje K, Richter J, Schäfersküpper M, Niederwieser C, Kunte A, Heidenreich S, Ayuk F, Kröger N
BONE MARROW TRANSPL. 2024;59(4):550-557.

Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)
Ortí G, Gras L, Koster L, Kulagin A, Byrne J, Apperley J, Halaburda K, Blau I, Clark A, Kröger N, Griskevicius L, Carlson K, Collin M, Bloor A, Raiola A, Blaise D, Aljurf M, López-Corral L, Sakellari I, Beguin Y, Wrobel T, de Rosa L, de Lavallade H, Hayden P, McLornan D, Chalandon Y, Yakoub-Agha I
TRANSPL CELL THER. 2024;30(1):93.e1-93.e12.

The Histogenetic Origin of Malignant Cells Predicts Their Susceptibility towards Synthetic Lethality Utilizing the TK.007 System
Pallasch F, Freytag V, Kriegs M, Gatzemeier D, Mair T, Voss H, Riecken K, Dawood M, Fehse B, Efferth T, Schlüter H, Schumacher U
CANCERS. 2024;16(12):.

Generation of adult hippocampal neural stem cells occurs in the early postnatal dentate gyrus and depends on cyclin D2
Pastor-Alonso O, Syeda Zahra A, Kaske B, García-Moreno F, Tetzlaff F, Bockelmann E, Grunwald V, Martín-Suárez S, Riecken K, Witte O, Encinas J, Urbach A
EMBO J. 2024;43(3):317-338.

PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation
Penack O, Abouqateb M, Peczynski C, Boreland W, Gülbas Z, Gedde-Dahl T, Castilla-Llorente C, Kröger N, Eder M, Rambaldi A, Bonifazi F, Blau I, Stelljes M, Dreger P, Moiseev I, Schoemans H, Koenecke C, Peric Z
BLOOD CANCER J. 2024;14(1):45.

ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?
Penack O, Abouqateb M, Peczynski C, Boreland W, Kröger N, Stelljes M, Gedde-Dahl T, Blau I, Schroeder T, Salmenniemi U, Kulagin A, Peffault de Latour R, Mielke S, Zeiser R, Moiseev I, Schoemans H, Koenecke C, Peric Z
LEUKEMIA. 2024;38(5):1156-1163.

Management of Patients Undergoing CAR-T Cell Therapy in Germany
Penack O, Dreger P, Ajib S, Ayuk F, Baermann B, Bug G, Kriege O, Jentzsch M, Kobbe G, Koenecke C, Lutz M, Martin S, Schlegel P, Schroers R, von Tresckow B, Vucinic V, Subklewe M, Bethge W, Wolff D
ONCOL RES TREAT. 2024;47(3):65-75.

Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte R, Giebel S, Greinix H, Hazenberg M, Kröger N, Mielke S, Mohty M, Nagler A, Passweg J, Patriarca F, Ruutu T, Schoemans H, Solano C, Vrhovac R, Wolff D, Zeiser R, Sureda A, Peric Z
LANCET HAEMATOL. 2024;11(2):e147-e159.

Upper and/or lower respiratory tract infection caused by human metapneumovirus after allogeneic hematopoietic stem cell transplantation
Piñana J, Tridello G, Xhaard A, Wendel L, Montoro J, Vazquez L, Heras I, Ljungman P, Mikulska M, Salmenniemi U, Perez A, Kröger N, Cornelissen J, Sala E, Martino R, Geurten C, Byrne J, Maertens J, Kerre T, Martin M, Pascual M, Yeshurun M, Finke J, Groll A, Shaw P, Blijlevens N, Arcese W, Ganser A, Suarez-Lledo M, Alzahrani M, Choi G, Forcade E, Paviglianiti A, Solano C, Wachowiak J, Zuckerman T, Bader P, Clausen J, Mayer J, Schroyens W, Metafuni E, Knelange N, Averbuch D, de la Camara R
J INFECT DIS. 2024;229(1):83-94.

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype
Poiré X, Labopin M, Polge E, Ganser A, Socié G, Gedde-Dahl T, Forcade E, Finke J, Chalandon Y, Bulabois C, Yakoub-Agha I, Aljurf M, Kröger N, Blau I, Nagler A, Esteve J, Mohty M
BONE MARROW TRANSPL. 2024;59(2):264-269.

Psychological Morbidity and Care
Polomeni A, Scherwath A
2024. The EBMT Handbook. Sureda A, Corbacioglu S, Greco R, Kröger N, Carreras E (Hrsg.). 8. Aufl. Cham, Switzerland: Springer, Cham, 265-271.

Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT
Polverelli N, Bonneville E, de Wreede L, Koster L, Kröger N, Schroeder T, Peffault de Latour R, Passweg J, Sockel K, Broers A, Clark A, Dreger P, Blaise D, Yakoub-Agha I, Petersen S, Finke J, Chevallier P, Helbig G, Rabitsch W, Sammassimo S, Arcaini L, Russo D, Drozd-Sokolowska J, Raj K, Robin M, Battipaglia G, Czerw T, Hernández-Boluda J, McLornan D
AM J HEMATOL. 2024;99(5):993-996.

Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT
Potter V, Gras L, Koster L, Kroger N, Sockel K, Ganser A, Finke J, Labussiere-Wallet H, Peffault de Latour R, Koc Y, Salmenniemi U, Smidstrup Friis L, Jindra P, Schroeder T, Tischer J, Arat M, Pascual Cascon M, de Wreede L, Hayden P, Raj K, Drozd-Sokolowska J, Scheid C, McLornan D, Robin M, Yakoub-Agha I
BONE MARROW TRANSPL. 2024;59(2):224-231.

A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD
Qayed M, Kapoor U, Gillespie S, Westbrook A, Aguayo-Hiraldo P, Ayuk F, Aziz M, Baez J, Choe H, DeFilipp Z, Etra A, Grupp S, Hexner E, Holler E, Hogan W, Kowalyk S, Merli P, Morales G, Nakamura R, Pulsipher M, Schechter T, Shah J, Spyrou N, Srinagesh H, Wölfl M, Yanik G, Young R, Kitko C, Ferrara J, Levine J
TRANSPL CELL THER. 2024;30(6):603.e1-603.e11.

Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients
Rios C, Qayed M, Etra A, Reshef R, Newcomb R, Yuhasz N, Hexner E, Aguayo-Hiraldo P, Merli P, Hogan W, Weber D, Kitko C, Ayuk F, Eder M, Grupp S, Kraus S, Sandhu K, Ullrich E, Vasova I, Wölfl M, Baez J, Beheshti R, Eng G, Gleich S, Katsivelos N, Kowalyk S, Louloudis I, Morales G, Spyrou N, Young R, Nakamura R, Levine J, Ferrara J, Akahoshi Y
TRANSPL CELL THER. 2024;30(11):1061.e1-1061.e10.

Pneumocystis pneumonia after allogeneic hematopoietic cell transplantation: A case-control study on epidemiology and risk factors on behalf of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation
Robin C, Cordonnier C, Tridello G, Knelange N, Xhaard A, Chantepie S, Tanguy-Schmidt A, Schouten H, Yesherun M, Rocha V, Srour M, Kröger N, Ledoux M, Dalgaard J, Thiebaut A, Giardino S, Calore E, Zuckerman T, Groll A, Raida L, Avcin S, Vicent M, Kaare A, Drozd-Sokolowska J, Turlure P, Bretagne S, Mikulska M, Camara R, Cesaro S, Styczynski J
TRANSPL CELL THER. 2024;30(2):235.e1-235.e10.

Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT
Robin M, Gras L, Koster L, Gagelmann N, van Gorkom G, Ederr M, Itälä-Remes M, Zuckerman T, Beguin Y, Schaap N, Drozd-Sokolowska J, Raj K, Hayden P, de Wreede L, Battipaglia G, Polverelli N, Czerw T, Hernandez Boluda J, Kröger N, Yakoub-Agha I, McLornan D
BRIT J HAEMATOL. 2024;204(2):715-718.

Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS-a study of the CMWP of the EBMT
Rovó A, Gras L, Piepenbroek B, Kröger N, Reinhardt H, Radujkovic A, Blaise D, Kobbe G, Niityvuopio R, Platzbecker U, Sockel K, Hunault-Berger M, Cornelissen J, Forcade E, Bourhis J, Chalandon Y, Kinsella F, Nguyen-Quoc S, Maertens J, Elmaagacli A, Mordini N, Hayden P, Raj K, Drozd-Sokolowska J, de Wreede L, McLornan D, Robin M, Yakoub-Agha I, Onida F
AM J HEMATOL. 2024;99(2):203-215.

Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: A retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Salas M, Eikema D, Koster L, Maertens J, Passweg J, Finke J, Broers A, Koc Y, Kröger N, Ozkurt Z, Pascual-Cascon M, Platzbecker U, Van Gorkom G, Schroeder T, López-Lorenzo J, Martino M, Chiusolo P, Kaufmann M, Onida F, Gurnari C, Scheid C, Drozd-Sokolowska J, Raj K, Robin M, McLornan D
BONE MARROW TRANSPL. 2024;59(4):479-488.

Haploidentical stem cell donor choice for patients with acute myeloid leukemia: A study from the ALWP of the EBMT
Sanz J, Labopin M, Blaise D, Raiola A, Busca A, Vydra J, Tischer J, Chevallier P, Bramanti S, Fanin R, Socié G, Forcade E, Kröger N, Koc Y, Itälä-Remes M, Zecca M, Nagler A, Brissot E, Spyridonidis A, Bazarbachi A, Giebel S, Piemontese S, Mohty M, Ciceri F
BLOOD ADV. 2024;8(10):2332-2341.

The potential of γδ CAR and TRuC T cells: An unearthed treasure
Schamel W, Zinchenko M, Nguyen T, Fehse B, Briquez P, Minguet S
EUR J IMMUNOL. 2024;54(11):e2451074.

Patient engagement in hematopoietic stem cell transplantation and cell therapy: a survey by the EBMT patient engagement task force & transplantation complications working party
Schoemans H, Burns L, Liptrott S, Murray J, Kenyon M, Barata A, Bolaños N, Scholl I, Hamilton B, Phelan R, Buchbinder D, Penack O, Moiseev I, Boreland W, Peczynski C, De Geest S, Sureda A, Snowden J, Shaw B, Peric Z, Kroeger N
BONE MARROW TRANSPL. 2024;59(9):1286-1294.

An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells
Seifert L, Riecken K, Zahner G, Hambach J, Hagenstein J, Dubberke G, Huber T, Koch-Nolte F, Fehse B, Tomas N
KIDNEY INT. 2024;105(4):886-889.

IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction
Shiri A, Zhang T, Bedke T, Zazara D, Zhao L, Lücke J, Sabihi M, Fazio A, Zhang S, Tauriello D, Batlle E, Steglich B, Kempski J, Agalioti T, Nawrocki M, Xu Y, Riecken K, Liebold I, Brockmann L, Konczalla L, Bosurgi L, Mercanoglu B, Seeger P, Küsters N, Lykoudis P, Heumann A, Arck P, Fehse B, Busch P, Grotelüschen R, Mann O, Izbicki J, Hackert T, Flavell R, Gagliani N, Giannou A, Huber S
J HEPATOL. 2024;80(4):634-644.

Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells
Smit D, Brauer H, Horn S, Yigit G, Haider M, Pogenberg V, Schumacher U, Pantel K, Jücker M
CELL SIGNAL. 2024;121:.

Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group
Spanjaart A, Ljungman P, Tridello G, Schwartz J, Martinez-Cibrián N, Barba P, Kwon M, Lopez-Corral L, Martinez-Lopez J, Ferra C, Di Blasi R, Ghesquieres H, Mutsaers P, Calkoen F, Jak M, van Doesum J, Vermaat J, van der Poel M, Maertens J, Gambella M, Metafuni E, Ciceri F, Saccardi R, Nicholson E, Tholouli E, Matthew C, Potter V, Bloor A, Besley C, Roddie C, Wilson K, Nagler A, Campos A, Petersen S, Folber F, Bader P, Finke J, Kroger N, Knelange N, de La Camara R, Kersten M, Mielke S
LEUKEMIA. 2024;38(9):1985-1991.

Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation
Spyridonidis A, Labopin M, Gedde-Dahl T, Ganser A, Stelljes M, Craddock C, Wagner-Drouet E, Versluis J, Schroeder T, Blau I, Wulf G, Dreger P, Olesen G, Sengeloev H, Kröger N, Potter V, Forcade E, Passweg J, de Latour R, Maertens J, Wilson K, Bourhis J, Finke J, Brissot E, Bazarbachi A, Giebel S, Savani B, Nagler A, Ciceri F, Mohty M
BONE MARROW TRANSPL. 2024;59(2):217-223.

A Day 14 Endpoint for Acute GVHD Clinical Trials
Spyrou N, Akahoshi Y, Kowalyk S, Morales G, Beheshti R, Aguayo-Hiraldo P, Al Malki M, Ayuk F, Bader P, Baez J, Capellini A, Choe H, DeFilipp Z, Eder M, Eng G, Etra A, Gleich S, Grupp S, Hexner E, Hoepting M, Hogan W, Kasikis S, Katsivelos N, Khan A, Kitko C, Kraus S, Kwon D, Merli P, Portelli J, Qayed M, Reshef R, Schechter T, Vasova I, Wölfl M, Wudhikarn K, Young R, Holler E, Chen Y, Nakamura R, Levine J, Ferrara J
TRANSPL CELL THER. 2024;30(4):421-432.

Factors Determining Quality of Drug Information by Hospital Pharmacies-Results from Five-Year Annual Quality Assessment
Strobach D, Chiriac U, Klausner S, Krebs S, Langebrake C, Querbach C, Schuhmacher C, Schulte R, Wiegrebe S, Amann U
PHARMACY-BASEL. 2024;12(4):.

Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: A report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT
Sureda A, Carpenter P, Bacigalupo A, Bhatt V, de la Fuente J, Ho A, Kean L, Lee J, Sánchez-Ortega I, Savani B, Schetelig J, Stadtmauer E, Takahashi Y, Atsuta Y, Koreth J, Kröger N, Ljungman P, Okamoto S, Popat U, Soiffer R, Stefanski H, Kharfan-Dabaja M
BONE MARROW TRANSPL. 2024;59(6):832-837.

All Three AKT Isoforms Can Upregulate Oxygen Metabolism and Lactate Production in Human Hepatocellular Carcinoma Cell Lines
Tian L, Smit D, Popova N, Horn S, Velasquez L, Huber S, Jucker M
INT J MOL SCI. 2024;25(4):.

"A second birthday"? Experiences of persons with multiple sclerosis treated with autologous hematopoietic stem cell transplantation-a qualitative interview study
Volz T, Sippel A, Fischbach F, Richter J, Willison A, Häußler V, Heesen C
FRONT NEUROL. 2024;15:1384551.

Development and Validation of a Concise Objectifiable Risk Evaluation Score for Non-Relapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation
Weise G, Massoud R, Krause R, Heidenreich S, Janson D, Klyuchnikov E, Wolschke C, Zeck G, Kröger N, Ayuk F
CANCERS. 2024;16(3):.

Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study
Weller J, Lengerke C, Finke J, Schetelig J, Platzbecker U, Einsele H, Schroeder T, Faul C, Stelljes M, Dreger P, Blau I, Wulf G, Tischer J, Scheid C, Elmaagacli A, Neidlinger H, Flossdorf S, Bornhäuser M, Bethge W, Fleischhauer K, Kröger N, De Wreede L, Christopeit M
HAEMATOLOGICA. 2024;109(2):431-443.

Chimeric antigen receptor T-cell therapy and fludarabine precision dosing imperatives
Wicha S, Wansing E, Dadkhah A, Ayuk F, Kröger N, Langebrake C
BLOOD ADV. 2024;8(3):797-798.

HLA-DPA1*02:01~B1*01:01 is a risk haplotype for primary sclerosing cholangitis mediating activation of NKp44+ NK cells
Zecher B, Ellinghaus D, Schloer S, Niehrs A, Padoan B, Baumdick M, Yuki Y, Martin M, Glow D, Schröder-Schwarz J, Niersch J, Brias S, Müller L, Habermann R, Kretschmer P, Früh T, Dänekas J, Wehmeyer M, Poch T, Sebode M, , Ellinghaus E, Degenhardt F, Körner C, Hoelzemer A, Fehse B, Oldhafer K, Schumacher U, Sauter G, Carrington M, Franke A, Bunders M, Schramm C, Altfeld M
GUT. 2024;73(2):325-337.

Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience

BONE MARROW TRANSPL. 2023;58(2):229-232.

Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Abou Dalle I, Labopin M, Kröger N, Schroeder T, Finke J, Stelljes M, Neubauer A, Blaise D, Yakoub-Agha I, Salmenniemi U, Forcade E, Itäla-Remes M, Dreger P, Bug G, Passweg J, Heuser M, Choi G, Brissot E, Giebel S, Nagler A, Ciceri F, Bazarbachi A, Mohty M
BONE MARROW TRANSPL. 2023;58(7):784-790.

Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
Akahoshi Y, Spyrou N, Hogan W, Ayuk F, DeFilipp Z, Weber D, Choe H, Hexner E, Rösler W, Etra A, Sandhu K, Yanik G, Chanswangphuwana C, Kitko C, Reshef R, Kraus S, Wölfl M, Eder M, Bertrand H, Qayed M, Merli P, Grupp S, Aguayo-Hiraldo P, Schechter T, Ullrich E, Baez J, Beheshti R, Gleich S, Kowalyk S, Morales G, Young R, Kwon D, Nakamura R, Levine J, Ferrara J, Chen Y
BLOOD ADV. 2023;7(16):4479-4491.

Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study
Al Hamed R, Ngoya M, Galimard J, Sengeloev H, Gedde-Dahl T, Kulagin A, Platzbecker U, Yakoub-Agha I, Byrne J, Valerius T, Socie G, Kröger N, Blaise D, Bazarbachi A, Sanz J, Ciceri F, Nagler A, Mohty M
CANCER-AM CANCER SOC. 2023;129(17):2645-2654.

Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease
Al Malki M, London K, Baez J, Akahoshi Y, Hogan W, Etra A, Choe H, Hexner E, Langston A, Abhyankar S, Ponce D, DeFilipp Z, Kitko C, Adekola K, Reshef R, Ayuk F, Capellini A, Chanswangphuwana C, Eder M, Eng G, Gandhi I, Grupp S, Gleich S, Holler E, Javorniczky N, Kasikis S, Kowalyk S, Morales G, Özbek U, Rösler W, Spyrou N, Yanik G, Young R, Chen Y, Nakamura R, Ferrara J, Levine J
BLOOD ADV. 2023;7(17):5189-5198.

Risk factors for a severe disease course in children with SARS-COV-2 infection following hematopoietic cell transplantation in the pre-Omicron period: A prospective multinational Infectious Disease Working Party from the European Society for Blood and Marrow Transplantation group (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH) study
Averbuch D, de la Camara R, Tridello G, Knelange N, Bykova T, Ifversen M, Dobsinska V, Ayas M, Hamidieh A, Pichler H, Perez-Martinez A, Cesaro S, Sundin M, Badell I, Bader P, Johansson J, Mirci-Danicar O, Sedlacek P, Paillard C, Gibson B, Lawson S, Kroeger N, Corbacioglu S, Mikulska M, Piñana J, Styczynski J, Ljungman P
BONE MARROW TRANSPL. 2023;58(5):558-566.

Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study
Ayuk F, Gagelmann N, von Tresckow B, Wulf G, Rejeski K, Stelljes M, Penack O, Baldus C, Kröger N, Bethge W, Dreger P
BLOOD ADV. 2023;7(18):5316-5319.

CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: Real-World Data from Germany
Bader P, Rossig C, Hutter M, Ayuk F, Baldus C, Bücklein V, Bonig H, Cario G, Einsele H, Holtick U, Koenecke C, Bakhtiar S, Künkele A, Meisel R, Mueller F, Müller I, Penack O, Rettinger E, Sauer M, Schlegel P, Soerensen J, von Stackelberg A, Strahm B, Feuchtinger T, Hauer J, Jarisch A
BLOOD ADV. 2023;7(11):2436-2448.

Microglia colonize the developing brain by clonal expansion of highly proliferative progenitors, following allometric scaling
Barry-Carroll L, Greulich P, Marshall A, Riecken K, Fehse B, Askew K, Li K, Garaschuk O, Menassa D, Gomez-Nicola D
CELL REP. 2023;42(5):112425.

Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline
Bayas A, Berthele A, Blank N, Dreger P, Faissner S, Friese M, Gerdes L, Grauer O, Häussler V, Heesen C, Janson D, Korporal-Kuhnke M, Kowarik M, Kröger N, Lünemann J, Martin R, Meier U, Meuth S, Muraro P, Platten M, Schirmer L, Stürner K, Stellmann J, Scheid C, Bergh F, Warnke C, Wildemann B, Ziemssen T
THER ADV NEUROL DISO. 2023;16:17562864231180730.

Data-driven grading of acute graft-versus-host disease
Bayraktar E, Graf T, Ayuk F, Beutel G, Penack O, Luft T, Brueder N, Castellani G, Reinhardt H, Kröger N, Beelen D, Turki A
NAT COMMUN. 2023;14(1):7799.

Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party
Bazarbachi A, Labopin M, Gedde-Dahl T, Remenyi P, Forcade E, Kröger N, Socié G, Craddock C, Bourhis J, Versluis J, Yakoub-Agha I, Salmenniemi U, El-Cheikh J, Bug G, Esteve J, Nagler A, Ciceri F, Mohty M
CLIN CANCER RES. 2023;29(21):4441-4448.

Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor-T cell therapy
Berger S, Fehse B, Akyüz N, Geffken M, Wolschke C, Janson D, Gagelmann N, Luther M, Wichmann D, Frenzel C, Thayssen G, Alegiani A, Badbaran A, Zeschke S, Dierlamm J, Kröger N, Ayuk F
HAEMATOLOGICA. 2023;108(2):444-456.

A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation
Bittrich M, Kriegsmann K, Tietze-Stolley C, Movassaghi K, Grube M, Vucinic V, Wehler D, Burchert A, Schmidt-Hieber M, Rank A, Dürk H, Metzner B, Kimmich C, Hentrich M, Kunz C, Hartmann F, Khandanpour C, de Wit M, Holtick U, Kiehl M, Stoltefuß A, Kiani A, Naumann R, Scholz C, Tischler H, Görner M, Brand F, Ehmer M, Kröger N
TRANSFUS MED HEMOTH. 2023;50(6):475-490.

Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors
Bonifacius A, Lamottke B, Tischer-Zimmermann S, Schultze-Florey R, Goudeva L, Heuft H, Arseniev L, Beier R, Beutel G, Cario G, Fröhlich B, Greil J, Hansmann L, Hasenkamp J, Höfs M, Hundsdoerfer P, Jost E, Kafa K, Kriege O, Kröger N, Mathas S, Meisel R, Nathrath M, Putkonen M, Ravens S, Reinhardt H, Sala E, Sauer M, Schmitt C, Schroers R, Steckel N, Trappe R, Verbeek M, Wolff D, Blasczyk R, Eiz-Vesper B, Maecker-Kolhoff B
J CLIN INVEST. 2023;133(12):.

Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease
Bonig H, Verbeek M, Herhaus P, Braitssch K, Beutel G, Schmid C, Müller N, Bug G, Döring M, von Stackelberg A, Tischer J, Ayuk F, Wulf G, Holtick U, Pfeffermann L, Jahrsdörfer B, Schrezenmeier H, Kuci S, Kuci Z, Zens A, Tribanek M, Zeiser R, Huenecke S, Bader P
J TRANSL MED. 2023;21(1):837.

Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation-Results from the LenaMain Trial (NCT00891384)
Boquoi A, Giagounidis A, Goldschmidt H, Heinsch M, Rummel M, Kröger N, Mai E, Strapatsas J, Haas R, Kobbe G
CANCERS. 2023;15(21):.

Rapid Development of cefiderocol resistance in a carbapenem-resistant Pseudomonas aeruginosa isolate associated with mutations in the pyoverdine biosynthesis pathway
Brakert L, Berneking L, Both A, Berinson B, Huang J, Aepfelbacher M, Wolschke C, Wichmann D, Rohde H
J GLOB ANTIMICROB RE. 2023;34:59-62.

Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT
Bug G, Labopin M, Niittyvuopio R, Stelljes M, Reinhardt H, Hilgendorf I, Kröger N, Kaare A, Bethge W, Schäfer-Eckart K, Verbeek M, Mielke S, Carlson K, Bazarbachi A, Spyridonidis A, Savani B, Nagler A, Mohty M
BONE MARROW TRANSPL. 2023;58(6):710-716.

Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT
Chalandon Y, Sbianchi G, Gras L, Koster L, Apperley J, Byrne J, Salmenniemi U, Sengeloev H, Aljurf M, Helbig G, Kinsella F, Choi G, Reményi P, Snowden J, Robin M, Lenhoff S, Mielke S, Passweg J, Broers A, Kröger N, Yegin Z, Tan S, Hayden P, McLornan D, Yakoub-Agha I
AM J HEMATOL. 2023;98(1):112-121.

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience
Chihara D, Gras L, Zinger N, Kröger N, Mayer J, Passweg J, De Latour R, Byrne J, Krüger W, Bohn J, Platzbecker U, Blau I, Bonifazi F, Helbig G, McDonald A, Mistrik M, Mohty M, Ram R, Sanz J, Llamas C, Kreitman R, Hayden P, McLornan D, Tournilhac O, Van Gelder M, Yakoub-Agha I
HAEMATOLOGICA. 2023;108(6):1676-1679.

Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines
DeFilipp Z, Ciurea S, Cutler C, Robin M, Warlick E, Nakamura R, Brunner A, Dholaria B, Walker A, Kroger N, Bejanyan N, Atallah E, Tamari R, Solh M, Percival M, de Lima M, Scott B, Oran B, Garcia-Manero G, Hamadani M, Carpenter P, DeZern A
TRANSPL CELL THER. 2023;29(2):71-81.

Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis
Derigs P, Bethge W, Krämer I, Holtick U, von Tresckow B, Ayuk F, Penack O, Vucinic V, von Bonin M, Baldus C, Mougiakakos D, Wulf G, Schnetzke U, Stelljes M, Fante M, Schroers R, Kroeger N, Dreger P
TRANSPL CELL THER. 2023;29(12):750-756.

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Drozd-Sokolowska J, Gras L, Zinger N, Zahrani M, Passweg J, Byrne J, Ho A, Huang X, Kröger N, Mayer J, Russo D, De Becker A, Tbakhi A, Stamatoullas A, Valerius T, Hayden P, McLornan D, Onida F, Scheid C, Robin M, Yakoub-Agha I
BONE MARROW TRANSPL. 2023;58(2):222-225.

Role and competencies of the EBMT clinical pharmacists and clinical pharmacologists: a pan-European survey
Duncan N, Moreno-Martinez M, Pires V, Domingos V, Bonnin A, Nezvalova-Henriksen K, Admiraal R, Bauters T, Langebrake C
BONE MARROW TRANSPL. 2023;58(7):829-831.

SHIP1 Is Present but Strongly Downregulated in T-ALL, and after Restoration Suppresses Leukemia Growth in a T-ALL Xenotransplantation Mouse Model
Ehm P, Rietow R, Wegner W, Bußmann L, Kriegs M, Dierck K, Horn S, Streichert T, Horstmann M, Jücker M
CELLS-BASEL. 2023;12(13):1798.

Iron Chelation with Deferasirox Suppresses the Appearance of Labile Plasma Iron During Conditioning Chemotherapy Prior to Allogeneic Stem Cell Transplantation
Essmann S, Heestermans M, Dadkhah A, Janson D, Wolschke C, Ayuk F, Kröger N, Langebrake C
TRANSPL CELL THER. 2023;29(1):42.e1-42.e6.

Effective treatment of low risk acute GVHD with itacitinib monotherapy
Etra A, Capellini A, Alousi A, Al Malki M, Choe H, DeFilipp Z, Hogan W, Kitko C, Ayuk F, Baez J, Gandhi I, Kasikis S, Gleich S, Hexner E, Hoepting M, Kapoor U, Kowalyk S, Kwon D, Langston A, Mielcarek M, Morales G, Özbek U, Qayed M, Reshef R, Roesler W, Spyrou N, Young R, Chen Y, Ferrara J, Levine J
BLOOD. 2023;141(5):481-489.

Einleitung: Gen- und Zelltherapie – „zwei Seiten zweier Medaillen“
Fehse B
2023. Gen- und Zelltherapie 2.023 - Forschung, klinische Anwendung und Gesellschaft. Fehse B, Schickl H, Bartfeld S, Zenke M (Hrsg.). 1. Aufl. Berlin, Heidelberg: Springer, 11-21.

Genome-Editing – Gentherapie 2.0 oder nur eine Wunschvorstellung?
Fehse B, Grünewald J, Petri K
2023. Gen- und Zelltherapie 2.023 - Forschung, klinische Anwendung und Gesellschaft. Fehse B, Schickl H, Bartfeld S, Zenke M (Hrsg.). 1. Aufl. Berlin, Heidelberg: Springer, 103-120.

Handlungsempfehlungen zur somatischen Gentherapie, Keimbahninterventionen und Zelltherapie
Fehse B, Walter J, Bartfeld S, Clemens S, Erb T, Fangerau H, Hampel J, Korte M, Müller-Terpitz R, Mundlos S, Jens R, Schicktanz S, Winkler E, Zenke M
2023. Gen- und Zelltherapie 2.023 - Forschung, klinische Anwendung und Gesellschaft. Fehse B, Schickl H, Bartfeld S, Zenke M (Hrsg.). 1. Aufl. Berlin, Heidelberg: Springer, 1-10.

Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia-a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Filippini Velázquez G, Labopin M, Tischer J, Raiola A, Angelucci E, Kulagin A, Galieni P, Bermúdez A, Bulabois C, Kröger N, Díez-Martín J, Kwon M, Nagler A, Schmid C, Ciceri F, Mohty M
BONE MARROW TRANSPL. 2023;58(8):907-915.

Donor Selection for Allogeneic Hematopoietic Cell Transplantation
Fleischhauer K, Tran T, Meisel R, Mytilineos J, Dreger P, Kröger N
DTSCH ARZTEBL INT. 2023;120(15):261-268.

Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany
Frietsch J, Flossdorf S, Beck J, Kröger N, Fleischhauer K, Dreger P, Schetelig J, Bornhäuser M, Hochhaus A, Hilgendorf I
BRIT J HAEMATOL. 2023;201(2):308-318.

Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients
Gagelmann N, Ayuk F, Klyuchnikov E, Wolschke C, Berger S, Kröger N
HAEMATOLOGICA. 2023;108(10):2799-2802.

Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation
Gagelmann N, Badbaran A, Salit R, Gurnari C, Pagliuca S, Panagiota V, Rautenberg C, Cassinat B, Thol F, Wolschke C, Robin M, Heuser M, Rubio M, Maciejewski J, Reinhardt H, Scott B, Kröger N
BLOOD. 2023;141(23):2901-2911.

GPRC5D-targeting chimeric antigen receptors: a new treatment for multiple myeloma?
Gagelmann N, Brudno J
LANCET HAEMATOL. 2023;10(2):e82-e83.

Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study
Gagelmann N, Eikema D, Koster L, Netelenbos T, McDonald A, Stoppa A, Fenk R, Anagnostopoulos A, van Gorkom G, Deconinck E, Bulabois C, Delforge M, Bunjes D, Arcese W, Reményi P, Itälä-Remes M, Thurner L, Bolaman A, Nabil Y, Lund J, Labussière-Wallet H, Hayden P, Beksac M, Schönland S, Yakoub-Agha I
EUR J HAEMATOL. 2023;111(2):181-190.

Reply to Shao and Zhou
Gagelmann N, Kröger N
HAEMATOLOGICA. 2023;108(2):655-656.

Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation
Gagelmann N, Wolschke C, Badbaran A, Janson D, Berger C, Klyuchnikov E, Ayuk F, Fehse B, Kröger N
HEMASPHERE. 2023;7(7):e921.

Hematopoietic stem cell boost for persistent neutropenia after CAR-T cell therapy: a GLA/DRST study
Gagelmann N, Wulf G, Duell J, Glass B, Heteren P, von Tresckow B, Fischer M, Penack O, Ayuk F, Einsele H, Holtick U, Thomson J, Dreger P, Kröger N
BLOOD ADV. 2023;7(4):555-559.

Tumor cell integrin β4 and tumor stroma E-/P-selectin cooperatively regulate tumor growth in vivo
Genduso S, Freytag V, Schetler D, Kirchner L, Schiecke A, Maar H, Wicklein D, Gebauer F, Bröker K, Stürken C, Milde-Langosch K, Oliveira-Ferrer L, Ricklefs F, Ewald F, Wolters-Eisfeld G, Riecken K, Unrau L, Krause L, Bohnenberger H, Offermann A, Perner S, Sebens S, Lamszus K, Diehl L, Linder S, Jücker M, Schumacher U, Lange T
J HEMATOL ONCOL. 2023;16(1):.

Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study
Gerbitz A, Gary R, Aigner M, Moosmann A, Kremer A, Schmid C, Hirschbuehl K, Wagner E, Hauptrock B, Teschner D, Roesler W, Spriewald B, Tischer J, Moi S, Balzer H, Schaffer S, Bausenwein J, Wagner A, Schmidt F, Brestrich J, Ullrich B, Maas S, Herold S, Strobel J, Zimmermann R, Weisbach V, Hansmann L, Lammoglia-Cobo F, Remberger M, Stelljes M, Ayuk F, Zeiser R, Mackensen A
FRONT IMMUNOL. 2023;14:1251593.

Tissue resident iNKT17 cells facilitate cancer cell extravasation in liver metastasis via interleukin-22
Giannou A, Kempski J, Shiri A, Lücke J, Zhang T, Zhao L, Zazara D, Cortesi F, Riecken K, Amezcua Vesely M, Low J, Xu H, Kaffe E, Garcia-Perez L, Agalioti T, Yamada Y, Jungraithmayr W, Zigmond E, Karstens K, Steglich B, Wagner J, Konczalla L, Carambia A, Schulze K, von Felden J, May P, Briukhovetska D, Bedke T, Brockmann L, Starzonek S, Lange T, Koch C, Riethdorf S, Pelczar P, Böttcher M, Sabihi M, Huber F, Reeh M, Grass J, Wahib R, Seese H, Stüben B, Fard-Aghaie M, Duprée A, Scognamiglio P, Plitzko G, Meiners J, Soukou S, Wittek A, Manthey C, Maroulis I, Arck P, Perez D, Gao B, Zarogiannis S, Strowig T, Pasqualini R, Arap W, Gosálvez J, Kobold S, Prinz I, Guse A, Tachezy M, Ghadban T, Heumann A, Li J, Melling N, Mann O, Izbicki J, Pantel K, Schumacher U, Lohse A, Flavell R, Gagliani N, Huber S
IMMUNITY. 2023;56(1):125-142.e12.

Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Giebel S, Labopin M, Salmenniemi U, Socié G, Bondarenko S, Blaise D, Kröger N, Vydra J, Grassi A, Bonifazi F, Czerw T, Anagnostopoulos A, Lioure B, Ruggeri A, Savani B, Spyridonidis A, Sanz J, Peric Z, Nagler A, Ciceri F, Mohty M
CANCER-AM CANCER SOC. 2023;129(23):3735-3745.

Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Giebel S, Labopin M, Schroeder T, Swoboda R, Maertens J, Bourhis J, Grillo G, Salmenniemi U, Hilgendorf I, Kröger N, Poiré X, Cornelissen J, Arat M, Savani B, Spyridonidis A, Nagler A, Mohty M
AM J HEMATOL. 2023;98(4):580-587.

Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT
Giebel S, Labopin M, Socié G, Aljurf M, Salmenniemi U, Labussière-Wallet H, Srour M, Kröger N, Zahrani M, Lioure B, Reményi P, Arat M, Bourhis J, Helbig G, Tbakhi A, Forcade E, Huynh A, Brissot E, Spirydonidis A, Savani B, Peric Z, Nagler A, Mohty M
BONE MARROW TRANSPL. 2023;58(5):506-513.

Impact of pre-transplantation depression and anxiety on the outcome of allogeneic hematopoietic stem cell transplantation: a study from the Transplant Complications Working Party of the EBMT
Gjærde L, Peczynski C, Polge E, Kröger N, de Latour R, Finke J, Holler E, Blaise D, Helbig G, Salmenniemi U, Potter V, Bunjes D, Erzsebet L, Penack O, Schoemans H, Koenecke C, Basak G, Perić Z
BONE MARROW TRANSPL. 2023;58(11):1279-1281.

KIR2DS4 and Its Variant KIR1D in KIR-AA Genotype Donors Showed Differential Survival Impact in Patients with Lymphoid Disease after HLA-Matched Unrelated Hematopoietic Stem Cell Transplantation
Gowdavally S, Tsamadou C, Platzbecker U, Sala E, Valerius T, Klein S, Kröger N, Wulf G, Einsele H, Thurner L, Schaefer-Eckart K, Freitag S, Casper J, Dürholt M, Kaufmann M, Hertenstein B, Ringhoffer M, Schmeller S, Neuchel C, Rode I, Amann E, Richter A, Schrezenmeier H, Mytilineos J, Fuerst D
TRANSPL CELL THER. 2023;29(7):457.e1-457.e10.

Chaperone-mediated autophagy in neuronal dendrites utilizes activity-dependent lysosomal exocytosis for protein disposal
Grochowska K, Sperveslage M, Raman R, Failla A, Głów D, Schulze C, Laprell L, Fehse B, Kreutz M
CELL REP. 2023;42(8):112998.

Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M
Gurnari C, Gagelmann N, Badbaran A, Awada H, Dima D, Pagliuca S, D'Aveni-Piney M, Attardi E, Voso M, Cerretti R, Wolschke C, Rubio M, Maciejewski J, Kröger N
LEUKEMIA. 2023;37(3):717-719.

Inequalities in the career pathway for paediatric HSCT and cellular therapy physicians
Gurnari C, Spadea M, Muratori R, Jimenez V, Radici V, Torrado S, Desai N, Ropero J, Muhsen I, Ibrahimova A, Du Toit J, Hendricks C, Gagelmann N, Horga C
LANCET HAEMATOL. 2023;10(7):e492-e494.

Clinical decision‐making and treatment of myelodysplastic syndromes
Hellstrom-Lindberg E, Kröger N
BLOOD. 2023;142(26):2268-2281.

Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis
Hermans S, Versluis J, Labopin M, Giebel S, van Norden Y, Moiseev I, Blaise D, Díez Martín J, Meijer E, Rovira M, Choi G, Raiola A, Koc Y, Reményi P, Vydra J, Kröger N, Sica S, Martino M, van Gorkom G, Chevallier P, Busca A, Herrera Arroyo C, Brissot E, Peric Z, Nagler A, Shouval R, Ciceri F, Cornelissen J, Mohty M
HEMASPHERE. 2023;7(3):e846.

Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: A study of the Chronic Malignancies Working Party of EBMT
Hernández-Boluda J, Eikema D, Koster L, Kröger N, Robin M, de Witte M, Finke J, Finazzi M, Broers A, Raida L, Schaap N, Chiusolo P, Verbeek M, Hazenberg C, Halaburda K, Kulagin A, Labussière-Wallet H, Gedde-Dahl T, Rabitsch W, Raj K, Drozd-Sokolowska J, Battipaglia G, Polverelli N, Czerw T, Yakoub-Agha I, McLornan D
BONE MARROW TRANSPL. 2023;58(12):1357-1367.

Clinical pharmacy services in critical care: results of an observational study comparing ward-based with remote pharmacy services
Hilgarth H, Wichmann D, Baehr M, Kluge S, Langebrake C
INT J CLIN PHARM-NET. 2023;45(4):847-856.

DHFR Inhibitors Display a Pleiotropic Anti-Viral Activity against SARS-CoV-2: Insights into the Mechanisms of Action
Iaconis D, Caccuri F, Manelfi C, Talarico C, Bugatti A, Filippini F, Zani A, Novelli R, Kuzikov M, Ellinger B, Gribbon P, Riecken K, Esposito F, Corona A, Tramontano E, Beccari A, Caruso A, Allegretti M
VIRUSES-BASEL. 2023;15(5):.

Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of the EBMT
Kharfan-Dabaja M, Labopin M, Ayala E, Bazarbachi A, Blaise D, Vydra J, Bramanti S, Itälä-Remes M, Schmid C, Busca A, Forcade E, Rabitsch W, Zecca M, Kröger N, Bulabois C, Grillo G, Rambaldi A, Fanin R, Zallio F, Di Renzo N, Koc Y, Novis Y, McDonald A, Herrera Arroyo C, Sanz J, Nagler A, Ciceri F, Mohty M
HEMASPHERE. 2023;7(7):e920.

Individualized busulfan dosing improves outcomes compared to fixed-dose administration in pre-transplant minimal residual disease-positive acute myeloid leukemia patients with intermediate-risk undergoing allogeneic stem cell transplantation in CR
Klyuchnikov E, Langebrake C, Badbaran A, Dadkhah A, Massoud R, Freiberger P, Ayuk F, Janson D, Wolschke C, Bacher U, Kröger N
EUR J HAEMATOL. 2023;110(2):188-197.

Hämatopoetische Stammzelltransplantation: seit Jahrzehnten etablierte Zelltherapie
Kolb H, Fehse B
2023. Gen- und Zelltherapie 2.023 - Forschung, klinische Anwendung und Gesellschaft. Fehse B, Schickl H, Bartfeld S, Zenke M (Hrsg.). 1. Aufl. Berlin, Heidelberg: 161-181.

Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study
Kriegsmann K, Bittrich M, Sauer S, Tietze-Stolley C, Movassaghi K, Grube M, Vucinic V, Wehler D, Burchert A, Schmidt-Hieber M, Rank A, Dürk H, Metzner B, Kimmich C, Hentrich M, Kunz C, Hartmann F, Khandanpour C, de Wit M, Holtick U, Kiehl M, Stoltefuß A, Kiani A, Naumann R, Scholz C, Tischler H, Görner M, Brand F, Ehmer M, Kröger N
TRANSFUS MED HEMOTH. 2023;50(5):403-416.

Chronological Age Alone Is not Decisive
Kröger N
DTSCH ARZTEBL INT. 2023;120(37):616.

How I treat transplant-eligible patients with myelofibrosis
Kröger N, Wolschke C, Gagelmann N
BLOOD. 2023;142(20):1683-1696.

Patient-individual 3D-printing of drugs within a machine-learning-assisted closed-loop medication management – Design and first results of a feasibility study
Langebrake C, Gottfried K, Dadkhah A, Eggert J, Gutowski T, Rosch M, Schönbeck N, Gundler C, Nürnberg S, Ückert F, Baehr M
Clinical eHealth. 2023;6:3-9.

Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling
Lawless S, Iacobelli S, Knelange N, Chevallier P, Blaise D, Milpied N, Foà R, Cornelissen J, Lioure B, Benjamin R, Poiré X, Minnema M, Collin M, Lenhoff S, Snowden J, Santarone S, Wilson K, Trigo F, Dreger P, Böhmer L, Putter H, Garderet L, Kröger N, Yaukoub-Agha I, Schönland S, Morris C
HAEMATOLOGICA. 2023;108(4):1105-1114.

Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry
Ljungman P, Tridello G, Piñana J, Ciceri F, Sengeloev H, Kulagin A, Mielke S, Yegin Z, Collin M, Einardottir S, Lepretre S, Maertens J, Campos A, Metafuni E, Pichler H, Folber F, Solano C, Nicholson E, Yüksel M, Carlson K, Aguado B, Besley C, Byrne J, Heras I, Dignan F, Kröger N, Robin C, Khan A, Lenhoff S, Grassi A, Dobsinska V, Miranda N, Jimenez M, Yonal-Hindilerden I, Wilson K, Averbuch D, Cesaro S, Xhaard A, Knelange N, Styczynski J, Mikulska M, de la Camara R
FRONT IMMUNOL. 2023;14:1125824.

Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis
Luther M, Henes F, Zabelina T, Massoud R, Janson D, Wolschke C, Klyuchnikov E, Gagelmann N, Fehse B, Adam G, Kröger N, Ayuk F
BONE MARROW TRANSPL. 2023;58(7):755-761.

Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Maffini E, Ngoya M, Galimard J, Harbi S, Kröger N, Platzbecker U, Sengeloev H, Craddock C, Potter V, Choi G, Chevallier P, Stölzel F, Tholouli E, Maertens J, Ciceri F, Cornelissen J, Sanz J, Spyridonidis A, Lanza F, Nagler A, Mohty M
BONE MARROW TRANSPL. 2023;58(9):1033-1041.

Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment
Marquard F, Langebrake C, Janson D, Mahmud M, Dadkhah A, Kröger N, Ayuk F
FRONT ONCOL. 2023;13:1288764.

Retrovirale Vektoren – Effiziente Gentaxis für unterschiedliche Gentherapien
Morgan M, Galla M, Fehse B, Schambach A
2023. Gen- und Zelltherapie 2.023 - Forschung, klinische Anwendung und Gesellschaft. Fehse B, Schickl H, Bartfeld S, Zenke M (Hrsg.). 1. Aufl. Berlin, Heidelberg: Springer, 25-49.

The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT
Nagler A, Labopin M, Kröger N, Schroeder T, Gedde-Dahl T, Eder M, Franke G, Blau I, Salmenniemi U, Socie G, Schetelig J, Stelljes M, Ciceri F, Mohty M
BONE MARROW TRANSPL. 2023;58(12):1339-1347.

Hypomethylating agent-based therapies in older adults with acute myeloid leukemia - A joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee
Neuendorff N, Gagelmann N, Singhal S, Meckstroth S, Thibaud V, Zhao Y, Mir N, Shih Y, Amaro D, Roy M, Lombardo J, Gjærde L, Loh K
J GERIATR ONCOL. 2023;14(3):101406.

Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma
Nitschke C, Markmann B, Walter P, Badbaran A, Tölle M, Kropidlowski J, Belloum Y, Goetz M, Bardenhagen J, Stern L, Tintelnot J, Schönlein M, Sinn M, van der Leest P, Simon R, Heumann A, Izbicki J, Pantel K, Wikman H, Uzunoglu F
CLIN CHEM. 2023;69(3):295-307.

Cognitive Deficits in Executive and Language Functions Predict Postoperative Delirium
Olotu C, Lebherz L, Ascone L, Scherwath A, Kühn S, Härter M, Kiefmann R
J CARDIOTHOR VASC AN. 2023;37(12):2552-2560.

Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Ortí G, Gras L, Zinger N, Finazzi M, Sockel K, Robin M, Forcade E, Avenoso D, Kröger N, Finke J, Radujkovic A, Hunault-Berger M, Schroyens W, Zuckerman T, Bourhis J, Chalandon Y, Bloor A, Schots R, de Wreede L, Drozd-Sokolowska J, Raj K, Polverelli N, Czerw T, Hernández-Boluda J, McLornan D, Yakoub-Agha I
AM J HEMATOL. 2023;98(4):628-638.

Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients
Panagiota V, Kerschbaum J, Penack O, Stein C, Arends C, Koenecke C, Strzelecka P, Kloos A, Wiegand L, Lasch A, Altwasser R, Halik A, Gabdoulline R, Thomson J, Weibl K, Franke G, Berger C, Hasenkamp J, Ayuk F, Na I, Beutel G, Keller U, Bullinger L, Wulf G, Kröger N, Vucinic V, Heuser M, Damm F
HEMASPHERE. 2023;7(10):e957.

Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party
Penack O, Peczynski C, Koenecke C, Polge E, Kuhnl A, Fegueux N, Daskalakis M, Kröger N, Dreger P, Besley C, Schanz U, Bloor A, Ganser A, Forcade E, Corral L, Passweg J, Novak U, Moiseev I, Schoemans H, Basak G, Chabannon C, Sureda A, Averbuch D, Glass B, de la Camara R, Peric Z
J IMMUNOTHER CANCER. 2023;11(4):.

Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
Penack O, Peczynski C, Koenecke C, Polge E, Sanderson R, Yakoub-Agha I, Fegueux N, Daskalakis M, Collin M, Dreger P, Kröger N, Schanz U, Bloor A, Ganser A, Besley C, Wulf G, Novak U, Moiseev I, Schoemans H, Basak G, Chabannon C, Sureda A, Glass B, Peric Z
FRONT IMMUNOL. 2023;14:1252811.

Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT
Polverelli N, Hernández-Boluda J, Czerw T, Barbui T, D'Adda M, Deeg H, Ditschkowski M, Harrison C, Kröger N, Mesa R, Passamonti F, Palandri F, Pemmaraju N, Popat U, Rondelli D, Vannucchi A, Verstovsek S, Robin M, Colecchia A, Grazioli L, Damiani E, Russo D, Brady J, Patch D, Blamek S, Damaj G, Hayden P, McLornan D, Yakoub-Agha I
LANCET HAEMATOL. 2023;10(1):e59-e70.

Primary Cancer Matters in Therapy-related Myeloid Neoplasm Patients Receiving Allogeneic Hematopoietic Cell Transplantation: A Study From the Chronic Malignancies Working Party of the EBMT
Robin M, de Wreede L, Schroeder T, Stölzel F, Kröger N, Koster L, Platzbecker U, Finke J, Ganser A, Blaise D, Ciceri F, Maertens J, Labussière Wallet H, Wang J, Chevallier P, Passweg J, Cornelissen J, Nguyen S, Forcade E, Charbonnier A, Bonifazi F, Hayden P, McLornan D, Yakoub-Agha I
HEMASPHERE. 2023;7(4):e851.

Development of an immediate release excipient composition for 3D printing via direct powder extrusion in a hospital
Rosch M, Gutowski T, Baehr M, Eggert J, Gottfried K, Gundler C, Nürnberg S, Langebrake C, Dadkhah A
INT J PHARMACEUT. 2023;643:.

Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study
Ruutu T, Peczynski C, Houhou M, Polge E, Mohty M, Kröger N, Moiseev I, Penack O, Salooja N, Schoemans H, Duarte R, Schroeder T, Passweg J, Wulf G, Ganser A, Sica S, Arat M, Salmenniemi U, Broers A, Bourhis J, Rambaldi A, Maertens J, Halaburda K, Zuckerman T, Labussière-Wallet H, Basak G, Koenecke C, Perić Z
BONE MARROW TRANSPL. 2023;58(11):1209-1214.

Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)
Saccardi R, Putter H, Eikema D, Busto M, McGrath E, Middelkoop B, Adams G, Atlija M, Ayuk F, Baldomero H, Beguin Y, de la Cámara R, Cedillo Á, Balari A, Chabannon C, Corbacioglu S, Dolstra H, Duarte R, Dulery R, Greco R, Gusi A, Hamad N, Kenyon M, Kröger N, Labopin M, Lee J, Ljungman P, Manson L, Mensil F, Milpied N, Mohty M, Oldani E, Orchard K, Passweg J, Pearce R, de Latour R, Poirel H, Rintala T, Rizzo J, Ruggeri A, Sanchez-Martinez C, Sanchez-Guijo F, Sánchez-Ortega I, Trnková M, Ferreiras D, Wilcox L, de Wreede L, Snowden J
BONE MARROW TRANSPL. 2023;58(6):659-666.

Analysis of Repeated Roles in Editorial Boards at Oncology Focused Journals
Sawalha L, Kelkar A, Mohyuddin G, Goodman A, Gagelmann N, Hadidi S
J CANCER POLICY. 2023;35:100380.

Evaluation of a short instrument for measuring health-related quality of life in oncological patients in routine care (HELP-6): an observational study
Schrage T, Görlach M, Betz C, Bokemeyer C, Kroger N, Muller V, Krüll A, Schulz H, Bleich C
FRONT PSYCHOL. 2023;14:1158449.

Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial
Schroeder T, Stelljes M, Christopeit M, Esseling E, Scheid C, Mikesch J, Rautenberg C, Jäger P, Cadeddu R, Drusenheimer N, Holtick U, Klein S, Trenschel R, Haas R, Germing U, Kröger N, Kobbe G
HAEMATOLOGICA. 2023;108(11):3001-3010.

Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study
Schubert M, Bethge W, Ayuk F, von Bonin M, Vucinic V, Wagner-Drouet E, Subklewe M, Baldus C, Glass B, Marks R, Mougiakakos D, Schroers R, Stelljes M, Topp M, Wulf G, Kröger N, Dreger P
BLOOD ADV. 2023;7(20):6191-6195.

Correction: Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application
Schwarze L, Głów D, Sonntag T, Uhde A, Fehse B
GENE THER. 2023;30(1-2):187.

Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the Acute Leukemia Working Party of the EBMT
Spyridonidis A, Labopin M, Savani B, Giebel S, Bug G, Schönland S, Kröger N, Stelljes M, Schroeder T, McDonald A, Blau I, Bornhäuser M, Rovira M, Bethge W, Neubauer A, Ganser A, Bourhis J, Edinger M, Lioure B, Wulf G, Schäfer-Eckart K, Arat M, Peric Z, Schmid C, Bazarbachi A, Ciceri F, Nagler A, Mohty M
HEMASPHERE. 2023;7(1):e812.

The utility of biomarkers in acute GVHD prognostication
Spyrou N, Akahoshi Y, Ayuk F, Holler E, Choe H, Etra A, Hogan W, Rösler W, Hexner E, DeFilipp Z, Reshef R, Chanswangphuwana C, Qayed M, Kraus S, Eder M, Javorniczky N, Grupp S, Kitko C, Merli P, Aguayo-Hiraldo P, Wölfl M, Baez J, Beheshti R, Eng G, Gleich S, Katsivelos N, Khan A, Kowalyk S, Morales G, Young R, Nakamura R, Chen Y, Levine J, Ferrara J
BLOOD ADV. 2023;7(17):5152-5155.

Use of ropeginterferon in inducing graft versus myelofibrosis effect in post-transplant myelofibrosis relapse
Srivastava B, Wolschke C, Gagelmann N, Badbaran A, Kröger N
CLIN CASE REP. 2023;11(9):e7942.

Generating Patient-Derived HCC Cell Lines Suitable for Predictive In Vitro and In Vivo Drug Screening by Orthotopic Transplantation
Staffeldt L, Mattert G, Riecken K, Rövenstrunk G, Volkmar A, Heumann A, Moustafa M, Jücker M, Fehse B, Schumacher U, Lüth S, Kah J
CELLS-BASEL. 2023;13(1):.

Identification of potential classes of glycoligands mediating dynamic endothelial adhesion of human tumor cells
Starzonek S, Maar H, Mereiter S, Freytag V, Haider M, Riecken K, Huang Y, Jacob F, Wicklein D, Schumacher U, Lange T
GLYCOBIOLOGY. 2023;33(8):637-650.

Decrease of lethal infectious complications in the context of causes of death (COD) after hematopoietic cell transplantation: COD-2 and COD-1 study of the Infectious Diseases Working Party EBMT
Styczynski J, Tridello G, Koster L, Knelange N, Wendel L, van Biezen A, van der Werf S, Mikulska M, Gil L, Cordonnier C, Ljungman P, Averbuch D, Cesaro S, Baldomero H, Chabannon C, Corbacioglu S, Dolstra H, Glass B, Greco R, Kröger N, de Latour R, Mohty M, Neven B, Peric Z, Snowden J, Sureda A, Yakoub-Agha I, de la Camara R
BONE MARROW TRANSPL. 2023;58(8):881-892.

Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT
Swoboda R, Labopin M, Giebel S, Schroeder T, Kröger N, Arat M, Savani B, Spyridonidis A, Hamladji R, Potter V, Berceanu A, Yakoub-Agha I, Rambaldi A, Ozdogu H, Sanz J, Nagler A, Mohty M
BONE MARROW TRANSPL. 2023;58(3):282-287.

Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT
Tilmont R, Yakoub-Agha I, Eikema D, Zinger N, Haenel M, Schaap N, Arroyo C, Schuermans C, Besemer B, Engelhardt M, Kuball J, Michieli M, Schub N, Wilson K, Bourhis J, Mateos M, Rabin N, Jost E, Kröger N, Moraleda J, Za T, Hayden P, Beksac M, Mclornan D, Schönland S, Manier S
BONE MARROW TRANSPL. 2023;58(11):1182-1188.

Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer
Tintelnot J, Xu Y, Lesker T, Schönlein M, Konczalla L, Giannou A, Pelczar P, Kylies D, Puelles V, Bielecka A, Peschka M, Cortesi F, Riecken K, Jung M, Amend L, Bröring T, Trajkovic-Arsic M, Siveke J, Renné T, Zhang D, Boeck S, Strowig T, Uzunoglu F, Güngör C, Stein A, Izbicki J, Bokemeyer C, Sinn M, Kimmelman A, Huber S, Gagliani N
NATURE. 2023;615(7950):168-174.

An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
Tokaz M, Baldomero H, Cowan A, Saber W, Greinix H, Koh M, Kröger N, Mohty M, Galeano S, Okamoto S, Chaudhri N, Karduss A, Ciceri F, Colturato V, Corbacioglu S, Elhaddad A, Force L, Frutos C, León A, Hamad N, Hamerschlak N, He N, Ho A, Huang X, Jacobs B, Kim H, Lida M, Lehmann L, de Latour R, Percival M, Perdomo M, Rasheed W, Schultz K, Seber A, Ko B, Simione A, Srivastava A, Szer J, Wood W, Kodera Y, Nagler A, Snowden J, Weisdorf D, Passweg J, Pasquini M, Sureda A, Atsuta Y, Aljurf M, Niederwieser D
TRANSPL CELL THER. 2023;29(4):279.e1-279.e10.

The European landscape on allogeneic haematopoietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: A perspective from the Chronic Malignancies Working Party of the EBMT
Tournilhac O, van Gelder M, Eikema D, Zinger N, Dreger P, Bornhäuser M, Vucinic V, Scheid C, Cornelissen J, Schroeder T, Jindra P, Sengeloev H, Nguyen Quoc S, Stelljes M, Blau I, Mayer J, Paneesha S, Chevallier P, Forcade E, Kröger N, Blaise D, Gribben J, Nielsen B, Johansson J, Kyriakou C, Beguin Y, Pioltelli P, Sampol A, McLornan D, Schetelig J, Hayden P, Yakoub-Agha I
BONE MARROW TRANSPL. 2023;58(6):621-624.

Abdominal emergency surgery in patients with hematological malignancies: a retrospective single-center analysis
von Kroge P, Duprée A, Mann O, Izbicki J, Wagner J, Ahmadi P, Weidemann S, Adjallé R, Kröger N, Bokemeyer C, Fiedler W, Modemann F, Ghandili S
WORLD J EMERG SURG. 2023;18(1):12.

Reg3α concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use
Weber D, Weber M, Meedt E, Ghimire S, Wolff D, Edinger M, Poeck H, Hiergeist A, Gessner A, Ayuk F, Roesler W, Wolfl M, Kraus S, Zeiser R, Bertrand H, Bader P, Ullrich E, Eder M, Gleich S, Young R, Herr W, Levine J, Ferrara J, Holler E
BLOOD ADV. 2023;7(7):1326-1335.

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
Westin J, Oluwole O, Kersten M, Miklos D, Perales M, Ghobadi A, Rapoport A, Sureda A, Jacobson C, Farooq U, van Meerten T, Ulrickson M, Elsawy M, Leslie L, Chaganti S, Dickinson M, Dorritie K, Reagan P, McGuirk J, Song K, Riedell P, Minnema M, Yang Y, Vardhanabhuti S, Filosto S, Cheng P, Shahani S, Schupp M, To C, Locke F
NEW ENGL J MED. 2023;389(2):148-157.

Deep Characterization and Comparison of Different Retrovirus-like Particles Preloaded with CRISPR/Cas9 RNPs
Wichmann M, Maire C, Nuppenau N, Habiballa M, Uhde A, Kolbe K, Schröder T, Lamszus K, Fehse B, Głów D
INT J MOL SCI. 2023;24(14):11399.

Pathophysiology of gastrointestinal acute graft-versus-host disease and the potential role of glucagon-like peptide 2
Zeiser R, Chen Y, Youssef N, Ayuk F
BRIT J HAEMATOL. 2023;201(4):620-627.

Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study
Albert M, Sirait T, Eikema D, Bakunina K, Wehr C, Suarez F, Fox M, Mahlaoui N, Gennery A, Lankester A, Beier R, Bernardo M, Bigley V, Lindemans C, Burns S, Carpenter B, Dybko J, Güngör T, Hauck F, Lum S, Balashov D, Meisel R, Moshous D, Schulz A, Speckmann C, Slatter M, Strahm B, Uckan-Cetinkaya D, Meyts I, Vallée T, Wynn R, Neven B, Morris E, Aiuti A, Maschan A, Aljurf M, Gedde-Dahl T, Gurman G, Bordon V, Kriván G, Locatelli F, Porta F, Valcárcel D, Beguin Y, Faraci M, Kröger N, Kulagin A, Shaw P, Veelken J, Diaz de Heredia C, Fagioli F, Felber M, Gruhn B, Holter W, Rössig C, Sedlacek P, Apperley J, Ayas M, Bodova I, Choi G, Cornelissen J, Sirvent A, Khan A, Kupesiz A, Lenhoff S, Ozdogu H, von der Weid N, Rovira M, Schots R, Vinh D
BLOOD. 2022;140(14):1635-1649.

Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia
Al Hamed R, Labopin M, Daguindau E, Niittyvuopio R, Huynh A, Socié G, Srour M, Henri Bourhis J, Kröger N, Tholouli E, Choi G, Poiré X, Martin H, Rubio M, Jindra P, Blaise D, Beelen D, Labussière-Wallet H, Nagler A, Bazarbachi A, Mohty M
CANCER MED-US. 2022;11(4):1068-1080.

Ciprofloxacin in Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): A Population Pharmacokinetic Study
Alihodzic D, Wicha S, Frey O, König C, Baehr M, Jarczak D, Kluge S, Langebrake C
PHARMACEUTICS. 2022;14(5):.

Worldwide Network for Blood and Marrow Transplantation Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy
Alseraihy A, McGrath E, Niederwieser D, Chabannon C, Szer J, Mohty M, Kharfan-Dabaja M, Orchard K, Schwartz J, Rasheed W, Koh M, Kröger N, Kodera Y, Fakih R, Worel N, Manson L, Rintala T, Tabakhi A, Savani B, Gergis U, Sureda A, Eldridge P, Yakoub-Agha I, Hamadani M, Weisdorf D, Greinix H, Aljurf M
TRANSPL CELL THER. 2022;28(8):455-462.

Nocardia infections in hematopoietic cell transplant recipients: a multicenter international retrospective study of the Infectious Diseases Working Party (IDWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Averbuch D, De Greef J, Duréault A, Wendel L, Tridello G, Lebeaux D, Mikulska M, Gil L, Knelange N, Zuckerman T, Roussel X, Robin C, Xhaard A, Aljurf M, Beguin Y, Le Bourgeois A, Botella-Garcia C, Khanna N, Van Praet J, Kröger N, Blijlevens N, Ducastelle Leprêtre S, Ho A, Roos-Weil D, Yeshurun M, Lortholary O, Fontanet A, de la Camara R, Coussement J, Maertens J, Styczynski J
CLIN INFECT DIS. 2022;75(1):88-97.

Management of Cytokine Release Syndrome (CRS) and HLH
Ayuketang F, Jäger U
2022. The EBMT/EHA CAR-T Cell Handbook. Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H (Hrsg.). 1. Aufl. Cham: Springer International Publishing, 135-139.

Long-Term Results of Allogeneic Stem Cell Transplantation in Adult Ph- Negative High-Risk Acute Lymphoblastic Leukemia
Beelen D, Arnold R, Stelljes M, Alakel N, Brecht A, Bug G, Bunjes D, Faul C, Finke J, Franke G, Holler E, Kobbe G, Kröger N, Rösler W, Scheid C, Schönland S, Stadler M, Tischer J, Wagner-Drouet E, Wendelin K, Brüggemann M, Reiser L, Hoelzer D, Gökbuget N
TRANSPL CELL THER. 2022;28(12):834-842.

Immune Monitoring
Berger S, Fehse B, Rubio M
2022. The EBMT/EHA CAR-T Cell Handbook. Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H (Hrsg.). 1. Aufl. Cham: Springer International Publishing, 177-182.

The impact of pharmacists' interventions within the Closed Loop Medication Management process on medication safety: An analysis in a German university hospital
Berger V, Sommer C, Boje P, Hollmann J, Hummelt J, König C, Lezius S, van der Linde A, Marhenke C, Melzer S, Michalowski N, Baehr M, Langebrake C
FRONT PHARMACOL. 2022;13:.

Detection of human herpes virus 6 DNA and chromosomal integration after allogeneic hematopoietic stem cell transplantation: a retrospective single center analysis
Berneking L, Both A, Langebrake C, Aepfelbacher M, Lütgehetmann M, Kröger N, Christopeit M
TRANSPL INFECT DIS. 2022;24(3):e13836.

GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany
Bethge W, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner-Drouet E, Wulf G, Marks R, Penack O, Schnetzke U, Koenecke C, von Bonin M, Stelljes M, Glass B, Baldus C, Vucinic V, Mougiakakos D, Topp M, Fante M, Schroers R, Bayir L, Borchmann P, Buecklein V, Hanoun C, Thomas S, Beelen D, Lengerke C, Kroeger N, Dreger P
BLOOD. 2022;140(4):349-358.

Population dynamics in colonizing vancomycin-resistant Enterococcus faecium isolated from immunosuppressed patients
Both A, Kruse F, Mirwald N, Franke G, Christner M, Huang J, Hansen J, Kröger N, Berneking L, Lellek H, Aepfelbacher M, Rohde H
J GLOB ANTIMICROB RE. 2022;28:267-273.

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
Buske C, Dreyling M, Alvarez-Larrán A, Apperley J, Arcaini L, Besson C, Bullinger L, Corradini P, Giovanni Della Porta M, Dimopoulos M, D'Sa S, Eich H, Foà R, Ghia P, da Silva M, Gribben J, Hajek R, Harrison C, Heuser M, Kiesewetter B, Kiladjian J, Kröger N, Moreau P, Passweg J, Peyvandi F, Rea D, Ribera J, Robak T, San-Miguel J, Santini V, Sanz G, Sonneveld P, von Lilienfeld-Toal M, Wendtner C, Pentheroudakis G, Passamonti F
ESMO OPEN. 2022;7(2):.

Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT
Czerw T, Iacobelli S, Malpassuti V, Koster L, Kröger N, Robin M, Maertens J, Chevallier P, Watz E, Poiré X, Snowden J, Kuball J, Kinsella F, Blaise D, Reményi P, Mear J, Cammenga J, Rubio M, Maury S, Daguindau E, Finnegan D, Hayden P, Hernández-Boluda J, McLornan D, Yakoub-Agha I
BONE MARROW TRANSPL. 2022;57(2):261-270.

Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation
Dadkhah A, Wicha S, Kröger N, Müller A, Pfaffendorf C, Riedner M, Badbaran A, Fehse B, Langebrake C
PHARMACEUTICS. 2022;14(6):.

Regulation of bone homeostasis by MERTK and TYRO3
Engelmann J, Zarrer J, Gensch V, Riecken K, Berenbrok N, Luu T, Beitzen-Heineke A, Vargas-Delgado M, Pantel K, Bokemeyer C, Bhamidipati S, Darwish I, Masuda E, Burstyn-Cohen T, Alberto E, Ghosh S, Rothlin C, Hesse E, Taipaleenmäki H, Ben Batalla I, Loges S
NAT COMMUN. 2022;13(1):.

Iron Chelation with Deferasirox increases Busulfan AUC during Conditioning Chemotherapy prior to Allogeneic Stem Cell Transplantation
Essmann S, Dadkhah A, Janson D, Wolschke C, Ayuk F, Kröger N, Langebrake C
TRANSPL CELL THER. 2022;28(2):115.e1-115.e5.

Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
Etra A, Gergoudis S, Morales G, Spyrou N, Shah J, Kowalyk S, Ayuk F, Baez J, Chanswangphuwana C, Chen Y, Choe H, DeFilipp Z, Gandhi I, Hexner E, Hogan W, Holler E, Kapoor U, Kitko C, Kraus S, Lin J, Al Malki M, Merli P, Pawarode A, Pulsipher M, Qayed M, Reshef R, Rösler W, Schechter T, Van Hyfte G, Weber D, Wölfl M, Young R, Özbek U, Ferrara J, Levine J
BLOOD ADV. 2022;6(12):3707-3715.

Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT
Forcade E, Chevret S, Finke J, Ehninger G, Ayuk F, Beelen D, Koster L, Ganser A, Volin L, Sengeloev H, Michallet M, Tischer J, Jindra P, Cascon M, Koc Y, Arat M, Tomaszewska A, Hayden P, de Witte T, Yakoub-Agha I, Kröger N, Robin M
BONE MARROW TRANSPL. 2022;57(5):768-774.

Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL
Gagelmann N, Gribben J, Kröger N
2022. The EBMT/EHA CAR-T Cell Handbook. Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H (Hrsg.). 1. Aufl. Cham: Springer International Publishing, 123-125.

Improving allogeneic stem cell transplantation in myelofibrosis
Gagelmann N, Kroger N
INT J HEMATOL. 2022;115(5):619-625.

Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
Gagelmann N, Passamonti F, Wolschke C, Massoud R, Niederwieser C, Adjallé R, Mora B, Ayuk F, Kröger N
HAEMATOLOGICA. 2022;107(8):1840-1849.

High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis
Gagelmann N, Salit R, Schroeder T, Badbaran A, Rautenberg C, Panagiota V, Wolschke C, Thol F, Cassinat B, Robin M, Heuser M, Reinhardt H, Scott B, Kröger N
HEMASPHERE. 2022;6(10):.

Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper
Gagelmann N, Sureda A, Montoto S, Murray J, Bolaños N, Kenyon M, Beksac M, Schönland S, Hayden P, Scheurer H, Morgan K, Garderet L, McLornan D, Ruggeri A
LANCET HAEMATOL. 2022;9(10):e786-e795.

Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis
Gagelmann N, Wolschke C, Salit R, Schroeder T, Ditschkowski M, Panagiota V, Cassinat B, Thol F, Badbaran A, Robin M, Reinhardt H, Ayuk F, Heuser M, Scott B, Kröger N
BLOOD ADV. 2022;6(4):1222-1231.

Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)
Gavriilaki E, Labopin M, Sakellari I, Salmenniemi U, Yakoub-Agha I, Potter V, Berceanu A, Rambaldi A, Hilgendorf I, Kröger N, Mielke S, Zuckerman T, Sanz J, Busca A, Ozdogu H, Anagnostopoulos A, Savani B, Giebel S, Bazarbachi A, Spyridonidis A, Nagler A, Mohty M
BONE MARROW TRANSPL. 2022;57(12):1803-1809.

Donor-transmitted extramedullary acute myeloid leukaemia after living donor kidney transplantation
Ghandili S, Kluger M, Leitner T, Grahammer F, Kirchner L, Modemann F, Achilles E, Kreipe H, Klein J, Steinemann D, Wolschke C, Fischer L, Bokemeyer C, Fiedler W, Huber T, Alsdorf W, Mahmud M
BRIT J HAEMATOL. 2022;198(1):199-202.

Clinical features of hepatitis E infections in patients with hematologic disorders
Ghandili S, Lindhauer C, Pischke S, Zur Wiesch J, Von Kroge P, Polywka S, Bokemeyer C, Fiedler W, Kröger N, Ayuk F, Adjallé R, Modemann F
HAEMATOLOGICA. 2022;107(12):2870-2883.

The Reconstitution Dynamics of Cultivated Hematopoietic Stem Cells and Progenitors Is Independent of Age
Gotzhein F, Aranyossy T, Thielecke L, Sonntag T, Thaden V, Fehse B, Müller I, Glauche I, Cornils K
INT J MOL SCI. 2022;23(6):.

Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape
Greinix H, Ayuk F, Zeiser R
LEUKEMIA. 2022;36(11):2558-2566.

Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study
Greinix H, Eikema D, Koster L, Penack O, Yakoub-Agha I, Montoto S, Chabannon C, Styczynski J, Nagler A, Robin M, Robinson S, Chalandon Y, Mikulska M, Schönland S, Peric Z, Ruggeri A, Lanza F, De Wreede L, Mohty M, Basak G, Kröger N
HAEMATOLOGICA. 2022;107(5):1054-1063.

Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients
Hagemann K, Riecken K, Jung J, Hildebrandt H, Menzel S, Bunders M, Fehse B, Koch-Nolte F, Heinrich F, Peine S, Schulze Zur Wiesch J, Brehm T, Addo M, Lütgehetmann M, Altfeld M
EUR J IMMUNOL. 2022;52(8):1297-1307.

Long-Term Follow-Up and Late Effects
Hayden P, Gagelmann N, Snowden J
2022. The EBMT/EHA CAR-T Cell Handbook. Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H (Hrsg.). 1. Aufl. Cham: Springer International Publishing, 183-187.

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
Hayden P, Roddie C, Bader P, Basak G, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jäger U, Hildebrandt M, Hudecek M, Kersten M, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Rees J, Rioufol C, Saccardi R, Snowden J, Styczynski J, Subklewe M, Thieblemont C, Topp M, Ispizua Á, Chen D, Vrhovac R, Gribben J, Kröger N, Einsele H, Yakoub-Agha I
ANN ONCOL. 2022;33(3):259-275.

Recognising inequalities in haematopoietic stem-cell transplantation and cellular therapy training
Horgan C, Serroukh Y, Gjærde L, Gagelmann N
LANCET HAEMATOL. 2022;9(5):e323-e324.

Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine
Klingler F, Alsdorf W, Ghandili S, Wolschke C, Brauneck F, Bokemeyer C, Fiedler W, Modemann F, Karagiannis P
LEUKEMIA LYMPHOMA. 2022;63(11):2645-2651.

Post-Transplantation Multicolored Flow Cytometry-Minimal Residual Disease Status on Day 100 Predicts Outcomes for Patients With Refractory Acute Myeloid Leukemia
Klyuchnikov E, Badbaran A, Massoud R, Fritsche-Friedland U, Janson D, Ayuk F, Christopeit M, Wolschke C, Bacher U, Kröger N
TRANSPL CELL THER. 2022;28(5):267.e1-267.e7.

Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission
Klyuchnikov E, Badbaran A, Massoud R, Fritzsche-Friedland U, Freiberger P, Ayuk F, Wolschke C, Bacher U, Kröger N
TRANSPL CELL THER. 2022;28(7):374.e1-374.e9.

A Lack of Effectiveness in the ATM-Orchestrated DNA Damage Response Contributes to the DNA Repair Defect of HPV-Positive Head and Neck Cancer Cells
Köcher S, Zech H, Krug L, Gatzemeier F, Christiansen S, Meyer F, Rietow R, Struve N, Mansour W, Kriegs M, Petersen C, Betz C, Rothkamm K, Rieckmann T
FRONT ONCOL. 2022;12:.

Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation: a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT
Koenecke C, Eikema D, Hazelaar S, Schroeder T, Potter V, Kröger N, Bornhäuser M, Finke J, Platzbecker U, Radujkovic A, Ganser A, Salmenniem U, Blaise D, Kobbe G, Meijer E, Friis L, Maertens J, Caballero D, Cornelissen J, Olivieri A, Gulsum O, Hayden P, Onida F, Robin M, Yakoub-Agha I
BONE MARROW TRANSPL. 2022;57(10):1607-1611.

Graft-versus-host disease in allogeneic transplantation: the good and the bad
Kröger N
HAEMATOLOGICA. 2022;107(7):1494-1495.

The Number of Stem Cell Transplantations During the COVID-19 Pandemic
Kröger N, Frank S, Neidlinger H, Fleischhauer K, Dreger P
DTSCH ARZTEBL INT. 2022;119(35-36):601-602.

Educational Needs for Physicians
Kröger N, Gribben J, Sánchez-Ortega I
2022. The EBMT/EHA CAR-T Cell Handbook. Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H (Hrsg.). 1. Aufl. Cham: Springer International Publishing, 203-206.

High-throughput drug screening allowed identification of entry inhibitors specifically targeting different routes of SARS-CoV-2 Delta and Omicron/BA.1
Kuzikov M, Woens J, Zaliani A, Hambach J, Eden T, Fehse B, Ellinger B, Riecken K
BIOMED PHARMACOTHER. 2022;151:.

Arzneimittelversorgung zwischen ambulanter und stationärer Behandlung
Langebrake C
2022. Arzneimittel-Kompass 2022. Schröder H, Thürmann P, Telschow C, Schröder M, Busse R (Hrsg.). 1. Aufl. Berlin: Springer-Verlag, Berlin, 161-170.

Telepharmazie
Langebrake C
2022. Die digitale Intensivstation. Marx G, Meister S (Hrsg.). 1. Aufl. Berlin: Medizinisch Wissenschaftliche Verlagsgesellschaft, 297-303.

Chemotherapie bei Bronchialkarzinom
Langebrake C, Christopeit M
2022. Medikationsmanagement im Krankenhaus. Gross I, Fischer A, Knoth H (Hrsg.). 1. Aufl. Stuttgart: Deutscher Apotheker Verlag, 242-245.

Clinical pharmacists' interventions across German hospitals: results from a repetitive cross-sectional study
Langebrake C, Hohmann C, Lezius S, Lueb M, Picksak G, Walter W, Kaden S, Hilgarth H, Ihbe-Heffinger A, Leichenberg K
INT J CLIN PHARM-NET. 2022;44(1):64-71.

Tumor cell E-selectin ligands determine partialefficacy of bortezomib on spontaneous lung metastasis formation of solid human tumors in vivo
Lange T, Valentiner U, Wicklein D, Maar H, Labitzky V, Ahlers A, Starzonek S, Genduso S, Staffeldt L, Pahlow C, Dück A, Stürken C, Baranowsky A, Bauer A, Bulk E, Schwab A, Riecken K, Börnchen C, Kiefmann R, Abraham V, DeLisser H, Gemoll T, Habermann J, Block A, Pantel K, Schumacher U
MOL THER. 2022;30(4):1536-1552.

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Locke F, Miklos D, Jacobson C, Perales M, Kersten M, Oluwole O, Ghobadi A, Rapoport A, McGuirk J, Pagel J, Muñoz J, Farooq U, van Meerten T, Reagan P, Sureda A, Flinn I, Vandenberghe P, Song K, Dickinson M, Minnema M, Riedell P, Leslie L, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon L, Westin J
NEW ENGL J MED. 2022;386(7):640-654.

Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia
Loke J, Labopin M, Craddock C, Cornelissen J, Labussière-Wallet H, Wagner-Drouet E, Van Gorkom G, Schaap N, Kröger N, Veelken J, Rovira M, Menard A, Bug G, Bazarbachi A, Giebel S, Brissot E, Nagler A, Esteve J, Mohty M
CANCER-AM CANCER SOC. 2022;128(15):2922-2931.

Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT
Machowicz R, Suarez F, Wiktor-Jedrzejczak W, Eikema D, de Wreede L, Blok H, Isaksson C, Einsele H, Poiré X, van Dorp S, Nikolousis E, Johansson J, Kobbe G, Zecca M, Arnold R, Gerbitz A, Finke J, Díez-Martín J, Bonifazi F, McQuaker G, Lenhoff S, Rohrlich P, Theobald M, Ljungman P, Collin M, Albert M, Ehninger G, Carlson K, Halaburda K, Lehmberg K, Schönland S, Yakoub-Agha I, Gennery A, Lankester A, Kröger N
BONE MARROW TRANSPL. 2022;57(5):817-823.

Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)
Maffini E, Labopin M, Beelen D, Kroeger N, Arat M, Wilson K, Bay J, Ganser A, Martin H, Passweg J, Kottaridis P, Yakoub-Agha I, Porras R, Wagner E, Esteve J, Lanza F, Nagler A, Mohty M
BONE MARROW TRANSPL. 2022;57(10):1556-1563.

Digital-droplet PCR assays for IDH, DNMT3A and driver mutations to monitor after allogeneic stem cell transplantation minimal residual disease of myelofibrosis
Mannina D, Badbaran A, Wolschke C, Klyuchnikov E, Christopeit M, Fehse B, Kröger N
BONE MARROW TRANSPL. 2022;57(3):510-512.

Influence of Fetomaternal Microchimerism on Maternal NK Cell Reactivity against the Child's Leukemic Blasts
Martin L, Kruchen A, Fehse B, Müller I
BIOMEDICINES. 2022;10(3):.

Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT
Masouridi-Levrat S, Olavarria E, Iacobelli S, Aljurf M, Morozova E, Niittyvuopio R, Sengeloev H, Reményi P, Helbig G, Browne P, Ganser A, Nagler A, Snowden J, Robin M, Passweg J, Van Gorkom G, Wallet H, Hoek J, Blok H, De Witte T, Kroeger N, Hayden P, Chalandon Y, Agha I
BONE MARROW TRANSPL. 2022;57(1):23-30.

Comparison of immune reconstitution between anti-T-lymphocyte globulin and post-transplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation
Massoud R, Gagelmann N, Fritzsche-Friedland U, Zeck G, Heidenreich S, Wolschke C, Ayuk F, Christopeit M, Kröger N
HAEMATOLOGICA. 2022;107(4):857-867.

Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation
Massoud R, Klyuchnikov E, Gagelmann N, Zabelina T, Wolschke C, Ayuk F, Fritzsche-Friedland U, Zander A, Kröger N
BONE MARROW TRANSPL. 2022;57(10):1548-1555.

HEV infection in stem cell transplant recipients-retrospective study of EBMT Infectious Diseases Working Party
Mikulska M, Penack O, Wendel L, Knelange N, Cornelissen J, Blijlevens N, Passweg J, Kroger N, Bruns A, Koenecke C, Bierings M, Piñana J, Labussiere-Wallet H, Ghesquieres H, Diaz M, Sampol A, Averbuch D, de la Camara R, Styczynski J
BONE MARROW TRANSPL. 2022;57(2):167-175.

COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies
Modemann F, Niederwieser C, Weisel K, Bokemeyer C, Fiedler W, Ghandili S
LEUKEMIA LYMPHOMA. 2022;63(3):664-671.

The first steps towards a diverse and inclusive EBMT: a position paper.
Montoto S, Snowden J, Chabannon C, Corbacioglu S, de la Camara R, Dolstra H, Greco R, Gusi A, Hamad N, Kenyon M, Kröger N, Mohty M, Murray J, Mueller A, Neven B, Peffault de Latour R, Peric Z, Sánchez-Ortega I, Sureda A, Verhoeven B, Villar A, Yakoub-Agha I
BONE MARROW TRANSPL. 2022;57(3):343-346.

Combined Targeting of AKT and mTOR Inhibits Tumor Formation of EpCAM+ and CD90+ Human Hepatocellular Carcinoma Cells in an Orthotopic Mouse Model
Moustafa M, Dähling K, Günther A, Riebandt L, Smit D, Riecken K, Schröder C, Zhuang R, Krech T, Kriegs M, Fehse B, Izbicki J, Fischer L, Nashan B, Li J, Jücker M
CANCERS. 2022;14(8):.

Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: A study of the Chronic Malignancies Working Party of the EBMT
Nabergoj M, Mauff K, Beelen D, Ganser A, Kröger N, Stölzel F, Finke J, Passweg J, Cornelissen J, Schub N, Veelken J, Beguin Y, Wilson K, Zuckerman T, Hunault-Berger M, Lioure B, Porras R, Turlure P, Kerre T, Koster L, Hayden P, Onida F, Scheid C, Chalandon Y, Robin M, Yakoub-Agha I
BONE MARROW TRANSPL. 2022;57(7):1072-1078.

Posttransplant cyclophosphamide-based anti-graft-vs-host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen-mismatched unrelated donors versus haploidentical donors: A study on behalf of the ALWP of the EBMT
Nagler A, Labopin M, Arat M, Reményi P, Koc Y, Blaise D, Angelucci E, Vydra J, Kulagin A, Socié G, Rovira M, Sica S, Aljurf M, Gülbas Z, Kröger N, Brissot E, Peric Z, Giebel S, Ciceri F, Mohty M
CANCER-AM CANCER SOC. 2022;128(22):3959-3968.

Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis
Nagler A, Ngoya M, Galimard J, Labopin M, Bornhäuser M, Stelljes M, Finke J, Ganser A, Einsele H, Kröger N, Brecht A, Bethge W, Edinger M, Kulagin A, Passweg J, Blau I, Elmaagacli A, Schäfer-Eckart K, Platzbecker U, Schroeder T, Bunjes D, Tischer J, Martin S, Spyridonidis A, Giebel S, Savani B, Mohty M
CLIN CANCER RES. 2022;28(19):4258-4266.

Correction: Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT
Nagler A, Ngoya M, Galimard J, Labopin M, Kröger N, Socié G, Gedde-Dahl T, Potter V, Schroeder T, Platzbecker U, Ganser A, Blaise D, Salmenniemi U, Maertens J, Craddock C, Labussière-Wallet H, Yakoub-Agha I, Savani B, Mohty M
BONE MARROW TRANSPL. 2022;57(12):.

Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT
Nagler A, Ngoya M, Galimard J, Labopin M, Kröger N, Socié G, Gedde-Dahl T, Potter V, Schroeder T, Platzbecker U, Ganser A, Blaise D, Salmenniemi U, Maertens J, Craddock C, Labussière-Wallet H, Yakoub-Agha I, Savani B, Mohty M
BONE MARROW TRANSPL. 2022;57(12):1788-1796.

Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia
Nagler A, Peczynski C, Dholaria B, Labopin M, Valerius T, Dreger P, Kröger N, Reinhardt H, Finke J, Franke G, Ciceri F, Verbeek M, Blau I, Bornhäuser M, Spyridonidis A, Bug G, Bazarbachi A, Schmid C, Yakoub-Agha I, Savani B, Mohty M
BONE MARROW TRANSPL. 2022;57(12):.

Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia
Nagler A, Peczynski C, Dholaria B, Labopin M, Valerius T, Dreger P, Kröger N, Reinhardt H, Finke J, Franke G, Ciceri F, Verbeek M, Blau I, Bornhäuser M, Spyridonidis A, Bug G, Bazarbachi A, Schmid C, Yakoub-Agha I, Savani B, Mohty M
BONE MARROW TRANSPL. 2022;57(7):1116-1123.

Higher risk for chronic graft-versus-host disease (GvHD) in HLA-G mismatched transplants following allogeneic hematopoietic stem cell transplantation: A retrospective study
Neuchel C, Gowdavally S, Tsamadou C, Platzbecker U, Sala E, Wagner-Drouet E, Valerius T, Kröger N, Wulf G, Einsele H, Thurner L, Schaefer-Eckart K, Freitag S, Casper J, Dürholt M, Kaufmann M, Hertenstein B, Klein S, Ringhoffer M, Frank S, Amann E, Rode I, Schrezenmeier H, Mytilineos J, Fürst D
HLA. 2022;100(4):349-360.

Transplantation in CML in the TKI era: who, when, and how?
Niederwieser C, Kröger N
HEMATOL-AM SOC HEMAT. 2022;2022(1):114-122.

Endothelial complications after allogeneic stem cell transplantation in patients with pretransplant resolved COVID-19
Niederwieser C, Weber B, Reichard M, Gagelmann N, Ajib S, Schlipfenbacher V, Zeng Z, Lang F, Janson D, Wolschke C, Ayuk F, Bug G, Kröger N
BONE MARROW TRANSPL. 2022;57(7):1180-1182.

One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors
Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, Elhaddad A, Frutos C, Galeano S, Hamad N, Hamidieh A, Hashmi S, Ho A, Horowitz M, Iida M, Jaimovich G, Karduss A, Kodera Y, Kröger N, Péffault de Latour R, Lee J, Martínez-Rolón J, Pasquini M, Passweg J, Paulson K, Seber A, Snowden J, Srivastava A, Szer J, Weisdorf D, Worel N, Koh M, Aljurf M, Greinix H, Atsuta Y, Saber W
HAEMATOLOGICA. 2022;107(5):1045-1053.

The effect of delirium preventive measures on the occurrence of postoperative cognitive dysfunction in older adults undergoing cardiovascular surgery. The DelPOCD randomised controlled trial
Olotu C, Ascone L, Wiede J, Manthey J, Kuehn S, Scherwath A, Kiefmann R
J CLIN ANESTH. 2022;78:.

Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP
Onida F, Sbianchi G, Radujkovic A, Sockel K, Kröger N, Sierra J, Socié G, Cornelissen J, Poiré X, Raida L, Bourhis J, Finke J, Passweg J, Salmenniemi U, Schouten H, Beguin Y, Martin S, Deconinck E, Ganser A, Zver S, Lioure B, Rohini R, Koster L, Hayden P, Iacobelli S, Robin M, Yakoub-Agha I
BONE MARROW TRANSPL. 2022;57(6):896-902.

Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey
Passweg J, Baldomero H, Chabannon C, Corbacioglu S, de la Cámara R, Dolstra H, Glass B, Greco R, Mohty M, Neven B, Peffault de Latour R, Perić Z, Snowden J, Yakoub-Agha I, Sureda A, Kröger N
BONE MARROW TRANSPL. 2022;57(5):742-752.

Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT
Penack O, Peczynski C, Mohty M, Yakoub-Agha I, de la Camara R, Glass B, Duarte R, Kröger N, Schoemans H, Koenecke C, Peric Z, Basak G
BONE MARROW TRANSPL. 2022;57(2):183-190.

Practice patterns in chronic graft-versus-host disease patient management and patient reported outcome measures across the EBMT allogeneic transplantation network
Perovic V, Sabol I, Grce M, Inngjerdingen M, Pulanic D, Peric Z, Peczynski C, Polge E, Koenecke C, Dickinson A, Greinix H, Basak G, Penack O, Scherwath A, Barata A, Olivieri A, Lawitschka A, Mensah-Glanowska P, Andrikovics H, Schoemans H, Wolff D
BONE MARROW TRANSPL. 2022;57(9):1458-1460.

Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis
Perram J, Ross D, McLornan D, Gowin K, Kröger N, Gupta V, Lewis C, Gagelmann N, Hamad N
AM J HEMATOL. 2022;97(11):1464-1477.

Patients With Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance
Piechotta V, Skoetz N, Engelhardt M, Einsele H, Goldschmidt H, Scheid C
DTSCH ARZTEBL INT. 2022;119(14):253-260.

Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT
Raj K, Eikema D, Sheth V, Koster L, de Wreede L, Blaise D, Di Grazia C, Koc Y, Potter V, Chevallier P, Lopez-Corral L, Wu D, Mielke S, Maertens J, Meijer E, Huynh A, Passweg J, Luft T, Pérez-Simón J, Ciceri F, Piekarska A, Hayri Ozsan G, Kröger N, Robin M, Yakoub-Agha I
BLOOD CANCER J. 2022;12(9):140.

Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis
Robin M, de Wreede L, Padron E, Bakunina K, Fenaux P, Koster L, Nazha A, Beelen D, Rampal R, Sockel K, Komrokji R, Gagelmann N, Eikema D, Radujkovic A, Finke J, Potter V, Killick S, Legrand F, Solary E, Broom A, Garcia-Manero G, Rizzoli V, Hayden P, Patnaik M, Onida F, Yakoub-Agha I, Itzykson R
BLOOD. 2022;140(12):1408-1418.

High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group
Schaffrath J, Brummer C, Wolff D, Holtick U, Kröger N, Bornhäuser M, Kraus S, Hilgendorf I, Blau I, Penack O, Wittke C, Steiner N, Nachbaur D, Thurner L, Hindahl H, Zeiser R, Maier C, Bethge W, Müller L
TRANSPL CELL THER. 2022;28(6):337.e1-337.e10.

Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party
Schetelig J, Chevallier P, van Gelder M, Hoek J, Hermine O, Chakraverty R, Browne P, Milpied N, Malagola M, Socié G, Delgado J, Deconinck E, Damaj G, Maury S, Beelen D, Quoc S, Shankara P, Brecht A, Mayer J, Hunault-Berger M, Bittenbring J, Thieblemont C, Lepretre S, Baldauf H, de Wreede L, Tournilhac O, Yakoub-Agha I, Kröger N, Dreger P
BONE MARROW TRANSPL. 2022;57(2):330.

Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study
Schetelig J, Hoek J, Stilgenbauer S, Middeke J, Andersen N, Fox C, Lenhoff S, Volin L, Shimoni A, Schroyens W, van Gelder M, Bunjes D, van Biezen A, Baldauf H, de Wreede L, Tournilhac O, Kröger N, Yakoub-Agha I, Dreger P
BONE MARROW TRANSPL. 2022;57(1):144.

A transcriptomic map of EGFR-induced epithelial-to-mesenchymal transition identifies prognostic and therapeutic targets for head and neck cancer
Schinke H, Shi E, Lin Z, Quadt T, Kranz G, Zhou J, Wang H, Hess J, Heuer S, Belka C, Zitzelsberger H, Schumacher U, Genduso S, Riecken K, Gao Y, Wu Z, Reichel C, Walz C, Canis M, Unger K, Baumeister P, Pan M, Gires O
MOL CANCER. 2022;21(1):.

Comparison of single copy gene‑based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19‑directed CAR T cells in treated patients
Schubert M, Berger C, Kunz A, Schmitt A, Badbaran A, Neuber B, Zeschke S, Wang L, Riecken K, Hückelhoven-Krauss A, Müller I, Müller-Tidow C, Dreger P, Kröger N, Ayuk F, Schmitt M, Fehse B
INT J ONCOL. 2022;60(5):.

Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022
Snowden J, Sánchez-Ortega I, Corbacioglu S, Basak G, Chabannon C, de la Camara R, Dolstra H, Duarte R, Glass B, Greco R, Lankester A, Mohty M, Neven B, de Latour R, Pedrazzoli P, Peric Z, Yakoub-Agha I, Sureda A, Kröger N
BONE MARROW TRANSPL. 2022;57(8):1217-1239.

Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT
Spyridonidis A, Labopin M, Brissot E, Moiseev I, Cornelissen J, Choi G, Ciceri F, Vydra J, Reményi P, Rovira M, Meijer E, Labussière-Wallet H, Blaise D, van Gorkom G, Kröger N, Koc Y, Giebel S, Bazarbachi A, Savani B, Nagler A, Mohty M
BONE MARROW TRANSPL. 2022;57(12):1774-1780.

Donor genetic determinant of thymopoiesis rs2204985 impacts clinical outcome after single HLA mismatched hematopoietic stem cell transplantation
Tsamadou C, Gowdavally S, Platzbecker U, Sala E, Valerius T, Wagner-Drouet E, Wulf G, Kröger N, Murawski N, Einsele H, Schaefer-Eckart K, Freitag S, Casper J, Kaufmann M, Dürholt M, Hertenstein B, Klein S, Ringhoffer M, Frank S, Neuchel C, Rode I, Schrezenmeier H, Mytilineos J, Fuerst D
BONE MARROW TRANSPL. 2022;57(10):1539-1547.

Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study
Waszczuk-Gajda A, Penack O, Sbianchi G, Koster L, Blaise D, Reményi P, Russell N, Ljungman P, Trneny M, Mayer J, Iacobelli S, Kobbe G, Scheid C, Apperley J, Touzeau C, Lenhoff S, Jantunen E, Anagnostopoulos A, Paris L, Browne P, Thieblemont C, Schaap N, Sierra J, Yakoub-Agha I, Garderet L, Styczynski J, Schoemans H, Moiseev I, Duarte R, Peric Z, Montoto S, van Biezen A, Mikulska M, Aljurf M, Ruutu T, Kröger N, Morris C, Koenecke C, Schoenland S, Basak G
J CLIN MED. 2022;11(12):.

Standardized supportive care documentation improves safety of high-dose methotrexate treatment
Alsdorf W, Karagiannis P, Langebrake C, Bokemeyer C, Frenzel C
ONCOLOGIST. 2021;26(2):e327-e332.

Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting
Ayuk F, Berger C, Badbaran A, Zabelina T, Sonntag T, Riecken K, Geffken M, Wichmann D, Frenzel C, Thayssen G, Zeschke S, Kröger N, Fehse B
BLOOD ADV. 2021;5(11):2523-2527.

Digital PCR to quantify ChAdOx1 nCoV-19 copies in blood and tissues
Badbaran A, Mailer R, Dahlke C, Woens J, Fathi A, Mellinghoff S, Renné T, Addo M, Riecken K, Fehse B
MOL THER-METH CLIN D. 2021;23:418-423.

Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT
Baron F, Ngoya M, Labopin M, Cornelissen J, Ganser A, Forcade E, Sengeloev H, Socié G, Blaise D, Bornhäuser M, Valerius T, Reinhardt H, Kröger N, Ruggeri A, Nagler A, Mohty M
BONE MARROW TRANSPL. 2021;56(11):2742-2748.

Neubewertung des Schutzes von In-vitro-Embryonen in Deutschland
Bartram C, Ellenberg J, Fehse B, Friedrich B, Kentenich H, Kumsta R, Niehrs C, Nöthen M, Schöne-Seifert B, Tanner K, Taupitz J, Thorn P, Vogel J, Wiesemann C, Winnacker E
2021.

Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT
Battipaglia G, Mauff K, Wendel L, Angelucci E, Mohty M, Arcese W, Santarone S, Rubio M, Kroger N, Fox M, Blaise D, Iori A, Fanin R, Chalandon Y, Pioltelli P, Marotta G, Chiusolo P, Sever M, Solano C, Contentin N, de Wreede L, Czerw T, Hernandez-Boluda J, Hayden P, McLornan D, Yakoub-Agha I
BONE MARROW TRANSPL. 2021;56(7):1593-1602.

Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia
Bazarbachi A, Labopin M, Blaise D, Forcade E, Socié G, Berceanu A, Angelucci E, Bulabois C, Kröger N, Rambaldi A, Ceballos P, Mielke S, El Cheikh J, Yakoub-Agha I, Savani B, Spyridonidis A, Nagler A, Mohty M
BONE MARROW TRANSPL. 2021;56(3):622-634.

Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia
Bazarbachi A, Labopin M, Kröger N, Brecht A, Blaise D, Clausen J, Fanin R, Einsele H, Cavanna L, Itäla-Remes M, Bulabois C, Kündgen L, Martin H, Schmid C, Wagner-Drouet E, Alakel N, Bazarbachi A, Savani B, Nagler A, Mohty M
CL LYMPH MYELOM LEUK. 2021;21(12):831-840.

AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms
Beitzen-Heineke A, Berenbrok N, Waizenegger J, Päsler S, Gensch V, Udonta F, Vargas-Delgado M, Engelmann J, Hoffmann F, Schafhausen P, von Amsberg G, Riecken K, Beumer N, Imbusch C, Lorens J, Fischer T, Pantel K, Bokemeyer C, Ben Batalla I, Loges S
HEMASPHERE. 2021;5(9):.

Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT)
Beksac M, Kröger N, Byrne J, Ganser A, Yeğin Z, Schönland S
BONE MARROW TRANSPL. 2021;56(3):529-531.

Patient Characteristics and Clinical Course of COVID-19 Patients Treated at a German Tertiary Center during the First and Second Waves in the Year 2020
Brehm T, Heyer A, Roedl K, Jarczak D, Nierhaus A, Nentwich M, van der Meirschen M, Schultze A, Christner M, Fiedler W, Kröger N, Huber T, Klose H, Sterneck M, Jordan S, Kreuels B, Schmiedel S, Addo M, Huber S, Lohse A, Kluge S, Schulze Zur Wiesch J
J CLIN MED. 2021;10(11):.

Comparison of clinical characteristics and disease outcome of COVID-19 and seasonal influenza
Brehm T, van der Meirschen M, Hennigs A, Roedl K, Jarczak D, Wichmann D, Frings D, Nierhaus A, Oqueka T, Fiedler W, Christopeit M, Kraef C, Schultze A, Lütgehetmann M, Addo M, Schmiedel S, Kluge S, Schulze Zur Wiesch J
SCI REP-UK. 2021;11(1):.

European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Bruno B, Wäsch R, Engelhardt M, Gay F, Giaccone L, D'Agostino M, Rodríguez-Lobato L, Danhof S, Gagelmann N, Kröger N, Popat R, Van de Donk N, Terpos E, Dimopoulos M, Sonneveld P, Einsele H, Boccadoro M
HAEMATOLOGICA. 2021;106(8):2054-2065.

Gene Therapy "Made in Germany": A Historical Perspective, Analysis of the Status Quo, and Recommendations for Action by the German Society for Gene Therapy
Büning H, Fehse B, Ivics Z, Kochanek S, Koehl U, Kupatt C, Mussolino C, Nettelbeck D, Schambach A, Uckert W, Wagner E, Cathomen T
HUM GENE THER. 2021;32(19-20):987-996.

In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets
Carlet M, Völse K, Vergalli J, Becker M, Herold T, Arner A, Senft D, Jurinovic V, Liu W, Gao Y, Dill V, Fehse B, Baldus C, Bastian L, Lenk L, Schewe D, Bagnoli J, Vick B, Schmid J, Wilhelm A, Marschalek R, Jost P, Miething C, Riecken K, Schmidt-Supprian M, Binder V, Jeremias I
NAT COMMUN. 2021;12(1):5655.

Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection
Christopeit M, Reichard M, Niederwieser C, Massoud R, Klyuchnikov E, Haase N, Wolschke C, Ayuk F, Heidenreich S, Kröger N
BONE MARROW TRANSPL. 2021;56(6):1478-1481.

Scabies crustosa in a recipient of an allogeneic stem cell transplantation
Christopeit M, Wichmann D
INFECTION. 2021;49(2):375-376.

Evaluation of the Robustness of Therapeutic Drug Monitoring Coupled with Bayesian Forecasting of Busulfan with Regard to Inaccurate Documentation
Dadkhah A, Alihodzic D, Broeker A, Kröger N, Langebrake C, Wicha S
PHARM RES-DORDR. 2021;38(10):1721-1729.

Immune Monitoring Assay for Extracorporeal Photopheresis Treatment Optimization After Heart Transplantation
Dieterlen M, Klaeske K, Bernhardt A, Borger M, Klein S, Garbade J, Lehmann S, Ayuk F, Reichenspurner H, Barten M
FRONT IMMUNOL. 2021;12:.

Arzneimitteltherapiesicherheit
Eisert A, Amkreutz J, Langebrake C
2021. Telemedizin. Marx G, Rossaint R, Marx N (Hrsg.). 1. Aufl. Berlin: Springer, 211-219.

Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program
El Fakih R, Greinix H, Koh M, Shaw B, Mohty M, Al Nahedh M, Saber W, Kharfan-Dabaja M, Perales M, Savani B, Majhail N, Passweg J, Sureda A, Ahmed S, Gluckman E, Riches M, El-Jawahri A, Rondelli D, Srivastava A, Faulkner L, Atsuta Y, Ballen K, Rasheed W, Okamoto S, Seber A, Chao N, Kröger N, Kodera Y, Szer J, Hashmi S, Horowitz M, Weisdorf D, Niederwieser D, Aljurf M
TRANSPL CELL THER. 2021;27(3):267.e1-267.e5.

Themenbereich somatische Gentherapie: aus dem Labor über klinische Studien zum kommerziellen Einsatz
Fehse B
2021. Fünfter Gentechnologiebericht. Fehse B, Hucho F, Bartfeld S, Clemens S, Erb T, Fangerau H, Hampel J, Korte M, Marx-Stölting L, Mundlos S, Osterheider A, Pichl A, Reich J, Schickl H, Schicktanz S, Taupitz J, Walter J, Winkler E, Zenke M (Hrsg.). 1. Aufl. Baden-Baden: Nomos Verlagsgesellschaft, 156-183.

Anwendung des Genome Editing in der somatischen Gentherapie: Eine Einführung
Fehse B, Abramowski-Mock U
2021. Anwendung des Genome Editing in der somatischen Gentherapie. 1. Aufl. Wiesbaden: Springer, .

Einleitung: Gentechnologien in Deutschland im Fokus der IAG Gentechnologiebericht
Fehse B, Marx-Stölting , Schickl H, Khachatryan A
2021. Fünfter Gentechnologiebericht. Fehse B, Hucho F, Bartfeld S, Clemens S, Erb T, Fangerau H, Hampel J, Korte M, Marx-Stölting L, Mundlos S, Osterheider A, Pichl A, Reich J, Schickl H, Schicktanz S, Taupitz J, Walter J, Winkler E, Zenke M (Hrsg.). 1. Aufl. Baden-Baden: Nomos Verlagsgesellschaft, 81-86.

Genome-Editing und Einzelzellanalyse: Neue Methoden und ihre Implikationen für Forschung, Anwendung und Gesellschaft
Fehse B, Walter J, Reich J, Marx-Stölting , Pichl A, Schickl H
2021. Fünfter Gentechnologiebericht. Fehse B, Hucho F, Bartfeld S, Clemens S, Erb T, Fangerau H, Hampel J, Korte M, Marx-Stölting L, Mundlos S, Osterheider A, Pichl A, Reich J, Schickl H, Schicktanz S, Taupitz J, Walter J, Winkler E, Zenke M (Hrsg.). 1. Aufl. Baden-Baden: Nomos Verlagsgesellschaft, 219-250.

A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation
Gagelmann N, Badbaran A, Beelen D, Salit R, Stölzel F, Rautenberg C, Becker H, Radujkovic A, Panagiota V, Bogdanov R, Christopeit M, Park Y, Nibourel O, Luft T, Koldehoff M, Corsten M, Heuser M, Finke J, Kobbe G, Platzbecker U, Robin M, Scott B, Kröger N
BLOOD ADV. 2021;5(6):1760-1769.

Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia
Gagelmann N, Bogdanov R, Stölzel F, Rautenberg C, Panagiota V, Becker H, Radujkovic A, Luft T, Christopeit M, Finke J, Platzbecker U, Ditschkowski M, Schroeder T, Koldehoff M, Heuser M, Kobbe G, Beelen D, Germing U, Kröger N
BIOL BLOOD MARROW TR. 2021;27(1):95.e1-95.e4.

Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT
Gagelmann N, Eikema D, de Wreede L, Rambaldi A, Iacobelli S, Koster L, Caillot D, Blaise D, Remémyi P, Bulabois C, Passweg J, Leleu X, Zver S, Kobbe G, Ljungman P, Chevallier P, Ringhoffer M, Martin M, Salmenniemi U, Poiré X, Lenhoff S, Pioltelli P, Mordini N, Delforge M, Garderet L, Schönland S, Yakoub-Agha I, Kröger N
BONE MARROW TRANSPL. 2021;56(1):210-217.

Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend "when and for whom" in 2021?
Gagelmann N, Kröger N
HAEMATOLOGICA. 2021;106(7):1794-1804.

The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review
Gagelmann N, Kröger N
ANN HEMATOL. 2021;100(2):405-419.

TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
Gagelmann N, Wolschke C, Klyuchnikov E, Christopeit M, Ayuk F, Kröger N
FRONT IMMUNOL. 2021;12:.

Erratum zu: Toxizitäten nach Chimärer-Antigenrezeptor-T-Zell-Therapie
Garcia Borrega J, Heindel K, Göreci Y, Warnke C, Onur O, Kochanek M, Schub N, Ayuk F, Wichmann D, Böll B
INTERNIST. 2021;62(6):694.

Toxizitäten nach Chimärer-Antigenrezeptor-T-Zell-Therapie : Übersicht und Management früher und verzögerter Nebenwirkungen
Garcia Borrega J, Heindel K, Göreci Y, Warnke C, Onur O, Kochanek M, Schub N, Ayuk F, Wichmann D, Böll B
INTERNIST. 2021;62(6):611-619.

CRISPR-to-Kill (C2K)–Employing the Bacterial Immune System to Kill Cancer Cells
Glow D, Maire C, Schwarze L, Lamszus K, Fehse B
CANCERS. 2021;13(24):.

LATE-a novel sensitive cell-based assay for the study of CRISPR/Cas9-related long-term adverse treatment effects
Głów D, Meyer S, García Roldán I, Akingunsade L, Riecken K, Fehse B
MOL THER-METH CLIN D. 2021;22:249-262.

Conditioning intensity before allogeneic haematopoietic stem cell transplantation: a quality control audit
Gratwohl A, Passweg J, Baldomero H, Orchard K, Kröger N, Snowden J
BRIT J HAEMATOL. 2021;192(6):e151-e154.

Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study
Greenfield D, Salooja N, Peczynski C, van der Werf S, Schoemans H, Hill K, Cortelezzi A, Lupo-Stangellini M, Özkurt Z, Arat M, Metzner B, Turlure P, Rovo A, Socié G, Mohty M, Nagler A, Kröger N, Dreger P, Labopin M, Han T, Tichelli A, Duarte R, Basak G, Snowden J
BONE MARROW TRANSPL. 2021;56(11):2820-2825.

Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia
Greinacher A, Selleng K, Palankar R, Wesche J, Handtke S, Wolff M, Aurich K, Lalk M, Methling K, Volker U, Hentschker C, Michalik S, Steil L, Reder A, Schönborn L, Beer M, Franzke K, Büttner A, Fehse B, Stavrou E, Rangaswamy C, Mailer R, Englert H, Frye M, Thiele T, Kochanek S, Krutzke L, Siegerist F, Endlich N, Warkentin T, Renné T
BLOOD. 2021;138(22):2256-2268.

Multiple genes surrounding Bcl-xL, a common retroviral insertion site, can influence hematopoiesis individually or in concert
Ha T, Stahlhut M, Rothe M, Paul G, Dziadek V, Morgan M, Brugman M, Fehse B, Kustikova O, Schambach A, Baum C
HUM GENE THER. 2021;32(9-10):458-472.

aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis
Häußler V, Ufer F, Pöttgen J, Wolschke C, Friese M, Kröger N, Heesen C, Stellmann J
ANN CLIN TRANSL NEUR. 2021;8(6):1269-1278.

Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party
Hayden P, Eikema D, de Wreede L, Koster L, Kröger N, Einsele H, Minnema M, Dominietto A, Potter M, Passweg J, Bermúdez A, Nguyen-Quoc S, Platzbecker U, Tischer J, Ciceri F, Veelken J, Ljungman P, Schaap N, Forcade E, Carella A, Gandemer V, Arcese W, Bloor A, Olivieri A, Vincent L, Beksac M, Schönland S, Yakoub-Agha I
BONE MARROW TRANSPL. 2021;56(10):2367-2381.

Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMT
Heinicke T, Labopin M, Polge E, Stelljes M, Ganser A, Tischer J, Brecht A, Kröger N, Beelen D, Scheid C, Bethge W, Dreger P, Bunjes D, Wagner E, Platzbecker U, Savani B, Nagler A, Mohty M
LEUKEMIA LYMPHOMA. 2021;62(2):399-409.

Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation
Hernández-Boluda J, Pereira A, Kröger N, Beelen D, Robin M, Bornhäuser M, Angelucci E, Vitek A, Blau I, Niittyvuopio R, Finke J, Cornelissen J, Passweg J, Dreger P, Petersen E, Kanz L, Sanz J, Zuckerman T, Zinger N, Iacobelli S, Hayden P, Czerw T, McLornan D, Yakoub-Agha I
LEUKEMIA. 2021;35(1):215-224.

Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
Hernández-Boluda J, Pereira A, Kröger N, Cornelissen J, Beelen D, de Witte M, Wilson K, Platzbecker U, Sengeloev H, Blaise D, Einsele H, Sockel K, Krüger W, Lenhoff S, Salaroli A, Martin H, García-Gutiérrez V, Pavone V, Alvarez-Larrán A, Raya J, Zinger N, Gras L, Hayden P, Czerw T, P McLornan D, Yakoub-Agha I
AM J HEMATOL. 2021;96(10):1186-1194.

Hepatitis E virus persists in the ejaculate of chronically infected men
Horvatits T, Wißmann J, Johne R, Groschup M, Gadicherla A, Wiesch J, Eiden M, Todt D, Reimer R, Dähnert L, Schöbel A, Horvatits K, Lübke R, Wolschke C, Ayuk F, Rybczynski M, Lohse A, Addo M, Herker E, Lütgehetmann M, Steinmann E, Pischke S
J HEPATOL. 2021;75(1):55-63.

Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone
Karagiannis P, Alsdorf W, Tallarek A, Blohm M, Oelrich J, Waizenegger J, Wolschke C, Hecher K, Singer D, Bokemeyer C, Fiedler W
BRIT J HAEMATOL. 2021;192(2):e60-e63.

Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression
Kemper M, Schiecke A, Maar H, Nikulin S, Poloznikov A, Galatenko V, Tachezy M, Gebauer F, Lange T, Riecken K, Tonevitsky A, Aigner A, Izbicki J, Schumacher U, Wicklein D
J EXP CLIN CANC RES. 2021;40(1):214.

Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia
Kharfan-Dabaja M, Labopin M, Brissot E, Kroger N, Finke J, Ciceri F, Deconinck E, Blaise D, Chevallier P, Gramatzki M, Ganser A, Stelljes M, Edinger M, Savani B, Ruggeri A, Sanz J, Nagler A, Mohty M
BRIT J HAEMATOL. 2021;193(3):592-601.

Enhanced Immune Reconstitution of γδ T Cells after Allogeneic Stem Cell Transplantation Overcomes the Negative Impact of Pretransplantation Minimal Residual Disease-Positive Status in Patients with Acute Myelogenous Leukemia
Klyuchnikov E, Badbaran A, Massoud R, Fritsche-Friedland U, Janson D, Ayuk F, Wolschke C, Bacher U, Kröger N
TRANSPL CELL THER. 2021;27(10):841-850.

Role of pre-transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML
Klyuchnikov E, Christopeit M, Badbaran A, Bacher U, Fritsche-Friedland U, von Pein U, Wolschke C, Kröger N
EUR J HAEMATOL. 2021;106(5):606-615.

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT
Kröger N, Sbianchi G, Sirait T, Wolschke C, Beelen D, Passweg J, Robin M, Vrhovac R, Helbig G, Sockel K, Conneally E, Rubio M, Beguin Y, Finke J, Bernasconi P, Morozova E, Clausen J, von dem Borne P, Schaap N, Schroyens W, Patriarca F, Di Renzo N, Yeğin Z, Hayden P, McLornan D, Yakoub-Agha I
LEUKEMIA. 2021;35(12):3551-3560.

Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)
Kröger N, Sockel K, Wolschke C, Bethge W, Schlenk R, Wolf D, Stadler M, Kobbe G, Wulf G, Bug G, Schäfer-Eckart K, Scheid C, Nolte F, Krönke J, Stelljes M, Beelen D, Heinzelmann M, Haase D, Buchner H, Bleckert G, Giagounidis A, Platzbecker U
J CLIN ONCOL. 2021;39(30):3318-3327.

Non-random relations in drug use expressed as patterns comprising prescription and over-the-counter drugs in multimorbid elderly patients in primary care: Data of the exploratory analysis of the multicentre, observational cohort study MultiCare
Krüger C, Schäfer I, Bussche van den H, Baehr M, Bickel H, Fuchs A, Gensichen J, Maier W, Riedel-Heller S, König H, Dahlhaus A, Schön G, Weyerer S, Wiese B, von Renteln-Kruse W, Langebrake C, Scherer M
EUR J GEN PRACT. 2021;27(1):119-129.

Comparison of FORTA, PRISCUS and EU(7)-PIM lists on identifying potentially inappropriate medication and its impact on cognitive function in multimorbid elderly German people in primary care: a multicentre observational study
Krüger C, Schäfer I, van den Bussche H, Bickel H, Dreischulte T, Fuchs A, König H, Maier W, Mergenthal K, Riedel-Heller S, Schön G, Weyerer S, Wiese B, von Renteln-Kruse W, Langebrake C, Scherer M
BMJ OPEN. 2021;11:e050344.

Anticholinergic drug burden according to the anticholinergic drug scale and the German anticholinergic burden and their impact on cognitive function in multimorbid elderly German people: a multicentre observational study
Krüger C, Schäfer I, van den Bussche H, Bickel H, Fuchs A, Gensichen J, König H, Maier W, Mergenthal K, Riedel-Heller S, Schön G, Weyerer S, Wiese B, von Renteln-Kruse W, Langebrake C, Scherer M
BMJ OPEN. 2021;11:.

Der moderne Weg zu mehr Arzneimitteltherapiesicherheit: Closed-Loop Medicaion Management (CLMM) im Krankenhaus
Langebrake C, Baehr M
KU Gesundheitsmanagement. 2021;90(6):56-58.

Infekt unter oraler Tumortherapie
Langebrake C, Christopeit M
2021. Medikationsmanagement im Krankenhaus. Gross I, Fischer A, Knoth H (Hrsg.). 1. Aufl. Stuttgart: 247-250.

IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study
Lawless S, Sbianchi G, Morris C, Iacobelli S, Bosman P, Blaise D, Reményi P, Byrne J, Mayer J, Apperley J, Lund J, Kobbe G, Schaap N, Isaksson C, Lenhoff S, Basak G, Touzeau C, Wilson K, González Muñiz S, Scheid C, Browne P, Anagnostopoulos A, Rambaldi A, Jantunen E, Kröger N, Schönland S, Yakoub-Agha I, Garderet L
CL LYMPH MYELOM LEUK. 2021;21(10):686-693.

Osteoblast-specific inactivation of p53 results in locally increased bone formation
Liao N, Koehne T, Tuckermann J, Triviai I, Amling M, David J, Schinke T, Luther J
PLOS ONE. 2021;16(11):e0249894.

COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey
Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Zahrani M, Apperley J, Berceanu A, Bofarull R, Calbacho M, Ciceri F, Lopez-Corral L, Crippa C, Fox M, Grassi A, Jimenez M, Demir S, Kwon M, Llamas C, Lorenzo J, Mielke S, Orchard K, Porras R, Vallisa D, Xhaard A, Knelange N, Cedillo A, Kröger N, Piñana J, Styczynski J
LEUKEMIA. 2021;35(10):2885-2894.

Correction: The challenge of COVID-19 and hematopoietic cell transplantation: EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy
Ljungman P, Mikulska M, de la Camara R, Basak G, Chabannon C, Corbacioglu S, Duarte R, Dolstra H, Lankester A, Mohty M, Montoto S, Murray J, de Latour R, Snowden J, Yakoub-Agha I, Verhoeven B, Kröger N, Styczynski J
BONE MARROW TRANSPL. 2021;56(3):755.

Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia
Lorentino F, Labopin M, Ciceri F, Vago L, Fleischhauer K, Afanasyev B, Kröger N, Cornelissen J, Lovira M, Meijer E, Vitek A, Elmaagacli A, Blaise D, Ruggeri A, Chabannon C, Nagler A, Mohty M
LEUKEMIA. 2021;35(2):585-594.

Anti-Thymocyte Globulin Treatment Augments 1,25-Dihydroxyvitamin D3 Serum Levels in Patients Undergoing Hematopoietic Stem Cell Transplantation
Matos C, Peter K, Weich L, Peuker A, Schoenhammer G, Roider T, Ghimire S, Babl N, Decking S, Güllstorf M, Kröger N, Hammon K, Herr W, Stark K, Heid I, Renner K, Holler E, Kreutz M
FRONT IMMUNOL. 2021;12:.

Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis
McLornan D, Eikema D, Czerw T, Kröger N, Koster L, Reinhardt H, Angelucci E, Robin M, Bornhäuser M, Passweg J, Clark A, Vydra J, Blau I, Niittyvuopio R, Platzbecker U, Cornelissen J, Chevallier P, Srour M, Stamatovic D, Martinez-Lopez J, de Wreede L, Hayden P, Hernández-Boluda J, Yakoub-Agha I
BONE MARROW TRANSPL. 2021;56(9):2160-2172.

Efficient Pseudotyping of Different Retroviral Vectors Using a Novel, Codon-Optimized Gene for Chimeric GALV Envelope
Mirow M, Schwarze L, Fehse B, Riecken K
VIRUSES-BASEL. 2021;13(8):.

Correction: Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
Modemann F, Ayuk F, Wolschke C, Christopeit M, Janson D, von Pein U, Kröger N
BONE MARROW TRANSPL. 2021;56(10):2617.

Hematopoietic Stem Cell Transplantation for Hepatitis-associated Aplastic Anemia Following Liver Transplantation for Nonviral Hepatitis: A Retrospective Analysis and a Review of the Literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (SAAWP-EBMT)
Mohseny A, Eikema D, Neven B, Kröger N, Shaw P, Damaj G, Dalle J, Bosman P, Delehaye F, Lankester A, Smiers F, Peffault de Latour R
J PEDIAT HEMATOL ONC. 2021;43(7):e1025-e1029.

Retroviral gene therapy in Germany with a view on previous experience and future perspectives
Morgan M, Galla M, Grez M, Fehse B, Schambach A
GENE THER. 2021;28(9):494-512.

Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT
Nabergoj M, Mauff K, Robin M, Kröger N, Angelucci E, Poiré X, Passweg J, Radujkovic A, Platzbecker U, Robinson S, Rambaldi A, Petersen S, Stölzel F, Stelljes M, Ciceri F, Mayer J, Ladetto M, de Wreede L, Koster L, Hayden P, Czerw T, Hernández-Boluda J, McLornan D, Chalandon Y, Yakoub-Agha I
BONE MARROW TRANSPL. 2021;56(8):1944-1952.

Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia
Nagler A, Labopin M, Dholaria B, Angelucci E, Afanasyev B, Cornelissen J, Sica S, Meijer E, Ciceri F, Van Gorkom G, Kröger N, Martin H, Pioltelli P, Risitano A, Canaani J, Savani B, Sanz J, Mohty M
CLIN CANCER RES. 2021;27(3):843-851.

Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome
Niederwieser C, Kröger N
BEST PRACT RES CL HA. 2021;34(4):.

Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML
Niederwieser C, Morozova E, Zubarovskaya L, Zabelina T, Klyuchnikov E, Janson D, Wolschke C, Christopeit M, Ayuk F, Moiseev I, Afanasyev B, Kröger N
BONE MARROW TRANSPL. 2021;56(11):2834-2841.

Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q
Panagiota V, Meggendorfer M, Kubasch A, Gabdoulline R, Krönke J, Mies A, Shahswar R, Kandziora C, Klement P, Schiller J, Göhring G, Haferlach C, Ganster C, Shirneshan K, Gutermuth A, Thiede C, Germing U, Schroeder T, Kobbe G, Klesse S, Koenecke C, Schlegelberger B, Kröger N, Haase D, Döhner K, Sperr W, Valent P, Ganser A, Thol F, Haferlach T, Platzbecker U, Heuser M
AM J HEMATOL. 2021;96(6):E207-E210.

Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years
Passweg J, Baldomero H, Chabannon C, Basak G, de la Cámara R, Corbacioglu S, Dolstra H, Duarte R, Glass B, Greco R, Lankester A, Mohty M, Peffault de Latour R, Snowden J, Yakoub-Agha I, Kröger N
BONE MARROW TRANSPL. 2021;56(7):1651-1664.

Influence of pretransplant inflammatory bowel disease on the outcome of allogeneic hematopoietic stem cell transplantation: a matched-pair analysis study from the Transplant Complications Working Party (TCWP) of the EBMT
Peric Z, Peczynski C, Polge E, Kröger N, Sengeloev H, Radujkovic A, Helbig G, Russell N, Bunjes D, Socié G, Potter V, Beelen D, Crawley C, Bloor A, Finke J, Schoemans H, Penack O, Snowden J, Koenecke C, Basak G
BONE MARROW TRANSPL. 2021;56(12):3084-3087.

1,25-dihydroxyvitamin-D3 but not the clinically applied marker 25-hydroxyvitamin-D3 predicts survival after stem cell transplantation
Peter K, Siska P, Roider T, Matos C, Bruns H, Renner K, Singer K, Weber D, Güllstorf M, Kröger N, Wolff D, Herr W, Ayuk F, Holler E, Stark K, Heid I, Kreutz M
BONE MARROW TRANSPL. 2021;56(2):419-433.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report
Pidala J, Kitko C, Lee S, Carpenter P, Cuvelier G, Holtan S, Flowers M, Cutler C, Jagasia M, Gooley T, Palmer J, Randolph T, Levine J, Ayuk F, Dignan F, Schoemans H, Tkaczyk E, Farhadfar N, Lawitschka A, Schultz K, Martin P, Sarantopoulos S, Inamoto Y, Socie G, Wolff D, Blazar B, Greinix H, Paczesny S, Pavletic S, Hill G
TRANSPL CELL THER. 2021;27(8):632-641.

The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT)
Poiani M, Labopin M, Battipaglia G, Beelen D, Tischer J, Finke J, Brecht A, Forcade E, Ganser A, Passweg J, Labussiere-Wallet H, Yakoub-Agha I, Schäfer-Eckart K, Kroeger N, Guffroy B, Ruggeri A, Esteve J, Nagler A, Mohty M
AM J HEMATOL. 2021;96(1):40-50.

Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)
Polverelli N, Mauff K, Kröger N, Robin M, Beelen D, Beauvais D, Chevallier P, Mohty M, Passweg J, Rubio M, Maertens J, Finke J, Bornhäuser M, Vrhovac R, Helbig G, Mear J, Castagna L, Reményi P, Angelucci E, Karakasis D, Rifòn J, Sirait T, Russo D, de Wreede L, Czerw T, Hernández-Boluda J, Hayden P, McLornan D, Yakoub-Agha I
AM J HEMATOL. 2021;96(1):69-79.

CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma
Rejeski K, Perez Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Buecklein V, Blumenberg V, Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Locke F, von Bergwelt-Baildon M, Mackensen A, Bethge W, Ayuk F, Bachy E, Salles G, Jain M, Subklewe M
BLOOD. 2021;138(24):2499-2513.

How to package and SEND mRNA: a novel "humanized" vector system based on endogenous retroviruses
Riecken K, Glow D, Fehse B
SIGNAL TRANSDUCT TAR. 2021;6(1):.

Viral Dynamics of SARS-CoV-2 in Critically Ill Allogeneic Hematopoietic Stem Cell Transplant Recipients and Immunocompetent Patients with COVID-19
Roedl K, Heidenreich S, Pfefferle S, Jarczak D, Urbanowicz T, Nörz D, Aepfelbacher M, Kröger N, Kluge S, Lütgehetmann M, Christopeit M, Wichmann D
AM J RESP CRIT CARE. 2021;203(2):242-245.

Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations
Rosiñol L, Beksac M, Zamagni E, Van de Donk N, Anderson K, Badros A, Caers J, Cavo M, Dimopoulos M, Dispenzieri A, Einsele H, Engelhardt M, Fernández de Larrea C, Gahrton G, Gay F, Hájek R, Hungria V, Jurczyszyn A, Kröger N, Kyle R, Leal da Costa F, Leleu X, Lentzsch S, Mateos M, Merlini G, Mohty M, Moreau P, Rasche L, Reece D, Sezer O, Sonneveld P, Usmani S, Vanderkerken K, Vesole D, Waage A, Zweegman S, Richardson P, Bladé J
BRIT J HAEMATOL. 2021;194(3):496-507.

Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation
Sahebi F, Eikema D, Koster L, Kroger N, Meijer E, van Doesum J, Rovira M, Koc Y, Angelucci E, Blaise D, Sammassimo S, McDonald A, Arroyo C, Sanchez J, Forcade E, Castagna L, Stölzel F, Sanz J, Tischer J, Ciceri F, Valcarcel D, Proia A, Hayden P, Beksac M, Yakoub-Agha I, Schönland S
TRANSPL CELL THER. 2021;27(12):999.e1-999.e10.

Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT
Sanz J, Galimard J, Labopin M, Afanasyev B, Sergeevich M, Angelucci E, Kröger N, Koc Y, Ciceri F, Diez-Martin J, Arat M, Sica S, Rovira M, Aljurf M, Tischer J, Savani B, Ruggeri A, Nagler A, Mohty M
J HEMATOL ONCOL. 2021;14(1):84.

Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT)
Saraceni F, Labopin M, Forcade E, Kröger N, Socié G, Niittyvuopio R, Cornelissen J, Labussière-Wallet H, Blaise D, Choi G, Byrne J, Guillerm G, Marchand T, Esteve J, Bazarbachi A, Savani B, Olivieri A, Nagler A, Mohty M
CANCER MED-US. 2021;10(1):23-33.

Two cases of T cell lymphoma following Piggybac-mediated CAR T cell therapy
Schambach A, Morgan M, Fehse B
MOL THER. 2021;29(9):2631-2633.

Corrigendum: Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
Schetelig J, Baldauf H, Koster L, Kuxhausen M, Heidenreich F, de Wreede L, Spellman S, van Gelder M, Bruno B, Onida F, Lange V, Massalski C, Potter V, Ljungman P, Schaap N, Hayden P, Lee S, Kröger N, Hsu K, Schmidt A, Yakoub-Agha I, Robin M
FRONT IMMUNOL. 2021;12:813838.

Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party
Schetelig J, Chevallier P, van Gelder M, Hoek J, Hermine O, Chakraverty R, Browne P, Milpied N, Malagola M, Socié G, Delgado J, Deconinck E, Damaj G, Maury S, Beelen D, Quoc S, Shankara P, Brecht A, Mayer J, Hunault-Berger M, Bittenbring J, Thieblemont C, Lepretre S, Baldauf H, de Wreede L, Tournilhac O, Yakoub-Agha I, Kröger N, Dreger P
BONE MARROW TRANSPL. 2021;56(3):605-613.

Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study
Schetelig J, Hoek J, Stilgenbauer S, Middeke J, Andersen N, Fox C, Lenhoff S, Volin L, Shimoni A, Schroyens W, van Gelder M, Bunjes D, van Biezen A, Baldauf H, de Wreede L, Tournilhac O, Kröger N, Yakoub-Agha I, Dreger P
BONE MARROW TRANSPL. 2021;56(3):692-695.

mRNA Transfection of T-Lymphocytes by Electroporation
Schwarze L, Fehse B
Methods Mol Biol. 2021;2285:217-226.

Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application
Schwarze L, Głów D, Sonntag T, Uhde A, Fehse B
GENE THER. 2021;28(9):588-601.

Automated production of CCR5-negative CD4+-T cells in a GMP-compatible, clinical scale for treatment of HIV-positive patients
Schwarze L, Sonntag T, Wild S, Schmitz S, Uhde A, Fehse B
GENE THER. 2021;28(9):572-587.

Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey
Sellner L, Schetelig J, Koster L, Choi G, Blaise D, Beelen D, Schianca F, Passweg J, Schanz U, Gyan E, Sora F, Kröger N, Wulf G, Van Gorkom G, Mayer J, Orvain C, Bourhis J, Jindra P, Potter V, Zallio F, Vandenberghe E, Robinson S, Hayden P, Yakoub-Agha I, Montoto S, Dreger P
BONE MARROW TRANSPL. 2021;56(12):.

Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT
Shimoni A, Robin M, Iacobelli S, Beelen D, Mufti G, Ciceri F, Bethge W, Volin L, Blaise D, Ganser A, Luft T, Chevallier P, Schwerdtfeger R, Koster L, de Witte T, Kröger N, Nagler A, Yakoub-Agha I
BRIT J HAEMATOL. 2021;195(3):417-428.

Visions for a JACIE Quality Management System 4.0
Snowden J, McGrath E, Orchard K, Kröger N, Sureda A, Gratwohl A
BONE MARROW TRANSPL. 2021;56(12):2876-2881.

Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Spanjaart A, Ljungman P, de La Camara R, Tridello G, Ortiz-Maldonado V, Urbano-Ispizua A, Barba P, Kwon M, Caballero D, Sesques P, Bachy E, Di Blasi R, Thieblemont C, Calkoen F, Mutsaers P, Maertens J, Giannoni L, Nicholson E, Collin M, Vaz C, Metafuni E, Martinez-Lopez J, Dignan F, Ribera J, Nagler A, Folber F, Sanderson R, Bloor A, Ciceri F, Knelange N, Ayuk F, Kroger N, Kersten M, Mielke S
LEUKEMIA. 2021;35(12):3585-3588.

Vertically transferred maternal immune cells promote neonatal immunity against early life infections
Stelzer I, Urbschat C, Schepanski S, Thiele K, Triviai I, Wieczorek A, Alawi M, Ohnezeit D, Kottlau J, Huang J, Fischer N, Mittrücker H, Solano M, Fehse B, Diemert A, Stahl F, Arck P
NAT COMMUN. 2021;12(1):4706.

HLA-DRB3/4/5 Matching Improves Outcome of Unrelated Hematopoietic Stem Cell Transplantation
Tsamadou C, Engelhardt D, Platzbecker U, Sala E, Valerius T, Wagner-Drouet E, Wulf G, Kröger N, Murawski N, Einsele H, Schaefer-Eckart K, Freitag S, Casper J, Kaufmann M, Dürholt M, Hertenstein B, Klein S, Ringhoffer M, Frank S, Neuchel C, Schrezenmeier H, Mytilineos J, Fuerst D
FRONT IMMUNOL. 2021;12:.

SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2
von Wenserski L, Schultheiß C, Bolz S, Schliffke S, Simnica D, Willscher E, Gerull H, Wolters-Eisfeld G, Riecken K, Fehse B, Altfeld M, Nollau P, Binder M
LEUKEMIA. 2021;35(4):1073-1086.

Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell Transplantation
Wagner-Drouet E, Teschner D, Wolschke C, Schäfer-Eckart K, Gärtner J, Mielke S, Schreder M, Kobbe G, Hilgendorf I, Klein S, Verbeek M, Ditschkowski M, Koch M, Lindemann M, Schmidt T, Rascle A, Barabas S, Deml L, Wagner R, Wolff D
DIAGNOSTICS. 2021;11(2):.

Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT
Waidhauser J, Labopin M, Esteve J, Kröger N, Cornelissen J, Gedde-Dahl T, Van Gorkom G, Finke J, Rovira M, Schaap N, Petersen E, Beelen D, Bunjes D, Savani B, Schmid C, Nagler A, Mohty M
BONE MARROW TRANSPL. 2021;56(10):2445-2453.

Steroid-refractory chronic graft-versus-host disease: treatment options and patient management
Wolff D, Fatobene G, Rocha V, Kröger N, Flowers M
BONE MARROW TRANSPL. 2021;56(9):2079-2087.

Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19
Woo M, Haag F, Nierhaus A, Jarczak D, Roedl K, Mayer C, Brehm T, van der Meirschen M, Hennigs A, Christopeit M, Fiedler W, Karagiannis P, Burdelski C, Schultze A, Huber S, Addo M, Schmiedel S, Friese M, Kluge S, Schulze Zur Wiesch J
ISCIENCE. 2021;24(7):102752.

Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease
Zewde M, Morales G, Gandhi I, Özbek U, Aguayo-Hiraldo P, Ayuk F, Baez J, Chanswangphuwana C, Choe H, DeFilipp Z, Etra A, Grupp S, Hexner E, Hogan W, Javorniczky N, Kasikis S, Kitko C, Kowalyk S, Meedt E, Merli P, Nakamura R, Qayed M, Reshef R, Rösler W, Schechter T, Weber D, Wölfl M, Yanik G, Young R, Levine J, Ferrara J, Chen Y
TRANSPL CELL THER. 2021;27(12):988.e1-988.e7.

Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee
Algwaiz G, Aljurf M, Koh M, Horowitz M, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, Wood W, Brazauskas R, Lehmann L, Pasquini M, Seber A, Lu P, Atsuta Y, Riches M, Perales M, Worel N, Okamoto S, Srivastava A, Chemaly R, Cordonnier C, Dandoy C, Wingard J, Kharfan-Dabaja M, Hamadani M, Majhail N, Waghmare A, Chao N, Kröger N, Shaw B, Mohty M, Niederwieser D, Greinix H, Hashmi S
BIOL BLOOD MARROW TR. 2020;26(12):2181-2189.

Incidence and Outcome of Late Relapse after Allogeneic Stem Cell Transplantation for Myelofibrosis
Atagunduz I, Christopeit M, Ayuk F, Zeck G, Wolschke C, Kröger N
BIOL BLOOD MARROW TR. 2020;26(12):2279-2284.

Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis
Atagunduz I, Klyuchnikov E, Wolschke C, Janson D, Heidenreich S, Christopeit M, Ayuk F, Kröger N
CANCERS. 2020;12(11):.

In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab
Atanackovic D, Yousef S, Shorter C, Tantravahi S, Steinbach M, Iglesias F, Sborov D, Radhakrishnan S, Chiron M, Miles R, Salama M, Kröger N, Luetkens T
LEUKEMIA. 2020;34(1):317-321.

Excellent proliferation and persistence of allogeneic donor-derived 41-BB based CAR-T cells despite immunosuppression with cyclosporine A
Ayuk F, Fehse B, Janson D, Berger C, Riecken K, Kröger N
HAEMATOLOGICA. 2020;105(6):322-324.

Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant
Aziz M, Shah J, Kapoor U, Dimopoulos C, Anand S, Augustine A, Ayuk F, Chaudhry M, Chen Y, Choe H, Etra A, Gergoudis S, Hartwell M, Hexner E, Hogan W, Kitko C, Kowalyk S, Kröger N, Merli P, Morales G, Nakamura R, Ordemann R, Pulsipher M, Qayed M, Reshef R, Rösler W, Schechter T, Schreiner E, Srinagesh H, Wölfl M, Wudhikarn K, Yanik G, Young R, Özbek U, Ferrara J, Levine J
LEUKEMIA. 2020;34(7):1898-1906.

Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR
Badbaran A, Berger C, Riecken K, Kruchen A, Geffken M, Müller I, Kröger N, Ayuk F, Fehse B
CANCERS. 2020;12(7):.

Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin
Baron F, Galimard J, Labopin M, Yakoub-Agha I, Niittyvuopio R, Kroger N, Griskevicius L, Wu D, Forcade E, Richard C, Aljurf M, Helbig G, Labussière-Wallet H, Mohty M, Nagler A
HAEMATOLOGICA. 2020;105(4):1138-1146.

Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT
Baron F, Labopin M, Savani B, Beohou E, Niederwieser D, Eder M, Potter V, Kröger N, Beelen D, Socié G, Itälä-Remes M, Bornhäuser M, Mohty M, Nagler A
BRIT J HAEMATOL. 2020;188(3):428-437.

Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party
Bazarbachi A, Al Hamed R, Labopin M, Afanasyev B, Hamladji R, Beelen D, Eder M, Scheid C, Wu D, Bunjes D, Stepensky P, Tischer J, Kröger N, Peric Z, Aljurf M, Giebel S, Nagler A, Mohty M
BONE MARROW TRANSPL. 2020;55(3):595-602.

Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel
Bonifazi F, Rubio M, Bacigalupo A, Boelens J, Finke J, Greinix H, Mohty M, Nagler A, Passweg J, Rambaldi A, Socie G, Solano C, Walker I, Barosi G, Kröger N
BONE MARROW TRANSPL. 2020;55(6):1093-1102.

S3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge: Zusammenfassung starker Empfehlungen
Brunkhorst F, Weigand M, Pletz M, Gastmeier P, Lemmen S, Meier-Hellmann A, Ragaller M, Weyland A, Marx G, Bucher M, Gerlach H, Salzberger B, Grabein B, Welte T, Werdan K, Kluge S, Bone H, Putensen C, Rossaint R, Quintel M, Spies C, Weiß B, John S, Oppert M, Jörres A, Brenner T, Elke G, Gründling M, Mayer K, Weimann A, Felbinger T, Axer H, Heller T, Gagelmann N
MED KLIN-INTENSIVMED. 2020;115(3):178-188.

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)
Burchert A, Bug G, Fritz L, Finke J, Stelljes M, Röllig C, Wollmer E, Wäsch R, Bornhäuser M, Berg T, Lang F, Ehninger G, Serve H, Zeiser R, Wagner E, Kröger N, Wolschke C, Schleuning M, Götze K, Schmid C, Crysandt M, Eßeling E, Wolf D, Wang Y, Böhm A, Thiede C, Haferlach T, Michel C, Bethge W, Wündisch T, Brandts C, Harnisch S, Wittenberg M, Hoeffkes H, Rospleszcz S, Burchardt A, Neubauer A, Brugger M, Strauch K, Schade-Brittinger C, Metzelder S
J CLIN ONCOL. 2020;38(26):2993-3002.

Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
Carré M, Porcher R, Finke J, Ehninger G, Koster L, Beelen D, Ganser A, Volin L, Lozano S, Friis L, Michallet M, Tischer J, Olavarria E, Cascon M, Iacobelli S, Koc Y, Jindra P, Arat M, de Witte T, Yakoub Agha I, Kröger N, Robin M
BIOL BLOOD MARROW TR. 2020;26(3):451-457.

Clonal Evolution after Allogeneic Hematopoietic Stem Cell Transplantation
Christopeit M, Badbaran A, Alawi M, Flach J, Fehse B, Kröger N
BIOL BLOOD MARROW TR. 2020;26(7):e167-e170.

The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study
Cowan A, Baldomero H, Atsuta Y, Mikhael J, Aljurf M, Seber A, Greinix H, Koh M, Worel N, Libby E, Pasquini M, Galeano S, Saber W, Iida M, Jaimovich G, Rolon J, Kodera Y, Benakli M, Nosa B, Elhaddad A, Szer J, Passweg J, Kroeger N, Weisdorf D, Niederwieser D
BIOL BLOOD MARROW TR. 2020;26(12):2372-2377.

Intravitreal Co-Administration of GDNF and CNTF Confers Synergistic and Long-Lasting Protection against Injury-Induced Cell Death of Retinal Ganglion Cells in Mice
Dulz S, Bassal M, Flachsbarth K, Riecken K, Fehse B, Schlichting S, Bartsch S, Bartsch U
CELLS-BASEL. 2020;9(9):.

Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1
Eberhard J, Angin M, Passaes C, Salgado M, Monceaux V, Knops E, Kobbe G, Jensen B, Christopeit M, Kröger N, Vandekerckhove L, Badiola J, Bandera A, Raj K, van Lunzen J, Hütter G, Kuball J, Martinez-Laperche C, Balsalobre P, Kwon M, Díez-Martín J, Nijhuis M, Wensing A, Martinez-Picado J, Schulze Zur Wiesch J, Sáez-Cirión A
SCI TRANSL MED. 2020;12(542):.

A High-Throughput HIV-1 Drug Screening Platform, Based on Lentiviral Vectors and Compatible with Biosafety Level-1
Ellinger B, Pohlmann D, Woens J, Jäkel F, Reinshagen J, Stocking C, Prassolov V, Fehse B, Riecken K
VIRUSES-BASEL. 2020;12(5):.

Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel
Fehse B, Badbaran A, Berger C, Sonntag T, Riecken K, Geffken M, Kröger N, Ayuk F
MOL THER-METH CLIN D. 2020;16:172-178.

Obituary Rolf Neth 1926-2020
Fehse B, Kröger N, Stocking C, Zander A
EXP HEMATOL. 2020;85:1-2.

Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
Fenk R, Giagounidis A, Goldschmidt H, Heinsch M, Rummel M, Kroger N, Boquoi A, Lopez D, Gerrlich C, Baier J, Liesenjohann S, Hauck K, Savickaite I, Mai E, Aul C, Strapatsas J, Dienst A, Kondakci M, Haas R, Kobbe G
CLIN CANCER RES. 2020;26(22):5879-5886.

Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer
Fischer S, Clements S, McWilliam A, Green A, Descamps T, Oing C, Gillessen S
Cancer treatment and research communications. 2020;25:100256.

Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMT
Frankiewicz A, Peczynski C, Giebel S, Harrington A, Socié G, Niederwieser D, Scheid C, Bornhäuser M, Kröger N, Elmaagacli A, Afanasyev B, Dreger P, Rössig C, Blaise D, Kratz C, Yakoub-Agha I, Kremens B, Niemeyer C, Wulf G, Blau I, Penack O, Greinix H, Basak G
FRONT IMMUNOL. 2020;11:1537.

B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma
Gagelmann N, Ayuk F, Atanackovic D, Kröger N
EUR J HAEMATOL. 2020;104(4):318-327.

Double Counting of Patients in Meta-analyses of Observational Studies-Reply
Gagelmann N, Kröger N
JAMA ONCOL. 2020;6(5):787-788.

Development of CAR-T cell therapies for multiple myeloma
Gagelmann N, Riecken K, Wolschke C, Berger C, Ayuk F, Fehse B, Kröger N
LEUKEMIA. 2020;34(9):2317-2332.

Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin
Gergoudis S, DeFilipp Z, Özbek U, Sandhu K, Etra A, Choe H, Kitko C, Ayuk F, Aziz M, Baez J, Ben-David K, Bunworasate U, Gandhi I, Hexner E, Hogan W, Holler E, Kasikis S, Kowalyk S, Lin J, Merli P, Morales G, Nakamura R, Reshef R, Rösler W, Srinagesh H, Young R, Chen Y, Ferrara J, Levine J
BLOOD ADV. 2020;4(24):6098-6105.

Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT group
Giardino S, de Latour R, Aljurf M, Eikema D, Bosman P, Bertrand Y, Tbakhi A, Holter W, Bornhäuser M, Rössig C, Burkhardt B, Zecca M, Afanasyev B, Michel G, Ganser A, Alseraihy A, Ayas M, Uckan-Cetinkaya D, Bruno B, Patrick K, Bader P, Itälä-Remes M, Rocha V, Jubert C, Diaz M, Shaw P, Junior L, Locatelli F, Kröger N, Faraci M, Pierri F, Lanino E, Miano M, Risitano A, Robin M, Dufour C
AM J HEMATOL. 2020;95(7):809-816.

Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN
Gleitz H, Dugourd A, Leimkühler N, Snoeren I, Fuchs S, Menzel S, Ziegler S, Kröger N, Triviai I, Büsche G, Kreipe H, Banjanin B, Pritchard J, Hoogenboezem R, Bindels E, Schumacher N, Rose-John S, Elf S, Saez-Rodriguez J, Kramann R, Schneider R
BLOOD. 2020;136(18):2051-2064.

Implementation analysis of patient reported outcomes (PROs) in oncological routine care: an observational study protocol
Görlach M, Schrage T, Bokemeyer C, Kröger N, Müller V, Petersen C, Betz C, Krüll A, Schulz H, Bleich C
HEALTH QUAL LIFE OUT. 2020;18(1):3.

Survival following allogeneic transplant in patients with myelofibrosis
Gowin K, Ballen K, Ahn K, Hu Z, Ali H, Arcasoy M, Devlin R, Coakley M, Gerds A, Green M, Gupta V, Hobbs G, Jain T, Kandarpa M, Komrokji R, Kuykendall A, Luber K, Masarova L, Michaelis L, Patches S, Pariser A, Rampal R, Stein B, Talpaz M, Verstovsek S, Wadleigh M, Agrawal V, Aljurf M, Angel Diaz M, Avalos B, Bacher U, Bashey A, Beitinjaneh A, Cerny J, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Gadalla S, Ganguly S, Grunwald M, Hashmi S, Kharfan-Dabaja M, Kindwall-Keller T, Kröger N, Lazarus H, Liesveld J, Litzow M, Marks D, Nathan S, Nishihori T, Olsson R, Pawarode A, Rowe J, Savani B, Savoie M, Seo S, Solh M, Tamari R, Verdonck L, Yared J, Alyea E, Popat U, Sobecks R, Scott B, Nakamura R, Mesa R, Saber W
BLOOD ADV. 2020;4(9):1965-1973.

Treosulfan conditioning for allogeneic transplantation in multiple myeloma - improved overall survival in first line haematopoietic stem cell transplantation - a large retrospective study by the Chronic Malignancies Working Party of the EBMT
Gran C, Wang J, Nahi H, Koster L, Gahrton G, Einsele H, Niittyvoupio R, Edinger M, Beelen D, Ciceri F, Bornhäuser M, Finke J, de Wreede L, Ljungman P, Mielke S, Tischer J, Garderet L, Schönland S, Yakoub-Agha I, Kröger N
BRIT J HAEMATOL. 2020;189(5):e213-e217.

Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)
Hambach J, Riecken K, Cichutek S, Schütze K, Albrecht B, Petry K, Röckendorf J, Baum N, Kröger N, Hansen T, Schuch G, Haag F, Adam G, Fehse B, Bannas P, Koch-Nolte F
CELLS-BASEL. 2020;9(2):.

Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP
Hayden P, Iacobelli S, Pérez-Simón J, van Biezen A, Minnema M, Niittyvuopio R, Schönland S, Meijer E, Blaise D, Milpied N, Márquez-Malaver F, Veelken J, Maertens J, Michallet M, Cammenga J, N'Guyen S, Niederwieser D, Hunault-Berger M, Bourhis J, Passweg J, Bermudez A, Chalandon Y, Yakoub-Agha I, Garderet L, Kröger N
EUR J HAEMATOL. 2020;104(3):181-189.

The initial engraftment of tumor cells is critical for the future growth pattern: a mathematical study based on simulations and animal experiments
Hoffmann B, Lange T, Labitzky V, Riecken K, Wree A, Schumacher U, Wedemann G
BMC CANCER. 2020;20(1):524.

Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects
Hossain J, Marchini A, Fehse B, Bjerkvig R, Miletic H
NEURO-ONCOL ADV. 2020;2(1):vdaa013.

Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects
Jansen L, Merz M, Engelhardt M, Weisel K, Scheid C, Straka C, Langer C, Salwender H, Einsele H, Kröger N, Beelen D, Dreger P, Goldschmidt H, Brenner H
LEUKEMIA LYMPHOMA. 2020;61(10):2365-2374.

IL22BP Mediates the Anti-Tumor Effects of Lymphotoxin Against Colorectal Tumors in Mice and Humans
Kempski J, Giannou A, Riecken K, Zhao L, Steglich B, Lücke J, Garcia-Perez L, Karstens K, Wöstemeier A, Nawrocki M, Pelczar P, Witkowski M, Nilsson S, Konczalla L, Shiri A, Kempska J, Wahib R, Brockmann L, Huber P, Gnirck A, Turner J, Zazara D, Arck P, Stein A, Simon R, Daubmann A, Meiners J, Perez D, Strowig T, Koni P, Kruglov A, Sauter G, Izbicki J, Guse A, Roesch T, Lohse A, Flavell R, Gagliani N, Huber S
GASTROENTEROLOGY. 2020;159(4):1417-1430.e3.

Sound-alikes - Wie entscheidend ein einziger Buchstabe sein kann
Kolnisko M, Langebrake C
Krankenhauspharmazie. 2020;41(2):69-70.

Preventing Graft-Versus-Host Disease Without Losing Graft-Versus-Leukemia Effect After Allogeneic Stem-Cell Transplantation
Kröger N
J CLIN ONCOL. 2020;38(29):3357-3360.

Successful Treatment of Delayed Methotrexate Clearance using Glucarpidase Dosed on Ideal Body Weight in Obese Patients
Krüger C, Engel N, Reinert J, Alsdorf W, Fiedler W, Dierlamm J, Bokemeyer C, Langebrake C
PHARMACOTHERAPY. 2020;40(5):479-483.

Modeling Spontaneous Bone Metastasis Formation of Solid Human Tumor Xenografts in Mice
Labitzky V, Baranowsky A, Maar H, Hanika S, Starzonek S, Ahlers A, Stübke K, Koziolek E, Heine M, Schäfer P, Windhorst S, Jücker M, Riecken K, Amling M, Schinke T, Schumacher U, Valentiner U, Lange T
CANCERS. 2020;12(2):.

Consensus recommendations for the role and competencies of the EBMT clinical pharmacist and clinical pharmacologist involved in hematopoietic stem cell transplantation
Langebrake C, Admiraal R, van Maarseveen E, Bonnin A, Bauters T
BONE MARROW TRANSPL. 2020;55(1):62-69.

Xenograft-derived mRNA/miR and protein interaction networks of systemic dissemination in human prostate cancer
Lange T, Samatov T, Galatenko V, Steffen P, von Kriegstein H, Spethmann T, Wicklein D, Maar H, Kupfernagel K, Labitzky V, Hanika S, Starzonek S, Ahlers A, Riecken K, Simon R, Polonski A, Sauter G, Schlomm T, Huland H, Johnsen S, Schlüter H, Tonevitsky A, Schumacher U
EUR J CANCER. 2020;137:93-107.

Glioma escape signature and clonal development under immune pressure
Maire C, Mohme M, Bockmayr M, Fita K, Riecken K, Börnigen D, Alawi M, Failla A, Kolbe K, Zapf S, Holz M, Neumann K, Dührsen L, Lange T, Fehse B, Westphal M, Lamszus K
J CLIN INVEST. 2020;130(10):5257-5271.

Major central nervous system complications after allogeneic stem cell transplantation: a large retrospective study on 888 consecutive adult patients
Mannina D, Berneking L, Both A, Timm W, Urbanowicz T, Wolschke C, Ayuk F, Fischer N, Fiehler J, Grzyska U, Rösner S, Choe C, Kröger N, Christopeit M
EUR J HAEMATOL. 2020;105(6):722-730.

Overcoming the delivery problem for therapeutic genome editing: Current status and perspective of non-viral methods
Mashel T, Tarakanchikova Y, Muslimov A, Zyuzin M, Timin A, Lepik K, Fehse B
BIOMATERIALS. 2020;258:120282.

Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT
McLornan D, Malpassuti V, Lippinkhof-Kozijn A, Potter V, Beelen D, Bunjes D, Sengeloev H, Radujkovic A, Passweg J, Chalandon Y, Kröger N, Wulf G, Johansson J, Ciceri F, Bornhäuser M, Holler E, Guffroy B, Martin S, Neubauer A, Gramatski M, Robin M, Iacobelli S, Hayden P, Hernández Boluda J, Czerw T, Yakoub-Agha I
BRIT J HAEMATOL. 2020;190(3):437-441.

Involvement of Wnt7a in the role of M2c microglia in neural stem cell oligodendrogenesis
Mecha M, Yanguas-Casás N, Feliú A, Mestre L, Carrillo-Salinas F, Riecken K, Gomez-Nicola D, Guaza C
J NEUROINFLAMM. 2020;17(1):88.

Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia
Michallet M, Dreger P, Sobh M, Koster L, Hoek J, Boumendil A, Scheid C, Fox C, Wulf G, Krüger W, van Gelder M, Corradini P, Russo D, Passweg J, Schoemans H, Bethge W, Schaap N, Cornelissen J, Browne P, Durakovic N, Muller L, Montoto S, Kroger N, Schetelig J
BONE MARROW TRANSPL. 2020;55(5):884-890.

Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
Modemann F, Ayuk F, Wolschke C, Christopeit M, Janson D, von Pein U, Kröger N
BONE MARROW TRANSPL. 2020;55(12):2286-2293.

Quantification of the dynamics of population heterogeneities in CHO cultures with stably integrated fluorescent markers
Möller J, Rosenberg M, Riecken K, Pörtner R, Zeng A, Jandt U
ANAL BIOANAL CHEM. 2020;412(9):2065-2080.

Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor
Morris C, Chabannon C, Masszi T, Russell N, Nahi H, Kobbe G, Krejci M, Auner H, Pohlreich D, Hayden P, Basak G, Lenhoff S, Schaap N, van Biezen A, Knol C, Iacobelli S, Liu Q, Celanovic M, Garderet L, Kröger N
BONE MARROW TRANSPL. 2020;55(2):356-366.

Correction: Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries
Muhsen I, Hashmi S, Niederwieser D, Kroeger N, Agrawal S, Pasquini M, Atsuta Y, Ballen K, Seber A, Saber W, Kharfan-Dabaja M, Rasheed W, Okamoto S, Khera N, Wood W, Koh M, Greinix H, Kodera Y, Szer J, Horowitz M, Weisdorf D, Aljurf M
BONE MARROW TRANSPL. 2020;55(4):837.

Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries
Muhsen I, Hashmi S, Niederwieser D, Kroeger N, Agrawal S, Pasquini M, Atsuta Y, Ballen K, Seber A, Saber W, Kharfan-Dabaja M, Rasheed W, Okamoto S, Khera N, Wood W, Koh M, Greinix H, Kodera Y, Szer J, Horowitz M, Weisdorf D, Aljurf M
BONE MARROW TRANSPL. 2020;55(4):698-707.

The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter Analysis
Mytilineos D, Tsamadou C, Neuchel C, Platzbecker U, Bunjes D, Schub N, Wagner-Drouet E, Wulf G, Kröger N, Murawski N, Einsele H, Schaefer-Eckart K, Freitag S, Casper J, Kaufmann M, Dürholt M, Hertenstein B, Klein S, Ringhoffer M, Mueller C, Frank S, Schrezenmeier H, Fuerst D, Mytilineos J
FRONT IMMUNOL. 2020;11:.

Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation
Nagler A, Labopin M, Canaani J, Niittyvuopio R, Socié G, Kröger N, Itäla-Remes M, Yakoub-Agha I, Labussière-Wallet H, Gallego-Hernanz M, Deconinck E, Chevallier P, Finke J, Esteve J, Mohty M
AM J HEMATOL. 2020;95(10):1135-1141.

Characterization of the substrate specificity of the inositol 5-phosphatase SHIP1
Nelson N, Wundenberg T, Lin H, Rehbach C, Horn S, Windhorst S, Jücker M
BIOCHEM BIOPH RES CO. 2020;524(2):366-370.

Glucagon like peptide-2 for Intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans
Norona J, Apostolova P, Schmidt D, Ihlemann R, Reischmann N, Taylor G, Köhler N, de Heer J, Heeg S, Andrieux G, Siranosian B, Schmitt-Graeff A, Pfeifer D, Catalano A, Frew I, Proietti M, Grimbacher B, Bulashevska A, Bhatt A, Brummer T, Clauditz T, Zabelina T, Kroeger N, Blazar B, Boerries M, Ayuk F, Zeiser R
BLOOD. 2020;136(12):1442-1455.

Second allogeneic stem cell transplantation for relapse after allografting in multiple myeloma using CD 34+ selected donor cells without immunosuppression
Novak P, Klyuchnikov E, von Pein U, Güllstorf M, Christopeit M, Ayuk F, Geffken M, Wolschke C, Kröger N
BONE MARROW TRANSPL. 2020;55(9):1817-1820.

Allogeneic Stem Cell Transplantation for Patients with Lower-Risk Myelodysplastic Syndrome
Novak P, Zabelina T, Wolschke C, Ayuk F, Christopeit M, Kröger N
BIOL BLOOD MARROW TR. 2020;26(11):2047-2052.

The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus
Passweg J, Baldomero H, Chabannon C, Basak G, Corbacioglu S, Duarte R, Dolstra H, Lankester A, Mohty M, Montoto S, Peffault de Latour R, Snowden J, Styczynski J, Yakoub-Agha I, Kröger N
BONE MARROW TRANSPL. 2020;55(8):1604-1613.

Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, Ciceri F, Cornelissen J, Malladi R, Duarte R, Giebel S, Greinix H, Holler E, Lawitschka A, Mielke S, Mohty M, Arat M, Nagler A, Passweg J, Schoemans H, Socié G, Solano C, Vrhovac R, Zeiser R, Kröger N, Basak G
LANCET HAEMATOL. 2020;7(2):e157-e167.

How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT
Penack O, Peczynski C, Mohty M, Yakoub-Agha I, Styczynski J, Montoto S, Duarte R, Kröger N, Schoemans H, Koenecke C, Peric Z, Basak G
BLOOD ADV. 2020;4(24):6283-6290.

Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party
Prata P, Eikema D, Afansyev B, Bosman P, Smiers F, Diez-Martin J, Arrais-Rodrigues C, Koc Y, Poiré X, Sirvent A, Kröger N, Porta F, Holter W, Bloor A, Jubert C, Ganser A, Tanase A, Ménard A, Pioltelli P, Pérez-Simón J, Ho A, Aljurf M, Russell N, Labussiere-Wallet H, Kerre T, Rocha V, Socié G, Risitano A, Dufour C, Peffault de Latour R
BONE MARROW TRANSPL. 2020;55(6):1050-1058.

Pharmaceutical management of elderly high-risk patients in perioperative settings (PHAROS): protocol of a pilot sequential intervention study
Richter J, Schönfeld M, Langebrake C, Bergelt C, Kriston L, Olotu C, Kiefmann R
BMJ OPEN. 2020;10(11):e039094.

FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Rodríguez-Arbolí E, Labopin M, Tischer J, Brecht A, Ganser A, Finke J, Blau I, Kröger N, Kalhs P, Forcade E, Bunjes D, Spyridonidis A, Savani B, Nagler A, Mohty M
BIOL BLOOD MARROW TR. 2020;26(11):2165-2173.

Monocenter study on epidemiology, outcomes, and risk factors of infections in recipients of 166 allogeneic stem cell transplantations during 1 year
Samek M, Iversen K, Belmar Campos C, Berneking L, Langebrake C, Wolschke C, Ayuk F, Kröger N, Christopeit M
EUR J HAEMATOL. 2020;105(2):126-137.

Publisher Correction: mTORC1 and mTORC2 Differentially Regulate Cell Fate Programs to Coordinate Osteoblastic Differentiation in Mesenchymal Stromal Cells
Schaub T, Gürgen D, Maus D, Lange C, Tarabykin V, Dragun D, Hegner B
SCI REP-UK. 2020;10(1):3740.

External Validation of Models for KIR2DS1/KIR3DL1-informed Selection of Hematopoietic Cell Donors fails
Schetelig J, Baldauf H, Heidenreich F, Massalski C, Frank S, Sauter J, Stelljes M, Ayuk F, Bethge W, Bug G, Klein S, Wendler S, Lange V, de Wreede L, Fuerst D, Kobbe G, Ottinger H, Beelen D, Mytilineos J, Fleischhauer K, Schmidt A, Bornhauser M
BLOOD. 2020;135(16):1386-1395.

Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
Schetelig J, Baldauf H, Koster L, Kuxhausen M, Heidenreich F, de Wreede L, Spellman S, van Gelder M, Bruno B, Onida F, Lange V, Massalski C, Potter V, Ljungman P, Schaap N, Hayden P, Lee S, Kröger N, Hsu K, Schmidt A, Yakoub-Agha I, Robin M
FRONT IMMUNOL. 2020;11:.

Development of a Short Instrument for Measuring Health-Related Quality of Life in Oncological Patients for Clinical Use: Protocol for an Observational Study
Schrage T, Görlach M, Betz C, Bokemeyer C, Kröger N, Mueller V, Petersen C, Krüll A, Schulz H, Bleich C
JMIR RES PROTOC. 2020;9(7):e17854.

Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies
Schriewer L, Schütze K, Petry K, Hambach J, Fumey W, Koenigsdorf J, Baum N, Menzel S, Rissiek B, Riecken K, Fehse B, Röckendorf J, Schmid J, Albrecht B, Pinnschmidt H, Ayuk F, Kröger N, Binder M, Schuch G, Hansen T, Haag F, Adam G, Koch-Nolte F, Bannas P
THERANOSTICS. 2020;10(6):2645-2658.

Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey
Sellner L, Schetelig J, Koster L, Choi G, Blaise D, Beelen D, Schianca F, Passweg J, Schanz U, Gyan E, Sora F, Kröger N, Wulf G, Van Gorkom G, Mayer J, Orvain C, Bourhis J, Jindra P, Potter V, Zallio F, Vandenberghe E, Robinson S, Hayden P, Yakoub-Agha I, Montoto S, Dreger P
BONE MARROW TRANSPL. 2020;55(12):2335-2338.

Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT
Shem-Tov N, Peczynski C, Labopin M, Itälä-Remes M, Blaise D, Labussière-Wallet H, Socié G, Kröger N, Mielke S, Afanasyev B, Chevallier P, Tischer J, Helbig G, Jindra P, Peric Z, Giebel S, Mohty M, Nagler A
LEUKEMIA. 2020;34(1):283-292.

Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Snowden J, Saccardi R, Orchard K, Ljungman P, Duarte R, Labopin M, McGrath E, Brook N, de Elvira C, Gordon D, Poirel H, Ayuk F, Beguin Y, Bonifazi F, Gratwohl A, Milpied N, Moore J, Passweg J, Rizzo J, Spellman S, Sierra J, Solano C, Sanchez-Guijo F, Worel N, Gusi A, Adams G, Balan T, Baldomero H, Macq G, Marry E, Mesnil F, Oldani E, Pearce R, Perry J, Raus N, Schanz U, Tran S, Wilcox L, Basak G, Chabannon C, Corbacioglu S, Dolstra H, Kuball J, Mohty M, Lankester A, Montoto S, Nagler A, Styczynski J, Yakoub-Agha I, de Latour R, Kroeger N, Brand R, de Wreede L, van Zwet E, Putter H
BONE MARROW TRANSPL. 2020;55(4):681-694.

Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Snowden J, Saccardi R, Orchard K, Ljungman P, Duarte R, Labopin M, McGrath E, Brook N, de Elvira C, Gordon D, Poirel H, Ayuk F, Beguin Y, Bonifazi F, Gratwohl A, Milpied N, Moore J, Passweg J, Rizzo J, Spellman S, Sierra J, Solano C, Sanchez-Guijo F, Worel N, Gusi A, Adams G, Balan T, Baldomero H, Macq G, Marry E, Mesnil F, Oldani E, Pearce R, Perry J, Raus N, Schanz U, Tran S, Wilcox L, Basak G, Chabannon C, Corbacioglu S, Dolstra H, Kuball J, Mohty M, Lankester A, Montoto S, Nagler A, Styczynski J, Yakoub-Agha I, de Latour R, Kroeger N, Brand R, de Wreede L, van Zwet E, Putter H
BONE MARROW TRANSPL. 2020;55(4):838-839.

Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors
Styczyński J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S, Mikulska M, Gil L, Cordonnier C, Ljungman P, Averbuch D, Cesaro S, de la Camara R, Baldomero H, Bader P, Basak G, Bonini C, Duarte R, Dufour C, Kuball J, Lankester A, Montoto S, Nagler A, Snowden J, Kröger N, Mohty M, Gratwohl A
BONE MARROW TRANSPL. 2020;55(1):126-136.

Fear of disease progression and relevant correlates in acute leukemia patients prior to allogeneic hematopoietic stem cell transplantation
Thiele S, Goebel S, Kröger N, Pedersen A
PSYCHO-ONCOLOGY. 2020;29(8):1248-1254.

Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies
Tomaszewska A, Jagasia M, Beohou E, van der Werf S, Blaise D, Kanfer E, Milpied N, Reményi P, Ciceri F, Bourhis J, Chevallier P, Solano C, Socié G, Bruno B, Rambaldi A, Castagna L, Kröger N, Corradini P, Afanasyev B, Ladetto M, Niederwieser D, Scheid C, Sengeloev H, Kroschinsky F, Yakoub-Agha I, Schoemans H, Koenecke C, Penack O, Perić Z, Greinix H, Duarte R, Basak G
FRONT IMMUNOL. 2020;11:.

Correction: Role of growth arrest-specific gene 6-mer axis in multiple myeloma
Waizenegger J, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Atanackovic D, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab M, Pantel K, Bokemeyer C, Loges S
LEUKEMIA. 2020;34(9):2542.

Evaluation of the Cost of Survivorship Care After Allogeneic Hematopoeitic Stem Cell Transplantation-An Analysis of 2 German Transplantation Centers
Wolff D, Bardak J, Edinger M, Klinger-Schindler U, Holler E, Lawitschka A, Schoemans H, Herr W, Kröger N, Ayuk Ayuketang F
FRONT PUBLIC HEALTH. 2020;8:572470.

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Yakoub-Agha I, Chabannon C, Bader P, Basak G, Bonig H, Ciceri F, Corbacioglu S, Duarte R, Einsele H, Hudecek M, Kersten M, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Robinson S, Saccardi R, Sanchez-Guijo F, Snowden J, Srour M, Styczynski J, Urbano-Ispizua A, Hayden P, Kröger N
HAEMATOLOGICA. 2020;105(2):297-316.

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner E, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi K, Socié G
NEW ENGL J MED. 2020;382(19):1800-1810.

DAMIAN an open source bioinformatics tool for fast, systematic and cohort based analysis of microorganisms in diagnostic samples
Alawi M, Burkhardt L, Indenbirken D, Reumann K, Christopeit M, Kröger N, Lütgehetmann M, Aepfelbacher M, Fischer N, Grundhoff A
SCI REP-UK. 2019;9(1):16841.

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Al-Batran S, Homann N, Pauligk C, Goetze T, Meiler J, Kasper S, Kopp H, Mayer F, Haag G, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens U, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer D, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal L, Hartmann J, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu F, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein W, Schuler M, Schmalenberg H, Hofheinz R
LANCET. 2019;393(10184):1948-1957.

"Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registries"
Aljurf M, Weisdorf D, Alfraih F, Szer J, Müller C, Confer D, Hashmi S, Kröger N, Shaw B, Greinix H, Kharfan-Dabaja M, Foeken L, Seber A, Ahmed S, El-Jawahri A, Al-Awwami M, Atsuta Y, Pasquini M, Hanbali A, Alzahrani H, Okamoto S, Gluckman E, Mohty M, Kodera Y, Horowitz M, Niederwieser D, El Fakih R
BONE MARROW TRANSPL. 2019;54(8):1179-1188.

Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning
Andersen N, Bornhäuser M, Gramatzki M, Dreger P, Vitek A, Karas M, Michallet M, Moreno C, van Gelder M, Henseler A, de Wreede L, Schönland S, Kröger N, Schetelig J
J CANCER RES CLIN. 2019;145(11):2823-2834.

Donor Selection for Adults and Pediatrics
Ayuk F, Balduzzi A
2019. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. Carreras E, Dufour C, Mohty M, Kröger N (Hrsg.). Springer Nature Switzerland AG, 87-97.

Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) Are Associated with Poorer Outcome after Single Mismatch Unrelated Donor Stem Cell Transplantation: A Study of the Cooperative Transplant Study Group (KTS) of the German Group for Bone Marrow and Stem Cell Transplantation (DAG-KBT)
Ayuk F, Bornhäuser M, Stelljes M, Zabelina T, Wagner E, Schmid C, Christopeit M, Guellstorf M, Kröger N, Bethge W
TRANSFUS MED HEMOTH. 2019;46(5):370-375.

Chancen und Risiken der CAR-T-Zell-Therapie
Ayuk F, Fehse B, Berger S, Riecken K, Kroger N
Hamb Ärztebl. 2019;73(10):30-32.

Skin, Hair and Musculosceletal Complications
Ayuk F, Savani B
2019. The EBMT Handbook. Carreras E, Dufour C, Mohty M, Kröger N (Hrsg.). 1. Aufl. Switzerland: Springer Open, 409-414.

Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends
Baldomero H, Aljurf M, Zaidi S, Hashmi S, Ghavamzadeh A, Elhaddad A, Hamladji R, Ahmed P, Torjemane L, Abboud M, Tbakhi A, Khabori M, El Quessar A, Bazuaye N, Bekadja M, Adil S, Fahmy O, Ramzi M, Ibrahim A, Alseraihy A, Ben Abdejalil N, Sarhan M, Huneini M, Mahmal L, ElSolh H, Hussain F, Nassar A, Al-Hashmi H, Hamidieh A, Pasquini M, Kodera Y, Kröger N, Mohty M, Jaimovich G, Rolon J, Paulson K, Greinix H, Weisdorf D, Horowitz M, Nunez J, Gratwohl A, Passweg J, Koh M, Szer J, Niederwieser D, Novitzky N
BONE MARROW TRANSPL. 2019;54(3):402-417.

Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT
Baron F, Labopin M, Ruggeri A, Ehninger G, Bonifazi F, Stelljes M, Sanz J, Stuhler G, Bosi A, Kröger N, Van Lint M, Ganser A, Forcade E, Mohty M, Gluckman E, Nagler A
BLOOD CANCER J. 2019;9(4):46.

Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation
Battipaglia G, Labopin M, Kröger N, Vitek A, Afanasyev B, Hilgendorf I, Schetelig J, Ganser A, Blaise D, Itälä-Remes M, Passweg J, Bonifazi F, Finke J, Ruggeri A, Nagler A, Mohty M
BLOOD. 2019;134(11):892-899.

Cellular Therapy with Engineered T Cells, Efficacy and Side Effects
Bondanza A, Bonini C, Fehse B, Hudecek M
2019. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. Carreras E, Dufour C, Mohty M, Kröger N (Hrsg.). 1. Aufl. Springer Nature Switzerland AG, 449-456.

Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study
Bonifazi F, Solano C, Wolschke C, Sessa M, Patriarca F, Zallio F, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, Herrera P, Sureda A, Carella A, Cimminiello M, Guidi S, Finke J, Sorasio R, Ferra C, Sierra J, Russo D, Benedetti E, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Kröger N
LANCET HAEMATOL. 2019;6(2):e89-e99.

Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT
Brissot E, Labopin M, Ehninger G, Stelljes M, Brecht A, Ganser A, Tischer J, Kröger N, Afanasyev B, Finke J, Elmaagacli A, Einsele H, Mohty M, Nagler A
HAEMATOLOGICA. 2019;104(3):524-532.

Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis
Canaani J, Beohou E, Labopin M, Ghavamzadeh A, Beelen D, Hamladji R, Niederwieser D, Volin L, Markiewicz M, Arnold R, Mufti G, Ehninger G, Socié G, Kröger N, Mohty M, Nagler A
J INTERN MED. 2019;285(4):407-418.

Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents
Chen Y, McCarthy P, Hahn T, Holstein S, Ueda M, Kröger N, Bishop M, de Lima M
BONE MARROW TRANSPL. 2019;54(4):497-507.

A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation
Cremers E, de Witte T, de Wreede L, Eikema D, Koster L, van Biezen A, Finke J, Socié G, Beelen D, Maertens J, Nagler A, Kobbe G, Ziagkos D, Itälä-Remes M, Gedde-Dahl T, Sierra J, Niederwieser D, Ljungman P, Beguin Y, Ozkurt Z, Anagnostopoulos A, Jindra P, Robin M, Kröger N
LEUKEMIA LYMPHOMA. 2019;60(10):2404-2414.

Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years
Daghia G, Zabelina T, Zeck G, von Pein U, Christopeit M, Wolschke C, Ayuk F, Kröger N
EUR J HAEMATOL. 2019;103(4):370-378.

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties
Dreger P, Michallet M, Bosman P, Dietrich S, Sobh M, Boumendil A, Nagler A, Scheid C, Cornelissen J, Niederwieser D, Müller L, Vandenberghe E, Scortechini I, Schoemans H, Andersen N, Finke J, Russo D, Ljungman P, Passweg J, van Gelder M, Durakovic N, Labussiere-Wallet H, Berg T, Wulf G, Bethge W, Bunjes D, Stilgenbauer S, Canepari M, Schaap M, Fox C, Kröger N, Montoto S, Schetelig J
BONE MARROW TRANSPL. 2019;54(1):44-52.

Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019
Duarte R, Labopin M, Bader P, Basak G, Bonini C, Chabannon C, Corbacioglu S, Dreger P, Dufour C, Gennery A, Kuball J, Lankester A, Lanza F, Montoto S, Nagler A, Peffault de Latour R, Snowden J, Styczynski J, Yakoub-Agha I, Kröger N, Mohty M
BONE MARROW TRANSPL. 2019;54(10):1525-1552.

Prevention and treatment of relapse after stem cell transplantation by cellular therapies
Falkenburg F, Ruggiero E, Bonini C, Porter D, Miller J, Malard F, Mohty M, Kröger N, Kolb H
BONE MARROW TRANSPL. 2019;54(1):26-34.

Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation
Frick M, Chan W, Arends C, Hablesreiter R, Halik A, Heuser M, Michonneau D, Blau O, Hoyer K, Christen F, Galan-Sousa J, Noerenberg D, Wais V, Stadler M, Yoshida K, Schetelig J, Schuler E, Thol F, Clappier E, Christopeit M, Ayuk F, Bornhäuser M, Blau I, Ogawa S, Zemojtel T, Gerbitz A, Wagner E, Spriewald B, Schrezenmeier H, Kuchenbauer F, Kobbe G, Wiesneth M, Koldehoff M, Socié G, Kroeger N, Bullinger L, Thiede C, Damm F
J CLIN ONCOL. 2019;37(5):375-385.

Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers: A Systematic Review and Meta-analysis
Gagelmann N, Bacigalupo A, Rambaldi A, Hoelzer D, Halter J, Sanz J, Bonifazi F, Meijer E, Itälä-Remes M, Marková M, Solano C, Kröger N
JAMA ONCOL. 2019;5(12):1739-1748.

Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation
Gagelmann N, Ditschkowski M, Bogdanov R, Bredin S, Robin M, Cassinat B, Shahswar R, Thol F, Heuser M, Socié G, Beelen D, Triviai I, Badbaran A, Kröger N
BLOOD. 2019;133(20):2233-2242.

Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation
Gagelmann N, Eikema D, de Wreede L, Koster L, Wolschke C, Arnold R, Kanz L, McQuaker G, Marchand T, Socié G, Bourhis J, Mohty M, Cornelissen J, Chevallier P, Bernasconi P, Stelljes M, Rohrlich P, Fanin R, Finke J, Maertens J, Blaise D, Itälä-Remes M, Labussière-Wallet H, Robin M, McLornan D, Chalandon Y, Yakoub-Agha I, Kröger N
BIOL BLOOD MARROW TR. 2019;25(6):e204-e208.

Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Gagelmann N, Eikema D, Koster L, Caillot D, Pioltelli P, Lleonart J, Reményi P, Blaise D, Schaap N, Trneny M, Passweg J, Porras R, Cahn J, Musso M, Poiré X, Fenk R, Itälä-Remes M, Pavone V, Fouillard L, Maertens J, Bron D, Pouli A, Schroyens W, Schönland S, Garderet L, Yakoub-Agha I, Kröger N
BIOL BLOOD MARROW TR. 2019;25(11):2134-2142.

Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation
Gagelmann N, Eikema D, Stelljes M, Beelen D, de Wreede L, Mufti G, Knelange N, Niederwieser D, Friis L, Ehnninger G, Nagler A, Yakoub-Agha I, Meijer E, Ljungman P, Maertens J, Kanz L, Lopez-Corral L, Brecht A, Craddock C, Finke J, Cornelissen J, Bernasconi P, Chevallier P, Sierra J, Robin M, Kröger N
HAEMATOLOGICA. 2019;104(5):929-936.

Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes
Ganster C, Müller-Thomas C, Haferlach C, Strupp C, Ogata K, Germing U, Hildebrandt B, Mallo M, Lübbert M, Müller C, Solé F, Götze K, Vandenberghe P, Göhring G, Steinmetz T, Kröger N, Platzbecker U, Söling U, Raynaud S, Shirneshan K, Schanz J, Haase D
GENE CHROMOSOME CANC. 2019;58(10):689-697.

Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo
Giersch K, Bhadra O, Volz T, Allweiss L, Riecken K, Fehse B, Lohse A, Petersen J, Sureau C, Urban S, Dandri M, Lütgehetmann M
GUT. 2019;68(1):150-157.

Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia
Gratwohl A, Duarte R, Snowden J, van Biezen A, Baldomero H, Apperley J, Cornelissen J, Greinix H, Grath E, Mohty M, Kroeger N, Nagler A, Niederwieser D, Putter H, Brand R
ECLINICALMEDICINE. 2019;15:33-41.

Technikfolgenabschätzung des CRISPR/Cas-Systems: Über die Anwendung in der menschlichen Keimbahn
Hardt A
2019. Technikfolgenabschätzung des CRISPR/Cas-Systems. 1. Aufl. Berlin/Boston: Walter de Gruyter GmbH, 1-322.

Unklare Panzytopenie bei einem 52-jährigen Patienten
Heidenreich S, van Randenbourgh A, Ayuk F, Kröger N, Schmiedel S, Asemissen A, Oelrich J, Wolschke C
INTERNIST. 2019;60(8):867-870.

The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma
Holderried T, Fraccaroli A, Schumacher M, Heine A, Brossart P, Stelljes M, Klobuch S, Kröger N, Apostolova P, Finke J, Zeiser R, Heinicke T, Bornhäuser M, von Bergwelt-Baildon M, Tischer J, Wolf D
BONE MARROW TRANSPL. 2019;54(10):1662-1667.

Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastoma
Hossain J, Latif M, Ystaas L, Ninzima S, Riecken K, Muller A, Azuaje F, Joseph J, Talasila K, Ghimire J, Fehse B, Bjerkvig R, Miletic H
NEURO-ONCOLOGY. 2019;21(7):890-900.

Cancer Suicide Gene Therapy with TK.007
Hossain J, Riecken K, Miletic H, Fehse B
Methods Mol Biol. 2019;1895:11-26.

Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party
Hübel K, Re A, Boumendil A, Finel H, Hentrich M, Robinson S, Wyen C, Michieli M, Kanfer E, Diez-Martin J, Balsalobre P, Vincent L, Schroyens W, Santasusana J, Kröger N, Schiel X, Cwynarski K, Esquirol A, Sousa A, Cattaneo C, Montoto S, Dreger P
BONE MARROW TRANSPL. 2019;54(10):1625-1631.

Prospective survey-based study on the categorization quality of hospital pharmacists' interventions using DokuPIK
Ihbe-Heffinger A, Langebrake C, Hohmann C, Leichenberg K, Hilgarth H, Kunkel M, Lueb M, Schuster T
INT J CLIN PHARM-NET. 2019;41(2):414-423.

Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD
Jagasia M, Scheid C, Socié G, Ayuk F, Tischer J, Donato M, Bátai Á, Chen H, Chen S, Chin T, Boodée H, Mitri G, Greinix H
BLOOD ADV. 2019;3(14):2218-2229.

Prevention and Treatment of Relapse by Drugs
Kroger N
2019. The EBMT Handbook. Carreras E, Dufour C, Mohty M, Kröger N (Hrsg.). 1. Aufl. Switzerland: Springer Open, 437-442.

Induction, Bridging, or Straight Ahead: The Ongoing Dilemma of Allografting in Advanced Myelodysplastic Syndrome
Kröger N
BIOL BLOOD MARROW TR. 2019;25(8):e247-e249.

Myeloproliferative Neoplasms
Kroger N, Chalandon Y
2019. The EBMT Handbook. Carreras E, Dufour C, Mohty M, Kröger N (Hrsg.). 1. Aufl. Switzerland: Springer Open, 569 - 578.

Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia
Kröger N, Eikema D, Köster L, Beelen D, de Wreede L, Finke J, Koenecke C, Niederwieser D, Bornhäuser M, Schoenland S, Potter V, Wolschke C, Maertens J, Theobald M, Kobbe G, Itälä-Remes M, Wulf G, Kahls P, Forcade E, Greinix H, Masszi T, Yakoub-Agha I, Chalandon Y, Robin M
BRIT J HAEMATOL. 2019;185(4):725-732.

Methods and role of minimal residual disease after stem cell transplantation
Ladetto M, Böttcher S, Kröger N, Pulsipher M, Bader P
BONE MARROW TRANSPL. 2019;54(5):681-690.

Aufgaben und Kompetenzen von klinischen Pharmazeuten und klinischen Pharmakologen in der hämatopoetischen Stammzelltransplantation
Langebrake C
Krankenhauspharmazie. 2019;40(8):401-402.

Overweight and Obese Patients
Langebrake C
2019. The EBMT Handbook. Carreras E, Dufour C, Mohty M, Kröger N (Hrsg.). 1. Aufl. Switzerland: Springer Open, 493-498.

Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation
Mannina D, Gagelmann N, Badbaran A, Ditschkowski M, Bogdanov R, Robin M, Cassinat B, Heuser M, Shahswar R, Thol F, Beelen D, Kröger N
EUR J HAEMATOL. 2019;103(6):552-557.

Janus Kinase Inhibition for Graft-Versus-Host Disease:Current Status and Future Prospects: Current Status and Future Prospects
Mannina D, Kröger N
DRUGS. 2019;79(14):1499-1509.

Reduced intensity allogeneic stem cell transplantation for younger patients with myelofibrosis
Mannina D, Zabelina T, Wolschke C, Heinzelmann M, Triviai I, Christopeit M, Badbaran A, Bonmann S, von Pein U, Janson D, Ayuk F, Kröger N
BRIT J HAEMATOL. 2019;186(3):484-489.

Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, Beelen D, Socié G, Bornhäuser M, Angelucci E, Niederwieser D, Gerbitz A, Finke J, Vitek A, Itälä-Remes M, Radujkovic A, Kanz L, Potter V, Chevallier P, Stelljes M, Petersen E, Robinson S, Poiré X, Klyuchnikov E, Hernández-Boluda J, Czerw T, Hayden P, Kröger N, Yakoub-Agha I
BIOL BLOOD MARROW TR. 2019;25(11):2167-2171.

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019: allogeneic stem cell transplantation for myelofibrosis in 2019
McLornan D, Yakoub-Agha I, Robin M, Chalandon Y, Harrison C, Kroger N
HAEMATOLOGICA. 2019;104(4):659-668.

Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial
Minnema M, Nasserinejad K, Hazenberg B, Hegenbart U, Vlummens P, Ypma P, Kröger N, Wu K, Kersten M, Schaafsma M, Croockewit S, de Waal E, Zweegman S, Tick L, Broijl A, Koene H, Bos G, Sonneveld P, Schönland S
HAEMATOLOGICA. 2019;104(11):2274-2282.

Process-induced cell cycle oscillations in CHO cultures: Online monitoring and model-based investigation
Möller J, Bhat K, Riecken K, Pörtner R, Zeng A, Jandt U
BIOTECHNOL BIOENG. 2019;116(11):2931-2943.

Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis
Palmer J, Kosiorek H, Wolschke C, Fauble V, Butterfield R, Geyer H, Scherber R, Dueck A, Gathany A, Mesa R, Kroger N
BIOL BLOOD MARROW TR. 2019;25(11):2267-2273.

The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies
Passweg J, Baldomero H, Basak G, Chabannon C, Corbacioglu S, Duarte R, Kuball J, Lankester A, Montoto S, de Latour R, Snowden J, Styczynski J, Yakoub-Agha I, Arat M, Mohty M, Kröger N
BONE MARROW TRANSPL. 2019;54(10):1575-1585.

Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT
Pavlů J, Labopin M, Niittyvuopio R, Socié G, Yakoub-Agha I, Wu D, Remenyi P, Passweg J, Beelen D, Aljurf M, Kröger N, Labussière-Wallet H, Perić Z, Giebel S, Nagler A, Mohty M
J HEMATOL ONCOL. 2019;12(1):108.

Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party
Radujkovic A, Dietrich S, Blok H, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sorà F, Passweg J, Byrne J, Jindra P, Veelken J, Socié G, Maertens J, Schaap N, Stadler M, Itälä-Remes M, Tholouli E, Arat M, Rocha V, Ljungman P, Yakoub-Agha I, Kröger N, Chalandon Y
BIOL BLOOD MARROW TR. 2019;25(10):2008-2016.

Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation
Raj K, Eikema D, McLornan D, Olavarria E, Blok H, Bregante S, Ciceri F, Passweg J, Ljungman P, Schaap N, Carlson K, Zuckerman T, de Wreede L, Volin L, Koc Y, Diez-Martin J, Brossart P, Wolf D, Blaise D, Bartolomeo P, Vitek A, Robin M, Yakoub-Agha I, Chalandon Y, Kroger N
BIOL BLOOD MARROW TR. 2019;25(3):522-528.

JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms
Rao T, Hansen N, Hilfiker J, Rai S, Majewska J, Leković D, Gezer D, Andina N, Galli S, Cassel T, Geier F, Delezie J, Nienhold R, Hao-Shen H, Beisel C, Di Palma S, Dimeloe S, Trebicka J, Wolf D, Gassmann M, Fan T, Lane A, Handschin C, Dirnhofer S, Kröger N, Hess C, Radimerski T, Koschmieder S, Čokić V, Skoda R
BLOOD. 2019;134(21):1832-1846.

Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia
Rice C, Eikema D, Marsh J, Knol C, Hebert K, Putter H, Peterson E, Deeg H, Halkes S, Pidala J, Anderlini P, Tischer J, Kroger N, McDonald A, Antin J, Schaap N, Hallek M, Einsele H, Mathews V, Kapoor N, Boelens J, Mufti G, Potter V, Pefault de la Tour R, Eapen M, Dufour C
BIOL BLOOD MARROW TR. 2019;25(3):488-495.

Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours
Ricklefs F, Maire C, Reimer R, Dührsen L, Kolbe K, Holz M, Schneider E, Rissiek A, Babayan A, Hille C, Pantel K, Krasemann S, Glatzel M, Heiland D, Flitsch J, Martens T, Schmidt N, Peine S, Breakefield X, Lawler S, Chiocca E, Fehse B, Giebel B, Görgens A, Westphal M, Lamszus K
J EXTRACELL VESICLES. 2019;8(1):1588555.

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Ringdén O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, Niederwieser D, Finke J, Stelljes M, Gerbitz A, Ganser A, Kröger N, Kantz L, Brecht A, Savani B, Sadeghi B, Mohty M, Nagler A
BIOL BLOOD MARROW TR. 2019;25(10):1975-1983.

Antilymphocyte Globulin for matched sibling donor transplantation in patients with myelofibrosis
Robin M, Chevret S, Koster L, Wolschke C, Yakoub-Agha I, Bourhis J, Chevallier P, Cornelissen J, Reményi P, Maertens J, Poiré X, Craddock C, Socié G, Itälä-Remes M, Schouten H, Marchand T, Passweg J, Blaise D, Damaj G, Ozkurt Z, Zuckerman T, Cluzeau T, Labussière-Wallet H, Cammenga J, McLornan D, Chalandon Y, Kröger N
HAEMATOLOGICA. 2019;104(6):1230-1236.

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
Robin M, de Wreede L, Wolschke C, Schetelig J, Eikema D, Van Lint M, Knelange N, Beelen D, Brecht A, Niederwieser D, Vitek A, Bethge W, Arnold R, Finke J, Volin L, Yakoub-Agha I, Nagler A, Poiré X, Einsele H, Chevallier P, Holler E, Ljungman P, Robinson S, Radujkovic A, McLornan D, Chalandon Y, Kröger N
HAEMATOLOGICA. 2019;104(9):1782-1788.

HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis
Robin M, Porcher R, Ruggeri A, Blaise D, Wolschke C, Koster L, Angelucci E, Stölzel F, Potter V, Yakoub-Agha I, Koc Y, Ciceri F, Finke J, Labussière-Wallet H, Cascon M, Verbeek M, Rambaldi A, Cornelissen J, Chevallier P, Radia R, Nagler A, Fegueux N, Gluckman E, de Witte T, Kröger N
BIOL BLOOD MARROW TR. 2019;25(1):114-120.

Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults a survey by the Transplant Complications Working Party of the EBMT
Ruutu T, van der Werf S, van Biezen A, Backman J, Peczynski C, Kröger N, Mohty M, Nagler A, Montoto S, Langebrake C, Niederwieser D, Peric Z, Koenecke C, Duarte R, Basak G
BONE MARROW TRANSPL. 2019;54(12):2013-2019.

Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report
Sahebi F, Garderet L, Kanate A, Eikema D, Knelange N, Alvelo O, Koc Y, Blaise D, Bashir Q, Moraleda J, Dreger P, Sanchez J, Ciurea S, Schouten H, Shah N, Verbeek M, Rösler W, Diez-Martin J, Schoenland S, D'Souza A, Kröger N, Hari P
BIOL BLOOD MARROW TR. 2019;25(2):335-342.

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Saraceni F, Labopin M, Brecht A, Kröger N, Eder M, Tischer J, Labussière-Wallet H, Einsele H, Beelen D, Bunjes D, Niederwieser D, Bochtler T, Savani B, Mohty M, Nagler A
J HEMATOL ONCOL. 2019;12(1):44.

mTORC1 and mTORC2 Differentially Regulate Cell Fate Programs to Coordinate Osteoblastic Differentiation in Mesenchymal Stromal Cells
Schaub T, Gürgen D, Maus D, Lange C, Tarabykin V, Dragun D, Hegner B
SCI REP-UK. 2019;9(1):20071.

Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia
Schetelig J, de Wreede L, van Gelder M, Koster L, Finke J, Niederwieser D, Beelen D, Mufti G, Platzbecker U, Ganser A, Heidenreich S, Maertens J, Socié G, Brecht A, Stelljes M, Kobbe G, Volin L, Nagler A, Vitek A, Luft T, Ljungman P, Yakoub-Agha I, Robin M, Kröger N
LEUKEMIA. 2019;33(3):686-695.

The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT
Schmidt-Hieber M, Tridello G, Ljungman P, Mikulska M, Knelange N, Blaise D, Socié G, Volin L, Blijlevens N, Fegueux N, Yakoub-Agha I, Forcade E, Maertens J, Chevallier P, Passweg J, Cornelissen J, Russell N, Craddock C, Bourhis J, Marchand T, Reményi P, Cahn J, Michallet M, Montoto S, Kröger N, Glaß B, Styczynski J
ANN HEMATOL. 2019;98(7):1755-1763.

Frequency of lethal central nervous system neurotoxicity in patients undergoing allogeneic stem cell transplantation: a retrospective registry analysis
Schultze-Florey C, Peczynski C, de Marino I, Polge E, Socié G, Blaise D, Beelen D, Franke G, Kröger N, Stelljes M, Afanasyev B, Potter V, Gerbitz A, Schetelig J, Peric Z, Schoemans H, Koenecke C, Basak G
BONE MARROW TRANSPL. 2019 [Epub ahead of print].

Dissecting hiPSC-CM pacemaker function in a cardiac organoid model
Schulze M, Lemoine M, Fischer A, Scherschel K, David R, Riecken K, Hansen A, Eschenhagen T, Ulmer B
BIOMATERIALS. 2019;206:133-145.

Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT
Shimoni A, Labopin M, Finke J, Ciceri F, Deconinck E, Kröger N, Gramatzki M, Stelljes M, Blaise D, Stoelzel F, Chevallier P, Holler E, Fegueux N, Mohty M, Nagler A
BLOOD CANCER J. 2019;9(12):88.

Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis
Shouval R, Fein J, Labopin M, Kröger N, Duarte R, Bader P, Chabannon C, Kuball J, Basak G, Dufour C, Galimard J, Polge E, Lankester A, Montoto S, Snowden J, Styczynski J, Yakoub-Agha I, Mohty M, Nagler A
LANCET HAEMATOL. 2019;6(11):e573-e584.

The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease
Srinagesh H, Özbek U, Kapoor U, Ayuk F, Aziz M, Ben-David K, Choe H, DeFilipp Z, Etra A, Grupp S, Hartwell M, Hexner E, Hogan W, Karol A, Kasikis S, Kitko C, Kowalyk S, Lin J, Major-Monfried H, Mielke S, Merli P, Morales G, Ordemann R, Pulsipher M, Qayed M, Reddy P, Reshef R, Rösler W, Sandhu K, Schechter T, Shah J, Sigel K, Weber D, Wölfl M, Wudhikarn K, Young R, Levine J, Ferrara J
BLOOD ADV. 2019;3(23):4034-4042.

Is multiple sclerosis progression associated with the HLA-DR15 haplotype?
Stürner K, Siembab I, Schön G, Stellmann J, Heidari N, Fehse B, Heesen C, Eiermann T, Martin R, Binder T
MULT SCLER J-EXP TRA. 2019;5(4):2055217319894615.

Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT
Styczynski J, Tridello G, Gil L, Ljungman P, Mikulska M, Ward K, Cordonnier C, de la Camara R, Averbuch D, Knelange N, Socié G, Chevallier P, Blaise D, Yakoub-Agha I, Forcade E, Cornelissen J, Maertens J, Petersen E, Nguyen-Quoc S, Veelken H, Schaap N, Passweg J, Michallet M, Fegueux N, Deconinck E, Russell N, Basak G, Bader P, Montoto S, Kröger N, Cesaro S
BONE MARROW TRANSPL. 2019;54(12):2060-2071.

Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies
Sureda A, Dreger P, Bishop M, Kroger N, Porter D
BONE MARROW TRANSPL. 2019;54(1):17-25.

Nanobody-targeting of epidermal growth factor receptor (EGFR) ectodomain variants overcomes resistance to therapeutic EGFR antibodies
Tintelnot J, Baum N, Schultheiss C, Braig F, Trentmann M, Finter J, Fumey W, Bannas P, Fehse B, Riecken K, Schütze K, Bokemeyer C, Rösner T, Valerius T, Peipp M, Koch-Nolte F, Binder M
MOL CANCER THER. 2019;18(4):823-833.

Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling
Tintelnot J, Metz S, Trentmann M, Oberle A, von Wenserski L, Schultheiß C, Braig F, Kriegs M, Fehse B, Riecken K, Bokemeyer C, Stein A, Binder M
FRONT ONCOL. 2019;9:1559.

ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF
Triviai I, Zeschke S, Rentel J, Spanakis M, Scherer T, Gabdoulline R, Panagiota V, Thol F, Heuser M, Stocking C, Kröger N
LEUKEMIA. 2019;33(1):99-109.

The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study
von Felden J, Alric L, Pischke S, Aitken C, Schlabe S, Spengler U, Giordani M, Schnitzler P, Bettinger D, Thimme R, Xhaard A, Binder M, Ayuk F, Lohse A, Cornelissen J, de Man R, Mallet V
J HEPATOL. 2019;71(3):465-472.

Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation
Wagner-Drouet E, Teschner D, Wolschke C, Janson D, Schäfer-Eckart K, Gärtner J, Mielke S, Schreder M, Kobbe G, Kondakci M, Hilgendorf I, von Lilienfeld-Toal M, Klein S, Heidenreich D, Kreil S, Verbeek M, Graß S, Ditschkowski M, Gromke T, Koch M, Lindemann M, Hünig T, Schmidt T, Rascle A, Guldan H, Barabas S, Deml L, Wagner R, Wolff D
HAEMATOLOGICA. 2019 [Epub ahead of print].

EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL)
Wiktor-Jedrzejczak W, Drozd-Sokolowska J, Eikema D, Hoek J, Potter M, Wulf G, Sellner L, Ljungman P, Chevallier P, Volin L, Koc Y, Martin S, Bunjes D, Rovira M, Itälä-Remes M, Foá R, Deconinck E, Gedde-Dahl T, Cornelissen J, Collin M, Brecht A, Patel A, de Groot M, Reményi P, Nagler A, Finke J, Turlure P, Iacobelli S, van Biezen A, Schetelig J, Kröger N, Dreger P
BONE MARROW TRANSPL. 2019;54(9):1391-1398.

Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland
Wolff D, Hilgendorf I, Wagner-Drouet E, Jedlickova Z, Ayuk F, Zeiser R, Schäfer-Eckart K, Gerbitz A, Stadler M, Klein S, Middeke J, Lawitschka A, Winkler J, Halter J, Holler E, Kobbe G, Stelljes M, Ditschkowski M, Greinix H
BIOL BLOOD MARROW TR. 2019;25(7):1450-1455.

Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma
Ye R, Kundrapu S, Gerson S, Driscoll J, Beck R, Ali N, Landgren O, VanHeeckeren W, Luo G, Kroger N, Caimi P, De Lima M, Malek E
CL LYMPH MYELOM LEUK. 2019;19(5):e213-e220.

Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation
Zeiser R, Beelen D, Bethge W, Bornhäuser M, Bug G, Burchert A, Christopeit M, Duyster J, Finke J, Gerbitz A, Klusmann J, Kobbe G, Lübbert M, Müller-Tidow C, Platzbecker U, Rösler W, Sauer M, Schmid C, Schroeder T, Stelljes M, Kröger N, Müller L
BIOL BLOOD MARROW TR. 2019;25(4):e128-e140.

Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party
Auner H, Iacobelli S, Sbianchi G, Knol-Bout C, Blaise D, Russell N, Apperley J, Pohlreich D, Browne P, Kobbe G, Isaksson C, Lenhoff S, Scheid C, Touzeau C, Jantunen E, Anagnostopoulos A, Yakoub-Agha I, Tanase A, Schaap N, Wiktor-Jedrzejczak W, Krejci M, Schönland S, Morris C, Garderet L, Kröger N
HAEMATOLOGICA. 2018;103(3):514-521.

Langzeitnachsorge von Patienten nach allogener Blutstammzelltransplantation
Ayuketang F, Kroger N
2018. Langzeitnachsorge von Patienten nach allogener Blutstammzelltransplantation. Ayuk F, Kröger N, Tichelli A (Hrsg.). 1.. Aufl. Uni-Med, .

Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Ayuk F, Beelen D, Bornhäuser M, Stelljes M, Zabelina T, Finke J, Kobbe G, Wolff D, Wagner E, Christopeit M, Schmid C, Ottinger H, Groth C, Faul C, Bertz H, Rachlis E, Wolschke C, Schetelig J, Horn P, Mytilineos J, Guellstorf M, Kelsch R, Fleischhauer K, Kröger N, Bethge W
BIOL BLOOD MARROW TR. 2018;24(12):2558-2567.

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Barbui T, Tefferi A, Vannucchi A, Passamonti F, Silver R, Hoffman R, Verstovsek S, Mesa R, Kiladjian J, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin M, Hasselbalch H, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G
LEUKEMIA. 2018;32(5):1057-1069.

Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Benten D, Behrang Y, Unrau L, Weissmann V, Wolters-Eisfeld G, Burdak-Rothkamm S, Stahl F, Anlauf M, Grabowski P, Möbs M, Dieckhoff J, Sipos B, Fahl M, Eggers C, Perez D, Bockhorn M, Izbicki J, Lohse A, Schrader J
MOL CANCER RES. 2018;16(3):496-507.

Transplant results in adults with Fanconi anaemia
Bierings M, Bonfim C, Peffault De Latour R, Aljurf M, Mehta P, Knol C, Boulad F, Tbakhi A, Esquirol A, McQuaker G, Sucak G, Othman T, Halkes C, Carpenter B, Niederwieser D, Zecca M, Kröger N, Michallet M, Risitano A, Ehninger G, Porcher R, Dufour C
BRIT J HAEMATOL. 2018;180(1):100-109.

Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharamcokinetic study
Braune S, König C, Roberts J, Nierhaus A, Steinmetz O, Baehr M, Kluge S, Langebrake C
CRIT CARE. 2018;22(1):25-34.

Clonal dynamics studied in cultured induced pluripotent stem cells reveal major growth imbalances within a few weeks
Brenière-Letuffe D, Domke-Shibamiya A, Hansen A, Eschenhagen T, Fehse B, Riecken K, Stenzig J
STEM CELL RES THER. 2018;9(1):165.

Consensus Statement of European Societies of Gene and Cell Therapy on the Reported Birth of Genome-Edited Babies in China
Büning H, Griesenbach U, Fehse B, Ylä-Herttuala S, Anagnou N, van Beusechem V, Raya A, Verhoeyen E
HUM GENE THER. 2018;29(12):1337–1338.

Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT
Christopeit M, Labopin M, Gorin N, Saraceni F, Passweg J, Forcade E, Maertens J, Van Lint M, Bosi A, Niederwieser D, Ehninger G, Polge E, Mohty M, Nagler A
AM J HEMATOL. 2018;93(12):1532-1542.

Lysosomal Proteome and Secretome Analysis Identifies Missorted Enzymes and Their Nondegraded Substrates in Mucolipidosis III Mouse Cells
Di Lorenzo G, Velho R, Winter D, Thelen M, Ahmadi S, Schweizer M, De Pace R, Cornils K, Yorgan T, Grüb S, Hermans-Borgmeyer I, Schinke T, Müller-Loennies S, Braulke T, Pohl S
MOL CELL PROTEOMICS. 2018;17(8):1612-1626.

Allogeneic hematopoietic cell transplantation in Farber disease
Ehlert K, Levade T, Di Rocco M, Lanino E, Albert M, Führer M, Jarisch A, Güngör T, Ayuk F, Vormoor J
J INHERIT METAB DIS. 2018 [Epub ahead of print].

Knockdown of L1CAM significantly reduces metastasis in a xenograft model of human melanoma: L1CAM is a potential target for anti-melanoma therapy
Ernst A, Putscher A, Samatov T, Suling A, Galatenko V, Shkurnikov M, Knyazev E, Tonevitsky A, Haalck T, Lange T, Maar H, Schröder-Schwarz J, Riecken K, Schumacher U, Wicklein D
PLOS ONE. 2018;13(2):e0192525.

Genomeditierung durch CRISPR und Co
Fehse B
2018. Stammzellforschung. Zenke M, Marx-Stölting L, Schickl H (Hrsg.). 1. Aufl. Baden-Baden: Nomos, 97-114.

„Rote Gentechnologie“ – Nachhaltiges Comeback der Gentherapie?!
Fehse B
2018. Vierter Gentechnologiebericht . Hucho F, Diekämper J, Fangerau H, Fehse B, Hampel J, Köchy K, Könninger S, Marx-Stölting L, Müller-Röber B, Reich J, Schickl H, Taupitz J, Walter J, Zenke M, Korte M (Hrsg.). 1. Aufl. Baden-Baden: Nomos Verlagsgesellschaft, 210-214.

The Time Is Ripe for Somatic Genome Editing: NIH Program to Strengthen Translation
Fehse B, Abramowski-Mock U
MOL THER. 2018;26(3):671-674.

Locally Ablative Radiation Therapy of a Primary Human Small Cell Lung Cancer Tumor Decreases the Number of Spontaneous Metastases in Two Xenograft Models
Frenzel T, Siekmann J, Grohmann C, Valentiner U, Schmitz R, Riecken K, Fehse B, Schumacher U, Lange T, Krüll A
INT J RADIAT ONCOL. 2018;100(4):1044-1056.

Competing-risk outcomes after hematopoietic stem cell transplantation from the perspective of time-dependent effects
Fuerst D, Frank S, Mueller C, Beelen D, Schetelig J, Niederwieser D, Finke J, Bunjes D, Kröger N, Neuchel C, Tsamadou C, Schrezenmeier H, Beyersmann J, Mytilineos J
HAEMATOLOGICA. 2018;103(9):1527-1534.

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the Chronic Malignancies Working Party of the EBMT
Gagelmann N, Eikema D, Iacobelli S, Koster L, Nahi H, Stoppa A, Masszi T, Caillot D, Lenhoff S, Udvardy M, Crawley C, Arcese W, Mariette C, Hunter A, Leleu X, Schipperus M, Delforge M, Pioltelli P, Snowden J, Itälä-Remes M, Musso M, van Biezen A, Garderet L, Kröger N
HAEMATOLOGICA. 2018;103(5):890-897.

Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis
Gagelmann N, Ljungman P, Styczynski J, Kröger N
BIOL BLOOD MARROW TR. 2018;24(10):2101-2109.

Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma
Garderet L, Iacobelli S, Koster L, Goldschmidt H, Johansson J, Bourhis J, Krejci M, Leleu X, Potter M, Blaise D, Koenecke C, Peschel C, Radocha J, Metzner B, Lenain P, Schäfer-Eckart K, Pohlreich D, Grasso M, Caillot D, Einsele H, Ladetto M, Schönland S, Kröger N
BIOL BLOOD MARROW TR. 2018;24(7):1372-1378.

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5Q Deletion
Garderet L, Ziagkos D, van Biezen A, Iacobelli S, Finke J, Maertens J, Volin L, Ljungman P, Chevallier P, Passweg J, Schaap N, Beelen D, Nagler A, Blaise D, Poiré X, Yakoub-Agha I, Lenhoff S, Craddock C, Schots R, Rambaldi A, Sanz J, Jindra P, Mufti G, Robin M, Kröger N
BIOL BLOOD MARROW TR. 2018;24(3):507-513.

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner H, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, Hajek R, Ludwig H, Einsele H, Dimopoulos M, Boccadoro M, Kröger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P
HAEMATOLOGICA. 2018;103(2):197-211.

Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?
Giammarco S, Peffault de Latour R, Sica S, Dufour C, Socie G, Passweg J, Kröger N, Petersen E, Van Lint M, Oneto R, Signori A, Bacigalupo A
BLOOD. 2018;131(17):1989-1992.

Prevention and treatment of relapse after stem cell transplantation with immunotherapy
Gökbuget N, Canaani J, Nagler A, Bishop M, Kröger N, Avigan D
BONE MARROW TRANSPL. 2018;53(6):664-672.

AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation
Halaburda K, Labopin M, Houhou M, Niederwieser D, Finke J, Volin L, Maertens J, Cornelissen J, Milpied N, Stuhler G, Kröger N, Esteve J, Mohty M, Nagler A
BONE MARROW TRANSPL. 2018;53(6):683-691.

Differential Proteome Analysis of Human Neuroblastoma Xenograft Primary Tumors and Matched Spontaneous Distant Metastases
Hänel L, Gosau T, Maar H, Valentiner U, Schumacher U, Riecken K, Windhorst S, Hansen N, Heikaus L, Wurlitzer M, Nolte I, Schlüter H, Lange T
SCI REP-UK. 2018;8(1):13986.

Return to Work in Patients with Hematological Cancers 1 Year after Treatment: A Prospective Longitudinal Study
Hartung T, Sautier L, Scherwath A, Sturm K, Kröger N, Koch U, Mehnert A
ONCOL RES TREAT. 2018;41(11):697-701.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival
Hartwell M, Özbek U, Holler E, Renteria A, Major-Monfried H, Reddy P, Aziz M, Hogan W, Ayuk F, Efebera Y, Hexner E, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen Y, Devine S, Harris A, Jagasia M, Kitko C, Litzow M, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik G, Levine J, Ferrara J
JCI INSIGHT. 2018;3(16):.

Improving Lentiviral Transduction of CD34(+) Hematopoietic Stem and Progenitor Cells
Hauber I, Beschorner N, Schrödel S, Chemnitz J, Kröger N, Hauber J, Thirion C
HUM GENE THER METHOD. 2018;29(2):104-113.

Targeting proinflammatory cytokines ameliorates calcifying phenotype conversion of vascular progenitors under uremic conditions in vitro
Hegner B, Schaub T, Janke D, Zickler D, Lange C, Girndt M, Jankowski J, Schindler R, Dragun D
SCI REP-UK. 2018;8(1):12087.

Allogeneic haematopoietic cell transplantation offers the chance of cure for patients with transformed follicular lymphoma
Heinzelmann F, Bethge W, Beelen D, Stelljes M, Dreger P, Engelhard M, Finke J, Kröger N, Holler E, Bornhäuser M, Müller A, Haubitz I, Ottinger H
J CANCER RES CLIN. 2018;144(6):1173-1183.

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802
Holtan S, DeFor T, Panoskaltsis-Mortari A, Khera N, Levine J, Flowers M, Lee S, Inamoto Y, Chen G, Mayer S, Arora M, Palmer J, Cutler C, Arai S, Lazaryan A, Newell L, Jagasia M, Pusic I, Wood W, Renteria A, Yanik G, Hogan W, Hexner E, Ayuk F, Holler E, Bunworasate U, Efebera Y, Ferrara J, Pidala J, Howard A, Wu J, Bolaños-Meade J, Ho V, Alousi A, Blazar B, Weisdorf D, MacMillan M
BLOOD ADV. 2018;2(15):1882-1888.

Epidemiology and biology of relapse after stem cell transplantation
Horowitz M, Schreiber H, Elder A, Heidenreich O, Vormoor J, Toffalori C, Vago L, Kröger N
BONE MARROW TRANSPL. 2018;53(11):1379-1389.

Transient Retrovirus-Based CRISPR/Cas9 All-in-One Particles for Efficient, Targeted Gene Knockout
Knopp Y, Geis F, Heckl D, Horn S, Neumann T, Kuehle J, Meyer J, Fehse B, Baum C, Morgan M, Meyer J, Schambach A, Galla M
MOL THER-NUCL ACIDS. 2018;13:256-274.

Third International workshop on the biology, prevention, and treatment of relapse after stem cell transplantation
Kröger N, Bishop M, Giralt S, Wayne A
BONE MARROW TRANSPL. 2018;53(1):1-2.

Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation
Kröger N, Shahnaz Syed Abd Kadir S, Zabelina T, Badbaran A, Christopeit M, Ayuk F, Wolschke C
BIOL BLOOD MARROW TR. 2018;24(10):2152-2156.

MAGIC biomarkers predict long term outcomes for steroid-resistant acute GVHD
Major-Monfried H, Renteria A, Pawarode A, Reddy P, Ayuk F, Holler E, Efebera Y, Hogan W, Wölfl M, Qayed M, Hexner E, Wudhikarn K, Ordemann R, Young R, Shah J, Hartwell M, Chaudhry M, Aziz M, Etra A, Yanik G, Kröger N, Weber D, Chen Y, Nakamura R, Rösler W, Kitko C, Harris A, Pulsipher M, Reshef R, Kowalyk S, Morales G, Torres I, Özbek U, Ferrara J, Levine J
BLOOD. 2018;131(25):2846-2855.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Mathew N, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller T, Hanke K, Taromi S, Apostolova P, Illert A, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan K, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong G, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder S, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller L, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert J, Feger D, Wagner E, Cahn J, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller A, Kondo T, Teshima T, Klaeger S, Kuster B, Kim D, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin J, Henden A, Hill G, Kennedy G, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin R, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri M, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar B, Zeiser R
NAT MED. 2018;24(4):526.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Mathew N, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller T, Hanke K, Taromi S, Apostolova P, Illert A, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan K, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong G, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder S, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller L, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert J, Feger D, Wagner E, Cahn J, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller A, Kondo T, Teshima T, Klaeger S, Kuster B, Kim D, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin J, Henden A, Hill G, Kennedy G, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin R, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri M, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar B, Zeiser R
NAT MED. 2018;24(3):282-291.

Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)
Mellinghoff S, Panse J, Alakel N, Behre G, Buchheidt D, Christopeit M, Hasenkamp J, Kiehl M, Koldehoff M, Krause S, Lehners N, von Lilienfeld-Toal M, Löhnert A, Maschmeyer G, Teschner D, Ullmann A, Penack O, Ruhnke M, Mayer K, Ostermann H, Wolf H, Cornely O
ANN HEMATOL. 2018;97(2):197-207.

Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation
Mohty M, Duarte R, Kuball J, Bader P, Basak G, Bonini C, Carreras E, Chabannon C, Dufour C, Gennery A, Lankester A, Lanza F, Ljungman P, Montoto S, Nagler A, Snowden J, Styczynski J, Sureda A, Kröger N
BONE MARROW TRANSPL. 2018;53(12):1548-1552.

In Vitro Model for Studying of the Role of IGFBP6 Gene in Breast Cancer Metastasizing
Nikulin S, Raigorodskaya M, Poloznikov A, Zakharova G, Schumacher U, Wicklein D, Stürken C, Riecken K, Fomicheva K, Alekseev B, Shkurnikov M
B EXP BIOL MED+. 2018;164(5):688-692.

Role of IGFBP6 Protein in the Regulation of Epithelial-Mesenchymal Transition Genes
Nikulin S, Raigorodskaya M, Poloznikov A, Zakharova G, Schumacher U, Wicklein D, Stürken C, Riecken K, Fomicheva K, Alekseev B, Shkurnikov M
B EXP BIOL MED+. 2018;164(5):650-654.

Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens
Oyekunle A, Shumilov E, Kostrewa P, Burchert A, Trümper L, Wuchter P, Wulf G, Bacher U, Kröger N
BIOL BLOOD MARROW TR. 2018;24(2):276-281.

Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report
Passweg J, Baldomero H, Bader P, Basak G, Bonini C, Duarte R, Dufour C, Kröger N, Kuball J, Lankester A, Montoto S, Nagler A, Snowden J, Styczynski J, Mohty M
BONE MARROW TRANSPL. 2018;53(9):1139-1148.

Oncogenic JAK2causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms
Prestipino A, Emhardt A, Aumann K, O'Sullivan D, Gorantla S, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholomä M, Shoumariyeh K, Jutzi J, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl F, Minguet S, Miething C, Heidel F, Kröger N, Triviai I, Brummer T, Finke J, Illert A, Ruggiero E, Bonini C, Duyster J, Pahl H, Lane S, Hill G, Blazar B, von Bubnoff N, Pearce E, Zeiser R
SCI TRANSL MED. 2018;10:429.

What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?
Ringdén O, Labopin M, Sadeghi B, Mailhol A, Beelen D, Fløisand Y, Ghavamzadeh A, Finke J, Ehninger G, Volin L, Socié G, Kröger N, Stuhler G, Ganser A, Schmid C, Giebel S, Mohty M, Nagler A
J INTERN MED. 2018;283(2):166-177.

Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party
Robinson S, Boumendil A, Finel H, Peggs K, Chevallier P, Sierra J, Finke J, Poiré X, Maillard N, Milpied N, Yakoub-Agha I, Koh M, Kröger N, Nagler A, Koc Y, Dietrich S, Montoto S, Dreger P
BONE MARROW TRANSPL. 2018;53(5):617-624.

Cellular Barcoding Identifies Clonal Substitution as a Hallmark of Local Recurrence in a Surgical Model of Head and Neck Squamous Cell Carcinoma
Roh V, Abramowski P, Hiou-Feige A, Cornils K, Rivals J, Zougman A, Aranyossy T, Thielecke L, Truan Z, Mermod M, Monnier Y, Prassolov V, Glauche I, Nowrouzi A, Abdollahi A, Fehse B, Simon C, Tolstonog G
CELL REP. 2018;25(8):2208-2222.e7.

Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT
Ruggeri A, Labopin M, Bacigalupo A, Afanasyev B, Cornelissen J, Elmaagacli A, Itälä-Remes M, Blaise D, Meijer E, Koc Y, Milpied N, Schouten H, Kroeger N, Mohty M, Nagler A
J HEMATOL ONCOL. 2018;11(1):40.

Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO)
Ruhnke M, Behre G, Buchheidt D, Christopeit M, Hamprecht A, Heinz W, Heussel C, Horger M, Kurzai O, Karthaus M, Löffler J, Maschmeyer G, Penack O, Rieger C, Rickerts V, Ritter J, Schmidt-Hieber M, Schuelper N, Schwartz S, Ullmann A, Vehreschild J, von Lilienfeld-Toal M, Weber T, Wolf H
MYCOSES. 2018;61(11):796-813.

Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents
Sahebi F, Iacobelli S, Sbianchi G, Koster L, Blaise D, Reményi P, Russell N, Ljungman P, Kobbe G, Apperley J, Trneny M, Krejci M, Wiktor-Jedrzejczak W, Sanchez J, Schaap N, Isaksson C, Lenhoff S, Browne P, Scheid C, Wilson K, Yakoub-Agha I, González Muñiz S, Schönland S, Morris C, Garderet L, Kröger N
BIOL BLOOD MARROW TR. 2018;24(5):930-936.

Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT
Santoro N, Labopin M, Giannotti F, Ehninger G, Niederwieser D, Brecht A, Stelljes M, Kröger N, Einsele H, Eder M, Hallek M, Glass B, Finke J, Ciceri F, Mohty M, Ruggeri A, Nagler A
J HEMATOL ONCOL. 2018;11(1):55.

The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia
Schliffke S, Buhs S, Bolz S, Gerull H, von Wenserski L, Riecken K, Fehse B, Nollau P, Binder M
BLOOD. 2018;131(15):1755-1758.

Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation
Schmid C, de Wreede L, van Biezen A, Finke J, Ehninger G, Ganser A, Volin L, Niederwieser D, Beelen D, Alessandrino P, Kanz L, Schleuning M, Passweg J, Veelken H, Maertens J, Cornelissen J, Blaise D, Gramatzki M, Milpied N, Yakub-Agha I, Mufti G, Rovira M, Arnold R, De Witte T, Robin M, Kröger N
HAEMATOLOGICA. 2018;103(2):237-245.

Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis
Shahnaz Syed Abd Kadir S, Christopeit M, Wulf G, Wagner E, Bornhauser M, Schroeder T, Crysandt M, Mayer K, Jonas J, Stelljes M, Badbaran A, Ayuketang Ayuk F, Triviai I, Wolf D, Wolschke C, Kröger N
EUR J HAEMATOL. 2018;101(3):305-317.

Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option
Stamm H, Klingler F, Grossjohann E, Muschhammer J, Vettorazzi E, Heuser M, Mock U, Thol F, Vohwinkel G, Latuske E, Bokemeyer C, Kischel R, Dos Santos C, Stienen S, Friedrich M, Lutteropp M, Nagorsen D, Wellbrock J, Fiedler W
ONCOGENE. 2018;37(39):5269-5280.

Efficient gene editing via non-viral delivery of CRISPR-Cas9 system using polymeric and hybrid microcarriers
Timin A, Muslimov A, Lepik K, Epifanovskaya O, Shakirova A, Mock U, Riecken K, Okilova M, Sergeev V, Afanasyev B, Fehse B, Sukhorukov G
NANOMED-NANOTECHNOL. 2018;14(1):97-108.

Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT
van Gorkom G, van Gelder M, Eikema D, Blok H, van Lint M, Koc Y, Ciceri F, Beelen D, Chevallier P, Selleslag D, Blaise D, Foá R, Corradini P, Castagna L, Moreno C, Solano C, Müller L, Tischer J, Hilgendorf I, Hallek M, Bittenbring J, Theobald M, Schetelig J, Kröger N
BONE MARROW TRANSPL. 2018;53(3):255-263.

High bone turnover in mice carrying a pathogenic Notch2-mutation causing Hajdu-Cheney syndrome
Vollersen N, Hermans-Borgmeyer I, Cornils K, Fehse B, Rolvien T, Triviai I, Jeschke A, Oheim R, Amling M, Schinke T, Yorgan T
J BONE MINER RES. 2018;33(1):70-83.

Acute hepatitis as a prequel to very severe aplastic anemia
Weiler-Normann C, Hartl J, Weidemann S, von Pein U, Fiedler W, Schramm C, Brinkert F, Kröger N, Christopeit M
Z GASTROENTEROL. 2018;56(1):51-54.

HEV-positive blood donations represent a relevant infection risk for immunosuppressed recipients
Westhölter D, Hiller J, Denzer U, Polywka S, Ayuk F, Rybczynski M, Horvatits T, Gundlach S, Blöcker J, Schulze Zur Wiesch J, Fischer N, Addo M, Peine S, Göke B, Lohse A, Lütgehetmann M, Pischke S
J HEPATOL. 2018;69(1):36-42.

Umstellung häufig verordneter Kapselrezepturen in der Pädiatrie und Neonatologie auf flüssige Oralia im Krankenhaus
Albrecht S, Scherließ R, Goerke A, Langebrake C
Krankenhauspharmazie. 2017;38(10):459-68.

Wenn dem Blut der Sauerstoff ausgeht... Bisherige Erkenntnisse und Besonderheiten der Pharmakotherapie bei erwachsenen ECMO-Patienten
Alihodzic D, Kluge S, Langebrake C
Krankenhauspharmazie. 2017;38(2):77-85.

Effective Immunological Guidance of Genetic Analyses Including Exome Sequencing in Patients Evaluated for Hemophagocytic Lymphohistiocytosis
Ammann S, Lehmberg K, Zur Stadt U, Klemann C, Bode S, Speckmann C, Janka G, Wustrau K, Rakhmanov M, Fuchs I, Hennies H, Ehl S
J CLIN IMMUNOL. 2017;37(8):770-780.

Genetic barcodes facilitate competitive clonal analyses in vivo
Aranyossy T, Thielecke L, Glauche I, Fehse B, Cornils K
HUM GENE THER. 2017;28(10):926-937.

Coupled Proliferation and Apoptosis Maintain the Rapid Turnover of Microglia in the Adult Brain
Askew K, Li K, Olmos-Alonso A, Garcia-Moreno F, Liang Y, Richardson P, Tipton T, Chapman M, Riecken K, Beccari S, Sierra A, Molnár Z, Cragg M, Garaschuk O, Perry V, Gomez-Nicola D
CELL REP. 2017;18(2):391-405.

Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma
Atanackovic D, Luetkens T, Radhakrishnan S, Kroger N
CURR CANCER DRUG TAR. 2017;17(9):839-845.

Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-KPolymorphism
Braig F, Kriegs M, Voigtlaender M, Habel B, Grob T, Biskup K, Blanchard V, Sack M, Thalhammer A, Ben Batalla I, Braren I, Laban S, Danielczyk A, Goletz S, Jakubowicz E, Märkl B, Trepel M, Knecht R, Riecken K, Fehse B, Loges S, Bokemeyer C, Binder M
CANCER RES. 2017;77(5):1188-1199.

Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT
Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R, Finke J, Kolb H, Ganser A, Schäfer-Eckart K, Zander A, Bunjes D, Mielke S, Bethge W, Milpied N, Kalhs P, Blau I, Kröger N, Vitek A, Gramatzki M, Holler E, Schmid C, Esteve J, Mohty M, Nagler A
J HEMATOL ONCOL. 2017;10(1):130.

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)
Bug G, Burchert A, Wagner E, Kröger N, Berg T, Güller S, Metzelder S, Wolf A, Hünecke S, Bader P, Schetelig J, Serve H, Ottmann O
LEUKEMIA. 2017;31(11):2523-2525.

CAR-T cells: the narrow path between hope and bankruptcy?
Chabannon C, Kuball J, Mcgrath E, Bader P, Dufour C, Lankester A, Basak G, Montoto S, Nagler A, Snowden J, Styczynski J, Duarte R, Kröger N, Mohty M
BONE MARROW TRANSPL. 2017;52(12):1588-1589.

High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation
Cook G, Iacobelli S, van Biezen A, Ziagkos D, LeBlond V, Abraham J, McQuaker G, Schoenland S, Rambaldi A, Halaburda K, Rovira M, Sica S, Byrne J, Sanz R, Nagler A, van de Donk N, Sinisalo M, Cook M, Kröger N, De Witte T, Morris C, Garderet L
HAEMATOLOGICA. 2017;102(1):160-167.

Clonal competition in BcrAbl-driven leukemia: how transplantations can accelerate clonal conversion
Cornils K, Thielecke L, Winkelmann D, Aranyossy T, Lesche M, Dahl A, Roeder I, Fehse B, Glauche I
MOL CANCER. 2017;16(1):120.

Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti G, Fenaux P, Sanz G, Martino R, Alessandrino E, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Finke J, van Gelder M, van de Loosdrecht A, Ljungman P, Stauder R, Volin L, Deeg H, Cutler C, Saber W, Champlin R, Giralt S, Anasetti C, Kröger N
BLOOD. 2017;129(13):1753-1762.

Investigating the temporal course, relevance and risk factors of fatigue over 5 years: a prospective study among patients receiving allogeneic HSCT
Esser P, Kuba K, Mehnert A, Schwinn A, Schirmer L, Schulz-Kindermann F, Kruse M, Koch U, Zander A, Kröger N, Schilling G, Götze H, Scherwath A
BONE MARROW TRANSPL. 2017;52(5):753-758.

Stability and priority of symptoms and symptom clusters among allogeneic HSCT patients within a 5-year longitudinal study
Esser P, Kuba K, Scherwath A, Johansen C, Schwinn A, Schirmer L, Schulz-Kindermann F, Kruse M, Koch U, Zander A, Kröger N, Götze H, Mehnert A
J PAIN SYMPTOM MANAG. 2017;54(4):493-500.

Posttraumatic stress disorder symptomatology in the course of allogeneic HSCT: a prospective study
Esser P, Kuba K, Scherwath A, Schirmer L, Schulz-Kindermann F, Dinkel A, Balck F, Koch U, Kröger N, Götze H, Mehnert A
J CANCER SURVIV. 2017;11(2):203-210.

CHO cells engineered for fluorescence read out of cell cycle and growth rate in real time
Fuge G, Hong Y, Riecken K, Zeng A, Jandt U
BIOTECHNOL PROGR. 2017;33(5):1408-1417.

Comparison of Different Rabbit Anti-Thymocyte Globulin Formulations in Allogeneic Stem Cell Transplantation: Systematic Literature Review and Network Meta-Analysis
Gagelmann N, Ayuk F, Wolschke C, Kröger N
BIOL BLOOD MARROW TR. 2017;23(12):2184-2191.

Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting
Garderet L, Cook G, Auner H, Bruno B, Lokhorst H, Perez-Simon J, Sahebi F, Scheid C, Morris C, van Biezen A, Sobh M, Michallet M, Gahrton G, Schönland S, Kröger N
LEUKEMIA LYMPHOMA. 2017;58(4):797-808.

Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances
Garderet L, D'Souza A, Jacobs P, van Biezen A, Schönland S, Kroeger N, Morris C, Hari P
BIOL BLOOD MARROW TR. 2017;23(7):1193-1202.

Alloreactivity: the Janus-face of hematopoietic stem cell transplantation
Gratwohl A, Sureda A, Cornelissen J, Apperley J, Dreger P, Duarte R, Greinix H, Mc Grath E, Kroeger N, Lanza F, Nagler A, Snowden J, Niederwieser D, Brand R
LEUKEMIA. 2017;31(8):1752-1759.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival
Hartwell M, Özbek U, Holler E, Renteria A, Major-Monfried H, Reddy P, Aziz M, Hogan W, Ayuketang F, Efebera Y, Hexner E, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen Y, Devine S, Harris A, Jagasia M, Kitko C, Litzow M, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik G, Levine J, Ferrara J
JCI INSIGHT. 2017;2(3):e89798.

Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection
Heidenreich S, Kröger N
FRONT IMMUNOL. 2017;8:41.

Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT
Heidenreich S, Ziagkos D, de Wreede L, van Biezen A, Finke J, Platzbecker U, Niederwieser D, Einsele H, Bethge W, Schleuning M, Beelen D, Tischer J, Nagler A, Glass B, Maertens J, Yáñez L, Beguin Y, Sill H, Scheid C, Stelljes M, Ganser A, Zachée P, Selleslag D, de Witte T, Robin M, Kröger N
BIOL BLOOD MARROW TR. 2017;23(1):44-52.

Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
Heinz W, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Cornely O, Einsele H, Karthaus M, Link H, Mahlberg R, Neumann S, Ostermann H, Penack O, Ruhnke M, Sandherr M, Schiel X, Vehreschild J, Weissinger F, Maschmeyer G
ANN HEMATOL. 2017;96(11):1775-1792.

Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation
Heuser M, Gabdoulline R, Löffeld P, Dobbernack V, Kreimeyer H, Pankratz M, Flintrop M, Liebich A, Klesse S, Panagiota V, Stadler M, Wichmann M, Shahswar R, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Geffers R, Schlegelberger B, Göhring G, Kreipe H, Germing U, Ganser A, Kröger N, Koenecke C, Thol F
ANN HEMATOL. 2017;96(8):1361-1372.

Impact of non-transferrin-bound iron (NTBI) in comparison to serum ferritin on outcome after allogeneic stem cell transplantation (ASCT)
Hilken A, Langebrake C, Wolschke C, Kersten J, Rohde H, Nielsen P, Kröger N
ANN HEMATOL. 2017;96(8):1379-1388.

PTEN mediates the cross talk between breast and glial cells in brain metastases leading to rapid disease progression
Hohensee I, Chuang H, Grottke A, Werner S, Schulte A, Horn S, Lamszus K, Bartkowiak K, Witzel I, Westphal M, Matschke J, Glatzel M, Jücker M, Pukrop T, Pantel K, Wikman H
ONCOTARGET. 2017;8(4):6155-6168.

Population pharmacokinetics and dosing simulations of ceftazidime in critically ill patients receiving sustained low-efficiency dialysis
König C, Braune S, Roberts J, Nierhaus A, Steinmetz O, Baehr M, Frey O, Langebrake C, Kluge S
J ANTIMICROB CHEMOTH. 2017;72(5):1433-1440.

Maximizing the benefit of allogeneic stem cell transplantation in myelodysplastic syndromes
Kröger N
SEMIN HEMATOL. 2017;54(3):154-158.

Raising the bar for chronic GVHD trials
Kröger N
BLOOD. 2017;130(3):241-242.

Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)
Kröger N, Iacobelli S, Franke G, Platzbecker U, Uddin R, Hübel K, Scheid C, Weber T, Robin M, Stelljes M, Afanasyev B, Heim D, Deliliers G, Onida F, Dreger P, Pini M, Guidi S, Volin L, Günther A, Bethge W, Poiré X, Kobbe G, van Os M, Brand R, de Witte T
J CLIN ONCOL. 2017;35(19):2157-2164.

Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation
Kröger N, Panagiota V, Badbaran A, Zabelina T, Triviai I, Araujo Cruz M, Shahswar R, Ayuketang F, Gehlhaar M, Wolschke C, Bollin R, Walter C, Dugas M, Wiehlmann L, Lehmann U, Koenecke C, Chaturvedi A, Alchalby H, Stadler M, Eder M, Christopeit M, Göhring G, Koenigsmann M, Schlegelberger B, Kreipe H, Ganser A, Stocking C, Fehse B, Thol F, Heuser M
BIOL BLOOD MARROW TR. 2017;23(7):1095-1101.

Depression and anxiety following hematopoietic stem cell transplantation: a prospective population-based study in Germany
Kuba K, Esser P, Mehnert A, Johansen C, Schwinn A, Schirmer L, Schulz-Kindermann F, Kruse M, Koch U, Zander A, Kröger N, Götze H, Scherwath A
BONE MARROW TRANSPL. 2017;52(12):1651-1657.

Cancer-and-treatment-specific distress and its impact on posttraumatic stress in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)
Kuba K, Esser P, Scherwath A, Schirmer L, Schulz-Kindermann F, Dinkel A, Balck F, Koch U, Kröger N, Götze H, Mehnert A
PSYCHO-ONCOLOGY. 2017;26(8):1164-1171.

CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
Locke F, Pidala J, Storer B, Martin P, Pulsipher M, Chauncey T, Jacobsen N, Kröger N, Walker I, Light S, Shaw B, Beato F, Laport G, Nademanee A, Keating A, Socie G, Anasetti C
BIOL BLOOD MARROW TR. 2017;23(3):405-411.

Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Malard F, Labopin M, Stuhler G, Bittenbring J, Ganser A, Tischer J, Michallet M, Kröger N, Schmid C, Huynh A, Hallek M, Savani B, Mohty M, Nagler A
BIOL BLOOD MARROW TR. 2017;23(2):278-284.

Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle: Examining Pieces of the Jigsaw Puzzle
Malek E, El-Jurdi N, Kröger N, de Lima M
FRONT ONCOL. 2017;7:287.

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations
Marchetti M, Barosi G, Cervantes F, Birgegård G, Griesshammer M, Harrison C, Hehlmann R, Kiladjian J, Kröger N, McMullin M, Passamonti F, Vannucchi A, Barbui T
LEUKEMIA. 2017;31(4):882-888.

Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes
Martino R, Henseler A, van Lint M, Schaap N, Finke J, Beelen D, Vigouroux S, Alessandrino E, Mufti G, Veelken J, Bruno B, Yakoub-Agha I, Volin L, Maertens J, Or R, Leblond V, Rovira M, Kalhs P, Alvarez A, Vitek A, Sierra J, Wagner E, Robin M, de Witte T, Kröger N
BONE MARROW TRANSPL. 2017;52(8):1107-1112.

Optical Barcoding for Single-Clone Tracking to Study Tumor Heterogeneity
Mohme M, Maire C, Riecken K, Zapf S, Aranyossy T, Westphal M, Lamszus K, Fehse B
MOL THER. 2017;25(3):621-633.

Jon van Rood (1926-2017)
Mueller C, Bonini C, Foeken L, Chabannon C, Bondanza A, Fleischhauer K, Velardi A, Kröger N, Kuball J, Mohty M
BONE MARROW TRANSPL. 2017;52(12):1587.

Mesenchymal stem cells engineering: microcapsules assisted gene transfection and magnetic cell separation.
Muslimov A, Timin A, Petrova A, Epifanovskaya O, Shakirova A, Lepik K, Gorshkov A, Il’inskaja E, Vasin A, Afanasyev B, Fehse B, Sukhorukov G
ACS BIOMATER SCI ENG. 2017;3(10):2314-2324.

ABR, a novel inducer of transcription factor C/EBPα, contributes to myeloid differentiation and is a favorable prognostic factor in acute myeloid leukemia
Namasu C, Katzerke C, Bräuer-Hartmann D, Wurm A, Gerloff D, Hartmann J, Schwind S, Müller-Tidow C, Hilger N, Fricke S, Christopeit M, Niederwieser D, Behre G
ONCOTARGET. 2017;8(61):103626-103639.

Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT
Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dössinger G, Schiemann M, Lakshmipathi S, Martin K, Bunjes D, Harsdorf S, Weissinger E, Menzel H, Verbeek M, Uharek L, Kröger N, Wagner E, Kobbe G, Schroeder T, Schmitt M, Held G, Herr W, Germeroth L, Bonig H, Tonn T, Einsele H, Busch D, Grigoleit G
LEUKEMIA. 2017;31(10):2161-2171.

Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection
Oberle A, Brandt A, Alawi M, Langebrake C, Janjetovic S, Wolschke C, Schütze K, Bannas P, Kröger N, Koch-Nolte F, Bokemeyer C, Binder M
HAEMATOLOGICA. 2017;102(9):e368-e370.

Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Onida F, de Wreede L, van Biezen A, Eikema D, Byrne J, Iori A, Schots R, Jungova A, Schetelig J, Finke J, Veelken H, Johansson J, Craddock C, Stelljes M, Theobald M, Holler E, Schanz U, Schaap N, Bittenbring J, Olavarria E, Chalandon Y, Kröger N
BRIT J HAEMATOL. 2017;177(5):759-765.

In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review
Oostvogels R, Uniken Venema S, de Witte M, Raymakers R, Kuball J, Kröger N, Minnema M
BONE MARROW TRANSPL. 2017;52(9):1233-1240.

Mutations in EXTL3 Cause Neuro-immuno-skeletal Dysplasia Syndrome
Oud M, Tuijnenburg P, Hempel M, van Vlies N, Ren Z, Ferdinandusse S, Jansen M, Santer R, Johannsen J, Bacchelli C, Alders M, Li R, Davies R, Dupuis L, Cale C, Wanders R, Pals S, Ocaka L, James C, Müller I, Lehmberg K, Strom T, Engels H, Williams H, Beales P, Roepman R, Dias P, Brunner H, Cobben J, Hall C, Hartley T, Le Quesne Stabej P, Mendoza-Londono R, Davies E, de Sousa S, Lessel D, Arts H, Kuijpers T
AM J HUM GENET. 2017;100(2):281-296.

Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT)
Passweg J, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte R, Dufour C, Kuball J, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Nagler A, Sureda A, Mohty M
BONE MARROW TRANSPL. 2017;52(2):191-196.

Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report
Passweg J, Baldomero H, Bader P, Bonini C, Duarte R, Dufour C, Gennery A, Kröger N, Kuball J, Lanza F, Montoto S, Nagler A, Snowden J, Styczynski J, Mohty M
BONE MARROW TRANSPL. 2017;52(6):811-817.

ГЕННАЯ КЛЕТОЧНАЯ ТЕРАПИЯ ВИЧ И ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ КРОВЕТВОРНОЙ И ЛИМФАТИЧЕСКОЙ ТКАНИ НА ОСНОВЕ ТРАНСПЛАНТАЦИИ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОК С ИСПОЛЬЗОВАНИЕМ САЙТ-СПЕЦИФИЧЕСКОГО РЕДАКТИРОВАНИЯ ГЕНОМА
Popova M, Sergeev V, Lepik K, Shakirova A, Potter A, Barkhatov I, Fehse B, Afanasyev B
Zhurnal infektologii. 2017;9(1):31-39.

IL-33-Mediated Expansion of Type 2 Innate Lymphoid Cells Protects from Progressive Glomerulosclerosis
Riedel J, Becker M, Kopp K, Düster M, Brix S, Meyer-Schwesinger C, Kluth L, Gnirck A, Attar M, Krohn S, Fehse B, Stahl R, Panzer U, Turner J
J AM SOC NEPHROL. 2017;28(7):2068-2080.

Haploidentical transplant in patients with myelodysplastic syndrome
Robin M, Porcher R, Ciceri F, van Lint M, Santarone S, Ehninger G, Blaise D, Güllbas Z, Gonzáles Muñiz S, Michallet M, Velardi A, Koster L, Maertens J, Sierra J, Selleslag D, Radujkovic A, Díez-Martin J, Kanz L, Arroyo C, Niederwieser D, Huang H, McDonald A, de Witte T, Koc Y, Kröger N
BLOOD ADV. 2017;1(22):1876-1883.

Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT
Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N
BONE MARROW TRANSPL. 2017;52(2):209-215.

Erratum for: Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT
Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N
BONE MARROW TRANSPL. 2017;52(7):1081.

The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis
Ruutu T, Gratwohl A, Niederwieser D, de Witte T, van der Werf S, van Biezen A, Mohty M, Kröger N, Rambaldi A, McGrath E, Sureda A, Basak G, Greinix H, Duarte R
BONE MARROW TRANSPL. 2017;52(3):357-362.

Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party
Scheid C, de Wreede L, van Biezen A, Koenecke C, Göhring G, Volin L, Maertens J, Finke J, Passweg J, Beelen D, Cornelissen J, Itälä-Remes M, Chevallier P, Russell N, Petersen E, Milpied N, Richard Espiga C, Peniket A, Sierra J, Mufti G, Crawley C, Veelken J, Ljungman P, Cahn J, Alessandrino E, de Witte T, Robin M, Kröger N
BONE MARROW TRANSPL. 2017;52(11):1519-1525.

Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT)
Schetelig J, de Wreede L, Andersen N, Moreno C, van Gelder M, Vitek A, Karas M, Michallet M, Machaczka M, Gramatzki M, Beelen D, Finke J, Delgado J, Volin L, Passweg J, Dreger P, Schaap N, Wagner E, Henseler A, van Biezen A, Bornhäuser M, Iacobelli S, Putter H, Schönland S, Kröger N
BRIT J HAEMATOL. 2017;178(4):521-533.

Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation
Schetelig J, de Wreede L, van Gelder M, Andersen N, Moreno C, Vitek A, Karas M, Michallet M, Machaczka M, Gramatzki M, Beelen D, Finke J, Delgado J, Volin L, Passweg J, Dreger P, Henseler A, van Biezen A, Bornhäuser M, Schönland S, Kröger N
BONE MARROW TRANSPL. 2017;52(4):552-560.

Mesenchymal Stromal Cell-Derived Extracellular Vesicles Provide Long-Term Survival After Total Body Irradiation Without Additional Hematopoietic Stem Cell Support
Schoefinius J, Brunswig-Spickenheier B, Speiseder T, Krebs S, Just U, Lange C
STEM CELLS. 2017;35(12):2379-2389.

Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party
Sobh M, Michallet M, Dubois V, Iacobelli S, Koster L, Van Biezen A, Fegueux N, Tabrizi R, Finke J, El-Cheikh J, Schipperus M, Meijer E, von dem Borne P, Petersen E, Russell N, Tholouli E, Passweg J, Garban F, Maertens J, Chevalier P, Maillard N, Volin L, Francois S, Lioure B, Beguin Y, Gluckman E, Ruggeri A, Garderet L, Kröger N
HAEMATOLOGICA. 2017;102(7):e271-e274.

SHIP1, but not an AML-derived SHIP1 mutant, suppresses myeloid leukemia growth in a xenotransplantation mouse model
Täger M, Horn S, Latuske E, Ehm P, Schaks M, Nalaskowski M, Fehse B, Fiedler W, Stocking C, Wellbrock J, Jücker M
GENE THER. 2017;24(11):749-753.

Limitations and challenges of genetic barcode quantification
Thielecke L, Aranyossy T, Dahl A, Tiwari R, Roeder I, Geiger H, Fehse B, Glauche I, Cornils K
SCI REP-UK. 2017;7:43249.

Multi-color RGB marking enables clonality assessment of liver tumors in a murine xenograft model
Thomaschewski M, Riecken K, Unrau L, Volz T, Cornils K, Ittrich H, Heim D, Wege H, Akgün E, Lütgehetmann M, Dieckhoff J, Köpke M, Dandri M, Benten D, Fehse B
ONCOTARGET. 2017;8(70):115582-115595.

Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation
van Gelder M, de Wreede L, Bornhäuser M, Niederwieser D, Karas M, Anderson N, Gramatzki M, Dreger P, Michallet M, Petersen E, Bunjes D, Potter M, Beelen D, Cornelissen J, Yakoub-Agha I, Russell N, Finke J, Schoemans H, Vitek A, Urbano-Ispízua Á, Blaise D, Volin L, Chevallier P, Caballero D, Putter H, van Biezen A, Henseler A, Schönland S, Kröger N, Schetelig J
BONE MARROW TRANSPL. 2017;52(3):372-380.

Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT
van Gelder M, Ziagkos D, de Wreede L, van Biezen A, Dreger P, Gramatzki M, Stelljes M, Andersen N, Schaap N, Vitek A, Beelen D, Lindström V, Finke J, Passweg J, Eder M, Machaczka M, Delgado J, Krüger W, Raida L, Socié G, Jindra P, Afanasyev B, Wagner E, Chalandon Y, Henseler A, Schoenland S, Kröger N, Schetelig J
CL LYMPH MYELOM LEUK. 2017;17(10):667-675.e2.

Evaluation des Quantos-Dosiersystems für die Kapselherstellung in der Klinikapotheke: Ein Vergleich zur DAC-Methode
Vitt M, Will N, Goerke A, Löbering M, Laukart J, Baehr M, Langebrake C
Krankenhauspharmazie. 2017;38(5):220-227.

Gene and Cell Therapy in Germany
von Kalle C, Fehse B, Büning H
HUM GENE THER. 2017;28(10):781.

Mesenchymal stem cells and myoblast differentiation under HGF and IGF-1 stimulation for 3D skeletal muscle tissue engineering
Witt R, Weigand M, Boos A, Cai A, Dippold D, Boccaccini A, Schubert D, Hardt M, Lange C, Arkudas A, Horch R, Beier J
BMC CELL BIOL. 2017;18(1):15.

Impact of molecular residual disease post allografting in myelofibrosis patients
Wolschke C, Badbaran A, Zabelina T, Christopeit M, Ayuketang F, Triviai I, Zander A, Alchalby H, Bacher U, Fehse B, Kröger N
BONE MARROW TRANSPL. 2017;52(11):1526-1529.

Mesenchymal Stromal/Stem Cells Do Not Ameliorate Experimental Autoimmune Encephalomyelitis and Are Not Detectable in the Central Nervous System of Transplanted Mice
Abramowski P, Krasemann S, Ernst T, Lange C, Ittrich H, Schweizer M, Zander A, Martin R, Fehse B
STEM CELLS DEV. 2016;25(15):1134-48.

Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis
Alchalby H, Yunus D, Zabelina T, Ayuketang F, Kröger N
BONE MARROW TRANSPL. 2016;51(9):1223-7.

β-MSCs: successful fusion of MSCs with β-cells results in a beta-cell like phenotype
Azizi-Varzaneh Z, Lange C, Paroni F, Ardestani A, Meyer A, Wu Y, Zander A, Westenfelder C, Maedler K
ONCOTARGET. 2016;7(31):48963-48977.

Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation
Badbaran A, Fehse B, Christopeit M, Aranyossy T, Ayuketang F, Wolschke C, Kröger N
BONE MARROW TRANSPL. 2016;51(6):872-3.

Runx1 downregulates stem cell and megakaryocytic transcription programs that support niche interactions
Behrens K, Triviai I, Schwieger M, Tekin N, Alawi M, Spohn M, Indenbirken D, Ziegler M, Müller U, Alexander W, Stocking C
BLOOD. 2016;127(26):3369-81.

Primary Human Hepatocytes Repopulate Livers of Mice After In Vitro Culturing and Lentiviral-Mediated Gene Transfer
Bierwolf J, Volz T, Lütgehetmann M, Allweiss L, Riecken K, Warlich M, Fehse B, Kalff J, Dandri-Petersen M, Pollok J
TISSUE ENG PT A. 2016;22(9-10):742-53.

Investigation of the Mesenchymal Stem Cell Compartment by Means of a Lentiviral Barcode Library
Bigildeev A, Cornils K, Aranyossy T, Sats N, Petinati N, Shipounova I, Surin V, Pshenichnikova O, Riecken K, Fehse B, Drize N
BIOCHEMISTRY-MOSCOW+. 2016;81(4):373-81.

Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting)
Bruno B, Auner H, Gahrton G, Garderet L, Festuccia M, Ladetto M, Lemoli R, Massaia M, Morris C, Palumbo A, Schönland S, Boccadoro M, Kröger N
LEUKEMIA LYMPHOMA. 2016;57(6):1256-1268.

When is second allogeneic HSCT for relapse of acute leukaemia an option?
Christopeit M
BONE MARROW TRANSPL. 2016;51(2):184-5.

Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with MDS
Christopeit M, Badbaran A, Alawi M, Zabelina T, Zeck G, Wolschke C, Ayuketang F, Kröger N
EUR J HAEMATOL. 2016;97(3):288-96.

Similar outcome of calreticulin type I and calreticulin type II mutations following RIC allogeneic haematopoietic stem cell transplantation for myelofibrosis
Christopeit M, Badbaran A, Zabelina T, Zeck G, Fehse B, Ayuketang F, Wolschke C, Kröger N
BONE MARROW TRANSPL. 2016;51(10):1391-1393.

Suspected encephalitis with Candida tropicalis and Fusarium detected by unbiased RNA sequencing
Christopeit M, Grundhoff A, Rohde H, Belmar-Campos C, Grzyska U, Fiehler J, Wolschke C, Kröger N, Fischer N
ANN HEMATOL. 2016;95(11):1919-1921.

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
Craddock C, Labopin M, Robin M, Finke J, Chevallier P, Yakoub-Agha I, Bourhis J, Sengelov H, Blaise D, Luft T, Hallek M, Kröger N, Nagler A, Mohty M
HAEMATOLOGICA. 2016;101(7):879-83.

Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT
Cremers E, van Biezen A, de Wreede L, Scholten M, Vitek A, Finke J, Platzbecker U, Beelen D, Schwerdtfeger R, Volin L, Harhalakis N, Blijlevens N, Nagler A, Kröger N, de Witte T
ANN HEMATOL. 2016;95(12):1971-1978.

Microglia regulate hippocampal neurogenesis during chronic neurodegeneration
De Lucia C, Rinchon A, Olmos-Alonso A, Riecken K, Fehse B, Boche D, Perry V, Gomez-Nicola D
BRAIN BEHAV IMMUN. 2016;55:179-190.

Serial 18F-FDG PET for Monitoring Treatment Response After Allogeneic Stem Cell Transplantation for Myelofibrosis
Derlin T, Alchalby H, Bannas P, Laqmani A, Ayuketang F, Triviai I, Kreipe H, Bengel F, Kröger N
J NUCL MED. 2016;57(10):1556-1559.

Достижения в разработке инструментов для редактирования генома.
Fehse B
2016. АЛЬМАНАХ 2016. 1. Aufl. Moskau: .

Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma
Fichtner M, Spies E, Seismann H, Riecken K, Engels N, Gösch B, Dierlamm J, Gerull H, Nollau P, Klapper W, Dreyling M, Binder M, Trepel M
HAEMATOLOGICA. 2016;101(9):e378-81.

Indication of Horizontal DNA Gene Transfer by Extracellular Vesicles
Fischer S, Cornils K, Speiseder T, Badbaran A, Reimer R, Indenbirken D, Grundhoff A, Brunswig-Spickenheier B, Alawi M, Lange C
PLOS ONE. 2016;11(9):e0163665.

Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study
Gratwohl A, Iacobelli S, Bootsman N, van Biezen A, Baldomero H, Arcese W, Arnold R, Bron D, Cordonnier C, Ernst P, Ferrant A, Frassoni F, Gahrton G, Richard C, Kolb H, Link H, Niederwieser D, Ruutu T, Schattenberg A, Schmitz N, Torres-Gomez A, Zwaan F, Apperley J, Olavarria E, Kröger N
ANN HEMATOL. 2016;95(6):967-72.

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia-A randomized comparison of stem cell transplantation with drug treatment
Gratwohl A, Pfirrmann M, Zander A, Kröger N, Beelen D, Novotny J, Nerl C, Scheid C, Spiekermann K, Mayer J, Sayer H, Falge C, Bunjes D, Döhner H, Ganser A, Schmidt-Wolf I, Schwerdtfeger R, Baurmann H, Kuse R, Schmitz N, Wehmeier A, Fischer J, Ho A, Wilhelm M, Goebeler M, Lindemann H, Bormann M, Hertenstein B, Schlimok G, Baerlocher G, Aul C, Pfreundschuh M, Fabian M, Staib P, Edinger M, Schatz M, Fauser A, Arnold R, Kindler T, Wulf G, Rosselet A, Hellmann A, Schäfer E, Prümmer O, Schenk M, Hasford J, Heimpel H, Hossfeld D, Kolb H, Büsche G, Haferlach C, Schnittger S, Müller M, Reiter A, Berger U, Saußele S, Hochhaus A, Hehlmann R
LEUKEMIA. 2016;30(3):562-9.

Acute effects of exercise on the inflammatory state in patients with idiopathic pulmonary arterial hypertension
Harbaum L, Renk E, Yousef S, Glatzel A, Lüneburg N, Hennigs J, Oqueka T, Baumann H, Atanackovic D, Grünig E, Böger R, Bokemeyer C, Klose H
BMC PULM MED. 2016;16(1):145.

International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium
Harris A, Young R, Devine S, Hogan W, Ayuketang F, Bunworasate U, Chanswangphuwana C, Efebera Y, Holler E, Litzow M, Ordemann R, Qayed M, Renteria A, Reshef R, Wölfl M, Chen Y, Goldstein S, Jagasia M, Locatelli F, Mielke S, Porter D, Schechter T, Shekhovtsova Z, Ferrara J, Levine J
BIOL BLOOD MARROW TR. 2016;22(1):4-10.

Intrinsic Deregulation of Vascular Smooth Muscle and Myofibroblast Differentiation in Mesenchymal Stromal Cells from Patients with Systemic Sclerosis
Hegner B, Schaub T, Catar R, Kusch A, Wagner P, Essin K, Lange C, Riemekasten G, Dragun D
PLOS ONE. 2016;11(4):e0153101.

Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas
Heinzelmann F, Bethge W, Beelen D, Engelhard M, Kröger N, Dreger P, Niederwieser D, Finke J, Bunjes D, Tischer J, Kobbe G, Holler E, Bornhäuser M, Stelljes M, Baurmann H, Müller A, Haubitz I, Schrezenmeier H, Müller C, Ottinger H
BONE MARROW TRANSPL. 2016;51(5):654-62.

Late acute graft versus host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors
Holtan S, Khera N, Levine J, Chai X, Storer B, Liu H, Inamoto Y, Chen G, Mayer S, Arora M, Palmer J, Flowers M, Cutler C, Lukez A, Arai S, Lazaryan A, Newell L, Krupski C, Jagasia M, Pusic I, Wood W, Renteria A, Yanik G, Hogan W, Hexner E, Ayuketang F, Holler E, Watanaboonyongcharoen P, Efebera Y, Ferrara J, Panoskaltsis-Mortari A, Weisdorf D, Lee S, Pidala J
BLOOD. 2016;128(19):2350-2358.

Lentiviral HSV-Tk.007-mediated suicide gene therapy is not toxic for normal brain cells
Hossain J, Ystaas L, Mrdalj J, Välk K, Riecken K, Fehse B, Bjerkvig R, Grønli J, Miletic H
J GENE MED. 2016;18(9):234-43.

Cytokine Expression Pattern in Bone Marrow Microenvironment after Allogeneic Stem Cell Transplantation in Primary Myelofibrosis
Hussein K, Stucki-Koch A, Alchalby H, Triviai I, Kröger N, Kreipe H
BIOL BLOOD MARROW TR. 2016;22(4):664-650.

Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation
Jaekel N, Lieder K, Albrecht S, Leismann O, Hubert K, Bug G, Kröger N, Platzbecker U, Stadler M, de Haas K, Altamura S, Muckenthaler M, Niederwieser D, Al-Ali H
BONE MARROW TRANSPL. 2016;51(1):89-95.

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors
Kanate A, Mussetti A, Kharfan-Dabaja M, Ahn K, DiGilio A, Beitinjaneh A, Chhabra S, Fenske T, Freytes C, Gale R, Ganguly S, Hertzberg M, Klyuchnikov E, Lazarus H, Olsson R, Perales M, Rezvani A, Riches M, Saad A, Slavin S, Smith S, Sureda A, Yared J, Ciurea S, Armand P, Salit R, Bolaños-Meade J, Hamadani M
BLOOD. 2016;127(7):938-47.

Tedizolid susceptibility in linezolid- and vancomycin-resistant Enterococcus faecium isolates
Klupp E, Both A, Belmar Campos C, Büttner H, König C, Christopeit M, Christner M, Aepfelbacher M, Rohde H
EUR J CLIN MICROBIOL. 2016;35(12):1957-1961.

Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party
Koenecke C, Heim D, van Biezen A, Heuser M, Aljurf M, Kyrcz-Krzemien S, Volin L, de Souza C, Gedde-Dahl T, Sengeloev H, Schanz U, Komarnicki M, Arroyo C, Tholouli E, Gluckman E, Esquirol A, Yakoub-Agha I, Gürman G, Olavarria E, Kröger N
BONE MARROW TRANSPL. 2016;51(9):1259-61.

Outcome Improvement After Allogeneic Stem-Cell Transplantation in Myelofibrosis
Kröger N
J ONCOL PRACT. 2016;12(7):629-31.

Response: Antilymphocyte Globulin for Chronic Graft-versus-Host Disease
Kröger N, Solano C, Bonifazi F
NEW ENGL J MED. 2016;374(19):1894-5.

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease
Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, Pérez de Oteiza J, Duarte R, Carella A, Cimminiello M, Guidi S, Finke J, Mordini N, Ferra C, Sierra J, Russo D, Petrini M, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuketang F, Ruutu T, Bonifazi F
NEW ENGL J MED. 2016;374(1):43-53.

Alpharetroviral self-inactivating vectors produced by a superinfection-resistant stable packaging cell line allow genetic modification of primary human T lymphocytes
Labenski V, Suerth J, Barczak E, Heckl D, Levy C, Bernadin O, Charpentier E, Williams D, Fehse B, Verhoeyen E, Schambach A
BIOMATERIALS. 2016;97:97-109.

Генная терапия на основе трансплантации гемопоэтичеcких стволовых клеток с использованием сайт-специфического редактирования генома
Lepik K, Popova M, Shakirova A, Sergeev V, Potter A, Barkhatov I, Fehse B, Afanasyev B
Genes & Cells (гены & клетки) . 2016;XI(2):21-31.

Long-term in vivo single-cell tracking reveals the switch of migration patterns in adult-born juxtaglomerular cells of the mouse olfactory bulb
Liang Y, Li K, Riecken K, Maslyukov A, Gomez-Nicola D, Kovalchuk Y, Fehse B, Garaschuk O
CELL RES. 2016;26(7):805-21.

Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation
Merz M, Jansen L, Castro F, Hillengass J, Salwender H, Weisel K, Scheid C, Luttmann S, Emrich K, Holleczek B, Katalinic A, Nennecke A, Straka C, Langer C, Engelhardt M, Einsele H, Kröger N, Beelen D, Dreger P, Brenner H, Goldschmidt H
EUR J CANCER. 2016;62:1-8.

Digital PCR to assess gene-editing frequencies (GEF-dPCR) mediated by designer nucleases
Mock U, Hauber I, Fehse B
NAT PROTOC. 2016;11(3):598-615.

Treosulfan based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicentre experience
Morillo-Gutierrez B, Beier R, Rao K, Burroughs L, Schulz A, Ewins A, Gibson B, Sedlacek P, Krol L, Strahm B, Zaidman I, Kalwak K, Talano J, Woolfrey A, Fraser C, Meyts I, Müller I, Wachowiak J, Bernardo M, Veys P, Sykora K, Gennery A, Slatter M
BLOOD. 2016;128(3):440-8.

Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually
Passweg J, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte R, Dufour C, Kuball J, Farge-Bancel D, Kröger N, Gennery A, Lanza F, Nagler A, Sureda A, Mohty M
BONE MARROW TRANSPL. 2016;51(6):786-92.

Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT
Paviglianiti A, Xavier E, Ruggeri A, Ceballos P, Deconinck E, Cornelissen J, Nguyen-Quoc S, Maillard N, Sanz G, Rohrlich P, Garderet L, Volt F, Rocha V, Kroeger N, Gluckman E, Fegueux N, Mohty M
HAEMATOLOGICA. 2016;101(9):1120-7.

Blood-borne Hepatitis E Virus Transmission: A Relevant Risk for Immunosuppressed Patients
Pischke S, Hiller J, Lütgehetmann M, Polywka S, Rybczynski M, Ayuketang F, Lohse A
CLIN INFECT DIS. 2016;63(4):569-570.

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research
Potter V, Iacobelli S, van Biezen A, Maertens J, Bourhis J, Passweg J, Yakhoub-Agha I, Tabrizi R, Bay J, Chevallier P, Chalandon Y, Huynh A, Cahn J, Ljungman P, Craddock C, Lenhoff S, Russell N, Fegueux N, Socié G, Benedetto B, Meijer E, Mufti G, de Witte T, Robin M, Kröger N
BIOL BLOOD MARROW TR. 2016;22(9):1615-1620.

Fracture Healing Is Delayed in Immunodeficient NOD/scid‑IL2Rγcnull Mice
Rapp A, Bindl R, Recknagel S, Erbacher A, Müller I, Schrezenmeier H, Ehrnthaller C, Gebhard F, Ignatius A
PLOS ONE. 2016;11(2):e0147465.

Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis
Robin M, Porcher R, Wolschke C, Sicre de Fontbrune F, Alchalby H, Christopeit M, Cassinat B, Zabelina T, Peffault de Latour R, Ayuketang F, Socié G, Kröger N
BIOL BLOOD MARROW TR. 2016;22(7):1206-11.

The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party
Rubio M, Savani B, Labopin M, Polge E, Niederwieser D, Ganser A, Schwerdtfeger R, Ehninger G, Finke J, Renate A, Craddock C, Kröger N, Hallek M, Jindra P, Mohty M, Nagler A
J HEMATOL ONCOL. 2016;9(1):65.

Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study
Ruggeri A, Battipaglia G, Labopin M, Ehninger G, Beelen D, Tischer J, Ganser A, Schwerdtfeger R, Glass B, Finke J, Michallet M, Stelljes M, Jindra P, Arnold R, Kröger N, Mohty M, Nagler A
J HEMATOL ONCOL. 2016;9(1):89.

Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT
Savani B, Labopin M, Kröger N, Finke J, Ehninger G, Niederwieser D, Schwerdtfeger R, Bunjes D, Glass B, Socié G, Ljungman P, Craddock C, Baron F, Ciceri F, Gorin N, Esteve J, Schmid C, Giebel S, Mohty M, Nagler A
HAEMATOLOGICA. 2016;101(6):773-80.

A transplant “immunome” screening platform defines a targetable epitope fingerprint of multiple myeloma
Schieferdecker A, Oberle A, Thiele B, Hofmann F, Göthel M, Miethe S, Hust M, Braig F, Voigt M, Pein U, Nolte F, Haag F, Alawi M, Indenbirken D, Grundhoff A, Bokemeyer C, Bacher U, Kröger N, Binder M
BLOOD. 2016;127(25):3202-14.

Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins
Schieferdecker A, Shoshani O, Westner B, Zipori D, Fehse B, Kröger N, Ayuketang F
ONCOTARGET. 2016;7(41):67061-67070.

Application of recombinant antigen 5 allergens from seven allergy-relevant Hymenoptera species in diagnostics
Schiener M, Eberlein B, Moreno-Aguilar C, Pietsch G, Serrano P, McIntyre M, Schwarze L, Russkamp D, Biedermann T, Spillner E, Darsow U, Ollert M, Schmidt-Weber C, Blank S
ALLERGY. 2016;72(1):98-108.

CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)-Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
Schmidt-Hieber M, Silling G, Schalk E, Heinz W, Panse J, Penack O, Christopeit M, Buchheidt D, Meyding-Lamadé U, Hähnel S, Wolf H, Ruhnke M, Schwartz S, Maschmeyer G
ANN ONCOL. 2016;27(7):1207-25.

Massive Clonal Selection and Transiently Contributing Clones During Expansion of Mesenchymal Stem Cell Cultures Revealed by Lentiviral RGB-Barcode Technology
Selich A, Daudert J, Hass R, Philipp F, von Kaisenberg C, Paul G, Cornils K, Fehse B, Rittinghausen S, Schambach A, Rothe M
STEM CELL TRANSL MED. 2016;5(5):591-601.

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party
Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Schönland S, Petersen E, Schaap N, Bonifazi F, Volin L, Meijer E, Niederwieser D, El Cheikh J, Tabrizi R, Fegeux N, Finke J, Bunjes D, Cornelissen J, Einsele H, Bruno B, Potter M, Fanin R, Mohty M, Garderet L, Kröger N
LEUKEMIA. 2016;30(10):2047-2054.

Efficient transformation of primary human mesenchymal stromal cells by adenovirus early region 1 oncogenes
Speiseder T, Hofmann-Sieber H, Rodríguez E, Schellenberg A, Akyüz N, Dierlamm J, Spruss T, Lange C, Dobner T
J VIROL. 2016;91(1):e01782-16.

Digital PCR Panel for Sensitive Hematopoietic Chimerism Quantification after Allogeneic Stem Cell Transplantation
Stahl T, Rothe C, Böhme M, Kohl A, Kröger N, Fehse B
INT J MOL SCI. 2016;17(9):E1515.

Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation
Styczynski J, Tridello G, Gil L, Ljungman P, Hoek J, Iacobelli S, Ward K, Cordonnier C, Einsele H, Socie G, Milpied N, Veelken H, Chevallier P, Yakoub-Agha I, Maertens J, Blaise D, Cornelissen J, Michallet M, Daguindau E, Petersen E, Passweg J, Greinix H, Duarte R, Kröger N, Dreger P, Mohty M, Nagler A, Cesaro S
J CLIN ONCOL. 2016;34(19):2212-20.

Increasing the sensitivity for stem cell monitoring in system-function based magnetic particle imaging
Them K, Salamon J, Szwargulski P, Sequeira S, Kaul M, Lange C, Ittrich H, Knopp T
PHYS MED BIOL. 2016;61(9):3279-90.

Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology
von Lilienfeld-Toal M, Berger A, Christopeit M, Hentrich M, Heussel C, Kalkreuth J, Klein M, Kochanek M, Penack O, Hauf E, Rieger C, Silling G, Vehreschild M, Weber T, Wolf H, Lehners N, Schalk E, Mayer K
EUR J CANCER. 2016;67:200-212.

Potentially Inappropriate Medication Use in Multimorbid Elderly Inpatients: Differences Between the FORTA, PRISCUS and STOPP Ratings
Wickop B, Härterich S, Sommer C, Daubmann A, Baehr M, Langebrake C
DRUGS-REAL WOR OUTC. 2016;3(3):317-325.

Übersicht - Gentherapeutische Konzepte in der Onkologie
Abramowski P, Fehse B
TUMORDIAGN THER. 2015;36(06):333-336.

Combined Application of RGB Marking and Mass Spectrometric Imaging Facilitates Detection of Tumor Heterogeneity
Abramowski P, Kraus O, Rohn S, Riecken K, Fehse B, Schlüter H
CANCER GENOM PROTEOM. 2015;12(4):179-187.

Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma
Auner H, Garderet L, Kröger N
BRIT J HAEMATOL. 2015;171(4):453-62.

Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria
Ayuketang F, Veit R, Zabelina T, Bussmann L, Christopeit M, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander A, Kröger N
ANN HEMATOL. 2015;94(10):1727-32.

Monitoring of Minimal Residual Disease After Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia Allows for the Identification of Impending Relapse: Results of the ALL-BFM-SCT 2003 Trial
Bader P, Kreyenberg H, von Stackelberg A, Eckert C, Salzmann-Manrique E, Meisel R, Poetschger U, Stachel D, Schrappe M, Alten J, Schrauder A, Schulz A, Lang P, Müller I, Albert M, Willasch A, Klingebiel T, Peters C
J CLIN ONCOL. 2015;33(11):1275 - 84.

How we manage JAK inhibition in allogeneic transplantation for myelofibrosis
Ballinger T, Savani B, Gupta V, Kröger N, Mohty M
EUR J HAEMATOL. 2015;94(2):115-119.

SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation
Bartels S, Lehmann U, Büsche G, Schlue J, Mozer M, Stadler J, Triviai I, Alchalby H, Kröger N, Kreipe H
LEUKEMIA. 2015;29(1):253-5.

Allogeneic Hematopoietic Stem Cell Transplantation in Solid Organ Transplant Recipients: A Retrospective, Multicenter Study of the EBMT
Basak G, Wiktor-Jedrzejczak W, Labopin M, Schoemans H, Ljungman P, Kobbe G, Beguin Y, Lang P, Koenecke C, Sykora K, Te Boome L, van Biezen A, van der Werf S, Mohty M, de Witte T, Marsh J, Dreger P, Kröger N, Duarte R, Ruutu T
AM J TRANSPLANT. 2015;15(3):705-14.

Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs
Ben-Batalla I, Cubas-Cordova M, Udonta F, Wroblewski M, Waizenegger J, Janning M, Sawall S, Gensch V, Zhao L, Martinez-Zubiaurre I, Riecken K, Fehse B, Pantel K, Bokemeyer C, Loges S
ONCOTARGET. 2015;6(8):6341-58.

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
Braig F, März M, Schieferdecker A, Schulte A, Voigt M, Stein A, Grob T, Alawi M, Indenbirken D, Kriegs M, Engel E, Vanhoefer U, Grundhoff A, Loges S, Riecken K, Fehse B, Bokemeyer C, Binder M
ONCOTARGET. 2015;6(14):12035-47.

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia
Brissot E, Labopin M, Beckers M, Socié G, Rambaldi A, Volin L, Finke J, Lenhoff S, Kröger N, Ossenkoppele G, Craddock C, Yakoub-Agha I, Gürman G, Russell N, Aljurf M, Potter M, Nagler A, Ottmann O, Cornelissen J, Esteve J, Mohty M
HAEMATOLOGICA. 2015;100(3):392-9.

Epigenetic reprogramming and blood development
Christopeit M
EPIGENOMICS-UK. 2015;7(1):9-11.

Assessment of bone marrow inflammation in patients with myelofibrosis: an (18)F-fluorodeoxyglucose PET/CT study
Derlin T, Alchalby H, Bannas P, Veldhoen S, Apostolova I, Triviai I, Bengel F, Kröger N
EUR J NUCL MED MOL I. 2015;42(5):696-705.

Diagnostic value of 18F-FDG-PET/CT for monitoring myelofibrosis after allogeneic stem cell transplantation
Derlin T, Büsche G, Kröger N
NUCL MED REV. 2015;18(1):35-6.

18F-FDG PET/CT for Detection of Leukemic Transformation in Myelofibrosis
Derlin T, Clauditz T, Kröger N
CLIN NUCL MED. 2015;40(6):521-2.

Magnetic resonance enterography for assessment of intestinal graft-versus-host disease after allogeneic stem cell transplantation
Derlin T, Laqmani A, Veldhoen S, Apostolova I, Ayuketang F, Adam G, Kröger N, Bannas P
EUR RADIOL. 2015;25(5):1229-1237.

Gentherapie - zurück in die Zukunft?
Fehse B
BIOspektrum. 2015;15(4):448.

Genetische Manipulation: klinische Anwendung.
Fehse B, Cornils K
2015. Hämatopoetische Stammzellen. Herr W, Theobald M, Ehninger G, Einsele H, Meyer R (Hrsg.). 1. Aufl. Köln: Deutscher Ärzte-Verlag, 21-24.

Themenbereich somatische Gentherapie: Translationale und klinische Forschung
Fehse B, Domasch S
2015. Dritter Gentechnologiebericht: Analyse einer Hochtechnologie. Müller-Röber B, Budisa N, Diekämper J, Domasch S, Fehse B, Hampel J, Hucho F, Hümpel A, Köchy K, Marx-Stölting L, Reich J, Rheinberger H, Ropers H, Taupitz J, Walter J, Zenke M (Hrsg.). 1. Aufl. Baden Baden: Nomos, 211-308.

Evaluation of Unbiased Next-Generation Sequencing of RNA (RNA-seq) as a Diagnostic Method in Influenza Virus-Positive Respiratory Samples
Fischer N, Indenbirken D, Meyer T, Lütgehetmann M, Lellek H, Spohn M, Aepfelbacher M, Alawi M, Grundhoff A
J CLIN MICROBIOL. 2015;53(7):2238-50.

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen H, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre C, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E
BIOL BLOOD MARROW TR. 2015;21(12):2039-51.

Multicolor RGB Marking Allows Morphometric and Functional Analysis of Hippocampal Granule Neurons at the Single-Cell Level
Gomez-Nicola D, Riecken K, Perry V, Fehse B
HUM GENE THER. 2015;26(6):332-333.

Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study
Gratwohl A, Sureda A, Baldomero H, Gratwohl M, Dreger P, Kröger N, Ljungman P, McGrath E, Mohty M, Nagler A, Rambaldi A, de Elvira C, Snowden J, Passweg J, Apperley J, Niederwieser D, Stijnen T, Brand R
EBIOMEDICINE. 2015;2(12):2101-9.

Retroviral insertional mutagenesis in telomerase-immortalized hepatocytes identifies RIPK4 as novel tumor suppressor in human hepatocarcinogenesis
Heim D, Cornils K, Schulze K, Fehse B, Lohse A, Brümmendorf T, Wege H
ONCOGENE. 2015;34(3):385-393.

Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q
Heuser M, Meggendorfer M, Cruz M, Fabisch J, Klesse S, Köhler L, Göhring G, Ganster C, Shirneshan K, Gutermuth A, Cerny-Reiterer S, Krönke J, Panagiota V, Haferlach C, Koenecke C, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Ehrlich S, Stamer K, Döhner K, Valent P, Schlegelberger B, Kroeger N, Ganser A, Haase D, Haferlach T, Thol F
LEUKEMIA. 2015;29(9):1942-45.

Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial
Iacobelli S, de Wreede L, Schönland S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella A, Beksac M, Bosi A, Milone G, Corradini P, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N, Gahrton G
BONE MARROW TRANSPL. 2015;50(4):505-510.

Activation of Cell Surface Bound 20S Proteasome Inhibits Vascular Cell Growth and Arteriogenesis
Ito W, Lund N, Zhang Z, Buck F, Lellek H, Horst A, Machens H, Schunkert H, Schaper W, Meinertz T
BIOMED RES INT . 2015;2015:719316.

Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Kharfan-Dabaja M, Labopin M, Bazarbachi A, Socie G, Kroeger N, Blaise D, Veelken H, Bermudez A, Or R, Lioure B, Beelen D, Fegueux N, Hamladji R, Nagler A, Mohty M
LEUKEMIA RES. 2015;39(9):933-7.

Risk of Rotavirus Vaccination for Children with SCID
Klinkenberg D, Blohm M, Hoehne M, Mas Marques A, Malecki M, Schildgen V, Schneppenheim R, Müller I, Schildgen O, Kobbe R
PEDIATR INFECT DIS J. 2015;34(1):114-5.

Stammzelltransplantation bei malignen Lymphomen Hat sie noch eine Bedeutung?
Klyuchnikov E, Bacher U
ONKOLOGE. 2015;21(10):925-935.

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors
Klyuchnikov E, Bacher U, Kröger N, Hari P, Ahn K, Carreras J, Bachanova V, Bashey A, Cohen J, D'Souza A, Freytes C, Gale R, Ganguly S, Hertzberg M, Holmberg L, Kharfan-Dabaja M, Klein A, Ku G, Laport G, Lazarus H, Miller A, Mussetti A, Olsson R, Slavin S, Usmani S, Vij R, Wood W, Maloney D, Sureda A, Smith S, Hamadani M
BIOL BLOOD MARROW TR. 2015;21(12):2091-2099.

Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma
Klyuchnikov E, Bacher U, Woo Ahn K, Carreras J, Kröger N, Hari P, Ku G, Ayala E, Chen A, Chen Y, Cohen J, Freytes C, Gale R, Kamble R, Kharfan-Dabaja M, Lazarus H, Martino R, Mussetti A, Savani B, Schouten H, Usmani S, Wiernik P, Wirk B, Smith S, Sureda A, Hamadani M
BONE MARROW TRANSPL. 2015;51(1):58-66.

Extracellular Vesicles from MSC Modulate the Immune Response to Renal Allografts in a MHC Disparate Rat Model
Koch M, Lemke A, Lange C
Stem Cells Int. 2015;2015:486141.

Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation
Koenecke C, Göhring G, de Wreede L, van Biezen A, Scheid C, Volin L, Maertens J, Finke J, Schaap N, Robin M, Passweg J, Cornelissen J, Beelen D, Heuser M, de Witte T, Kröger N
HAEMATOLOGICA. 2015;100(3):400-8.

Current Challenges in Stem Cell Transplantation in Myelofibrosis
Kröger N
CURR HEMATOL MALIG R. 2015;10(4):344-50.

Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL)
Kröger N, Bornhäuser M, Stelljes M, Pichlmeier U, Trenschel R, Schmid C, Arnold R, Martin H, Heinzelmann M, Wolschke C, Meyer R, Bethge W, Kobbe G, Ayuketang F, Gökbuget N, Hölzer D, Zander A, Beelen D
BONE MARROW TRANSPL. 2015;50(12):1503-7.

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
Kröger N, Deeg J, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, Rambaldi A, Mesa R, Tefferi A, Griesshammer M, Gupta V, Harrison C, Alchalby H, Vannucchi A, Cervantes F, Robin M, Ditschkowski M, Fauble V, McLornan D, Ballen K, Popat U, Passamonti F, Rondelli D, Barosi G
LEUKEMIA. 2015;29(11):2126-33.

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years with primary myelofibrosis
Kröger N, Giorgino T, Scott B, Ditschkowski M, Alchalby H, Cervantes F, Vannucchi A, Cazzola M, Morra E, Zabelina T, Maffioli M, Pereira A, Beelen D, Deeg H, Passamonti F
BLOOD. 2015;125(21):3347-3350.

Donor choice in haploidentical stem cell transplantation: fetal microchimerism is associated with better outcome in pediatric leukemia patients
Kruchen A, Stahl T, Gieseke F, Binder T, Özcan Z, Meisel R, Kreyenberg H, Bader P, Gruhn B, Greil J, Pfeiffer M, Döring M, Handgretinger R, Fehse B, Müller I
BONE MARROW TRANSPL. 2015;50(10):1367-1370.

Impaired bone remodeling and its correction by combination therapy in a mouse model of mucopolysaccharidosis-I
Kühn S, Koehne T, Cornils K, Markmann S, Riedel C, Pestka J, Schweizer M, Baldauf C, Yorgan T, Krause M, Keller J, Neven M, Breyer S, Stücker R, Muschol N, Busse B, Braulke T, Fehse B, Amling M, Schinke T
HUM MOL GENET. 2015;24(24):7075-7086.

Cancer-testis antigen MAGEC2 promotes proliferation and resistance to apoptosis in Multiple Myeloma
Lajmi N, Luetkens T, Yousef S, Templin J, Cao Y, Hildebrandt Y, Bartels K, Kröger N, Atanackovic D
BRIT J HAEMATOL. 2015;171(5):752-62.

Nationwide Evaluation of Day-to-Day Clinical Pharmacists' Interventions in German Hospitals
Langebrake C, Ihbe-Heffinger A, Leichenberg K, Kaden S, Kunkel M, Lueb M, Hilgarth H, Hohmann C
PHARMACOTHERAPY. 2015;35(4):370-9.

Mesenchymal Stromal Cells Protect From Acute Radiation Syndromes: Insights into Possible Mechanisms
Lange C
Medico-Biological and Socio-Psychological Problems of Safety in Emergency Situations. 2015;1(1):5-17.

Treatment of Acute Radiation Syndromes with Transplantation of Bone Marrow-derived Mesenchymal Stromal Cells.
Lange C, Reimer R, Zustin J, Brunswig-Spickenheier B
2015. Biological Responses, Monitoring and Protection from Radiation Exposure. Mishra K (Hrsg.). 1.. Aufl. Hauppauge, NY 11788-3619, USA: Nova Science Publishers, 149-164.

Emergence of daptomycin non-susceptibility in colonizing vancomycin-resistant Enterococcus faecium isolates during daptomycin therapy
Lellek H, Franke G, Ruckert C, Wolters M, Wolschke C, Christner M, Büttner H, Alawi M, Kröger N, Rohde H
INT J MED MICROBIOL. 2015;305(8):902-909.

Drosophila homologue of Diaphanous 1 (DIAPH1) controls the metastatic potential of colon cancer cells by regulating microtubule-dependent adhesion
Lin Y, Bhuwania R, Gromova K, Failla A, Lange T, Riecken K, Linder S, Kneussel M, Izbicki J, Windhorst S
ONCOTARGET. 2015;6(21):18577-89.

Lrp1/LDL receptor play critical roles in mannose 6-phosphate-independent lysosomal enzyme targeting
Markmann S, Thelen M, Cornils K, Schweizer M, Brocke-Ahmadinejad N, Willnow T, Heeren J, Gieselmann V, Braulke T, Kollmann K
TRAFFIC. 2015.

Atovaquone for Prophylaxis of Toxoplasmosis after Allogeneic Hematopoietic Stem Cell Transplantation.
Mendorf A, Klyuchnikov E, Langebrake C, Rohde H, Ayuketang F, Regier M, Christopeit M, Zabelina T, Bacher A, Stübig T, Wolschke C, Bacher U, Kroger N
ACTA HAEMATOL-BASEL. 2015;134(3):146-154.

Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen
Michaelis M, Agha B, Rothweiler F, Löschmann N, Voges Y, Mittelbronn M, Starzetz T, Harter P, Abhari B, Fulda S, Westermann F, Riecken K, Spek S, Langer K, Wiese M, Dirks W, Zehner R, Cinatl J, Wass M, Cinatl J
SCI REP-UK. 2015;5:8202.

Gezielter CCR5-Knockout in primären T-Lymphozyten zur Verhinderung der HIV-Infektion
Mock U, Fehse B
2015. Connexi. The Paideia Group, 14-16.

mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5
Mock U, Machowicz R, Hauber I, Horn S, Abramowski P, Berdien B, Hauber J, Fehse B
NUCLEIC ACIDS RES. 2015;43(11):5560-5571.

Efficacy and outcome of allogeneic transplantation in IgD and non secretory myeloma. A report on behalf of the myeloma subcommittee of the Chronic Malignancies Working Party of the EBMT
Morris C, Iacobelli S, Gahrton G, van Biezen A, Drake M, Garderet L, Potter M, Schattenberg A, Cornelissen J, Hamladji R, Martelli M, Petersen E, Rovira M, Bandini G, Kröger N, de Witte T
BIOL BLOOD MARROW TR. 2015;21(6):1054-8.

Targeting species D adenoviruses replication to counteract the epidemic keratoconjunctivitis
Nikitenko N, Speiseder T, Groitl P, Spirin P, Prokofjeva M, Lebedev T, Rubtsov P, Lam E, Riecken K, Fehse B, Dobner T, Prassolov V
BIOCHIMIE. 2015;113:10-16.

New IDH1 mutant inhibitors for treatment of acute myeloid leukemia
Okoye-Okafor U, Bartholdy B, Cartier J, Gao E, Pietrak B, Rendina A, Rominger C, Quinn C, Smallwood A, Wiggall K, Reif A, Schmidt S, Qi H, Zhao H, Joberty G, Faelth-Savitski M, Bantscheff M, Drewes G, Duraiswami C, Brady P, Groy A, Narayanagari S, Antony-Debre I, Mitchell K, Wang H, Kao Y, Christopeit M, Carvajal L, Barreyro L, Paietta E, Makishima H, Will B, Concha N, Adams N, Schwartz B, McCabe M, Maciejewski J, Verma A, Steidl U
NAT CHEM BIOL. 2015;11(11):878-86.

JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms
Parampalli Yajnanarayana S, Stübig T, Cornez I, Alchalby H, Schönberg K, Rudolph J, Triviai I, Wolschke C, Heine A, Brossart P, Kröger N, Wolf D
BRIT J HAEMATOL. 2015;169(6):824-33.

Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants
Passweg J, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte R, Dufour C, Falkenburg J, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Nagler A, Sureda A, Mohty M
BONE MARROW TRANSPL. 2015;50(4):476-482.

УНИВЕРСАЛЬНАЯ МОДУЛЬНАЯ СИСТЕМА СКРИНИНГА IN VITRO ПОТЕНЦИАЛЬНЫХ ИНГИБИТОРОВ РЕПЛИКАЦИИ ВИЧ-1
Prokof'eva M, Orlova N, Gornostaeva A, Shul'gin A, Nikitenko N, Senchenko V, Lebedev T, Spirin P, Riecken K, Fehse B, Stocking C, Prasolov V
MOL BIOL (MOSK). 2015;48(2):344-8.

Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A, Guglielmi C, Bergantini S, Iacobelli S, van Biezen A, Milojkovic D, Gratwohl A, Schattenberg A, Verdonck L, Niederwieser D, de Witte T, Kröger N, Olavarria E
BIOL BLOOD MARROW TR. 2015;21(7):1230-1236.

Systemic mesenchymal stem cell administration enhances bone formation in fracture repair but not load-induced bone formation
Rapp A, Bindl R, Heilmann A, Erbacher A, Müller I, Brenner R, Ignatius A
EUR CELLS MATER. 2015;29:22-34.

Comparison of Unrelated Cord Blood and Peripheral Blood Stem Cell Transplantation in Adults with Myelodysplastic Syndrome after Reduced-Intensity Conditioning Regimen: A Collaborative Study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party
Robin M, Ruggeri A, Labopin M, Niederwieser D, Tabrizi R, Sanz G, Bourhis J, van Biezen A, Koenecke C, Blaise D, Tischer J, Craddock C, Maillard N, Mohty M, Russel N, Schetelig J, Finke J, Gluckman E, de Witte T, Rocha V, Kroger N, Kröger N
BIOL BLOOD MARROW TR. 2015;21(3):489-95.

Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT
Ruutu T, de Wreede L, van Biezen A, Brand R, Mohty M, Dreger P, Duarte R, Peters C, Garderet L, Schönland S, Gratwohl A, Niederwieser D, de Witte T, Kröger N
BONE MARROW TRANSPL. 2015;50(12):1542-50.

Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma
Sahebi F, Iacobelli S, Biezen A, Volin L, Dreger P, Michallet M, Ljungman P, de Witte T, Henseler A, Schaap N, López-Corral L, Poire X, Passweg J, Hamljadi R, Thomas S, Schonland S, Gahrton G, Morris C, Kröger N, Garderet L
BONE MARROW TRANSPL. 2015;50(6):802-807.

Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study
Shouval R, Labopin M, Bondi O, Mishan-Shamay H, Shimoni A, Ciceri F, Esteve J, Giebel S, Gorin N, Schmid C, Polge E, Aljurf M, Kroger N, Craddock C, Bacigalupo A, Cornelissen J, Baron F, Unger R, Nagler A, Mohty M
J CLIN ONCOL. 2015;33(28):3144-51.

Digital PCR to assess hematopoietic chimerism after allogeneic stem cell transplantation
Stahl T, Böhme M, Kröger N, Fehse B
EXP HEMATOL. 2015;43(6):462-468.

Stammzelltransplantation bei Multipler Sklerose. Hamburger Erfahrungen und internationaler Forschungsstand
Stellmann J, Stürner K, Ufer F, Havemeister S, Pöttgen J, Ayuketang F, Kröger N, Friese M, Heesen C
NERVENARZT. 2015;86(8):989-96.

Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015
Sureda A, Bader P, Cesaro S, Dreger P, Duarte R, Dufour C, Falkenburg J, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Marsh J, Nagler A, Peters C, Velardi A, Mohty M, Madrigal A
BONE MARROW TRANSPL. 2015;50(8):1037-56.

Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
Symeonidis A, van Biezen A, de Wreede L, Piciocchi A, Finke J, Beelen D, Bornhäuser M, Cornelissen J, Volin L, Mufti G, Chalandon Y, Ganser A, Bruno B, Niederwieser D, Kobbe G, Schwerdtfeger R, de Witte T, Robin M, Kröger N
BRIT J HAEMATOL. 2015;171(2):239-246.

Erratum for "Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors"
Trepel M, Körbelin J, Spies E, Heckmann M, Hunger A, Fehse B, Katus H, Kleinschmidt J, Müller O, Michelfelder S
GENE THER. 2015;22(10):840-847.

Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors
Trepel M, Körbelin J, Spies E, Heckmann M, Hunger A, Fehse B, Katus H, Kleinschmidt J, Müller O, Michelfelder S
GENE THER. 2015;22(10):840-7.

CD133 marks a stem cell population that drives human Primary Myelofibrosis
Triviai I, Stübig T, Niebuhr B, Hussein K, Tsiftsoglou A, Fehse B, Stocking C, Kröger N
HAEMATOLOGICA. 2015;100(6):768-79.

Possible role of minor h antigens in the persistence of donor chimerism after stem cell transplantation; relevance for sustained leukemia remission
van der Torren C, van Hensbergen Y, Luther S, Aghai Z, Rychnavská Z, Slot M, Scherjon S, Kröger N, Ganser A, Weissinger E, Goulmy E, Hambach L
PLOS ONE. 2015;10(3):e0119595.

Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Vannucchi A, Barbui T, Cervantes F, Harrison C, Kiladjian J, Kröger N, Thiele J, Buske C
ANN ONCOL. 2015;26 Suppl 5:v85-99.

Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma
Waizenegger J, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab M, Pantel K, Bokemeyer C, Loges S
LEUKEMIA. 2015;29(3):696-704.

Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects
Wellbrock J, Latuske E, Köhler J, Wagner K, Stamm H, Vettorazzi E, Vohwinkel G, Klokow M, Uibeleisen R, Ehm P, Riecken K, Loges S, Thol F, Schubert C, Amling M, Jücker M, Bokemeyer C, Heuser M, Krauter J, Fiedler W
CLIN CANCER RES. 2015.

Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societé Française de Greffe de Moelle et Therapie Cellulaire
Xavier E, Cornillon J, Ruggeri A, Chevallier P, Cornelissen J, Andersen N, Maillard N, Nguyen S, Blaise D, Deconinck E, Veelken H, Milpied N, Van Gelder M, Peffault de Latour R, Gluckman E, Kröger N, Schetelig J, Rocha V
BIOL BLOOD MARROW TR. 2015;21(8):1515-23.

Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma
Yousef S, Heise J, Lajmi N, Bartels K, Kröger N, Luetkens T, Atanackovic D
J TRANSL MED. 2015;13:197.

CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma
Yousef S, Kovacsovics-Bankowski M, Salama M, Bhardwaj N, Steinbach M, Langemo A, Kovacsovics T, Marvin J, Binder M, Panse J, Kröger N, Luetkens T, Atanackovic D
HUM VACC IMMUNOTHER. 2015;11(7):1606-11.

Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients
Yousef S, Marvin J, Steinbach M, Langemo A, Kovacsovics T, Binder M, Kröger N, Luetkens T, Atanackovic D
BLOOD CANCER J. 2015;5:e285.

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder S, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuketang F, Ajib S, de Fontbrune F, Na I, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit G, Kuball J, Flynn R, Ihorst G, Du J, Blazar B, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N
LEUKEMIA. 2015;29(10):2062-8.

A truncation variant of the cation channel P2RX5 is upregulated during T cell activation
Abramowski P, Ogrodowczyk C, Martin R, Pongs O
PLOS ONE. 2014;9(9):e104692.

The orally available, synthetic ether lipid edelfosine inhibits T cell proliferation and induces a type I interferon response
Abramowski P, Otto B, Martin R
PLOS ONE. 2014;9(3):e91970.

Immunomodulatory effects of the ether phospholipid edelfosine in experimental autoimmune encephalomyelitis
Abramowski P, Steinbach K, Zander A, Martin R
J NEUROIMMUNOL. 2014;274(1-2):111-24.

Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera
Alchalby H, Kröger N
CL LYMPH MYELOM LEUK. 2014;14 Suppl:S36-41.

Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation
Alchalby H, Zabelina T, Stübig T, van Biezen A, Bornhäuser M, Di Bartolomeo P, Beelen D, Cahn J, Dreger P, Schroyens W, de Witte T, Olavarria E, Kröger N
BIOL BLOOD MARROW TR. 2014;20(2):279-81.

Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma
Atanackovic D, Luetkens T, Kröger N
LEUKEMIA. 2014;28(5):993-1000.

Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years
Auner H, Szydlo R, Hoek J, Goldschmidt H, Stoppa A, Morgan G, Moreau P, Attal M, Marit G, Russell N, Brune M, Cook G, Sonneveld P, Schönland S, Garderet L, Kröger N
BONE MARROW TRANSPL. 2014;50(2):209-215.

Selected CD34 Stem cells for Graft Engineering: 34 Case Reports in Hematopoietic Stem Cell Transplantation
Aversa F, Kroger N
2014;1:.

Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation
Ayuketang F, Bussmann L, Zabelina T, Veit R, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander A, Kröger N
ANN HEMATOL. 2014;93(5):855-61.

Kopplung von elektronischer Verordnung und patientenorientierter Logistik
Baehr M, van der Linde A, König R, Melzer S, Langebrake C, Grothe-Tenberge C, Hug M
Krankenhauspharmazie. 2014;35(4):110-117.

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
Barosi G, Tefferi A, Besses C, Birgegard G, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Harrison C, Hehlmann R, Hermouet S, Kiladjian J, Kröger N, Mesa R, Mc Mullin M, Pardanani A, Passamonti F, Samuelsson J, Vannucchi A, Reiter A, Silver R, Verstovsek S, Tognoni G, Barbui T
LEUKEMIA. 2014.

TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer
Berdien B, Mock U, Atanackovic D, Fehse B
GENE THER. 2014;21:539–548.

Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT
Chalandon Y, Passweg J, Guglielmi C, Iacobelli S, Apperley J, Schaap N, Finke J, Robin M, Fedele R, Bron D, Yakoub-Agha I, van Biezen A, de Witte T, Kröger N, Olavarria E
HAEMATOLOGICA. 2014;99(9):1492-8.

Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation
Chemaly R, Ullmann A, Stoelben S, Richard M, Bornhäuser M, Groth C, Einsele H, Silverman M, Mullane K, Brown J, Nowak H, Kölling K, Stobernack H, Lischka P, Zimmermann H, Rübsamen-Schaeff H, Champlin R, Ehninger G
NEW ENGL J MED. 2014;370(19):1781-9.

IMWG consensus on risk stratification in multiple myeloma
Chng W, Dispenzieri A, Chim C, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel J, Sonneveld P, Cavo M, Usmani S, Durie B, Avet-Loiseau H
LEUKEMIA. 2014;28(2):269-77.

Epigenetic signatures as prognostic tools in acute myeloid leukemia and myelodysplastic syndromes
Christopeit M, Bartholdy B
EPIGENOMICS-UK. 2014;6(4):371-4.

Relapse assessment following allogeneic SCT in patients with MDS and AML
Christopeit M, Kröger N, Haferlach T, Bacher U
ANN HEMATOL. 2014;93(7):1097-110.

Multiplexing clonality: combining RGB marking and genetic barcoding
Cornils K, Thielecke L, Hüser S, Forgber M, Thomaschewski M, Kleist N, Hussein K, Riecken K, Volz T, Gerdes S, Glauche I, Dahl A, Dandri M, Roeder I, Fehse B
NUCLEIC ACIDS RES. 2014;42(7):e56.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation
de Lima M, Porter D, Battiwalla M, Bishop M, Giralt S, Hardy N, Kröger N, Wayne A, Schmid C
BIOL BLOOD MARROW TR. 2014;20(1):4-13.

Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy?
de Witte T, Bowen D, Robin M, Malcovati L, Mufti G, Niederwieser D, Yakoubagha I, Kröger N
CL LYMPH MYELOM LEUK. 2014;14 Suppl:S42-5.

Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study
de Wreede L, Watson M, van Os M, Milligan D, van Gelder M, Michallet M, Dreger P, Dearden C, Homewood J, Dupuis J, Leporrier M, Karas M, Corront B, Baerlocher G, Herr W, Choquet S, Niederwieser D, Sutton L, Kröger N, de Witte T, Schetelig On Behalf Of The Chronic Malignancies Working Party Of The Ebmt And The Uk Medical Research Council J
AM J HEMATOL. 2014;89(2):174-80.

Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
Döring M, Blume O, Haufe S, Hartmann U, Kimmig A, Schwarze C, Lang P, Handgretinger R, Müller I
EUR J CLIN MICROBIOL. 2014;33(4):629-38.

Neural stem cell-based intraocular administration of ciliary neurotrophic factor attenuates the loss of axotomized ganglion cells in adult mice
Flachsbarth K, Kruszewski K, Jung G, Jankowiak W, Riecken K, Wagenfeld L, Richard G, Fehse B, Bartsch U
INVEST OPHTH VIS SCI. 2014;55(11):7029-7039.

Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms
Fu Y, Schroeder T, Zabelina T, Badbaran A, Bacher U, Kobbe G, Ayuketang F, Wolschke C, Schnittger S, Kohlmann A, Haferlach T, Kröger N
EUR J HAEMATOL. 2014;92(3):189-94.

In-vivo RGB marking and multicolour single-cell tracking in the adult brain
Gomez-Nicola D, Riecken K, Fehse B, Perry V
SCI REP-UK. 2014;4:7520.

Temporal dynamics of hippocampal neurogenesis in chronic neurodegeneration
Gomez-Nicola D, Suzzi S, Vargas-Caballero M, Fransen N, Al-Malki H, Cebrian-Silla A, Garcia-Verdugo J, Riecken K, Fehse B, Perry V
BRAIN. 2014;137(Pt 8):2312-28.

Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis
Gupta V, Gotlib J, Radich J, Kröger N, Rondelli D, Verstovsek S, Deeg H
BIOL BLOOD MARROW TR. 2014;20(9):1274-81.

Selectins mediate small cell lung cancer systemic metastasis
Heidemann F, Schildt A, Schmid K, Bruns O, Riecken K, Jung C, Ittrich H, Wicklein D, Reimer R, Fehse B, Heeren J, Lüers G, Schumacher U, Heine M
PLOS ONE. 2014;9(4):e92327.

Low frequency of calreticulin mutations in MDS patients
Heuser M, Panagiota V, Koenecke C, Fehse B, Alchalby H, Badbaran A, Shahswar R, Stadler M, Eder M, Göhring G, Trummer A, Schroeder T, Kobbe G, Thiede C, Platzbecker U, Schlegelberger B, Kroeger N, Ganser A, Thol F
LEUKEMIA. 2014.

Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: a report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation
Hussein A, Halkes C, Socié G, Tichelli A, von dem Borne P, Schaap M, Foa R, Ganser A, Dufour C, Bacigalupo A, Locasciulli A, Aljurf M, Peters C, Robin M, van Biezen A, Volin L, De Witte T, Marsh J, Passweg J, Kröger N
BIOL BLOOD MARROW TR. 2014;20(9):1448-50.

Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?
Klyuchnikov E, Bacher U, Kroll T, Shea T, Lazarus H, Bredeson C, Fenske T
BONE MARROW TRANSPL. 2014;49(1):1-7.

CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies
Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S, Chabannon C, Crocchiolo R, Lemarié C, Faucher C, Bacher U, Alchalby H, Stübig T, Wolschke C, Ayuketang F, Reckhaus M, Blaise D, Kröger N
BIOL BLOOD MARROW TR. 2014;20(3):382-6.

Gentherapie
Köchy K, Domasch S, Fehse B
2014. Handbuch Ethik & Recht der Forschung am Menschen. Lenk C, Duttge G, Fangerau H (Hrsg.). 1. Aufl. Berlin, Heidelberg: Springer, 427 - 432.

Inhibition of PARP1-dependent end-joining contributes to Olaparib-mediated radiosensitization in tumor cells
Kötter A, Cornils K, Borgmann K, Dahm-Daphi J, Petersen C, Dikomey E, Mansour Khalfallah W
MOL ONCOL. 2014;8(8):1616-25.

Immune-modulating drugs and hypomethylating agents to prevent or treat relapse after allogeneic stem cell transplantation
Kröger N, Stübig T, Atanackovic D
BIOL BLOOD MARROW TR. 2014;20(2):168-72.

Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis
Kröger N, Zabelina T, Alchalby H, Stübig T, Wolschke C, Ayuketang F, von Huenerbein N, Kvasnicka H, Thiele J, Kreipe H, Büsche G
BIOL BLOOD MARROW TR. 2014;20(6):812-5.

Global scaling for semi-quantitative analysis in FP-CIT SPECT
Kupitz D, Apostolova I, Lange C, Ulrich G, Amthauer H, Brenner W, Buchert R
NUKLEARMED-NUCL MED. 2014;53(6):234-41.

Formale Kriterien für eine gute Verordnung im stationären Bereich
Langebrake C, Melzer S, Baehr M
THER UMSCH. 2014;71(6):343-351.

Micafungin as antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell Transplantation: results of different dosage levels in clinical practice
Langebrake C, Rohde H, Lellek H, Wolschke C, Kröger N
CLIN TRANSPLANT. 2014;28(3):286-91.

Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis
Lehmberg K, Albert M, Beier R, Beutel K, Gruhn B, Kröger N, Meisel R, Schulz A, Stachel D, Woessmann W, Janka G, Müller I
HAEMATOLOGICA. 2014;99(1):180-4.

Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation
Luetkens T, Kobold S, Cao Y, Ristic M, Schilling G, Tams S, Bartels B, Templin J, Bartels K, Hildebrandt Y, Yousef S, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic D
CANCER IMMUNOL IMMUN. 2014;63(11):1151-62.

Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
Lussana F, Rambaldi A, Finazzi M, van Biezen A, Scholten M, Oldani E, Carobbio A, Iacobelli S, Finke J, Nagler A, Volin L, Lamy T, Arnold R, Mohty M, Michallet M, de Witte T, Olavarria E, Kröger N
HAEMATOLOGICA. 2014;99(5):916-21.

Novel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases
Mock U, Riecken K, Berdien B, Qasim W, Chan E, Cathomen T, Fehse B
SCI REP-UK. 2014;4:6409.

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
Mohty M, Hübel K, Kröger N, Aljurf M, Apperley J, Basak G, Bazarbachi A, Douglas K, Gabriel I, Garderet L, Geraldes C, Jaksic O, Kattan M, Koristek Z, Lanza F, Lemoli R, Mendeleeva L, Mikala G, Mikhailova N, Nagler A, Schouten H, Selleslag D, Suciu S, Sureda A, Worel N, Wuchter P, Chabannon C, Duarte R
BONE MARROW TRANSPL. 2014;49(7):865-72.

Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide
Morris C, de Wreede L, Scholten M, Brand R, van Biezen A, Sureda A, Dickmeiss E, Trneny M, Apperley J, Chiusolo P, van Imhoff G, Lenhoff S, Martinelli G, Hentrich M, Pabst T, Onida F, Quinn M, Kröger N, de Witte T, Ruutu T
TRANSFUSION. 2014;54(10):2514-22.

Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome
Nagler A, Labopin M, Berger R, Bunjes D, Campos A, Socié G, Kröger N, Goker H, Yakoub-Agha I, Shimoni A, Mohty M, Rocha V
BONE MARROW TRANSPL. 2014;49(5):628-33.

Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines
Nitsch E, Mina S, Brammer I, Pace A, Schuch G, Bokemeyer C, Zander A, Kröger N, Ayuketang F
ANTICANCER RES. 2014;34(4):1779-84.

Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism
Oehler N, Volz T, Bhadra O, Kah J, Allweiss L, Giersch K, Bierwolf J, Riecken K, Pollok J, Lohse A, Fehse B, Petersen J, Urban S, Lütgehetmann M, Heeren J, Dandri M
HEPATOLOGY. 2014.

Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party
Onida F, Brand R, van Biezen A, Schaap M, von dem Borne P, Maertens J, Beelen D, Carreras E, Alessandrino E, Volin L, Kuball J, Figuera A, Sierra J, Finke J, Kröger N, de Witte T
HAEMATOLOGICA. 2014;99(10):1582-90.

Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation
Panagiota V, Thol F, Markus B, Fehse B, Alchalby H, Badbaran A, Lehmann U, Koenecke C, Shahswar R, Chaturvedi A, Stadler M, Eder M, Göhring G, Koenigsmann M, Kloos A, Trummer A, Schroeder T, Kobbe G, Thiede C, Platzbecker U, Schlegelberger B, Kreipe H, Ganser A, Kröger N, Heuser M
LEUKEMIA. 2014;28(7):1552-5.

Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation
Passweg J, Baldomero H, Peters C, Gaspar H, Cesaro S, Dreger P, Duarte R, Falkenburg J, Farge-Bancel D, Gennery A, Halter J, Kröger N, Lanza F, Marsh J, Mohty M, Sureda A, Velardi A, Madrigal A
BONE MARROW TRANSPL. 2014;49(6):744-50.

Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO)
Penack O, Becker C, Buchheidt D, Christopeit M, Kiehl M, von Lilienfeld-Toal M, Hentrich M, Reinwald M, Salwender H, Schalk E, Schmidt-Hieber M, Weber T, Ostermann H
ANN HEMATOL. 2014;93(7):1083-95.

Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients
Reinhard H, Yousef S, Luetkens T, Fehse B, Berdien B, Kröger N, Atanackovic D
BLOOD CANCER J. 2014;4:e212.

Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis
Robin M, Giannotti F, Deconinck E, Mohty M, Michallet M, Sanz G, Chevallier P, Cahn J, Legrand F, Rovira M, Passweg J, Sierra J, Nguyen S, Maillard N, Yakoub-Agha I, Linkesch W, Cannell P, Marcatti M, Bay J, Chalandon Y, Kröger N, Gluckman E, Rocha V, Olavarria E, Ruggeri A
BIOL BLOOD MARROW TR. 2014;20(11):1841-6.

Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice
Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, Dazzi F, Dreger P, Duarte R, Finke J, Garderet L, Greinix H, Holler E, Kröger N, Lawitschka A, Mohty M, Nagler A, Passweg J, Ringdén O, Socié G, Sierra J, Sureda A, Wiktor-Jedrzejczak W, Madrigal A, Niederwieser D
BONE MARROW TRANSPL. 2014;49(2):168-73.

Magnetic resonance imaging of single co-labeled mesenchymal stromal cells after intracardial injection in mice
Salamon J, Wicklein D, Didié M, Lange C, Schumacher U, Adam G, Peldschus K
ROFO-FORTSCHR RONTG. 2014;186(4):367-76.

Fear of recurrence and its impact on quality of life in patients with hematological cancers in the course of allogeneic hematopoietic SCT
Sarkar S, Scherwath A, Schirmer L, Schulz-Kindermann F, Neumann K, Kruse M, Dinkel A, Kunze S, Balck F, Kröger N, Koch U, Mehnert A
BONE MARROW TRANSPL. 2014;49(9):1217-22.

Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL
Schieferdecker A, Voigt M, Riecken K, Braig F, Schinke T, Loges S, Bokemeyer C, Fehse B, Binder M
ONCOTARGET. 2014;5(16):6647-53.

Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions-A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group
Schroeder T, Rachlis E, Bug G, Stelljes M, Klein S, Steckel N, Wolf D, Ringhoffer M, Czibere A, Nachtkamp K, Dienst A, Kondakci M, Stadler M, Platzbecker U, Uharek L, Luft T, Fenk R, Germing U, Bornhäuser M, Kröger N, Beelen D, Haas R, Kobbe G
BIOL BLOOD MARROW TR. 2014.

Cell adhesion molecules in metastatic neuroblastoma models
Schwankhaus N, Gathmann C, Wicklein D, Riecken K, Schumacher U, Valentiner U
CLIN EXP METASTAS. 2014;31(4):483-96.

Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis
Stern M, de Wreede L, Brand R, van Biezen A, Dreger P, Mohty M, de Witte T, Kröger N, Ruutu T
LEUKEMIA. 2014;28(11):2235-40.

JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis
Stübig T, Alchalby H, Ditschkowski M, Wolf D, Wulf G, Zabelina T, Wolschke C, Ayuketang F, Kröger N
LEUKEMIA. 2014;28(8):1736-8.

5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity
Stübig T, Badbaran A, Luetkens T, Hildebrandt Y, Atanackovic D, Binder T, Fehse B, Kröger N
MEDIAT INFLAMM. 2014;2014:418292.

Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia
Thol F, Scherr M, Kirchner A, Shahswar R, Battmer K, Kade S, Chaturvedi A, Koenecke C, Stadler M, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Bug G, Ottmann O, Hofmann W, Kröger N, Fiedler W, Schlenk R, Döhner K, Döhner H, Krauter J, Eder M, Ganser A, Heuser M
HAEMATOLOGICA. 2014.

Endogenous retrovirus induces leukemia in a xenograft mouse model for primary myelofibrosis
Triviai I, Ziegler M, Bergholz U, Oler A, Stübig T, Prassolov V, Fehse B, Kozak C, Kröger N, Stocking C
P NATL ACAD SCI USA. 2014;111(23):8595 - 8600.

Gute Verordnungspraxis bei älteren Patienten
Wickop B, Langebrake C
THER UMSCH. 2014;71(6):366-373.

Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation
Wolschke C, Zabelina T, Ayuketang F, Alchalby H, Berger J, Klyuchnikov E, Pein U, Schumacher S, Amtsfeld G, Adjallé R, Wortmann F, Lellek H, Randenborgh A, Zander A, Kröger N
BONE MARROW TRANSPL. 2014;49(1):126-30.

Acute psychological stress increases peripheral blood CD3+CD56+ natural killer T cells in healthy men: possible implications for the development and treatment of allergic and autoimmune disorders
Atanackovic D, Nowottne U, Freier E, Weber C, Meyer S, Bartels K, Hildebrandt Y, Cao Y, Kröger N, Brunner-Weinzierl M, Bokemeyer C, Deter H
STRESS. 2013;16(4):421-8.

The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting
Atanackovic D, Reinhard H, Meyer S, Spöck S, Grob T, Luetkens T, Yousef S, Cao Y, Hildebrandt Y, Templin J, Bartels K, Lajmi N, Stoiber H, Kröger N, Atz J, Seimetz D, Izbicki J, Bokemeyer C
HUM VACC IMMUNOTHER. 2013;9(12):2533-42.

Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous Transplantation: a study by the European Group for Blood and Marrow Transplantation
Auner H, Szydlo R, van Biezen A, Iacobelli S, Gahrton G, Milpied N, Volin L, Janssen J, Nguyen Quoc S, Michallet M, Schoemans H, El Cheikh J, Petersen E, Guilhot F, Schönland S, Ahlberg L, Morris C, Garderet L, de Witte T, Kröger N
BONE MARROW TRANSPL. 2013;48(11):1395-400.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies
Avigan D, Hari P, Battiwalla M, Bishop M, Giralt S, Hardy N, Kröger N, Wayne A, Hsu K
BIOL BLOOD MARROW TR. 2013;19(12):1661-9.

Donor choice according to age for allo-SCT for AML in complete remission
Ayuketang F, Zabelina T, Wortmann F, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander A, Kröger N
BONE MARROW TRANSPL. 2013;48(8):1028-32.

Moderne Bildgebungsverfahren beim Multiplen Myelom
Bannas P, Kröger N, Adam G, Derlin T
ROFO-FORTSCHR RONTG. 2013;185(1):26-33.

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
Ben Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger J, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens J, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S
BLOOD. 2013;122(14):2443-52.

Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy
Berdien B, Reinhard H, Meyer S, Spöck S, Kröger N, Atanackovic D, Fehse B
HUM VACC IMMUNOTHER. 2013;9(6):1205-16.

Genome-wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer
Bhattacharyya S, Yu Y, Suzuki M, Campbell N, Mazdo J, Vasanthakumar A, Bhagat T, Nischal S, Christopeit M, Parekh S, Steidl U, Godley L, Maitra A, Greally J, Verma A
NUCLEIC ACIDS RES. 2013;41(16):e157.

Cytogenetics of extramedullary manifestations in multiple myeloma
Billecke L, Murga Penas E, May A, Engelhardt M, Nagler A, Leiba M, Schiby G, Kröger N, Zustin J, Marx A, Matschke J, Tiemann M, Goekkurt E, Heidtmann H, Vettorazzi E, Dierlamm J, Bokemeyer C, Schilling G
BRIT J HAEMATOL. 2013;161(1):87-94.

Myogenic differentiation of mesenchymal stem cells in a newly developed neurotised AV-loop model
Bitto F, Klumpp D, Lange C, Boos A, Arkudas A, Bleiziffer O, Horch R, Kneser U, Beier J
BIOMED RES INT . 2013;2013:935046.

Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic Syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data
Brand R, Putter H, van Biezen A, Niederwieser D, Martino R, Mufti G, Onida F, Symeonidis A, Schmid C, Garderet L, Robin M, van Gelder M, Finke J, Bornhäuser M, Kobbe G, Germing U, de Witte T, Kröger N
PLOS ONE. 2013;8(10):e74368.

The Gonads and their Magic Bullet, Lysophosphatidic Acid: Physiological and Toxicological Functions of Lysophosphatidic Acid (LPA) In Female and Male Reproductive Systems
Budnik L, Brunswig-Spickenheier B, Müller D
2013. Lysophospholipid Receptors: Signaling and Biochemistry. Chun J, Hla T, Spiegel S, Moolenaar W (Hrsg.). Wiley & Sons, Inc , 569-586.

Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML
Christopeit M, Heiland A, Binder M, Zabelina T, Ayuketang F, Horn C, Haferlach T, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2013;48(9):1257-9.

Cyclosporine area under the curve after allogeneic hematopoietic stem cell transplantation is an indicator of Epstein-Barr virus DNAemia
Christopeit M, Janssen N, Weber T, Bacher U, Lautenschläger C, Oehme A, Kekulé A, Schmoll H
LEUKEMIA LYMPHOMA. 2013;54(1):133-7.

Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change
Christopeit M, Kuss O, Finke J, Bacher U, Beelen D, Bornhäuser M, Schwerdtfeger R, Bethge W, Basara N, Gramatzki M, Tischer J, Kolb H, Uharek L, Meyer R, Bunjes D, Scheid C, Martin H, Niederwieser D, Kröger N, Bertz H, Schrezenmeier H, Schmid C
J CLIN ONCOL. 2013;31(26):3259-71.

Right flank pain and high fever in a neutropenic patient with acute lymphoblastic leukaemia
Christopeit M, Lindner A, Surov A, Weber T, Vehreschild M, Bialek R, Schmoll H
MYCOSES. 2013;56(1):90-2.

Evaluation of BM cytomorphology after allo-SCT in patients with MDS
Christopeit M, Ocheni S, Haferlach T, Miersch K, Zabelina T, Klyuchnikov E, Binder M, Ayuketang F, Schafhausen P, Zander A, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2013;48(3):465-6.

Comparative clonal analysis of reconstitution kinetics after transplantation of hematopoietic stem cells gene marked with a lentiviral SIN or a γ-retroviral LTR vector
Cornils K, Bartholomae C, Thielecke L, Lange C, Arens A, Glauche I, Mock U, Riecken K, Gerdes S, von Kalle C, Schmidt M, Roeder I, Fehse B
EXP HEMATOL. 2013;41(1):28-38.e3.

Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation
Derlin T, Peldschus K, Münster S, Bannas P, Herrmann J, Stübig T, Habermann C, Adam G, Kröger N, Weber C
EUR RADIOL. 2013;23(2):570-8.

Parthenogenetic stem cells for tissue-engineered heart repair
Didié M, Christalla P, Rubart M, Muppala V, Döker S, Unsöld B, El-Armouche A, Rau T, Eschenhagen T, Schwoerer A, Ehmke H, Schumacher U, Fuchs S, Lange C, Becker A, Tao W, Scherschel J, Soonpaa M, Yang T, Lin Q, Zenke M, Han D, Schöler H, Rudolph C, Steinemann D, Schlegelberger B, Kattman S, Witty A, Keller G, Field L, Zimmermann W
J CLIN INVEST. 2013;123(3):1285-98.

Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study
Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella A, Beksac M, Bosi A, Milone G, Corradini P, Schönland S, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N
BLOOD. 2013;121(25):5055-63.

Syngeneic transplantation in aplastic anemia: pre-transplant conditioning and peripheral blood are associated with improved engraftment: an observational study on behalf of the Severe Aplastic Anemia and Pediatric Diseases Working Parties of the European Group for Blood and Marrow Transplantation
Gerull S, Stern M, Apperley J, Beelen D, Brinch L, Bunjes D, Butler A, Ganser A, Ghavamzadeh A, Koh M, Komarnicki M, Kröger N, Maertens J, Maschan A, Peters C, Rovira M, Sengeløv H, Socié G, Tischer J, Oneto R, Passweg J, Marsh J
HAEMATOLOGICA. 2013;98(11):1804-9.

Stem cell clonality -- theoretical concepts, experimental techniques, and clinical challenges
Glauche I, Bystrykh L, Eaves C, Roeder I
BLOOD CELL MOL DIS. 2013;50(4):232-40.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation
Gress R, Miller J, Battiwalla M, Bishop M, Giralt S, Hardy N, Kröger N, Wayne A, Landau D, Wu C
BIOL BLOOD MARROW TR. 2013;19(11):1537-45.

Genetically modified neural stem cells for a local and sustained delivery of neuroprotective factors to the dystrophic mouse retina
Jung G, Sun J, Petrowitz B, Riecken K, Kruszewski K, Jankowiak W, Kunst F, Skevas C, Richard G, Fehse B, Bartsch U
STEM CELL TRANSL MED. 2013;2(12):1001-10.

Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib.
Koch M, Graeser C, Lehnhardt A, Pollok J, Kröger N, Verboom M, Thaiss F, Eiermann T, Nashan B
TRANSPL INT. 2013;26(8):64-68.

Isogeneic MSC application in a rat model of acute renal allograft rejection modulates immune response but does not prolong allograft survival
Koch M, Lehnhardt A, Hu X, Brunswig-Spickenheier B, Stolk M, Bröcker V, Noriega M, Seifert M, Lange C
TRANSPL IMMUNOL. 2013;29(1-4):43-50.

Aktuelle Therapieoptionen bei der Myelofibrose
Kröger N
2013. Aktuelle Therapieoptionen bei der Myelofibrose. Döhner K, Griesshammer M (Hrsg.). 2. Aufl. Uni-Med, 56-63.

From nuclear to a global Family: more donors for MDS
Kröger N
BLOOD. 2013;122(11):1848-50.

Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
Kröger N, Badbaran A, Zabelina T, Ayuketang F, Wolschke C, Alchalby H, Klyuchnikov E, Atanackovic D, Schilling G, Hansen T, Schwarz S, Heinzelmann M, Zeschke S, Bacher U, Stübig T, Fehse B, Zander A
BIOL BLOOD MARROW TR. 2013;19(3):398-404.

Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings.
Kröger N, Zabelina T, de Wreede L, Berger J, Alchalby H, van Biezen A, Milpied N, Volin L, Mohty M, Leblond V, Blaise D, Finke J, Schaap N, Robin M, de Witte T
LEUKEMIA. 2013;27(3):604-609.

Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.
Kröger N, Zabelina T, Klyuchnikov E, Kropff M, Pflüger K, Burchert A, Stübig T, Wolschke C, Ayuketang F, Hildebrandt Y, Bacher U, Badbaran A, Schilling G, Hansen T, Atanackovic D, Zander A
BONE MARROW TRANSPL. 2013;48(3):403-407.

Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomerase
Langer F, Spath B, Fischer C, Stolz M, Ayuketang F, Kröger N, Bokemeyer C, Ruf W
BLOOD. 2013;121(12):2324-35.

Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs
Löschmann N, Michaelis M, Rothweiler F, Zehner R, Cinatl J, Voges Y, Sharifi M, Riecken K, Meyer J, von Deimling A, Fichtner I, Ghafourian T, Westermann F, Cinatl J
TRANSL ONCOL. 2013;6(6):685-96.

Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT.
Martino R, de Wreede L, Fiocco M, van Biezen A, von Dem Borne P, Hamladji R, Volin L, Bornhäuser M, Robin M, Rocha V, de Witte T, Kröger N, Mohty M
BONE MARROW TRANSPL. 2013;48(6):761-770.

Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms
Nischal S, Bhattacharyya S, Christopeit M, Yu Y, Zhou L, Bhagat T, Sohal D, Will B, Mo Y, Suzuki M, Pardanani A, McDevitt M, Maciejewski J, Melnick A, Greally J, Steidl U, Moliterno A, Verma A
CANCER RES. 2013;73(3):1076-85.

MAGE-C1/CT7 spontaneously triggers a CD4+ T-cell response in multiple myeloma patients
Nuber N, Curioni-Fontecedro A, Dannenmann S, Matter C, von Boehmer L, Atanackovic D, Knuth A, van den Broek M
LEUKEMIA. 2013;27(8):1767-9.

Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Oyekunle A, Zander A, Binder M, Ayuketang F, Zabelina T, Christopeit M, Stübig T, Alchalby H, Schafhausen P, Lellek H, Wolschke C, Müller I, Bacher U, Kröger N
ANN HEMATOL. 2013;92(4):487-496.

Hematopoietic SCT in Europe: data and trends in 2011
Passweg J, Baldomero H, Bregni M, Cesaro S, Dreger P, Duarte R, Falkenburg J, Kröger N, Farge-Bancel D, Gaspar H, Marsh J, Mohty M, Peters C, Sureda A, Velardi A, Ruiz de Elvira C, Madrigal A
BONE MARROW TRANSPL. 2013;48(9):1161-7.

Interaction of magnetically labeled multipotent mesenchymal stromal cells and E-and P-selectins monitored by magnetic resonance imaging in mice
Peldschus K, Salamon J, Wicklein D, Lange C, Ittrich H, Adam G, Schumacher U
MOL IMAGING. 2013;12(2):100-10.

Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse
Pfeiffer T, Schleuning M, Mayer J, Haude K, Tischer J, Buchholz S, Bunjes D, Bug G, Holler E, Meyer R, Greinix H, Scheid C, Christopeit M, Schnittger S, Braess J, Schlimok G, Spiekermann K, Ganser A, Kolb H, Schmid C
HAEMATOLOGICA. 2013;98(4):518-25.

Fucoidans as potential inhibitors of HIV-1
Prokofjeva M, Imbs T, Shevchenko N, Spirin P, Horn S, Fehse B, Zvyagintseva T, Prassolov V
MAR DRUGS. 2013;11(8):3000-14.

A new system for parallel drug screening against multiple-resistant HIV mutants based on lentiviral self-inactivating (SIN) vectors and multi-colour analyses
Prokofjeva M, Riecken K, Spirin P, Yanvarév D, Düsedau A, Ellinger B, Fehse B, Stocking C, Prassolov V
AIDS RES THER. 2013;10(1):1.

Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation.
Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, Arturo I, Arcese W, Beelen D, Cornelissen J, Kröger N, Milone G, Rossi G, Jardin F, Peters C, Rocha V, Sureda A, Mohty M, Dreger P
BLOOD. 2013;121(3):440-446.

Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study.
Scherwath A, Schirmer L, Kruse M, Ernst G, Eder M, Dinkel A, Kunze S, Balck F, Bornhäuser M, Ehninger G, Dolan K, Gramatzki M, Kolb H, Heußner P, Wilhelm H, Beelen D, Schulz-Kindermann F, Zander A, Koch-Gromus U, Mehnert A
PSYCHO-ONCOLOGY. 2013;22(7):1509-1516.

CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell Transplantation: a report from the Acute Leukemia Working Party of EBMT
Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J, Socié G, Schwerdtfeger R, Kröger N, Ganser A, Niederwieser D, Polge E, Blau I, Mohty M
BLOOD. 2013;122(19):3359-64.

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation
Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, Giagounidis A, Zohren F, Bruns I, Wolschke C, Rieger K, Fenk R, Germing U, Haas R, Kröger N, Kobbe G
LEUKEMIA. 2013;27(6):1229-35.

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation
Schroeder T, Fröbel J, Cadeddu R, Czibere A, Dienst A, Platzbecker U, Bug G, Uharek L, Fenk R, Germing U, Kröger N, Haas R, Kobbe G
LEUKEMIA. 2013;27(9):1910-3.

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi A, Gotlib J, Dupriez B, Pardanani A, Harrison C, Hoffman R, Gisslinger H, Kröger N, Thiele J, Barbui T, Barosi G
BLOOD. 2013;122(8):1395-8.

SETBP1 mutation analysis in 944 patients with MDS and AML
Thol F, Suchanek K, Koenecke C, Stadler M, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Kade S, Löffeld P, Banihosseini S, Bug G, Ottmann O, Hofmann W, Krauter J, Kröger N, Ganser A, Heuser M
LEUKEMIA. 2013;27(10):2072-5.

Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia.
van Gelder M, de Wreede L, Schetelig J, van Biezen A, Volin L, Maertens J, Robin M, Petersen E, de Witte T, Kröger N
LEUKEMIA. 2013;27(4):879-888.

Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12
Vater A, Sahlmann J, Kröger N, Zöllner S, Lioznov M, Maasch C, Buchner K, Vossmeyer D, Schwoebel F, Purschke W, Vonhoff S, Kruschinski A, Hübel K, Humphrey M, Klussmann S, Fliegert F
CLIN PHARMACOL THER. 2013;94(1):150-7.

Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
Vehreschild M, Vehreschild J, Hübel K, Hentrich M, Schmidt-Hieber M, Christopeit M, Maschmeyer G, Schalk E, Cornely O, Neumann S
ANN ONCOL. 2013;24(5):1189-202.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction
Wayne A, Giralt S, Kröger N, Bishop M
BIOL BLOOD MARROW TR. 2013;19(11):1534-6.

Allogeneic hematopoietic stem cell transplantation: an option for long-term survival for patients with simultaneous appearance of myeloid and lymphatic malignancies.
Weber T, Ocheni S, Binder M, Theurich S, Scheid C, Schmid C, Müller L, Christopeit M, Bacher U
ACTA HAEMATOL-BASEL. 2013;129(3):135-136.

Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
Wolschke C, Stübig T, Hegenbart U, Schönland S, Heinzelmann M, Hildebrandt Y, Ayuketang Ayuk F, Atanackovic D, Dreger P, Zander A, Kröger N
EXP HEMATOL. 2013;41(2):133-134.

Production and first-in-man use of T cells engineered to express a HSVTK-CD34 sort-suicide gene
Zhan H, Gilmour K, Chan L, Farzaneh F, McNicol A, Xu J, Adams S, Fehse B, Veys P, Thrasher A, Gaspar H, Qasim W
PLOS ONE. 2013;8(10):e77106.

Discovered on gastrointestinal stromal tumour 1 (DOG1): a useful immunohistochemical marker for diagnosing chondroblastoma.
Akpalo H, Lange C, Zustin J
HISTOPATHOLOGY. 2012;60(7):1099-1106.

Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.
Alchalby H, Yunus D, Zabelina T, Kobbe G, Holler E, Bornhäuser M, Schwerdtfeger R, Bethge W, Kvasnicka H, Büsche G, Ayuketang Ayuk F, Bacher U, Zander A, Kröger N
BRIT J HAEMATOL. 2012;157(1):75-85.

Role of interleukin 16 in multiple myeloma.
Atanackovic D, Hildebrandt Y, Templin J, Cao Y, Keller C, Panse J, Meyer S, Reinhard H, Bartels K, Lajmi N, Sezer O, Zander A, Marx A, Uhlig R, Zustin J, Bokemeyer C, Kröger N
JNCI-J NATL CANCER I. 2012;104(13):1005-1020.

Identification of genetic parameters associated with disease progression in plasma cell myeloma.
Bacher U, Binder M
LEUKEMIA RES. 2012;36(1):23-24.

[Diagnostics of acute leukemias: interaction of phenotypic and genetic methods].
Bacher U, Haferlach C, Schnittger S, Kern W, Ott M, Haferlach T
PATHOLOGE. 2012;33(6):528-538.

The benefit of population-based studies for older patients with acute myeloid leukemia.
Bacher U, Haferlach T
HAEMATOLOGICA. 2012;97(12):1781-1782.

Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course.
Bacher U, Kern W, Alpermann T, Schnittger S, Haferlach C, Haferlach T
LEUKEMIA RES. 2012;36(7):826-831.

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop M, Bredeson C, Cairo M, Fenske T, Freytes C, Gale R, Gibson J, Isola L, Inwards D, Laport G, Lazarus H, Maziarz R, Wiernik P, Schouten H, Slavin S, Smith S, Vose J, Waller E, Hari P, Lymphoma W
BLOOD. 2012;120(20):4256-4262.

Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity.
Bacher U, Schnittger S, Macijewski K, Grossmann V, Kohlmann A, Alpermann T, Kowarsch A, Nadarajah N, Kern W, Haferlach C, Haferlach T
BLOOD. 2012;119(20):4719-4722.

Monitoring and prevention of relapse after allogeneic hematopoietic cell transplantation for myeloid malignancies.
Bacher U, Talano J, Bishop M
BIOL BLOOD MARROW TR. 2012;18(1 Suppl):62-73.

TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.
Bacher U, Weissmann S, Kohlmann A, Schindela S, Alpermann T, Schnittger S, Kern W, Haferlach T, Haferlach C
BRIT J HAEMATOL. 2012;156(1):67-75.

Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation.
Bannas P, Hentschel H, Bley T, Treszl A, Zu Eulenburg C, Derlin T, Yamamura J, Adam G, Stübig T, Kröger N, Weber C
EUR RADIOL. 2012;22(9):2007-2012.

Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma.
Billecke L, Murga-Penas E, May A, Engelhardt M, Nagler A, Leiba M, Schiby G, Kröger N, Zustin J, Marx A, Matschke J, Tiemann M, Goekkurt E, Bokemeyer C, Schilling G
ANTICANCER RES. 2012;32(5):2031-2034.

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.
Bornhäuser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, Baurmann H, Schäfer-Eckart K, Holler E, Kröger N, Schmid C, Einsele H, Kiehl M, Hiddemann W, Schwerdtfeger R, Buchholz S, Dreger P, Neubauer A, Berdel W, Ehninger G, Beelen D, Schetelig J, Stelljes M
LANCET ONCOL. 2012;13(10):1035-1044.

The role of regulatory T cells and TH17 cells in multiple myeloma.
Braga W, Atanackovic D, Colleoni G
Clin Dev Immunol. 2012;2012:293479.

Evaluation of BM cytomorphology after allo-SCT in patients with AML
Christopeit M, Miersch K, Klyuchnikov E, Haferlach T, Binder M, Zabelina T, Ayuketang Ayuk F, Schafhausen P, Zander A, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2012;47(12):1538-1544.

18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation
Derlin T, Weber C, Habermann C, Herrmann J, Wisotzki C, Ayuk F, Wolschke C, Klutmann S, Kröger N
EUR J NUCL MED MOL I. 2012;39(3):493-500.

Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study
Federmann B, Bornhauser M, Meisner C, Kordelas L, Beelen D, Stuhler G, Stelljes M, Schwerdtfeger R, Christopeit M, Behre G, Faul C, Vogel W, Schumm M, Handgretinger R, Kanz L, Bethge W
HAEMATOLOGICA. 2012;97(10):1523-31.

Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial.
Finke J, Schmoor C, Bethge W, Ottinger H, Stelljes M, Zander A, Volin L, Heim D, Schwerdtfeger R, Kolbe K, Mayer J, Maertens J, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Bertz H, Grishina O, Socié G, , Kröger N
BIOL BLOOD MARROW TR. 2012;18(11):1716-1726.

Critical imbalance of TNF-α and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment.
Flammiger A, Fiedler W, Bacher U, Bokemeyer C, Schneider M, Binder M
ACTA HAEMATOL-BASEL. 2012;128(2):69-72.

Molecular analysis of RAS-RAF tyrosine-kinase signaling pathway alterations in patients with plasma cell myeloma.
Grossmann V, Bacher U, Artusi V, Kohlmann A, Nadarajah N, Kern W, Schnittger S, Haferlach T, Haferlach C
BLOOD CANCER J. 2012;2:85.

EZH2 mutations and their association with PICALM-MLLT10 positive acute leukaemia.
Grossmann V, Bacher U, Kohlmann A, Artusi V, Klein H, Dugas M, Schnittger S, Alpermann T, Kern W, Haferlach T, Haferlach C
BRIT J HAEMATOL. 2012;157(3):387-390.

Expression of CEBPA is reduced in RUNX1-mutated acute myeloid leukemia.
Grossmann V, Bacher U, Kohlmann A, Butschalowski K, Roller A, Jeromin S, Dicker F, Kern W, Schnittger S, Haferlach T, Haferlach C
BLOOD CANCER J. 2012;2:86.

Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
Haferlach C, Bacher U, Grossmann V, Schindela S, Zenger M, Kohlmann A, Kern W, Haferlach T, Schnittger S
GENE CHROMOSOME CANC. 2012;51(12):1079-1085.

ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
Haferlach C, Bacher U, Schnittger S, Alpermann T, Zenger M, Kern W, Haferlach T
GENE CHROMOSOME CANC. 2012;51(4):328-337.

Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype.
Haferlach T, Bacher U, Alpermann T, Haferlach C, Kern W, Schnittger S
LEUKEMIA RES. 2012;36(1):51-58.

Impact of the NK cell receptor LIR-1 (ILT-2/CD85j/LILRB1) on cytotoxicity against multiple myeloma.
Heidenreich S, Zu Eulenburg C, Hildebrandt Y, Stübig T, Sierich H, Badbaran A, Eiermann T, Binder T, Kröger N
Clin Dev Immunol. 2012;2012:652130.

European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization.
Hübel K, Fresen M, Apperley J, Basak G, Douglas K, Gabriel I, Geraldes C, Jaksic O, Koristek Z, Kröger N, Lanza F, Lemoli R, Mikala G, Selleslag D, Worel N, Mohty M, Duarte R
BONE MARROW TRANSPL. 2012;47(8):1046-1050.

Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia.
Kern W, Bacher U, Haferlach C, Alpermann T, Dicker F, Schnittger S, Haferlach T
CYTOM PART B-CLIN CY. 2012;82(3):145-150.

Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL.
Kern W, Bacher U, Haferlach C, Dicker F, Alpermann T, Schnittger S, Haferlach T
BRIT J HAEMATOL. 2012;157(1):86-96.

SOCS3 promotes interleukin-17 expression of human T cells.
Kleinsteuber K, Heesch K, Schattling S, Sander-Juelch C, Mock U, Riecken K, Fehse B, Fleischer B, Jacobsen M
BLOOD. 2012;120(22):4374-4382.

Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting.
Klyuchnikov E, Holler E, Bornhäuser M, Kobbe G, Nagler A, Shimoni A, Könecke C, Wolschke C, Bacher U, Zander A, Kröger N
BRIT J HAEMATOL. 2012;159(2):172-181.

Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients.
Kobold S, Luetkens T, Bartels B, Cao Y, Hildebrandt Y, Sezer O, Reinhard H, Templin J, Bartels K, Lajmi N, Haag F, Bokemeyer C, Kröger N, Atanackovic D
Clin Dev Immunol. 2012;2012:134081.

Allogene Blutstammzelltransplantation
Kröger N
2012. Multiples Myelom: Moderne Diagnoseverfahren, aktuelle Behandlungsoptionen und Supportivtherapie. Deutscher Ärzte-Verlag: 105-116.

Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome.
Kröger N
BLOOD. 2012;119(24):5632-5639.

Allogene Stammzelltransplantation zur Therapie der Osteomyelofibrose
Kröger N
2012. Blutstammzelltransplantation - Bilanz des aktuellen Wissens. düsseldorf university press: 139-155.

Allogene Stammzelltransplantation bei Myelofibrose
Kröger N, Alchalby H
2012. Aktuelle Therapieoptionen bei der Myelofibrose. UNI-MED Verlag: 47-56.

Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis.
Kröger N, Kvasnicka M, Thiele J
Fibrogenesis Tissue Repair. 2012;5 Suppl 1:25.

Immunotherapy for multiple myeloma.
Kröger N, Mohty M, Nagler A, Yi Q
Clin Dev Immunol. 2012;2012:797165.

Platelet lysate suppresses the expression of lipocalin-type prostaglandin D2 synthase that positively controls adipogenic differentiation of human mesenchymal stromal cells.
Lange C, Brunswig-Spickenheier B, Eissing L, Scheja L
EXP CELL RES. 2012;318(18):2284-2296.

Treatment of Ischemia/Reperfusion Injury of the Kidney with Mesenchymal Stromal Cells
Lange C, Zander A, Westenfelder C
2012. Stem Cells and Cancer Stem Cells,Volume 3. Springer Berlin Heidelberg: 241-250.

Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience.
Le Gouill S, Kröger N, Dhedin N, Nagler A, Bouabdallah K, Yakoub-Agha I, Kanouni T, Bulabois C, Tournilhac O, Buzyn A, Rio B, Moles M, Shimoni A, Bacher U, Ocheni S, Milpied N, Harousseau J, Moreau P, Leux C, Mohty M
ANN ONCOL. 2012;23(10):2695-2703.

Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
Malard F, Kröger N, Gabriel I, Hübel K, Apperley J, Basak G, Douglas K, Geraldes C, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Worel N, Mohty M, Duarte R
BIOL BLOOD MARROW TR. 2012;18(2):314-317.

Efficient lentiviral transduction and transgene expression in primary human B cells.
Mock U, Thiele R, Uhde A, Fehse B, Horn S
HUM GENE THER METHOD. 2012;23(6):408-415.

Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies.
Preukschas M, Hagel C, Schulte A, Riecken K, Lamszus K, Sievert H, Pällmann N, Bokemeyer C, Hauber J, Balabanov M, Balabanov S
PLOS ONE. 2012;7(8):43468.

Screening of Potential HIV-1 Inhibitors/Replication Blockers Using Secure Lentiviral in Vitro System.
Prokofjeva M, Spirin P, Yanvarev D, Ivanov A, Novikov M, Stepanov O, Gottikh M, Kochetkov S, Fehse B, Stocking C, Prassolov V
ACTA NATURAE. 2012;3(4):55-65.

Antigen-specificity of oligoclonal abnormal protein bands in multiple myeloma after allogeneic stem cell transplantation.
Rahlff J, Trusch M, Haag F, Bacher U, Horst A, Schlüter H, Binder M
CANCER IMMUNOL IMMUN. 2012;61(10):1639-1651.

RGB marking with lentiviral vectors for multicolor clonal cell tracking.
Riecken K, Thomaschewski M, Benten D, Fehse B
NAT PHYS. 2012;7(5):839-849.

RGB marking : Vielfarbige Zellmarkierung zur klonalen Analyse
Riecken K, Thomaschewski M, Warlich M, Cornils K, Benten D, Fehse B
Laborwelt. 2012;13(1):7-9.

Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation.
Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, Stadler M, Kuball J, Cornelissen J, Vorlicek J, Socié G, Falda M, Vindeløv L, Ljungman P, Jackson G, Kröger N, Rank A, Polge E, Rocha V, Mohty M, Blood A, Transplantation M
BLOOD. 2012;119(6):1599-1606.

Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.
Schnittger S, Bacher U, Alpermann T, Reiter A, Ulke M, Dicker F, Eder C, Kohlmann A, Grossmann V, Kowarsch A, Kern W, Haferlach C, Haferlach T
HAEMATOLOGICA. 2012;97(12):1890-1894.

Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow.
Schnittger S, Bacher U, Eder C, Dicker F, Alpermann T, Grossmann V, Kohlmann A, Kern W, Haferlach C, Haferlach T
HAEMATOLOGICA. 2012;97(10):1582-1585.

Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data.
Schnittger S, Bacher U, Haferlach C, Alpermann T, Kern W, Haferlach T
GENE CHROMOSOME CANC. 2012;51(10):910-924.

Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia.
Schnittger S, Bacher U, Haferlach T, Wendland N, Ulke M, Dicker F, Grossmann V, Haferlach C, Kern W
BLOOD. 2012;119(13):3151-3154.

Therapy-related myeloid neoplasms following treatment with radioiodine.
Schroeder T, Kuendgen A, Kayser S, Kröger N, Braulke F, Platzbecker U, Klärner V, Zohren F, Haase D, Stadler M, Schlenk R, Czibere A, Bruns I, Fenk R, Gattermann N, Haas R, Kobbe G, Germing U
HAEMATOLOGICA. 2012;97(2):206-212.

p65-Dependent production of interleukin-1β by osteolytic prostate cancer cells causes an induction of chemokine expression in osteoblasts.
Schulze J, Riecken K, Baranowsky A, Streichert T, Lange T, Spiro A, Albers J, Seitz S, Zustin J, Amling M, Fehse B, Schinke T
CANCER LETT. 2012;317(1):106-113.

Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges.
Shah N, Bacher U, Fry T, Calvo K, Stetler-Stevenson M, Arthur D, Kurlander R, Baird K, Wise B, Giralt S, Bishop M, Hardy N, Wayne A
AM J HEMATOL. 2012;87(9):916-922.

Control of bone formation by the serpentine receptor Frizzled-9.
Albers J, Schulze J, Beil F, Gebauer M, Baranowsky A, Keller J, Marshall R, Wintges K, Friedrich F, Priemel M, Schilling A, Rueger J, Cornils K, Fehse B, Streichert T, Sauter G, Jakob F, Insogna K, Pober B, Knobeloch K, Francke U, Amling M, Schinke T
J CELL BIOL. 2011;192(6):1057-1072.

Circulating CD34(+) cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT.
Alchalby H, Lioznov M, Fritzsche-Friedland U, Badbaran A, Zabelina T, Bacher U, Stübig T, Ayuketang Ayuk F, Zander A, Kröger N
BONE MARROW TRANSPL. 2011;47(1):143-145.

Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
Atanackovic D, Luetkens T, Kloth B, Fuchs G, Cao Y, Hildebrandt Y, Meyer S, Bartels K, Reinhard H, Lajmi N, Hegewisch-Becker S, Schilling G, Platzbecker U, Kobbe G, Schroeder T, Bokemeyer C, Kröger N
AM J HEMATOL. 2011;86(11):918-922.

Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma.
Atanackovic D, Panse J, Hildebrandt Y, Jadczak A, Kobold S, Cao Y, Templin J, Meyer S, Reinhard H, Bartels K, Lajmi N, Zander A, Marx A, Bokemeyer C, Kröger N
HAEMATOLOGICA. 2011;96(10):1512-1520.

Ganglioneuroblastoma infiltrating the bone marrow in an adult.
Bacher U, Christopeit M, Wiedemann B, Leuschner I, Haferlach T, Choschzick M
BRIT J HAEMATOL. 2011;153(5):544.

Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells.
Bacher U, Haferlach C, Alpermann T, Kern W, Schnittger S, Haferlach T
HAEMATOLOGICA. 2011;96(9):1284-1292.

Several lymphoma-specific genetic events in parallel can be found in mature B-cell neoplasms.
Bacher U, Haferlach T, Alpermann T, Kern W, Schnittger S, Haferlach C
GENE CHROMOSOME CANC. 2011;50(1):43-50.

Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations.
Bacher U, Haferlach T, Alpermann T, Zenger M, Hochhaus A, Beelen D, Uppenkamp M, Rummel M, Kern W, Schnittger S, Haferlach C
BRIT J HAEMATOL. 2011;152(6):713-720.

Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia.
Bacher U, Haferlach T, Fehse B, Schnittger S, Kröger N
SCI WORLD J. 2011;11:310-319.

Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia.
Bacher U, Haferlach T, Schnittger S, Kreipe H, Kröger N
BRIT J HAEMATOL. 2011;153(2):149-167.

Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics.
Bacher U, Kern W, Alpermann T, Schnittger S, Kohlmann A, Klein H, Dugas M, Haferlach C, Haferlach T
LEUKEMIA. 2011;25(8):1361-1364.

Unusual course of myelodysplastic syndrome with presumed familial origin.
Bacher U, Ocheni S, Schafhausen P, Oyekunle A, Dierlamm J, Zander A, Bokemeyer C, Haferlach T, Kröger N
ACTA HAEMATOL-BASEL. 2011;126(4):234-237.

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.
Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H, Hehlmann R, Hoffman R, Kiladjian J, Kröger N, Mesa R, McMullin M, Pardanani A, Passamonti F, Vannucchi A, Reiter A, Silver R, Verstovsek S, Tefferi A, LeukemiaNet E
J CLIN ONCOL. 2011;29(6):761-770.

Myogenic differentiation of mesenchymal stem cells co-cultured with primary myoblasts.
Beier J, Bitto F, Lange C, Klumpp D, Arkudas A, Bleiziffer O, Boos A, Horch R, Kneser U
CELL BIOL INT. 2011;35(4):397-406.

Expression of CD133 and other putative stem cell markers in uveal melanoma.
Berna-Thill M, Berna M, Grierson R, Reinhart I, Voelkel T, Piechaczek C, Galambos P, Jager M, Richard G, Lange C, Gehling U
MELANOMA RES. 2011;21(5):405-416.

B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia.
Binder M, Müller F, Jackst A, Lechenne B, Pantic M, Bacher U, Zu Eulenburg C, Veelken H, Mertelsmann R, Pasqualini R, Arap W, Trepel M
CANCER-AM CANCER SOC. 2011;117(9):1891-1900.

National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee.
Bishop M, Alyea E, Cairo M, Falkenburg J, June C, Kröger N, Little R, Miller J, Pavletic S, Porter D, Riddell S, van Besien K, Wayne A, Weisdorf D, Wu R, Giralt S
BIOL BLOOD MARROW TR. 2011;17(4):443-454.

Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells.
Brassat U, Balabanov S, Bali D, Dierlamm J, Balabanov M, Hartmann U, Sirma H, Günes C, Wege H, Fehse B, Gontarewicz A, Dikomey E, Borgmann K, Brümmendorf T
EXP HEMATOL. 2011;39(1):62-66.

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.
Cavo M, Rajkumar S, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos M, Attal M, Sonneveld P, Boccadoro M, Anderson K, Richardson P, Bensinger W, Johnsen H, Kröger N, Gahrton G, Bergsagel P, Vesole D, Einsele H, Jagannath S, Niesvizky R, Durie B, Jesus S, Lonial S, Group I
BLOOD. 2011;117(23):6063-6073.

Do centrally pre-prepared solutions achieve more reliable drug concentrations than solutions prepared on the ward?
Dehmel C, Braune S, Kreymann K, Baehr M, Langebrake C, Hilgarth H, Nierhaus A, Dartsch D, Kluge S
INTENS CARE MED. 2011;37(8):1311-1316.

Gentherapie in Deutschland. Eine Einführung
Domasch S, Fehse B
2011. Gentherapie in Deutschland: Eine interdisziplinäre Bestandsaufnahme. Themenband des Gentechnologieberichts. Forum W - Wissenschaftlicher Verlag: 31-40.

Assessment of physiologic natural killer cell cytotoxicity in vitro.
Duske H, Sputtek A, Binder T, Kröger N, Schrepfer S, Eiermann T
HUM IMMUNOL. 2011;72(11):1007-1012.

Genetic Modifications – Possibilities and Limits of Gene Therapy
Fehse B
2011. Human Nature and Self Design. mentis Verlag Paderborn: 113-136.

Stand wissenschaftlicher und medizinischer Entwicklungen
Fehse B, Baum C, Schmidt M, Kalle C
2011. Gentherapie in Deutschland: Eine interdisziplinäre Bestandsaufnahme. Themenband des Gentechnologieberichts. Forum W - Wissenschaftlicher Verlag: 41-126.

Perspektivische Entwicklungen in der Stammzelltransplantation: Zelltherapie.
Fehse B, Lange C
2011. Allogene Stammzelltherapie – Grundlagen, Indikationen und Perspektiven.. Kröger N, Zander A (Hrsg.). 1.-3.. Aufl. Bremen: Uni-Med, 134-142.

Cytogenetic methods in chronic lymphocytic leukemia.
Haferlach C, Bacher U
Methods Mol Biol. 2011;730:119-130.

CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia.
Haferlach C, Bacher U, Kohlmann A, Schindela S, Alpermann T, Kern W, Schnittger S, Haferlach T
HAEMATOLOGICA. 2011;96(6):829-836.

Emergence of carbapenemases in Gram-negative bacteria in Hamburg, Germany.
Hentschke M, Goritzka V, Belmar Campos C, Merkel P, Ilchmann C, Lellek H, Scherpe S, Aepfelbacher M, Rohde H
DIAGN MICR INFEC DIS. 2011;71(3):312-315.

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.
Hübel K, Fresen M, Salwender H, Basara N, Beier R, Theurich S, Christopeit M, Bogner C, Galm O, Hartwig R, Heits F, Lordick F, Rösler W, Wehler D, Zander A, Albert M, Dressler S, Ebinger M, Frickhofen N, Hertenstein B, Kiehl M, Liebler S, von Lilienfeld-Toal M, Weidmann E, Weigelt C, Lange F, Kröger N
BONE MARROW TRANSPL. 2011;46(8):1045-1052.

Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells.
Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T
LEUKEMIA LYMPHOMA. 2011;52(1):92-100.

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.
Klyuchnikov E, Bacher U, Kröger N, Kazantsev I, Zabelina T, Ayuketang Ayuk F, Zander A
ANN HEMATOL. 2011;2011:974658.

Purification of CD4+ T cells for adoptive immunotherapy after allogeneic hematopoietic stem cell transplantation
Klyuchnikov E, Sputtek A, Slesarchuk O, Lioznov M, Stübig T, Bacher U, Amtsfeld G, Merle E, Reckhaus M, Fehse B, Wolschke C, Adjalle R, Ayuketang Ayuk F, Zander A, Kröger N
BIOL BLOOD MARROW TR. 2011;17(3):374-383.

Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation.
Kobold S, Tams S, Luetkens T, Cao Y, Sezer O, Bartels B, Reinhard H, Templin J, Bartels K, Hildebrandt Y, Lajmi N, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic D
Clin Dev Immunol. 2011;2011:302145.

Approaches to relapse after allogeneic stem cell transplantation.
Kröger N
CURR OPIN ONCOL. 2011;23(2):203-208.

Minimal residual disease following allogeneic hematopoietic stem cell transplantation.
Kröger N, Miyamura K, Bishop M
BIOL BLOOD MARROW TR. 2011;17(1):94-100.

Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.
Kröger N, Zabelina T, Berger J, Duske H, Klyuchnikov E, Binder T, Stübig T, Hildebrandt Y, Atanackovic D, Alchalby H, Ayuketang Ayuk F, Zander A, Bacher U, Eiermann T
LEUKEMIA. 2011;25(10):1657-1661.

Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis.
Kröger N, Zabelina T, van Biezen A, Brand R, Niederwieser D, Martino R, Lim Z, Onida F, Schmid C, Garderet L, Robin M, van Gelder M, Marks R, Symeonidis A, Kobbe G, de Witte T
HAEMATOLOGICA. 2011;96(2):291-297.

Drug dosing and monitoring in obese patients undergoing allogenic stem cell transplantation.
Langebrake C, Bernhardt F, Baehr M, Kröger N, Zander A
INT J CLIN PHARM-NET. 2011;33(6):918-924.

Radiation rescue: mesenchymal stromal cells protect from lethal irradiation.
Lange C, Brunswig-Spickenheier B, Capallo-Obermann H, Eggert K, Gehling U, Rudolph C, Schlegelberger B, Cornils K, Zustin J, Spiess A, Zander A
PLOS ONE. 2011;6(1):14486.

Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients.
Lellek H, Waldenmaier D, Dahlke J, Ayuketang Ayuk F, Wolschke C, Kröger N, Zander A
MYCOSES. 2011;54(1):39-44.

Bone marrow-derived progenitor cells do not contribute to podocyte turnover in the puromycin aminoglycoside and renal ablation models in rats.
Meyer-Schwesinger C, Lange C, Bröcker V, Agustian P, Putri A, Lehmann U, Raabe A, Brinkmeyer M, Kobayashi E, Schiffer M, Büsche G, Kreipe H, Thaiss F, Becker J
AM J PATHOL. 2011;178(2):494-499.

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells
Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, Löschmann N, Voges Y, Breitling R, von Deimling A, Rödel F, Riecken K, Fehse B, Mack E, Stiewe T, Doerr H, Speidel D, Cinatl J, Riecken K
CELL DEATH DIS. 2011;2:e243.

Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) - a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia.
Muth M, Engelhardt B, Kröger N, Hussein K, Schlué J, Büsche G, Kreipe H, Bock O
ANN HEMATOL. 2011;90(1):33-40.

Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes.
Newrzela S, Cornils K, Heinrich T, Schläger J, Yi J, Lysenko O, Kimpel J, Fehse B, Dorothee V
MOL MED. 2011;17(11-12):1223-1232.

Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia.
Oyekunle A, Haferlach T, Kröger N, Klyuchnikov E, Zander A, Schnittger S, Bacher U
Adv Hematol. 2011;2011:154745.

Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Oyekunle A, Klyuchnikov E, Ocheni S, Kröger N, Zander A, Baccarani M, Bacher U
ACTA HAEMATOL-BASEL. 2011;126(1):30-39.

First-line matched related donor hematopoietic stem cell transplantation compared to immunosuppressive therapy in acquired severe aplastic anemia.
Peinemann F, Grouven U, Kröger N, Bartel C, Pittler M, Lange S
PLOS ONE. 2011;6(4):18572.

High-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma--a systematic review.
Peinemann F, Kröger N, Bartel C, Grouven U, Pittler M, Erttmann R, Kulig M
PLOS ONE. 2011;6(2):17127.

Cancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect.
Preuß E, Muik A, Riecken K, Otte J, von Laer D, Fehse B
J MOL MED. 2011;89(11):1113-1124.

RGB marking facilitates multicolor clonal cell tracking.
Riecken K, Thomaschewski M, Warlich M, Volz T, Cornils K, Niebuhr B, Täger M, Lütgehetmann M, Pollok J, Stocking C, Dandri-Petersen M, Benten D, Fehse B
NAT MED. 2011;17(4):504-509.

Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT.
Robin M, Sanz G, Ionescu I, Rio B, Sirvent A, Renaud M, Carreras E, Milpied N, Mohty M, Beguin Y, Bordigoni P, de Witte T, Picardi A, Purtill D, Gluckman E, Kröger N, Rocha V
LEUKEMIA. 2011;25(1):75-81.

Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents.
Schmidt-Hieber M, Schwender J, Heinz W, Zabelina T, Kühl J, Mousset S, Schüttrumpf S, Junghanss C, Silling G, Basara N, Neuburger S, Thiel E, Blau I
HAEMATOLOGICA. 2011;96(1):142-149.

A copy number repeat polymorphism in the transactivation domain of the CEPBA gene is possibly associated with a protective effect against acquired CEBPA mutations: an analysis in 1135 patients with AML and 187 healthy controls.
Schnittger S, Bacher U, Eder C, Lohse P, Haferlach C, Kern W, Haferlach T
EXP HEMATOL. 2011;39(1):87-94.

Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
Schnittger S, Bacher U, Haferlach C, Alpermann T, Dicker F, Sundermann J, Kern W, Haferlach T
LEUKEMIA. 2011;25(4):615-621.

Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.
Schnittger S, Bacher U, Haferlach C, Kern W, Alpermann T, Haferlach T
HAEMATOLOGICA. 2011;96(12):1799-1807.

Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.
Schnittger S, Bacher U, Kern W, Alpermann T, Haferlach C, Haferlach T
LEUKEMIA. 2011;25(8):1297-1304.

Bioequivalence comparison of a new freezing bag (CryoMACS(®)) with the Cryocyte(®) freezing bag for cryogenic storage of human hematopoietic progenitor cells.
Sputtek A, Lioznov M, Kröger N, Rowe A
CYTOTHERAPY. 2011;13(4):481-489.

Gene therapy strategies: can we eradicate HIV?
van Lunzen J, Fehse B, Hauber J
CURR HIV-AIDS REP. 2011;8(2):78-84.

Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.
Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, Ayuketang Ayuk F, Kiani A, Schwerdtfeger R, Vogelsang G, Kobbe G, Gramatzki M, Lawitschka A, Mohty M, Pavletic S, Greinix H, Holler E
BIOL BLOOD MARROW TR. 2011;17(1):1-17.

Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT.
Alchalby H, Badbaran A, Bock O, Fehse B, Bacher U, Zander A, Kröger N
BONE MARROW TRANSPL. 2010;45(9):1404-1407.

Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.
Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D, Bornhäuser M, Christian T, Baurmann H, Bethge W, Hildebrandt Y, Bacher U, Fehse B, Zander A, Kröger N
BLOOD. 2010;116(18):3572-3581.

Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis.
Alchalby H, Kröger N
CURR HEMATOL MALIG R. 2010;5(2):53-61.

Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes.
Bacher U, Haferlach C, Kröger N, Schnittger S, Kern W, Wiedemann B, Zander A, Haferlach T
BIOL BLOOD MARROW TR. 2010;16(1):1-11.

Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies.
Bacher U, Haferlach C, Schnittger S, Kohlmann A, Kern W, Haferlach T
ANN HEMATOL. 2010;89(7):643-652.

Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML.
Bacher U, Haferlach T, Alpermann T, Zenger M, Kröger N, Beelen D, Kern W, Schnittger S, Haferlach C
BIOL BLOOD MARROW TR. 2010;16(12):1649-1657.

Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma.
Bacher U, Haferlach T, Kern W, Alpermann T, Schnittger S, Haferlach C
CANCER GENET-NY. 2010;203(2):169-175.

Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia.
Bacher U, Haferlach T, Schnittger S, Weiss T, Burkhard O, Bechtel B, Kern W, Haferlach C
CANCER GENET-NY. 2010;200(2):170-174.

Gene expression profiling for diagnosis and therapy in acute leukaemia and other haematologic malignancies.
Bacher U, Kohlmann A, Haferlach T
CANCER TREAT REV. 2010;36(8):637-646.

Molecular genetics in acute myeloid leukemia.
Bacher U, Schnittger S, Haferlach T
CURR OPIN ONCOL. 2010;22(6):646-655.

Neue Wege der Stammzellforschung: Reprogrammierung von differenzierten Körperzellen
Beier H, Fehse B, Friedrich B, Götz M, Hansmann I, Hucho F, Köchy K, Müller-Röber B, Rheinberger H, Reich J, Robpers H, Schöler H, Schöne-Seifert B, Sperling K, Tanner K, Taupitz J, Wobus A
J Reprodmed Endokrinol. 2010;7:68-77.

Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Bishop M, Alyea E, Cairo M, Falkenburg J, June C, Kröger N, Little R, Miller J, Pavletic S, Porter D, Riddell S, van Besien K, Wayne A, Weisdorf D, Wu R, Giralt S
BIOL BLOOD MARROW TR. 2010;16(5):563-564.

Limited immune-modulating activity of porcine mesenchymal stromal cells abolishes their protective efficacy in acute kidney injury.
Brunswig-Spickenheier B, Boche J, Westenfelder C, Peimann F, Gruber A, Jaquet K, Krause K, Zustin J, Zander A, Lange C
STEM CELLS DEV. 2010;19(5):719-729.

An optimized assay for the enumeration of antigen-specific memory B cells in different compartments of the human body.
Cao Y, Gordic M, Kobold S, Lajmi N, Meyer S, Bartels K, Hildebrandt Y, Luetkens T, Ihloff A, Kröger N, Bokemeyer C, Atanackovic D
J IMMUNOL METHODS. 2010;358(1-2):56-65.

The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients.
Cao Y, Luetkens T, Kobold S, Hildebrandt Y, Gordic M, Lajmi N, Meyer S, Bartels K, Zander A, Bokemeyer C, Kröger N, Atanackovic D
EXP HEMATOL. 2010;38(10):860-867.

Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data.
Carreras E, Cahn J, Puozzo C, Kröger N, Sanz G, Buzyn A, Bacigalupo A, Vernant J
ANTICANCER RES. 2010;30(7):2977-2984.

Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.
Casper J, Wolff D, Knauf W, Blau I, Ruutu T, Volin L, Wandt H, Schäfer-Eckart K, Holowiecki J, Giebel S, Aschan J, Zander A, Kröger N, Hilgendorf I, Baumgart J, Mylius H, Pichlmeier U, Freund M
J CLIN ONCOL. 2010;28(20):3344-3351.

Diagnosis of Toxoplasma gondii infection after allogeneic stem cell transplant can be difficult and requires intensive scrutiny.
Cavattoni I, Ayuketang Ayuk F, Zander A, Zabelina T, Bacher A, Cayiroglu E, Knospe V, Illies T, Aepfelbacher M, Richard G, Kröger N, Bacher U
LEUKEMIA LYMPHOMA. 2010;51(8):1530-1535.

Pilot study of rituximab plus donor-lymphocyte infusion to prevent or treat relapse in B-cell lymphoma after allogeneic stem cell transplantation.
Cavattoni I, Zabelina T, Ayuketang Ayuk F, Wolschke C, Bacher U, Zander A, Kröger N
LEUKEMIA LYMPHOMA. 2010;51(1):146-148.

Immunohistochemistry and molecular analyses in myeloid sarcoma of the breast in a patient with relapse of NPM1-mutated and FLT3-mutated AML after allogeneic stem cell transplantation.
Choschzick M, Bacher U, Ayuketang Ayuk F, Lebeau A
J CLIN PATHOL. 2010;63(6):558-561.

Mimicking the haematopoietic niche microenvironment provides a novel strategy for expansion of haematopoietic and megakaryocyte-progenitor cells from cord blood.
Deutsch V, Hubel E, Kay S, Ohayon T, Katz B, Many A, Zander A, Naparstek E, Grisaru D
BRIT J HAEMATOL. 2010;149(1):137-149.

Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).
Falini B, Macijewski K, Weiss T, Bacher U, Schnittger S, Kern W, Kohlmann A, Klein H, Vignetti M, Piciocchi A, Fazi P, Martelli M, Vitale A, Pileri S, Miesner M, Santucci A, Haferlach C, Mandelli F, Haferlach T
BLOOD. 2010;115(18):3776-3786.

Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells
Gieseke F, Böhringer J, Bussolari R, Dominici M, Handgretinger R, Müller I
BLOOD. 2010;116(19):3770-9.

Peptide length extension skews the minor HA-1 antigen presentation toward activated dendritic cells but reduces its presentation efficiency.
Hambach L, Aghai Z, Pool J, Kröger N, Goulmy E
J IMMUNOL. 2010;185(8):4582-4589.

Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells
Holzwarth C, Vaegler M, Gieseke F, Pfister S, Handgretinger R, Kerst G, Müller I
BMC CELL BIOL. 2010;11:11.

Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT).
Hoogduijn M, Popp F, Grohnert A, Crop M, van Rhijn M, Rowshani A, Eggenhofer E, Renner P, Reinders M, Rabelink T, van der Laan L, Dor F, Ijzermans J, Genever P, Lange C, Durrbach A, Houtgraaf J, Christ B, Seifert M, Shagidulin M, Donckier V, Deans R, Ringden O, Perico N, Remuzzi G, Bartholomew A, Schlitt H, Weimar W, Baan C, Dahlke M
TRANSPLANTATION. 2010;90(2):124-126.

Tumour stromal cells derived from paediatric malignancies display MSC-like properties and impair NK cell cytotoxicity
Johann P, Vaegler M, Gieseke F, Mang P, Armeanu-Ebinger S, Kluba T, Handgretinger R, Müller I
BMC CANCER. 2010;10:501.

The role of multiparameter flow cytometry for disease monitoring in AML.
Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T
BEST PRACT RES CL HA. 2010;23(3):379-390.

Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia.
Klyuchnikov E, Asenova S, Kern W, Kilinc G, Ayuketang Ayuk F, Wiedemann B, Lioznov M, Freiberger P, Zalyalov Y, Zander A, Kröger N, Bacher U
LEUKEMIA LYMPHOMA. 2010;51(8):1450-1463.

Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML)
Klyuchnikov E, Kröger N, Brummendorf T, Wiedemann B, Zander A, Bacher U
BIOL BLOOD MARROW TR. 2010;16(3):301-10.

Solid organ transplantation after allogeneic hematopoietic stem cell transplantation: a retrospective, multicenter study of the EBMT.
Koenecke C, Hertenstein B, Schetelig J, van Biezen A, Dammann E, Gratwohl A, Ganser A, Schleuning M, Bornhäuser M, Jacobsen N, Kröger N, Niederwieser D, de Witte T, Ruutu T
AM J TRANSPLANT. 2010;10(8):1897-1906.

Neurogenic transdifferentiation of human adipose-derived stem cells? A critical protocol reevaluation with special emphasis on cell proliferation and cell cycle alterations.
Kompisch K, Lange C, Steinemann D, Skawran B, Schlegelberger B, Müller R, Schumacher U
HISTOCHEM CELL BIOL. 2010;134(5):453-468.

Unrelated stem cell transplantation for patients with multiple myeloma.
Kröger N
CURR OPIN HEMATOL. 2010;17(6):538-543.

Questionable role of free light chain assay ratio to determine stringent complete remission in multiple myeloma patients.
Kröger N, Asenova S, Gerritzen A, Bacher U, Zander A
BLOOD. 2010;115(16):3413-3415.

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.
Kröger N, Bacher U, Bader P, Böttcher S, Borowitz M, Dreger P, Khouri I, Macapinlac H, Macapintac H, Olavarria E, Radich J, Stock W, Vose J, Weisdorf D, Willasch A, Giralt S, Bishop M, Wayne A
BIOL BLOOD MARROW TR. 2010;16(9):1187-1211.

NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies.
Kröger N, Bacher U, Bader P, Böttcher S, Borowitz M, Dreger P, Khouri I, Olavarria E, Radich J, Stock W, Vose J, Weisdorf D, Willasch A, Giralt S, Bishop M, Wayne A
BIOL BLOOD MARROW TR. 2010;16(10):1325-1346.

Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myeloma.
Kröger N, Einsele H, Derigs G, Wandt H, Krüll A, Zander A
BIOL BLOOD MARROW TR. 2010;16(6):861-864.

Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation.
Kröger N, Shimoni A, Schilling G, Schwerdtfeger R, Bornhäuser M, Nagler A, Zander A, Heinzelmann M, Brand R, Gahrton G, Morris C, Niederwieser D, de Witte T
BRIT J HAEMATOL. 2010;148(2):323-331.

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
Kyle R, Durie B, Rajkumar S, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole D, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen W, Anderson K, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson P, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M, Group I
LEUKEMIA. 2010;24(6):1121-1127.

The MSCs' in vitro community: where to go?
Lange S, Zander A, Lange C
CTT-Cell Ther Transpl. 2010;1(4):1.

Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia.
Lim Z, Brand R, Martino R, van Biezen A, Finke J, Bacigalupo A, Beelen D, Devergie A, Alessandrino E, Willemze R, Ruutu T, Boogaerts M, Falda M, Jouet J, Niederwieser D, Kröger N, Mufti G, Witte D, Theo M
J CLIN ONCOL. 2010;28(3):405-411.

International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma.
Lokhorst H, Einsele H, Vesole D, Bruno B, Jesus S, Pérez-Simon J, Kröger N, Moreau P, Gahrton G, Gasparetto C, Giralt S, Bensinger W
J CLIN ONCOL. 2010;28(29):4521-4530.

Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia.
Luetkens T, Schafhausen P, Uhlich F, Stasche T, Akbulak R, Bartels B, Hildebrandt Y, Gontarewicz A, Kobold S, Meyer S, Gordic M, Bartels K, Lajmi N, Cao Y, Kröger N, Bokemeyer C, Brümmendorf T, Atanackovic D
LEUKEMIA RES. 2010;34(12):1647-1655.

Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC).
Miesner M, Haferlach C, Bacher U, Weiss T, Macijewski K, Kohlmann A, Klein H, Dugas M, Kern W, Schnittger S, Haferlach T
BLOOD. 2010;116(15):2742-2751.

MUTYH-associated polyposis - variability of the clinical phenotype in patients with biallelic and monoallelic MUTYH mutations and report on novel mutations.
Morak M, Laner A, Bacher U, Keiling C, Holinski-Feder E
CLIN GENET. 2010;78(4):353-363.

Influence of mannose-binding lectin genotypes and serostatus in allo-SCT: analysis of 131 recipients and donors.
Neth O, Bacher U, Das P, Zabelina T, Kabisch H, Kroeger N, Ayuketang F, Lioznov M, Waschke O, Fehse B, Thiébaut R, Haston R, Klein N, Zander A
BONE MARROW TRANSPL. 2010;45(1):13-9.

Second Allogeneic Stem Cell Transplantation in a Patient with Hypoplastic Myelodysplastic Syndrome following a Primary Diagnosis of Aplastic Anaemia.
Ocheni S, Oyekunle A, Kröger N, Ayuketang Ayuk F, Klyuchnikov E, Arps S, Held K, Zabelina T, Adjalle R, Wolschke C, Zander A, Bacher U
ACTA HAEMATOL-BASEL. 2010;125(3):175-178.

Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma.
Pabst C, Zustin J, Jacobsen F, Luetkens T, Kröger N, Schilling G, Bokemeyer C, Sauter G, Atanackovic D, Marx A
EXP MOL PATHOL. 2010;89(2):175-181.

Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children
Pfeiffer M, Feuchtinger T, Teltschik H, Schumm M, Müller I, Handgretinger R, Lang P
HAEMATOLOGICA. 2010;95(8):1381-8.

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Porter D, Alyea E, Antin J, DeLima M, Estey E, Falkenburg J, Hardy N, Kröger N, Leis J, Levine J, Maloney D, Peggs K, Rowe J, Wayne A, Giralt S, Bishop M, van Besien K
BIOL BLOOD MARROW TR. 2010;16(11):1467-1503.

TK.007: A novel, codon-optimized HSVtk(A168H) mutant for suicide gene therapy.
Preuß E, Treschow A, Newrzela S, Brücher D, Riecken K, Felldin U, Alici E, Gahrton G, von Laer D, Dilber M, Fehse B
HUM GENE THER. 2010;21(8):929-941.

Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasms.
Reindl L, Bacher U, Dicker F, Alpermann T, Kern W, Schnittger S, Haferlach T, Haferlach C
BRIT J HAEMATOL. 2010;151(1):25-36.

Chronic inflammatory bowel disease as key manifestation of atypical ARTEMIS deficiency
Rohr J, Pannicke U, Döring M, Schmitt-Graeff A, Wiech E, Busch A, Speckmann C, Müller I, Lang P, Handgretinger R, Fisch P, Schwarz K, Ehl S
J CLIN IMMUNOL. 2010;30(2):314-20.

Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells.
Rothweiler F, Michaelis M, Brauer P, Otte J, Riecken K, Fehse B, Doerr H, Wiese M, Kreuter J, Al-Abed Y, Nicoletti F, Cinatl J
NEOPLASIA. 2010;12(12):1023-1030.

Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML.
Schnittger S, Bacher U, Dicker F, Kern W, Alpermann T, Haferlach T, Haferlach C
GENE CHROMOSOME CANC. 2010;49(10):910-918.

Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.
Shimoni A, Hardan I, Ayuketang Ayuk F, Schilling G, Atanackovic D, Zeller W, Yerushalmi R, Zander A, Kröger N, Nagler A
CANCER-AM CANCER SOC. 2010;116(15):3621-3630.

Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis.
Stahl T, Badbaran A, Kröger N, Klyuchnikov E, Zabelina T, Zeschke S, Schafhausen P, Schultz W, Asenova S, Smirnova A, Wolschke C, Ayuketang Ayuk F, Zander A, Fehse B, Bacher U
LEUKEMIA LYMPHOMA. 2010;51(10):1837-1843.

Cell and virus genetics at the roots of gene therapy, retrovirology, and hematopoietic stem cell biology: Wolfram Ostertag (1937-2010).
Stocking C, Grez M, Fehse B, von Laer D, Itoh K, Prassolov V, Nowock J, Kühlcke K, Just U, Schröder T, Klump H, Schiedlmeier B, Grassman E, Meyer J, Li Z, Schambach A, Modlich U, Kustikova O, Galla M, Jürgen B, Zander A, Baum C
HUM GENE THER. 2010;21(11):1501-1503.

Highly efficient lentiviral transduction of phenotypically and genotypically characterized endothelial progenitor cells from adult peripheral blood.
Stockschlaeder M, Shardakova O, Riecken K, Stoldt V, Fehse B, Giers G, Scharf R
BLOOD COAGUL FIBRIN. 2010;21(5):464-473.

Infektionsdiagnostik in der Pneumologie
Strassburg A, Dalhoff K, Engelmann I, Ewig S, Herth F, Knobloch J, Rohde G, Sahly H, Schaaf B, Lange C
PNEUMOLOGIE. 2010;64(5):291-9.

Mammary epithelial reconstitution with gene-modified stem cells assigns roles to Stat5 in luminal alveolar cell fate decisions, differentiation, involution, and mammary tumor formation.
Vafaizadeh V, Klemmt P, Brendel C, Riecken K, Doebele C, Britt K, Grez M, Fehse B, Desriviéres S, Groner B
STEM CELLS. 2010;28(5):928-938.

Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia.
Wiedemann B, Klyuchnikov E, Kröger N, Zabelina T, Stahl T, Zeschke S, Badbaran A, Ayuketang Ayuk F, Alchalby H, Wolschke C, Bokemeyer C, Fehse B, Zander A, Bacher U
EXP HEMATOL. 2010;38(12):1261-1271.

Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.
Wolff D, Gerbitz A, Ayuketang Ayuk F, Kiani A, Hildebrandt G, Vogelsang G, Elad S, Lawitschka A, Socie G, Pavletic S, Holler E, Greinix H
BIOL BLOOD MARROW TR. 2010;16(12):1611-1628.

Phenotypic diversity in chondromyxoid fibroma reveals differentiation pattern of tumor mimicking fetal cartilage canals development: an immunohistochemical study.
Zustin J, Akpalo H, Gambarotti M, Priemel M, Rueger J, Lübke A, Reske D, Lange C, Püschel K, Lohmann C, Rüther W, Amling M, Alberghini M
AM J PATHOL. 2010;177(3):1072-1078.

Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells.
Atanackovic D, Hildebrandt Y, Jadczak A, Cao Y, Luetkens T, Meyer S, Kobold S, Bartels K, Pabst C, Lajmi N, Gordic M, Stahl T, Zander A, Bokemeyer C, Kröger N
HAEMATOLOGICA. 2009;*95*(5):785-793.

Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma.
Atanackovic D, Luetkens T, Hildebrandt Y, Arfsten J, Bartels K, Horn C, Stahl T, Cao Y, Zander A, Bokemeyer C, Kröger N
CLIN CANCER RES. 2009;15(4):1343-1352.

Comparison of the cytotoxicity of 4 preparations of anti-T-cell globulins in various hematological malignancies.
Ayuketang Ayuk F, Maywald N, Hannemann S, Larsen U, Zander A, Kröger N
ANTICANCER RES. 2009;29(4):1355-1360.

Antitumor effects of polyclonal antithymocyte globulins: focus on B-cell malignancies and multiple myeloma.
Ayuketang Ayuk F, Zander A, Kröger N
ANN HEMATOL. 2009;88(5):401-404.

Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis.
Bacher U, Asenova S, Badbaran A, Zander A, Alchalby H, Fehse B, Kröger N, Lange C, Ayuketang Ayuk F
CLIN EXP MED. 2009.

Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation.
Bacher U, Badbaran A, Fehse B, Zabelina T, Zander A, Kröger N
EXP HEMATOL. 2009;37(1):135-142.

Molecular determinants of prognosis in acute myeloid leukemia (AML) with normal karyotype.
Bacher U, Haferlach C
LEUKEMIA LYMPHOMA. 2009;50(9):1403-1405.

Interactive diagnostics in the indication to allogeneic SCT in AML.
Bacher U, Haferlach C, Schnittger S, Kern W, Kröger N, Zander A, Haferlach T
BONE MARROW TRANSPL. 2009;43(10):745-756.

The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes.
Bacher U, Haferlach T, Kern W, Weiss T, Schnittger S, Haferlach C
CANCER-AM CANCER SOC. 2009;115(19):4524-4532.

Safety of conditioning agents for allogeneic haematopoietic transplantation.
Bacher U, Klyuchnikov E, Wiedemann B, Kröger N, Zander A
EXPERT OPIN DRUG SAF. 2009;8(3):305-315.

The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia-a report from the German Registry covering the period from 1998 to 2004.
Bacher U, Klyuchnikov E, Zabelina T, Ottinger H, Beelen D, Schrezenmeier H, Ehninger G, Müller C, Berger J, Suttorp M, Kolb H, Kröger N, Zander A
ANN HEMATOL. 2009.

Gene expression profiling in acute myeloid leukaemia (AML).
Bacher U, Kohlmann A, Haferlach C, Haferlach T
BEST PRACT RES CL HA. 2009;22(2):169-180.

Current status of gene expression profiling in the diagnosis and management of acute leukaemia.
Bacher U, Kohlmann A, Haferlach T
BRIT J HAEMATOL. 2009;145(5):555-568.

Perspectives of gene expression profiling for diagnosis and therapy in haematological malignancies.
Bacher U, Kohlmann A, Haferlach T
Brief Funct Genomic Proteomic. 2009;8(3):184-193.

Molecular diagnostics in acute leukemias.
Bacher U, Schnittger S, Haferlach C, Haferlach T
CLIN CHEM LAB MED. 2009;47(11):1333-1341.

Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
Bacher U, Schnittger S, Kern W, Weiss T, Haferlach T, Haferlach C
ANN HEMATOL. 2009;88(12):1207-1213.

Outcome of transplantation for myelofibrosis.
Ballen K, Shrestha S, Sobocinski K, Zhang M, Bashey A, Bolwell B, Cervantes F, Devine S, Gale R, Gupta V, Hahn T, Hogan W, Kröger N, Litzow M, Marks D, Maziarz R, McCarthy P, Schiller G, Harry C, Roy V, Wiernik P, Horowitz M, Giralt S, Arora M
BIOL BLOOD MARROW TR. 2009;*16*(3):358-367.

Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1
Battula V, Treml S, Bareiss P, Gieseke F, Roelofs H, de Zwart P, Müller I, Schewe B, Skutella T, Fibbe W, Kanz L, Bühring H
HAEMATOLOGICA. 2009;94(2):173-84.

PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation
Blalock W, Grimaldi C, Fala F, Follo M, Horn S, Basecke J, Martinelli G, Cocco L, Martelli A
J CELL PHYSIOL. 2009;221(1):232-41.

Identification of new target molecules PTK2, TGFBR2 and CD9 overexpressed during advanced bone marrow remodelling in primary myelofibrosis.
Bock O, Muth M, Theophile K, Winter M, Hussein K, Büsche G, Kröger N, Kreipe H
BRIT J HAEMATOL. 2009.

Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT.
Chevallier P, Labopin M, Nagler A, Ljungman P, Verdonck L, Volin L, Zander A, Finke J, Socie G, Cordonnier C, Harousseau J, Mohty M, Rocha V
BONE MARROW TRANSPL. 2009;44(9):589-594.

Stem cell marking with promotor-deprived self-inactivating retroviral vectors does not lead to induced clonal imbalance.
Cornils K, Lange C, Schambach A, Brugman M, Nowak R, Lioznov M, Baum C, Fehse B
MOL THER. 2009;17(1):131-143.

5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis.
Czibere A, Bruns I, Kröger N, Platzbecker U, Lind J, Zohren F, Fenk R, Germing U, Schröder T, Gräf T, Haas R, Kobbe G
BONE MARROW TRANSPL. 2009;*45*(5):872-876.

Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group.
Dahlke M, Hoogduijn M, Eggenhofer E, Popp F, Renner P, Slowik P, Rosenauer A, Piso P, Geissler E, Lange C, Chabannes D, Mazzanti B, Bigenzahn S, Bertolino P, Kunter U, Introna M, Alessandro R, Capelli C, Perico N, Casiraghi F, Noris M, Gotti E, Seifert M, Riccardo S, Verspaget H, van Hoek B, Bartholomew A, Wekerle T, Volk H, Remuzzi G, Deans R, Lazarus H, Schlitt H, Baan C
TRANSPLANTATION. 2009;88(5):614-619.

Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival.
de Witte T, Brand R, van Biezen A, Mufti G, Ruutu T, Finke J, von Dem Borne P, Vitek A, Delforge M, Alessandrino P, Harlahakis N, Russell N, Martino R, Verdonck L, Kröger N, Niederwieser D
BRIT J HAEMATOL. 2009.

Dendritic cells: functional aspects of glycosylation and lectins
Erbacher A, Gieseke F, Handgretinger R, Müller I
HUM IMMUNOL. 2009;70(5):308-12.

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J, Bethge W, Schmoor C, Ottinger H, Stelljes M, Zander A, Volin L, Ruutu T, Heim D, Schwerdtfeger R, Kolbe K, Mayer J, Maertens J, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb H, Bertz H, Egger M, Grishina O, Socié G
LANCET ONCOL. 2009;10(9):855-864.

Diffusion-driven device for a high-resolution dose-response profiling of combination chemotherapy
Ganser A, Roth G, van Galen J, Hilderink J, Wammes J, Müller I, van Leeuwen F, Wiesmüller K, Brock R
ANAL CHEM. 2009;81(13):5233-40.

A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis.
Gupta V, Kröger N, Aschan J, Xu W, Leber B, Dalley C, Sabloff M, Lipton J, Messner H, Brune M
BONE MARROW TRANSPL. 2009.

Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment.
Haferlach C, Bacher U, Schnittger S, Weiss T, Kern W, Haferlach T
LEUKEMIA. 2009.

Discussion of the applicability of microarrays: profiling of leukemias.
Haferlach T, Bacher U, Kohlmann A, Haferlach C
Methods Mol Biol. 2009;509:15-33.

AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features.
Haferlach T, Kohlmann A, Klein H, Ruckert C, Dugas M, Williams P, Kern W, Schnittger S, Bacher U, Löffler H, Haferlach C
LEUKEMIA. 2009;23(5):934-943.

Second allogeneic stem cell transplantation in myeloid malignancies.
Hartwig M, Ocheni S, Asenova S, Wiedemann B, Zabelina T, Ayuketang Ayuk F, Kabisch H, Erttmann R, Kröger N, Zander A, Bacher U
ACTA HAEMATOL-BASEL. 2009;122(4):185-192.

Biclonal expansion and heterogeneous lineage involvement in a case of chronic myeloproliferative disease with concurrent MPLW515L/JAK2V617F mutation.
Hussein K, Bock O, Theophile K, Schlue J, Ballmaier M, Kröger N, Göhring G, Büsche G, Kreipe H
BLOOD. 2009;113(6):1391-1392.

Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity.
Kern W, Haferlach C, Bacher U, Haferlach T, Schnittger S
LEUKEMIA. 2009;23(7):1361-1364.

Sensitising leukemic cells by targeting microenvironment.
Klyuchnikov E, Kröger N
LEUKEMIA LYMPHOMA. 2009;50(3):319-320.

Current status and perspectives of tyrosine kinase inhibitor treatment in the post-transplant period in patients with chronic myeloid leukemia (CML).
Klyuchnikov E, Kröger N, Brümmendorf T, Wiedemann B, Zander A, Bacher U
BIOL BLOOD MARROW TR. 2009.

Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.
Klyuchnikov E, Schafhausen P, Kröger N, Brümmendorf T, Osanmaz O, Asenova S, Zabelina T, Ocheni S, Ayuketang Ayuk F, Zander A, Bacher U
ACTA HAEMATOL-BASEL. 2009;122(1):6-10.

Percutaneous intramyocardial stem cell injection in patients with acute myocardial infarction: first-in-man study.
Krause K, Jaquet K, Schneider C, Haupt S, Lioznov M, Otte K, Kuck K
HEART. 2009;95(14):1145-1152.

Endocardial electrogram analysis after intramyocardial injection of mesenchymal stem cells in the chronic ischemic myocardium.
Krause K, Schneider C, Lange C, Kokturk B, Boczor S, Geidel S, Salhi A, Alaser J, Zander A, Kuck K, Jaquet K
PACE. 2009;32(10):1319-1328.

JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.
Kröger N, Alchalby H, Klyuchnikov E, Badbaran A, Hildebrandt Y, Ayuketang Ayuk F, Bacher U, Bock O, Kvasnicka M, Fehse B, Zander A
BLOOD. 2009;113(8):1866-1868.

Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma.
Kröger N, Badbaran A, Lioznov M, Schwartz S, Zeschke S, Hildebrandt Y, Ayuketang Ayuk F, Atanackovic D, Schilling G, Zabelina T, Bacher U, Klyuchnikov E, Shimoni A, Nagler A, Corradini P, Fehse B, Zander A
EXP HEMATOL. 2009;37(7):791-798.

Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation.
Kröger N, Brand R, van Biezen A, Zander A, Dierlamm J, Niederwieser D, Devergie A, Ruutu T, Cornish J, Ljungman P, Gratwohl A, Cordonnier C, Beelen D, Deconinck E, Symeonidis A, de Witte T
HAEMATOLOGICA. 2009;94(4):542-549.

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Kröger N, Holler E, Kobbe G, Bornhäuser M, Schwerdtfeger R, Baurmann H, Nagler A, Bethge W, Stelljes M, Uharek L, Wandt H, Burchert A, Corradini P, Schubert J, Kaufmann M, Dreger P, Wulf G, Einsele H, Zabelina T, Kvasnicka H, Thiele J, Brand R, Zander A, Niederwieser D, Witte d, Theo M
BLOOD. 2009;114(26):5264-5270.

HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen.
Kröger N, Zabelina T, Binder T, Ayuketang Ayuk F, Bacher U, Amtsfeld G, Lellek H, Schrum J, Erttmann R, Eiermann T, Zander A
BIOL BLOOD MARROW TR. 2009;15(4):454-462.

Retroviral insertion site analysis in dominant haematopoietic clones.
Kustikova O, Modlich U, Fehse B
Methods Mol Biol. 2009;506:373-390.

Platelet derived bFGF mediates vascular integrative mechanisms of mesenchymal stem cells in vitro
Langer H, Stellos K, Steingen C, Froihofer A, Schönberger T, Krämer B, Bigalke B, May A, Seizer P, Müller I, Gieseke F, Siegel-Axel D, Meuth S, Schmidt A, Wendel H, Müller I, Bloch W, Gawaz M
J MOL CELL CARDIOL. 2009;47(2):315-25.

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.
Lioznov M, El-Cheikh J, Hoffmann F, Hildebrandt Y, Ayuketang Ayuk F, Wolschke C, Atanackovic D, Schilling G, Badbaran A, Bacher U, Fehse B, Zander A, Blaise D, Mohty M, Kröger N
BONE MARROW TRANSPL. 2009.

Concordance of assays designed for the quantification of JAK2V617F: a multicenter study.
Lippert E, Girodon F, Hammond E, Jelinek J, Reading N, Fehse B, Hanlon K, Hermans M, Richard C, Swierczek S, Ugo V, Carillo S, Harrivel V, Marzac C, Pietra D, Sobas M, Mounier M, Migeon M, Ellard S, Kröger N, Herrmann R, Prchal J, Skoda R, Hermouet S
HAEMATOLOGICA. 2009;94(1):38-45.

Reduced proliferation of CD34(+) cells from patients with acute myeloid leukemia after gene transfer of INPP5D.
Metzner A, Precht C, Fehse B, Fiedler W, Stocking C, Günther A, Mayr G, Jücker M
GENE THER. 2009;16(4):570-573.

Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
Michaelis M, Rothweiler F, Klassert D, von Deimling A, Riecken K, Fehse B, Kammerer B, Doerr H, Cinatl J
CANCER RES. 2009;69(2):416-421.

Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation.
Ocheni S, Iwanski G, Schafhausen P, Zander A, Ayuketang Ayuk F, Klyuchnikov E, Zabelina T, Fiedler W, Schnittger S, Hochhaus A, Brümmendorf T, Kröger N, Bacher U
LEUKEMIA LYMPHOMA. 2009;50(4):551-558.

Outcome of allo-SCT for chronic myelomonocytic leukemia.
Ocheni S, Kröger N, Zabelina T, Zander A, Bacher U
BONE MARROW TRANSPL. 2009;43(8):659-661.

Syngenic graft-versus-chronic-myeloid-leukemia-effect?
Ocheni S, Schafhausen P, Bacher U, Fehse B, Kröger N
CTT-Cell Ther Transpl. 2009;1(3):66-68.

Pegfilgrastim compared to lenograstim after allogeneic peripheral blood stem-cell transplantation from unrelated donors.
Ocheni S, Zabelina T, Bacher U, Ayuketang Ayuk F, Zander A, Kröger N
LEUKEMIA LYMPHOMA. 2009;50(4):612-618.

Unrelated donor stem cell transplantation in acquired severe aplastic anemia: a systematic review.
Peinemann F, Grouven U, Kröger N, Pittler M, Zschorlich B, Lange S
HAEMATOLOGICA. 2009;94(12):1732-1742.

Successful unrelated donor stem cell transplantation for advanced myelofibrosis in an adult patient with history of orthotopic liver transplantation.
Perz J, Hegenbart U, Kröger N, Otto G, Ho A, Dreger P
HAEMATOLOGICA. 2009;94(4):594-596.

Diva-Fit: A step-by-step manual for generating high-resolution graphs and histogram overlays of flow cytometry data obtained with FACSDiva software
Riecken K, Fehse B
CTT-Cell Ther Transpl. 2009;1(4):1-4.

Lentiviral gene ontology (LeGO) vectors equipped with novel drug-selectable fluorescent proteins: new building blocks for cell marking and multi-gene analysis.
Riecken K, Mock U, Petrowitz B, Bartsch U, Fehse B
GENE THER. 2009.

Sleep disturbances and emotional distress in the acute course of hematopoietic stem cell transplantation.
Rischer J, Scherwath A, Zander A, Koch U, Schulz-Kindermann F
BONE MARROW TRANSPL. 2009.

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
Saussele S, Lauseker M, Gratwohl A, Beelen D, Bunjes D, Schwerdtfeger R, Kolb H, Ho A, Falge C, Holler E, Schlimok G, Zander A, Arnold R, Kanz L, Dengler R, Haferlach C, Schlegelberger B, Pfirrmann M, Muller M, Schnittger S, Leitner A, Pletsch N, Hochhaus A, Hasford J, Hehlmann R
BLOOD. 2009;*115*(10):1880-1885.

Basic research and clinical applications of non-hematopoietic stem cells, 4-5 April 2008, Tubingen, Germany
Schäfer R, Dominici M, Müller I, Horwitz E, Asahara T, Bulte J, Bieback K, Le Blanc K, Bühring H, Capogrossi M, Dazzi F, Gorodetsky R, Henschler R, Handgretinger R, Kajstura J, Kluger P, Lange C, Luettichau I, Mertsching H, Schrezenmeier H, Sievert K, Strunk D, Verfaillie C, Northoff H
CYTOTHERAPY. 2009;11(2):245-55.

Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib.
Schafhausen P, Dierlamm J, Bokemeyer C, Brümmendorf T, Bacher U, Zander A, Schnittger S, Hochhaus A
CANCER GENET-NY. 2009;189(1):63-67.

Stehen kognitive Funktionen im Zusammenhang mit Angst, Depression und Posttraumatischer Belastungsstörung bei Brustkrebspatientinnen nach onkologischer Behandlung?
Schirmer L, Mehnert A, Scherwath A, Schleimer B, Schulz-Kindermann F, Zander A, Koch-Gromus U
Z PSYCHIATR PSYCH PS. 2009;57(1):33-42.

Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis.
Schnittger S, Bacher U, Haferlach C, Beelen D, Bojko P, Bürkle D, Dengler R, Distelrath A, Eckart M, Eckert R, Fries S, Knoblich J, Köchling G, Laubenstein H, Petrides P, Planker M, Pihusch R, Weide R, Kern W, Haferlach T
HAEMATOLOGICA. 2009;94(1):141-144.

Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera.
Schnittger S, Bacher U, Haferlach C, Geer T, Müller P, Mittermüller J, Petrides P, Schlag R, Sandner R, Selbach J, Slawik H, Tessen H, Wehmeyer J, Kern W, Haferlach T
HAEMATOLOGICA. 2009;94(3):414-418.

RQ-PCR based WT1 expression in comparison to BCR-ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib-treated chronic myeloid leukaemia.
Schnittger S, Bacher U, Kern W, Tschulik C, Weiss T, Haferlach C, Haferlach T
BRIT J HAEMATOL. 2009;146(6):665-668.

Donor lymphocyte infusions in amyloid light chain amyloidosis: induction of a "graft-versus-plasma cell-dyscrasia effect".
Schonland S, Kröger N, Wolschke C, Dreger P, Ho A, Hegenbart U
HAEMATOLOGICA. 2009;94(3):439-441.

Severe aplastic anaemia following leflunomide therapy.
Wüsthof M, Smirnova A, Bacher U, Kröger N, Zander A, Schuch G, Bokemeyer C
RHEUMATOLOGY. 2009.

CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D, Cao Y, Luetkens T, Panse J, Faltz C, Arfsten J, Bartels K, Wolschke C, Eiermann T, Zander A, Fehse B, Bokemeyer C, Kröger N
HAEMATOLOGICA. 2008;93(3):423-430.

Complement-dependent and complement-independent cytotoxicity of polyclonal antithymocyte globulins in chronic lymphocytic leukemia.
Ayuketang Ayuk F, Atassi N, Schuch G, Mina S, Fang L, Bokemeyer C, Fehse B, Zander A, Kröger N
LEUKEMIA RES. 2008;32(8):1200-1206.

Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuketang Ayuk F, Diyachenko G, Zabelina T, Panse J, Wolschke C, Eiermann T, Binder T, Fehse B, Erttmann R, Kabisch H, Bacher U, Kröger N, Zander A
EXP HEMATOL. 2008;36(8):1047-1054.

Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
Ayuketang Ayuk F, Diyachenko G, Zabelina T, Wolschke C, Fehse B, Bacher U, Erttmann R, Kröger N, Zander A
BIOL BLOOD MARROW TR. 2008;14(8):913-919.

Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.
Ayuketang Ayuk F, Perez-Simon J, Shimoni A, Sureda A, Zabelina T, Schwerdtfeger R, Martino R, Sayer H, Alegre A, Lahuerta J, Atanackovic D, Wolschke C, Nagler A, Zander A, Miguel S, Kröger N, Kröger N
HAEMATOLOGICA. 2008;93(9):1343-1350.

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.
Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S
BLOOD. 2008;111(5):2527-2537.

Minimal residual disease diagnostics in myeloid malignancies in the post transplant period.
Bacher U, Zander A, Haferlach T, Schnittger S, Fehse B, Kröger N
BONE MARROW TRANSPL. 2008;42(3):145-157.

Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation.
Benjamini O, Koren-Michowitz M, Amariglio N, Kröger N, Nagler A, Shimoni A
LEUKEMIA. 2008;22(10):1961-1963.

Abnormal expression of only the CD34 part of a transgenic CD34/herpes simplex virus-thymidine kinase fusion protein is associated with ganciclovir resistance.
Bennour E, Ferrand C, Rémy-Martin J, Certoux J, Gorke S, Qasim W, Gaspar H, Baumert T, Duperrier A, Deschamps M, Fehse B, Tiberghien P, Robinet E
HUM GENE THER. 2008;19(7):699-709.

Clinical application of a retroviral gene transfer protocol based on centrifugation-mediated vector preloading.
Fehse B
HUM GENE THER. 2008;19(6):655-658.

Insertional mutagenesis and clonal dominance: biological and statistical considerations.
Fehse B, Roeder I
GENE THER. 2008;15(2):143-153.

Analysis of sternotomy as treatment option for the resection of bilateral pulmonary metastases in pediatric solid tumors
Fuchs J, Seitz G, Ellerkamp V, Dietz K, Bosk A, Müller I, Warmann S, Schäfer J
J SURG ONCOL. 2008;17(4):323-30.

Initial report on a phase I clinical trial: Prevention and treatment of post-operative Acute Kidney Injury with allogeneic Mesenchymal Stem Cells in patients who require on-pump cardiac surgery.
Gooch A, Doty , Flores J, Toegel F, Reiss G, Lange C, Zander A, Zhang P, Westenfelder C
2008.

Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
Haferlach C, Bacher U, Tiu R, Maciejewski J, List A
CANCER GENET-NY. 2008;187(2):101-111.

The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers.
Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C
ANN HEMATOL. 2008;87(1):1-10.

Overexpression of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase inhibits GM-CSF-dependent colony formation of CD34+ hematopoietic progenitor cells.
Hoxha E, Fehse B, Ortmeyer G, Stocking C, Mayr G, Jücker M
LEUKEMIA LYMPHOMA. 2008;49(6):1206-1208.

WT1 protein expression in childhood acute leukemia
Kerst G, Bergold N, Gieseke F, Coustan-Smith E, Lang P, Kalinova M, Handgretinger R, Trka J, Müller I
AM J HEMATOL. 2008;83(5):382-6.

WT1 protein expression in slowly proliferating myeloid leukemic cell lines is scarce throughout the cell cycle with a minimum in G0/G1 phase
Kerst G, Bergold N, Viebahn S, Gieseke F, Kalinova M, Trka J, Handgretinger R, Müller I
LEUKEMIA RES. 2008;32(9):1393-9.

Safety of percutaneous dilational tracheostomy in hematopoietic stem cell transplantation recipients requiring long-term mechanical ventilation.
Kluge S, Baumann H, Nierhaus A, Kröger N, Meyer A, Kreymann K
J CRIT CARE. 2008;23(3):394-398.

Epigenetic modulation and other options to improve outcome of stem cell transplantation in MDS.
Kröger N
HEMATOL-AM SOC HEMAT. 2008;60-67.

Choosing between stem cell therapy and drugs in myelofibrosis.
Kröger N, Mesa R
LEUKEMIA. 2008;22(3):474-486.

Efficient in vitro generation of adult multipotent cells from mobilized peripheral blood CD133+ cells
Kuçi S, Kuçi Z, Schmid S, Seitz G, Müller I, Dufke A, Leimig T, Murti G, Jurecic R, Schumm M, Lang P, Bruchelt G, Bader P, Klingebiel T, Niethammer D, Handgretinger R
CELL PROLIFERAT. 2008;41(1):12-27.

Retroviral integration site analysis in hematopoietic stem cells.
Kustikova O, Baum C, Fehse B
Methods Mol Biol. 2008;430:255-267.

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.
Lee S, Kukreja M, Wang T, Giralt S, Szer J, Arora M, Woolfrey A, Cervantes F, Champlin R, Gale R, Halter J, Keating A, Marks D, McCarthy P, Olavarria E, Stadtmauer E, Abecasis M, Gupta V, Khoury H, George B, Hale G, Liesveld J, Rizzieri D, Antin J, Bolwell B, Carabasi M, Copelan E, Ilhan O, Litzow M, Schouten H, Zander A, Horowitz M, Maziarz R
BLOOD. 2008;112(8):3500-3507.

Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques.
Lioznov M, Badbaran A, Fehse B, Bacher U, Zander A, Kröger N
BONE MARROW TRANSPL. 2008;41(10):913-916.

Transportation and cryopreservation may impair haematopoietic stem cell function and engraftment of allogeneic PBSCs, but not BM.
Lioznov M, Dellbrügger C, Sputtek A, Fehse B, Kröger N, Zander A
BONE MARROW TRANSPL. 2008;42(2):121-128.

Primary Cells As Feeder Cells For Coculture Expansion Of Human Hematopoietic Stem Cells From Umbilical Cord Blood A Comparative Study.
Magin A, Koerfer N, Partenheimer H, Lange C, Zander A, Noll T
STEM CELLS DEV. 2008.

Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy
McCubrey J, Sokolosky M, Lehmann B, Taylor J, Navolanic P, Chappell W, Abrams S, Stadelman K, Wong E, Misaghian N, Horn S, Bäsecke J, Libra M, Stivala F, Ligresti G, Tafuri A, Milella M, Zarzycki M, Dzugaj A, Chiarini F, Evangelisti C, Martelli A, Terrian D, Franklin R, Steelman L
Advances in enzyme regulation. 2008;48:113-35.

Mesenchymal stem cell therapy for degenerative inflammatory disorders
Müller I, Lymperi S, Dazzi F
CURR OPIN ORGAN TRAN. 2008;13(6):639-44.

Secretion of angiogenic proteins by human multipotent mesenchymal stromal cells and their clinical potential in the treatment of avascular osteonecrosis
Müller I, Vaegler M, Holzwarth C, Tzaribatchev N, Pfister S, Schütt B, Reize P, Greil J, Handgretinger R, Rudert M
LEUKEMIA. 2008;22(11):2054-61.

Resistance of mature T cells to oncogene transformation.
Newrzela S, Cornils K, Li Z, Baum C, Brugman M, Hartmann M, Meyer J, Hartmann S, Hansmann M, Fehse B, von Laer D
BLOOD. 2008;112(6):2278-2286.

EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT.
Ocheni S, Kröger N, Zabelina T, Sobottka I, Ayuketang Ayuk F, Wolschke C, Muth A, Lellek H, Petersen L, Erttmann R, Kabisch H, Zander A, Bacher U
BONE MARROW TRANSPL. 2008;42(3):181-186.

Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients.
Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Barrels K, Horn C, Stahl T, Cao Y, Milde-Langosch K, Niendorf A, Kröger N, Wenzel S, Leuwer R, Bokemeyer C, Hegewisch-Becker S, Atanackovic D
BRIT J CANCER. 2008;99(6):930-938.

Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS).
Platzbecker U, Bornhäuser M, Germing U, Stumpf J, Scott B, Kröger N, Schwerdtfeger R, Böhm A, Kobbe G, Theuser C, Rabitsch W, Valent P, Sorror M, Ehninger G, Deeg H
BIOL BLOOD MARROW TR. 2008;14(11):1217-1225.

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.
Rawstron A, Orfao A, Beksac M, Bezdickova L, Brooimans R, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, Kovarova L, Lioznov M, Mateo G, Morilla R, Mylin A, Omedé P, Pellat-Deceunynck C, Martin P, Petrucci M, Ruggeri M, Rymkiewicz G, Schmitz A, Schreder M, Seynaeve C, Spacek M, Tute d, Ruth M, Els V, Weston-Bell N, Owen R, Miguel S, Jesús F, Sonneveld P, Johnsen H
HAEMATOLOGICA. 2008;93(3):431-438.

Molecular characterisation of linezolid resistance in two vancomycin-resistant (VanB) Enterococcus faecium isolates using Pyrosequencing.
Saager B, Rohde H, Timmerbeil B, Franke G, Pothmann W, Dahlke J, Scherpe S, Sobottka I, Heisig P, Horstkotte M
EUR J CLIN MICROBIOL. 2008;27(9):873-878.

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
Schilling G, Hansen T, Shimoni A, Zabelina T, Pérez-Simón J, Simon-Perez J, Gutierrez N, Fiedler W, Liebisch P, Schwerdtfeger R, Bornhäuser M, Otterstetter S, Murga-Penas E, Dierlamm J, Ayuketang Ayuk F, Atanackovic D, Bacher U, Bokemeyer C, Zander A, San Miguel J, Miguel J, Nagler A, Kröger N
LEUKEMIA. 2008;22(6):1250-1255.

Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis.
Schnittger S, Bacher U, Haferlach C, Dengler R, Kröber A, Kern W, Haferlach T
LEUKEMIA. 2008;22(2):453-455.

A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment.
Schnittger S, Bacher U, Kern W, Haferlach T, Hertenstein B, Haferlach C
LEUKEMIA. 2008;22(4):856-858.

The MADS transcription factor Mef2c is a pivotal modulator of myeloid cell fate.
Schüler A, Schwieger M, Engelmann A, Riecken K, Horn S, Müller U, Arnold M, Olson E, Stocking C
BLOOD. 2008;111(9):4532-4541.

Differences in proportion and dynamics of recipient hematopoiesis following hematopoietic cell transplantation in CML and IMF.
Siebolts U, Thiele J, Zander T, Ditschkowski M, Beelen D, Kröger N, Fehse B, Wickenhauser C
ONCOL REP. 2008;19(1):287-292.

Akt as a therapeutic target in cancer
Steelman L, Stadelman K, Chappell W, Horn S, Bäsecke J, Cervello M, Nicoletti F, Libra M, Stivala F, Martelli A, McCubrey J
EXPERT OPIN THER TAR. 2008;12(9):1139-65.

Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation.
Tichelli A, Passweg J, Wójcik D, Rovó A, Harousseau J, Masszi T, Zander A, Békássy A, Crawley C, Arat M, Sica S, Lutz P, Socié G
HAEMATOLOGICA. 2008;93(8):1203-1210.

Mesenchymal stromal cells: a novel treatment option for steroid-induced avascular osteonecrosis
Tzaribachev N, Vaegler M, Schaefer J, Reize P, Rudert M, Handgretinger R, Müller I
CAN MED ASSOC J. 2008;10(3):232-4.

A multicolor panel of novel lentiviral "gene ontology" (LeGO) vectors for functional gene analysis
Weber K, Bartsch U, Stocking C, Fehse B
MOL THER. 2008;16(4):698-706.

Allogeneic stem cell transplantation in acute myeloid leukemia: establishment of indications on the basis of individual risk stratification.
Zander A, Bacher U, Finke J
DTSCH ARZTEBL INT. 2008;105(39):663-669.

Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up.
Zander A, Schmoor C, Kröger N, Krüger W, Möbus V, Frickhofen N, Metzner B, Berdel W, Koenigsmann M, Thiel E, Wandt H, Possinger K, Kreienberg R, Schumacher M, Jonat W
ANN ONCOL. 2008;19(6):1082-1089.

Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.
Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F, Bartels K, Schilling G, Faltz C, Wolschke C, Dierlamm J, Ritter G, Eiermann T, Hossfeld D, Zander A, Jungbluth A, Old L, Bokemeyer C, Kröger N
BLOOD. 2007;109(3):1103-1112.

A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia.
Bacher U, Haferlach T, Kern W, Haferlach C, Schnittger S
HAEMATOLOGICA. 2007;92(6):744-752.

A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia.
Bacher U, Haferlach T, Kern W, Harich H, Schnittger S, Haferlach C
CANCER GENET-NY. 2007;175(1):52-56.

Long-term safety of filgrastim (rhG-CSF) administration: application of haematopoietic growth factors in healthy individuals.
Bacher U, Zander A
BRIT J HAEMATOL. 2007;137(1):78-80.

Autologous stem cell transplantation in myelodysplastic syndromes.
de Witte T, Suciu S, Brand R, Muus P, Kröger N
SEMIN HEMATOL. 2007;44(4):274-277.

Farber disease: clinical presentation, pathogenesis and a new approach to treatment.
Ehlert K, Frosch M, Fehse N, Zander A, Roth J, Vormoor J
PEDIATR RHEUMATOL. 2007;5:15.

Modulation of Ca2+ entry and plasma membrane potential by human TRPM4b.
Fliegert R, Glassmeier G, Schmid F, Cornils K, Genisyuerek S, Harneit A, Schwarz J, Guse A
FEBS J. 2007;274(3):704-713.

Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.
Gahrton G, Iacobelli S, Bandini G, Björkstrand B, Corradini P, Crawley C, Hegenbart U, Morgan G, Kröger N, Schattenberg A, Schönland S, Verdonck L, Volin L, de Witte T, Niederwieser D
HAEMATOLOGICA. 2007;92(11):1513-1518.

Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNgammaR1 signaling and IDO expression
Gieseke F, Schütt B, Viebahn S, Koscielniak E, Friedrich W, Handgretinger R, Müller I
BLOOD. 2007;110(6):2197-200.

Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation.
Goekkurt E, Stoehlmacher J, Stueber C, Wolschke C, Eiermann T, Iacobelli S, Zander A, Ehninger G, Kröger N
ANTICANCER RES. 2007;27(6):4377-4380.

Insight into the molecular pathogenesis of myeloid malignancies.
Haferlach T, Bacher U, Haferlach C, Kern W, Schnittger S
CURR OPIN HEMATOL. 2007;14(2):90-97.

[Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)]
Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C
MED KLIN-INTENSIVMED. 2007;102(9):770-777.

Diagnostic pathways in acute leukemias: a proposal for a multimodal approach.
Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C
ANN HEMATOL. 2007;86(5):311-327.

Gene expression profiling for the diagnosis of acute leukaemia.
Haferlach T, Kohlmann A, Bacher U, Schnittger S, Haferlach C, Kern W
BRIT J CANCER. 2007;96(4):535-540.

Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation
Handgretinger R, Chen X, Pfeiffer M, Müller I, Feuchtinger T, Hale G, Lang P
ANN NY ACAD SCI. 2007;1106:279-89.

In vivo magnetic resonance imaging of iron oxide-labeled, arterially-injected mesenchymal stem cells in kidneys of rats with acute ischemic kidney injury: detection and monitoring at 3T.
Ittrich H, Lange C, Tögel F, Zander A, Dahnke H, Westenfelder C, Adam G, Nolte-Ernsting C
J MAGN RESON IMAGING. 2007;25(6):1179-1191.

A new interphase fluorescence in situ hybridization approach for genomic rearrangements involving MLH1 and MSH6 in hereditary nonpolyposis colorectal cancer-suspected mutation-negative patients.
Koehler U, Grabowski M, Bacher U, Holinski-Feder E
CANCER GENET-NY. 2007;175(1):81-84.

Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation.
Kröger N
LEUKEMIA. 2007;21(9):1851-1858.

Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.
Kröger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhäuser M, Reiter A, Zabelina T, Zander A, Fehse B
BLOOD. 2007;109(3):1316-1321.

Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
Kröger N, Thiele J, Zander A, Schwerdtfeger R, Kobbe G, Bornhäuser M, Bethge W, Schubert J, de Witte T, Kvasnicka H
EXP HEMATOL. 2007;35(11):1719-1722.

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.
Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M, Dechow T, Kröger N, Salwender H, Metzner B, Sezer O, Engelhardt M, Wolf H, Einsele H, Volpert S, Heinecke A, Berdel W, Kienast J
BRIT J HAEMATOL. 2007;138(3):330-337.

Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways.
Kustikova O, Geiger H, Li Z, Brugman M, Chambers S, Shaw C, Pike-Overzet K, de Ridder D, Staal F, von Keudell G, Cornils K, Nattamai K, Modlich U, Wagemaker G, Goodell M, Fehse B, Baum C
BLOOD. 2007;109(5):1897-1907.

Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine
Lange C, Cakiroglu F, Spiess A, Cappallo-Obermann H, Dierlamm J, Zander A
J CELL PHYSIOL. 2007;213(1):18-26.

CD34 modulates the trafficking behavior of hematopoietic cells in vivo.
Lange C, Li Z, Fang L, Baum C, Fehse B
STEM CELLS DEV. 2007;16(2):297-304.

Non-hematopoietic bone marrow cells for regenerative medicine.
Lange C, Tögel F, Jaquet K, Ittrich H, Westenfelder C, Zander A
2007. Stem cells and their potential for clinical application. Bilko et al. (Ed.) (Hrsg.). NATO ASI Series, .

Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients
Lang P, Müller I, Greil J, Bader P, Schumm M, Pfeiffer M, Hoelle W, Klingebiel T, Heinzelmann F, Belka C, Schlegel P, Kremens B, Woessmann W, Handgretinger R
BLOOD CELL MOL DIS. 2007;40(1):33-9.

Insertional mutagenesis by replication-deficient retroviral vectors encoding the large T oncogene.
Li Z, Kustikova O, Kamino K, Neumann T, Rhein M, Grassman E, Fehse B, Baum C
ANN NY ACAD SCI. 2007;1106:95-113.

The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy.
Mehnert A, Scherwath A, Schirmer L, Schleimer B, Petersen-Ewert C, Schulz-Kindermann F, Zander A, Koch-Gromus U
PATIENT EDUC COUNS. 2007;66(1):108-118.

Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations.
Metzner A, Horstmann M, Fehse B, Ortmeyer G, Niemeyer C, Stocking C, Mayr G, Jücker M
GENE THER. 2007;14(8):699-703.

Remarkable leukemogenic potency and quality of a constitutively active neurotrophin receptor, deltaTrkA.
Meyer J, Rhein M, Schiedlmeier B, Kustikova O, Rudolph C, Kamino K, Neumann T, Yang M, Wahlers A, Fehse B, Reuther G, Schlegelberger B, Ganser A, Baum C, Li Z
LEUKEMIA. 2007;21(10):2171-2180.

Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene.
Miletic H, Fischer Y, Litwak S, Giroglou T, Waerzeggers Y, Winkeler A, Li H, Himmelreich U, Lange C, Stenzel W, Deckert M, Neumann H, Jacobs A, von Laer D
MOL THER. 2007;15(7):1373-1381.

Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation.
Mösbauer U, Ayuketang Ayuk F, Schieder H, Lioznov M, Zander A, Kröger N
HAEMATOLOGICA. 2007;92(2):275-276.

Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation
Müller I, Kordowich S, Holzwarth C, Isensee G, Lang P, Neunhoeffer F, Dominici M, Greil J, Handgretinger R
BLOOD CELL MOL DIS. 2007;40(1):25-32.

Magnetresonanz-Bildgebung von einzelnen SPIO-markierten mesenchymalen Stammzellen bei 3 Tesla
Peldschus K, Kaul M, Lange C, Nolte-Ernsting C, Adam G, Ittrich H
ROFO-FORTSCHR RONTG. 2007;179(5):473-479.

Progress in characterization, preparation and clinical applications of non-hematopoietic stem cells, 29-30 September 2006, Tübingen, Germany
Schäfer R, Dominici M, Müller I, Dazzi F, Bieback K, Godthardt K, Le Blanc K, Meisel R, Pochampally R, Richter R, Skutella T, Steinhoff G, Mitterberger M, Wendel H, Wiskirchen J, Handgretinger R, Northoff H
CYTOTHERAPY. 2007;9(4):397-405.

Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients.
Schnittger S, Bacher U, Haferlach C, Kern W, Haferlach T
LEUKEMIA. 2007;21(4):725-731.

JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML.
Schnittger S, Bacher U, Kern W, Haferlach C, Haferlach T
LEUKEMIA. 2007;21(1):183-184.

JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases.
Schnittger S, Bacher U, Kern W, Haferlach T, Haferlach C
LEUKEMIA. 2007;21(8):1843-1845.

Simplified protocol to isolate, purify, and culture expand mesenchymal stem cells.
Schrepfer S, Deuse T, Lange C, Katzenberg R, Reichenspurner H, Robbins R, Pelletier M
STEM CELLS DEV. 2007;16(1):105-107.

Cognitive function in the acute course of allogeneic hematopoietic stem cell transplantation for hematological malignancies.
Schulz-Kindermann F, Mehnert A, Scherwath A, Schirmer L, Schleimer B, Zander A, Koch-Gromus U
BONE MARROW TRANSPL. 2007;39(12):789-799.

Dualism of mixed chimerism between hematopoiesis and stroma in chronic idiopathic myelofibrosis after allogeneic stem cell transplantation.
Thiele J, Varus E, Siebolts U, Kvasnicka H, Wickenhauser C, Metz K, Beelen D, Ditschkowski M, Zander A, Kröger N
HISTOL HISTOPATHOL. 2007;22(4):365-372.

[Recovery of peripheral blood lymphocytes in patients with hematological diseases after allogenic non-relative transplantation of hemopoietic stem cells]
Vavilov V, Zander A, Afanas'iev B
TERAPEVT ARKH. 2007;79(7):44-47.

L1 is associated with favorable outcome in neuroblastomas in contrast to adult tumors.
Wachowiak R, Fiegel H, Kaifi J, Quaas A, Krickhahn A, Schurr P, Erttmann R, Schachner M, Kluth D, Sauter G, Izbicki J
ANN SURG ONCOL. 2007;14(12):3575-3580.

Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Weissinger E, Schiffer E, Hertenstein B, Ferrara J, Holler E, Stadler M, Kolb H, Zander A, Zürbig P, Kellmann M, Ganser A
BLOOD. 2007;109(12):5511-5519.

Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors.
Baum C, Kustikova O, Modlich U, Li Z, Fehse B
HUM GENE THER. 2006;17(3):253-263.

Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
Bornhäuser M, Kröger N, Schwerdtfeger R, Schafer-Eckart K, Sayer H, Scheid C, Stelljes M, Kienast J, Mundhenk P, Fruehauf S, Kiehl M, Wandt H, Theuser C, Ehninger G, Zander A
EUR J HAEMATOL. 2006;76(1):9-17.

Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation.
Dahlke J, Kröger N, Zabelina T, Ayuketang Ayuk F, Wolschke C, Renges H, Krüger W, Kruell A, Hinke A, Erttmann R, Kabisch H, Zander A
BONE MARROW TRANSPL. 2006;37(2):155-163.

The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes.
de Witte T, Brand R, van Biezen A, Delforge M, Biersack H, Or R, Meloni G, Bandini B, Sierra J, Kröger N, Gratwohl A, Niederwieser D
HAEMATOLOGICA. 2006;91(6):750-756.

Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.
Donk v, Kröger N, Kröger N, Hegenbart U, Corradini P, Miguel S, Jesus F, Goldschmidt H, Perez-Simon J, Zijlmans M, Ayuketang Ayuk F, Montefusco V, Ayuk F, Oers v, Marinus H, Nagler A, Verdonck L, Lokhorst H
BLOOD. 2006;107(8):3415-3416.

Bovine herpesvirus 4 based vector interaction with liver cells in vitro and in vivo
Donofrio G, Martignani E, Poli E, Lange C, Martini F, Cavirani S, Cabassi C, Taddei S, Flammini C
J VIROL METHODS. 2006;136(1-2):126-36.

Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation.
Einsele H, Reusser P, Bornhäuser M, Kalhs P, Ehninger G, Hebart H, Chalandon Y, Kröger N, Hertenstein B, Rohde F
BLOOD. 2006;107(7):3002-3008.

Sensitive balance of suppressing and activating effects of mesenchymal stem cells on T-cell proliferation.
Fang L, Lange C, Engel M, Zander A, Fehse B
TRANSPLANTATION. 2006;82(10):1370-1373.

Cell growth and differentiation of different hepatic cells isolated from fetal rat liver in vitro.
Fiegel H, Bruns H, Höper C, Lioznov M, Kluth D
TISSUE ENG. 2006;12(1):123-130.

Fetal and adult liver stem cells for liver regeneration and tissue engineering.
Fiegel H, Lange C, Kneser U, Lambrecht W, Zander A, Rogiers X, Kluth D
J CELL MOL MED. 2006;10(3):577-587.

Retroviral vector insertions in T-lymphocytes used for suicide gene therapy occur in gene groups with specific molecular functions.
Giordano F, Fehse B, Hotz-Wagenblatt A, Jonnakuty S, Del Val C, Appelt J, Nagy K, Kuehlcke K, Naundorf S, Zander A, Zeller W, Ho A, Fruehauf S, Laufs S
BONE MARROW TRANSPL. 2006;38(3):229-235.

Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients.
Goekkurt E, Hoehn S, Wolschke C, Wittmer C, Stueber C, Hossfeld D, Stoehlmacher J
BRIT J CANCER. 2006;94(2):281-286.

Comparison of flow cytometry vs. a haematology cell analyser-based method to guide the optimal time-point for peripheral blood stem cell apheresis.
Gutensohn K, Magens M, Krüger W, Kröger N, Kühnl P
VOX SANG. 2006;90(1):53-58.

Increased alpha2,6-sialylation of surface proteins on tolerogenic, immature dendritic cells and regulatory T cells
Jenner J, Kerst G, Handgretinger R, Müller I
EXP HEMATOL. 2006;34(9):1212-8.

Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation.
Kröger N, Binder T, Zabelina T, Wolschke C, Schieder H, Renges H, Ayuketang Ayuk F, Dahlke J, Eiermann T, Zander A
TRANSPLANTATION. 2006;82(8):1024-1030.

Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
Kröger N, Brand R, van Biezen A, Cahn J, Slavin S, Blaise D, Sierra J, Zander A, Niederwieser D, de Witte T
BONE MARROW TRANSPL. 2006;37(2):183-189.

Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.
Kröger N, Frick M, Gluz O, Mohrmann S, Metzner B, Jackisch C, Ko Y, Lindemann H, Meier C, Lohrmann H, Ruffert U, Hänel M, Bodenstein H, Neubauer A, Ehninger G, Wolf H, Kolbe K, Burock K, Zander A, Nitz U
J CLIN ONCOL. 2006;24(24):3919-3926.

Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
Kröger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander A, Löning T
CLIN CANCER RES. 2006;12(1):159-168.

Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Kröger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuketang Ayuk F, Wolschke C, Renges H, Dahlke J, Atanackovic D, Nagler A, Zander A
BONE MARROW TRANSPL. 2006;37(4):339-344.

Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.
Kröger N, Zabelina T, Ayuketang Ayuk F, Atanackovic D, Schieder H, Renges H, Zander A
EXP HEMATOL. 2006;34(6):770-775.

Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma.
Kröger N, Zagrivnaja M, Schwartz S, Badbaran A, Zabelina T, Lioznov M, Ayuketang Ayuk F, Zander A, Fehse B
EXP HEMATOL. 2006;34(5):688-694.

Hepatocytic differentiation of mesenchymal stem cells in cocultures with fetal liver cells.
Lange C, Bruns H, Kluth D, Zander A, Fiegel H
WORLD J GASTROENTERO. 2006;12(15):2394-2397.

Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects
Lang P, Pfeiffer M, Müller I, Schumm M, Ebinger M, Koscielniak E, Feuchtinger T, Föll J, Martin D, Handgretinger R
KLIN PADIATR. 2006;218(6):321-6.

Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A, Mufti G, Kröger N, Zander A, Heim D, Paluszewska M, Selleslag D, Steinerova K, Ljungman P, Cesaro S, Nihtinen A, Cordonnier C, Vazquez L, López-Duarte M, Lopez J, Cabrera R, Rovira M, Neuburger S, Cornely O, Hunter A, Marr K, Dornbusch H, Einsele H
BLOOD. 2006;108(9):2928-2936.

Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM
Müller I, Kordowich S, Holzwarth C, Spano C, Isensee G, Staiber A, Viebahn S, Gieseke F, Langer H, Gawaz M, Horwitz E, Conte P, Handgretinger R, Dominici M
CYTOTHERAPY. 2006;8(5):437-44.

In vitro analysis of multipotent mesenchymal stromal cells as potential cellular therapeutics in neurometabolic diseases in pediatric patients
Müller I, Kustermann-Kuhn B, Holzwarth C, Isensee G, Vaegler M, Harzer K, Krägeloh-Mann I, Handgretinger R, Bruchelt G
EXP HEMATOL. 2006;34(10):1413-9.

Dynamic expression of LIM cofactors in the developing mouse neural tube.
Ostendorff H, Tursun B, Cornils K, Schlüter A, Drung A, Güngör C, Bach I
DEV DYNAM. 2006;235(3):786-791.

CD34(+)-selected stem cell boost for delayed or insufficient engraftment after allogeneic stem cell transplantation.
Oyekunle A, Koehl U, Schieder H, Ayuketang Ayuk F, Renges H, Fehse N, Zabelina T, Fehse B, Klingebiel T, Sputtek A, Zander A, Kröger N
CYTOTHERAPY. 2006;8(4):375-380.

Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up.
Oyekunle A, Kröger N, Zabelina T, Ayuketang Ayuk F, Schieder H, Renges H, Fehse N, Waschke O, Fehse B, Kabisch H, Zander A
BONE MARROW TRANSPL. 2006;37(1):45-50.

Hyaluronate and its receptors in bone marrow.
Schade U, Nehmann N, Horny H, Prehm P, Delpech B, Krüger W, Zander A, Schumacher U
ACTA HISTOCHEM. 2006;108(2):141-147.

Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects.
Scherwath A, Mehnert A, Schleimer B, Schirmer L, Fehlauer F, Kreienberg R, Metzner B, Thiel E, Zander A, Schulz-Kindermann F, Koch U
ANN ONCOL. 2006;17(3):415-423.

Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation.
Schönland S, Lokhorst H, Buzyn A, Leblond V, Hegenbart U, Bandini G, Campbell A, Carreras E, Ferrant A, Grommisch L, Jacobs P, Kröger N, Giorgio L, Russell N, Zachee P, Goldschmidt H, Iacobelli S, Niederwieser D, Gahrton G
BLOOD. 2006;107(6):2578-2584.

Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.
van de Donk N, Kröger N, Hegenbart U, Corradini P, San Miguel J, Goldschmidt H, Perez-Simon J, Zijlmans M, Raymakers R, Montefusco V, Ayuketang Ayuk F, van Oers M, Nagler A, Verdonck L, Lokhorst H
BONE MARROW TRANSPL. 2006;37(12):1135-1141.

Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A.
Zur Stadt U, Beutel K, Kolberg S, Schneppenheim R, Kabisch H, Janka G, Hennies H
HUM MUTAT. 2006;27(1):62-68.

Antithymocyte globulin induces complement-dependent cell lysis and caspase-dependent apoptosis in myeloma cells.
Ayuketang Ayuk F, Fang L, Fehse B, Zander A, Kröger N
EXP HEMATOL. 2005;33(12):1531-1536.

Antithymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells
Fang L, Fehse B, Engel M, Zander A, Kröger N
TRANSPLANTATION. 2005;79(3):369-371.

Untersuchungen zur Markierung von mesenchymalen Stammzellen mit unterschiedlichen superparamagnetischen Eisenoxidpartikeln und Nachweisbarkeit in der MRT bei 3T
Ittrich H, Lange C, Dahnke H, Zander A, Adam G, Nolte Ernsting C
ROFO-FORTSCHR RONTG. 2005;177(8):1151-1163.

Reduction of myocardial scar size after implantation of mesenchymal stem cells in rats: what is the mechanism?
Jaquet K, Krause K, Denschel J, Faessler P, Nauerz M, Geidel S, Boczor S, Lange C, Stute N, Zander A, Kuck K
STEM CELLS DEV. 2005;14(3):299-309.

Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR
Kerst G, Kreyenberg H, Roth C, Well C, Dietz K, Coustan-Smith E, Campana D, Koscielniak E, Niemeyer C, Schlegel P, Müller I, Niethammer D, Bader P
BRIT J HAEMATOL. 2005;128(6):774-82.

Analysis of progenitor cell mobilization and erythropoietin plasma levels in patients with acute myocardial infarction
Krause K, Fehse B, Jaquet K, Lange C, Kyriazis K, Boczor S, Zander A, Kuck K
EXP CLIN CARDIOL. 2005;10(2):104-7.

Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma.
Kröger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, Nagler A, Binder T, Eiermann T, Madrigal A, Schwerdtfeger R, Kiehl M, Sayer H, Beyer J, Bornhäuser M, Ayuketang Ayuk F, Zander A, Marks D
BRIT J HAEMATOL. 2005;129(5):631-643.

Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis.
Kröger N, Zabelina T, Schieder H, Panse J, Ayuk F, Stute N, Fehse N, Waschke O, Fehse B, Kvasnicka H, Thiele J, Zander A
BRIT J HAEMATOL. 2005;128(5):690-697.

Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking
Kustikova O, Fehse B, Modlich U, Yang M, Düllmann J, Kamino K, von Neuhoff N, Schlegelberger B, Li Z, Baum C
SCIENCE. 2005;308(5725):1171-4.

Hepatocytic gene expression in cultured rat mesenchymal stem cells.
Lange C, Bassler P, Lioznov M, Bruns H, Kluth D, Zander A, Fiegel H
TRANSPL P. 2005;37(1):276-279.

Liver-specific gene expression in mesenchymal stem cells is induced by liver cells.
Lange C, Bassler P, Lioznov M, Bruns H, Kluth D, Zander A, Fiegel H
WORLD J GASTROENTERO. 2005;11(29):4497-4504.

High-potential human mesenchymal stem cells.
Lange C, Schroeder J, Stute N, Lioznov M, Zander A
STEM CELLS DEV. 2005;14(1):70-80.

Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats
Lange C, Tögel F, Ittrich H, Clayton F, Nolte-Ernsting C, Zander A, Westenfelder C
KIDNEY INT. 2005;68(4):1613-7.

A comparison between three graft manipulation methods for haploidentical stem cell transplantation in pediatric patients: preliminary results of a pilot study
Lang P, Schumm M, Greil J, Bader P, Klingebiel T, Müller I, Feuchtinger T, Pfeiffer M, Schlegel P, Niethammer D, Handgretinger R
KLIN PADIATR. 2005;217(6):334-8.

Aldehyde dehydrogenase activity as a marker for the quality of hematopoietic stem cell transplants.
Lioznov M, Freiberger P, Kröger N, Zander A, Fehse B
BONE MARROW TRANSPL. 2005;35(9):909-914.

Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis
Modlich U, Kustikova O, Schmidt M, Rudolph C, Meyer J, Li Z, Kamino K, von Neuhoff N, Schlegelberger B, Kuehlcke K, Bunting K, Schmidt S, Deichmann A, von Kalle C, Fehse B, Baum C
BLOOD. 2005;105(11):4235-46.

Improving the ex vivo retroviral-mediated suicide-gene transfer process in T lymphocytes to preserve immune function
Robinet E, Fehse B, Ebeling S, Sauce D, Ferrand C, Tiberghien P
CYTOTHERAPY. 2005;7(2):150-7.

After major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B.
Schetelig J, Breitschaft A, Kröger N, Zabelina T, Ebell W, Bornhäuser M, Haack A, Ehninger G, Salama A, Siegert W
TRANSFUSION. 2005;45(5):779-787.

Cytotoxic minor histocompatibility antigen HA-1-specific CD8+ effector memory T cells: artificial APCs pave the way for clinical application by potent primary in vitro induction
Schilbach K, Kerst G, Walter S, Eyrich M, Wernet D, Handgretinger R, Xie W, Rammensee H, Müller I, Bühring H, Niethammer D
BLOOD. 2005;106(1):144-9.

Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning.
Shimoni A, Kröger N, Zabelina T, Ayuketang Ayuk F, Hardan I, Yeshurun M, Shem-Tov N, Avigdor A, Ben-Bassat I, Zander A, Nagler A
LEUKEMIA. 2005;19(1):7-12.

Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation.
Thiele J, Kvasnicka H, Dietrich H, Stein G, Hann M, Kaminski A, Rathjen N, Metz K, Beelen D, Ditschkowski M, Zander A, Kröger N
HISTOL HISTOPATHOL. 2005;20(3):879-889.

Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms
Tögel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C
AM J PHYSIOL-RENAL. 2005;289(1):F31-42.

DHPLC based fraction collection of TCR-gamma rearrangements in childhood ALL: direct sequencing of products amplified by a single or a multiplex PCR approach.
Zur Stadt U, Isbarn H, Schneppenheim R, Kabisch H
INT J ONCOL. 2005;27(2):547-552.

Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma.
Ayuketang Ayuk F, Shimoni A, Nagler A, Schwerdtfeger R, Kiehl M, Sayer H, Zabelina T, Zander A, Kröger N
LEUKEMIA. 2004;18(3):659-662.

Chance or necessity?: Insertional mutagenesis in gene therapy and its consequences
Baum C, von Kalle C, Staal F, Li Z, Fehse B, Schmidt M, Weerkamp F, Karlsson S, Wagemaker G, Williams D
MOL THER. 2004;9(1):5-13.

Evidence for increased risk of secondary graft failure after in vivo depletion of suicide gene-modified T lymphocytes transplanted in conjunction with CD34+-enriched blood stem cells.
Fehse B, Ayuketang Ayuk F, Kröger N, Fang L, Kühlcke K, Heinzelmann M, Zabelina T, Fauser A, Zander A
BLOOD. 2004;104(10):3408-3409.

Pois(s)on--it's a question of dose
Fehse B, Kustikova O, Bubenheim M, Baum C
GENE THER. 2004;11(11):879-81.

Tumor cells escape suicide gene therapy by genetic and epigenetic instability
Frank O, Rudolph C, Heberlein C, von Neuhoff N, Schröck E, Schambach A, Schlegelberger B, Fehse B, Ostertag W, Stocking C, Baum C
BLOOD. 2004;104(12):3543-9.

Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission.
Kiehl M, Kraut L, Schwerdtfeger R, Hertenstein B, Remberger M, Kröger N, Stelljes M, Bornhaeuser M, Martin H, Scheid C, Ganser A, Zander A, Kienast J, Ehninger G, Hoelzer D, Diehl V, Fauser A, Ringden O
J CLIN ONCOL. 2004;22(14):2816-2825.

Self-inactivating retroviral vectors with improved RNA processing
Kraunus J, Schaumann D, Meyer J, Modlich U, Fehse B, Brandenburg G, von Laer D, Klump H, Schambach A, Bohne J, Baum C
GENE THER. 2004;11(21):1568-78.

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N, Perez-Simon J, Myint H, Klingemann H, Shimoni A, Nagler A, Martino R, Alegre A, Tomas J, Schwerdtfeger R, Kiehl M, Fauser A, Sayer H, Leon A, Beyer J, Zabelina T, Ayuketang Ayuk F, Miguel S, Jesus F, Brand R, Zander A
BIOL BLOOD MARROW TR. 2004;10(10):698-708.

Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation.
Kröger N, Schilling G, Einsele H, Liebisch P, Shimoni A, Nagler A, Perez-Simon J, Miguel S, Jesus F, Kiehl M, Fauser A, Schwerdtfeger R, Wandt H, Sayer H, Myint H, Zabelina T, Zabelina T, Dierlamm J, Hinke A, Zander A
BLOOD. 2004;103(11):4056-4061.

Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N, Shimoni A, Zagrivnaja M, Ayuketang Ayuk F, Lioznov M, Schieder H, Renges H, Fehse B, Zabelina T, Nagler A, Zander A
BLOOD. 2004;104(10):3361-3363.

Simplified generation of high-titer retrovirus producer cells for clinically relevant retroviral vectors by reversible inclusion of a lox-P-flanked marker gene
Loew R, Selevsek N, Fehse B, von Laer D, Baum C, Fauser A, Kuehlcke K
MOL THER. 2004;9(5):738-46.

Glycosylation and lectins-examples of immunesurveillance and immune evasion
Müller I, Jenner J, Handgretinger R, Riberdy J, Kerst G
HISTOL HISTOPATHOL. 2004;19(2):527-33.

Human gammadelta T cells from G-CSF-mobilized donors retain strong tumoricidal activity and produce immunomodulatory cytokines after clinical-scale isolation
Otto M, Barfield R, Iyengar R, Gatewood J, Müller I, Holladay M, Houston J, Leung W, Handgretinger R
J IMMUNOTHER. 2004;28(1):73-8.

Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
Schetelig J, Bornhäuser M, Kiehl M, Schwerdtfeger R, Kröger N, Runde V, Zabelina T, Held T, Thiede C, Fauser A, Beelen D, Zander A, Ehninger G, Siegert W
BONE MARROW TRANSPL. 2004;33(5):483-490.

Autologous serum for isolation and expansion of human mesenchymal stem cells for clinical use
Stute N, Holtz K, Bubenheim M, Lange C, Blake F, Zander A
EXP HEMATOL. 2004;32(12):1212-25.

Stem cell clonality and genotoxicity in hematopoietic cells: gene activation side effects should be avoidable
von Kalle C, Fehse B, Layh-Schmitt G, Schmidt M, Kelly P, Baum C
SEMIN HEMATOL. 2004;41(4):303-18.

Side effects of retroviral gene transfer into hematopoietic stem cells
Baum C, Düllmann J, Li Z, Fehse B, Meyer J, Williams D, von Kalle C
BLOOD. 2003;101(6):2099-114.

Mutagenesis by retroviral transgene insertion: risk assessment and potential alternatives
Baum C, Fehse B
Current opinion in molecular therapeutics. 2003;5(5):458-62.

Influence of anti-thymocyte globulin as part of the conditioning regimen on immune reconstitution following matched related bone marrow transplantation.
Fehse N, Fehse B, Kröger N, Zabelina T, Freiberger P, Krüger W, Kabisch H, Erttmann R, Zander A
J HEMATOTH STEM CELL. 2003;12(2):237-242.

Hepatic lineages isolated from developing rat liver show different ways of maturation.
Fiegel H, Kluth J, Lioznov M, Holzhüter S, Fehse B, Zander A, Kluth D
BIOCHEM BIOPH RES CO. 2003;305(1):46-53.

Liver-specific gene expression in cultured human hematopoietic stem cells.
Fiegel H, Lioznov M, Cortes-Dericks L, Lange C, Kluth D, Fehse B, Zander A
STEM CELLS. 2003;21(1):98-104.

Characterization of cell types during rat liver development.
Fiegel H, Park J, Lioznov M, Martin A, Jaeschke-Melli S, Kaufmann P, Fehse B, Zander A, Kluth D
HEPATOLOGY. 2003;37(1):148-154.

Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
Kröger N, Einsele H, Wolff D, Casper J, Freund M, Derigs G, Wandt H, Schäfer-Eckart K, Wittkowsky G, Schmitz N, Krüger W, Zabelina T, Renges H, Ayuketang Ayuk F, Krüll A, Zander A
BONE MARROW TRANSPL. 2003;31(11):973-979.

Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population
Kustikova O, Wahlers A, Kuhlcke K, Stahle B, Zander A, Baum C, Fehse B
BLOOD. 2003;102(12):3934-7.

Predictable and efficient retroviral gene transfer into murine bone marrow repopulating cells using a defined vector dose
Li Z, Schwieger M, Lange C, Kraunus J, Sun H, van den Akker E, Modlich U, Serinsöz E, Will E, von Laer D, Stocking C, Fehse B, Schiedlmeier B, Baum C
EXP HEMATOL. 2003;31(12):1206-14.

Receptor activator of nuclear factor kappaB ligand plays a nonredundant role in doxorubicin-induced apoptosis
Müller I, Pfister S, Grohs U, Zweigner J, Handgretinger R, Niethammer D, Bruchelt G
CANCER RES. 2003;63(8):1772-5.

Non-overt disseminated intravascular coagulation in patients during treatment with antithymocyte globulin for unrelated allogeneic hematopoietic stem cell transplantation.
Weber M, Kröger N, Langer F, Hansen A, Zabelina T, Eifrig B, Hossfeld D, Zander A
BONE MARROW TRANSPL. 2003;31(9):817-822.

Minor histocompatibility antigens on canine hemopoietic progenitor cells
Weber M, Lange C, Günther W, Franz M, Kremmer E, Kolb H
J IMMUNOL. 2003;170(12):5861-8.

ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML).
Zander A, Kröger N, Schleuning M, Finke J, Zabelina T, Beelen D, Schwerdtfeger R, Baurmann H, Bornhäuser M, Ehninger G, Fauser A, Kiehl M, Trenschel R, Ottinger H, Bertz H, Berger J, Kolb H, Schaefer U
BONE MARROW TRANSPL. 2003;32(4):355-361.

A novel 'sort-suicide' fusion gene vector for T cell manipulation
Fehse B, Kustikova O, Li Z, Wahlers A, Bohn W, Beyer W, Chalmers D, Tiberghien P, Kühlcke K, Zander A, Baum C
GENE THER. 2002;9(23):1633-1638.

[Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG]
Graf Finckenstein F, Zabelina T, Dürken M, Dahlke J, Kröger N, Krüger W, Janka-Schaub G, Erttmann R, Zander A, Kabisch H
KLIN PADIATR. 2002;214(4):206-211.

Binding of activated platelets to WBCs in vivo after transfusion.
Gutensohn K, Geidel K, Brockmann M, Siemensen M, Krueger W, Kröger N, Kuehnl P
TRANSFUSION. 2002;42(10):1373-1380.

Platelet function testing in apheresis products: flow cytometric, resonance thrombographic (RTG) and rotational thrombelastographic (roTEG) analyses.
Gutensohn K, Geidel K, Kröger N, Eifrig B, Crespeigne N, Kuehnl P
TRANSFUS APHER SCI. 2002;26(3):147-155.

Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia.
Hessling J, Kröger N, Werner M, Zabelina T, Hansen A, Kordes U, Ayuketang Ayuk F, Renges H, Panse J, Erttmann R, Zander A
BRIT J HAEMATOL. 2002;119(3):769-772.

Radiotherapy after high-dose chemotherapy and peripheral blood stem cell support in high-risk breast cancer.
Hoeller U, Juergen H, Kröger N, Krueger W, Jaenicke F, Alberti W
INT J RADIAT ONCOL. 2002;53(5):1234-1239.

Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality.
Kröger N, Sayer H, Schwerdtfeger R, Kiehl M, Nagler A, Renges H, Zabelina T, Fehse B, Ayuketang Ayuk F, Wittkowsky G, Schmitz N, Zander A
BLOOD. 2002;100(12):3919-3924.

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma.
Kröger N, Schwerdtfeger R, Kiehl M, Sayer H, Renges H, Zabelina T, Fehse B, Tögel F, Wittkowsky G, Kuse R, Zander A
BLOOD. 2002;100(3):755-760.

Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
Kröger N, Zabelina T, Guardiola P, Volker R, Sierra J, Anja V, Niederwieser D, Zander A, Theo D
BRIT J HAEMATOL. 2002;118(1):67-73.

In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors.
Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Rischewski J, Sonnenberg S, Ayuk F, Ayuketang Ayuk F, Schade U, Fiegel H, Erttmann R, Löliger C, Zander A
BONE MARROW TRANSPL. 2002;29(8):683-689.

Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin.
Kröger N, Zabelina T, Renges H, Krüger W, Kordes U, Rischewski J, Schrum J, Horstmann M, Ayuketang Ayuk F, Erttmann R, Kabisch H, Zander A
ANN HEMATOL. 2002;81(11):627-631.

Highly efficient retroviral gene transfer based on centrifugation-mediated vector preloading of tissue culture vessels.
Kühlcke K, Fehse B, Schilz A, Loges S, Lindemann C, Ayuketang Ayuk F, Lehmann F, Stute N, Fauser A, Zander A, Eckert H
MOL THER. 2002;5(4):473-478.

Reconstitution of mRNA editing in yeast using a Gal4-apoB-Gal80 fusion transcript as the selectable marker.
Lellek H, Welker S, Diehl I, Kirsten R, Greeve J
J BIOL CHEM. 2002;277(26):23638-23644.

Murine leukemia induced by retroviral gene marking
Li Z, Düllmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J, Forster M, Stocking C, Wahlers A, Frank O, Ostertag W, Kühlcke K, Eckert H, Fehse B, Baum C
SCIENCE. 2002;296(5567):497.

Persisting multilineage transgene expression in the clonal progeny of a hematopoietic stem cell
Li Z, Fehse B, Schiedlmeier B, Düllmann J, Frank O, Zander A, Ostertag W, Baum C
LEUKEMIA. 2002;16(9):1655-63.

Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease.
Schetelig J, Kröger N, Held T, Christian T, Krusch A, Zabelina T, Dubiel M, Rick O, Bornhäuser M, Ehninger G, Zander A, Siegert W
HAEMATOLOGICA. 2002;87(3):299-305.

Human mesenchymal stem cells are not of donor origin in patients with severe aplastic anemia who underwent sex-mismatched allogeneic bone marrow transplant
Stute N, Fehse B, Schröder J, Arps S, Adamietz P, Held K, Zander A
J HEMATOTH STEM CELL. 2002;11(6):977-984.

Molecular methods for detection and quantification of myeloma cells after bone marrow transplantation: comparison between real-time quantitative and nested PCR
Tögel F, Kröger N, Korioth F, Fehse B, Zander A
J HEMATOTH STEM CELL. 2002;11(6):971-976.

Upstream conserved sequences of mouse leukemia viruses are important for high transgene expression in lymphoid and hematopoietic cells
Wahlers A, Kustikova O, Zipfel P, Itoh K, Koester M, Heberlein C, Li Z, Schiedlmeier B, Skerka C, Fehse B, Baum C
MOL THER. 2002;6(3):313-320.

Interleukin-10 modulation of alloreactivity and graft-versus-host reactions
Wang X, Lange C, Schulz U, Sviland L, Eissner G, Oliver K, Jackson G, Holler E, Dickinson A
TRANSPLANTATION. 2002;74(6):772-8.

T lymphocytes as targets of gene transfer with Moloney-type retroviral vectors.
Ayuketang Ayuk F, Zander A, Fehse B
CURR GENE THER. 2001;1(4):325-337.

Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation.
Fehse B, Chukhlovin A, Kühlcke K, Marinetz O, Vorwig O, Renges H, Krüger W, Zabelina T, Dudina O, Finckenstein F, Kröger N, Kabisch H, Hochhaus A, Zander A
J HEMATOTH STEM CELL. 2001;10(3):419-425.

Membrane-anchored peptide inhibits human immunodeficiency virus entry
Hildinger M, Dittmar M, Schult-Dietrich P, Fehse B, Schnierle B, Thaler S, Stiegler G, Welker R, von Laer D
J VIROL. 2001;75(6):3038-42.

The inositol 5-phosphatase SHIP is expressed as 145 and 135 kDa proteins in blood and bone marrow cells in vivo, whereas carboxyl-truncated forms of SHIP are generated by proteolytic cleavage in vitro
Horn S, Meyer J, Heukeshoven J, Fehse B, Schulze C, Li S, Frey J, Poll S, Stocking C, Jücker M
LEUKEMIA. 2001;15(1):112-20.

Mass-spectrometry-linked screening of protein fractions for enzymatic activities--a tool for functional genomics
Jankowski J, Stephan N, Knobloch M, Fischer S, Schmaltz D, Zidek W, Schlüter H
ANAL BIOCHEM. 2001;290(2):324-9.

Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma.
Kröger N, Krüger W, Renges H, Zabelina T, Stute N, Jung R, Wittkowsky G, Kuse R, Zander A
BRIT J HAEMATOL. 2001;112(2):421-423.

A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander A
BONE MARROW TRANSPL. 2001;28(7):643-647.

Anti-thymocyte-globulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors.
Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Dürken M, Graf von Finkenstein F, Erttmann R, Kabisch H, Schafhausen P, Jaburg N, Löliger C, Zander A
ANN HEMATOL. 2001;80(4):209-215.

Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Kabisch H, Jaburg N, Löliger C, Krüll A, Zander A
BONE MARROW TRANSPL. 2001;27(4):349-354.

Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin.
Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Schafhausen P, Jaburg N, Löliger C, Schäfer P, Hinke A, Zander A
BRIT J HAEMATOL. 2001;113(4):1060-1071.

Noncutaneous varicella-zoster virus (VZV) infection with fatal liver failure in a child with acute lymphoblastic leukemia (ALL)
Müller I, Aepinus C, Beck R, Bültmann B, Niethammer D, Klingebiel T
Med Pediatr Oncol. 2001;37(2):145-7.

CD34 splice variant: an attractive marker for selection of gene-modified cells
Fehse B, Richters A, Putimtseva-Scharf K, Klump H, Li Z, Ostertag W, Zander A, Baum C
MOL THER. 2000;1(5 Pt 1):448-456.

Extracorporeal plateletpheresis induces the interaction of activated platelets with white blood cells.
Gutensohn K, Alisch A, Krueger W, Kröger N, Kuehnl P
VOX SANG. 2000;78(2):101-105.

Quiescence of CD34-negative haematopoietic stem cells is mediated by downregulation of Cyclin B and no stat activation
Huss R, Gatsios P, Graeve L, Lange C, Eissner G, Kolb H, Thalmeier K, Heinrich P
CYTOKINE. 2000;12(8):1195-204.

Evidence of peripheral blood-derived, plastic-adherent CD34(-/low) hematopoietic stem cell clones with mesenchymal stem cell characteristics
Huss R, Lange C, Weissinger E, Kolb H, Thalmeier K
STEM CELLS. 2000;18(4):252-60.

In vitro-generated stem cell leukaemia showing altered cell cycle progression with distinct signalling of the tyrosine-phosphorylated rasGAP-associated p62(dok) protein
Huss R, Weissinger E, Lange C, Gatsios P, Eissner G, Kolb H, Diebold J, Heinrich P, Graeve L
J PATHOL. 2000;192(3):363-72.

Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, Del Valle F, Erttmann R, Kabisch H, Zander A
BONE MARROW TRANSPL. 2000;26(7):711-716.

Retroviral transduction of T lymphocytes for suicide gene therapy in allogeneic stem cell transplantation.
Kühlcke K, Ayuketang Ayuk F, Li Z, Lindemann C, Schilz A, Schade U M, Fauser A, Zander A, Eckert H, Fehse B
BONE MARROW TRANSPL. 2000;25(2):96-98.

Purification and molecular cloning of a novel essential component of the apolipoprotein B mRNA editing enzyme-complex.
Lellek H, Kirsten R, Diehl I, Apostel F, Buck F, Greeve J
J BIOL CHEM. 2000;275(26):19848-19856.

Low molecular thymic peptides stimulate human blood dendritic cells
Mayer G, Pohlmeyer K, Caliebe A, Heimueller E, Behnke B, Steimann G, Lange C, Beuth J
ANTICANCER RES. 2000;20(5A):2873-83.

Generation of functionally mature dendritic cells from the multipotential stem cell line FDCP-mix
Schroeder T, Strehl J, Lange C, Just U
BRIT J HAEMATOL. 2000;111(3):890-7.

Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements.
Ayuketang Ayuk F, Li Z, Kühlcke K, Lindemann C, Schade U, Eckert H, Zander A, Fehse B
GENE THER. 1999;6(10):1788-1792.

Improved outcome in haemophagocytic lymphohistiocytosis after bone marrow transplantation from related and unrelated donors: a single-centre experience of 12 patients.
Dürken M, Horstmann M, Bieling P, Erttmann R, Kabisch H, Löliger C, Schneider E, Hellwege H, Krüger W, Kröger N, Zander A, Janka G
BRIT J HAEMATOL. 1999;106(4):1052-1058.

Rapid and efficient cloning of proviral flanking fragments by kanamycin resistance gene complementation
Fehse B, Kühlcke K, Langer A, Ostertag W, Lother H
NUCLEIC ACIDS RES. 1999;27(2):706-7.

Absence of APOBEC-1 mediated mRNA editing in human carcinomas.
Greeve J, Lellek H, Apostel F, Hundoegger K, Barialai A, Kirsten R, Welker S, Greten H
ONCOGENE. 1999;18(46):6357-6366.

Semi-automated flow cytometric analysis of CD34-expressing hematopoietic cells in peripheral blood progenitor cell apheresis products.
Gutensohn K, Carrero I, Krueger W, Kröger N, Schäfer P, Luedemann K, Kuehnl P
TRANSFUSION. 1999;39(11-12):1220-1226.

Hematopoietic reconstitution of syngeneic mice with a peripheral blood-derived, monoclonal CD34-, Sca-1+, Thy-1(low), c-kit+ stem cell line
Lange C, Kaltz C, Thalmeier K, Kolb H, Huss R
J HEMATOTH STEM CELL. 1999;8(4):335-42.

Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow.
Zander A, Zabelina T, Kröger N, Renges H, Krüger W, Löliger C, Dürken M, Stockschläder M, de Wit M, Wacker-Backhaus G, Bielack S, Jaburg N, Rüssmann B, Erttmann R, Kabisch H
BONE MARROW TRANSPL. 1999;23(9):889-893.

Impact of a new generation of gene transfer markers on gene therapy
Fehse B, Li Z, Schade U, Uhde A, Zander A
GENE THER. 1998;5(4):429-430.

Highly-efficient gene transfer with retroviral vectors into human T lymphocytes on fibronectin
Fehse B, Schade U, Li Z, Uhde A, Koch S, Goller B, Rüger R, Fehse N, Stockschläder M, Zander A
BRIT J HAEMATOL. 1998;102(2):566-74.

Inhibition of the apolipoprotein B mRNA editing enzyme-complex by hnRNP C1 protein and 40S hnRNP complexes.
Greeve J, Lellek H, Rautenberg P, Greten H
BIOL CHEM. 1998;379(8-9):1063-1073.

Dominant selection of hematopoietic progenitor cells with retroviral MDR1 co-expression vectors
Hildinger M, Fehse B, Hegewisch-Becker S, John J, Rafferty J, Ostertag W, Baum C
HUM GENE THER. 1998;9(1):33-42.

Purging and haemopoietic progenitor cell selection by CD34+ cell separation
Krüger W, Gruber M, Hennings S, Fehse N, Fehse B, Gutensohn K, Kröger N, Zander A
BONE MARROW TRANSPL. 1998;21(7):665-671.

Interleukin 4 gene-defective mice reconstituted with wild-type bone marrow fail to produce normal immunoglobulin E levels
Lange C, Schüler T, Blankenstein T
J EXP MED. 1998;187(9):1487-93.

Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer.
Lehnert M, Mross K, Schueller J, Thuerlimann B, Kröger N, Kupper H
BRIT J CANCER. 1998;77(7):1155-1163.

High-efficiency retroviral vector-mediated gene transfer into human T lymphocytes
Li Z, Schade U, Fehse B, Stockschläder M, Uhde A, Koch S, Goller B, Rüger R, Fehse N, Zander A
ADV EXP MED BIOL. 1998;451:375-378.

Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review)
Müller I, Niethammer D, Bruchelt G
INT J MOL MED. 1998;1(2):491-4.

Selective immunoaffinity-based enrichment of CD34+ cells transduced with retroviral vectors containing an intracytoplasmatically truncated version of the human low-affinity nerve growth factor receptor (deltaLNGFR) gene
Fehse B, Uhde A, Fehse N, Eckert H, Clausen J, Rüger R, Koch S, Ostertag W, Zander A, Stockschläder M
HUM GENE THER. 1997;8(15):1815-1824.

Loss of retroviral gene expression in bone marrow reconstituted mice correlates with down-regulation of gene expression in long-term culture initiating cells
Lange C, Blankenstein T
GENE THER. 1997;4(4):303-8.

High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Zander A, Berger C, Kröger N, Stockshläder M, Krüger W, Horstmann M, Grimm J, Zeller W, Kabisch H, Erttmann R, Schönrock P, Kuse R, Braumann D, Illiger H, Fiedler W, de Witt M, Hossfeld K, Weh H
CLIN CANCER RES. 1997;3(12 Pt 2):2671-2675.

Mobilisation kinetics of primitive haemopoietic cells following G-CSF with or without chemotherapy for advanced breast cancer
Baumann I, Swindell R, Van Hoeff M, Dexter T, de Wynter E, Lange C, Luft T, Howell A, Testa N
ANN ONCOL. 1996;7(10):1051-7.

Excision of specific DNA-sequences from integrated retroviral vectors via site-specific recombination
Bergemann J, Kühlcke K, Fehse B, Ratz I, Ostertag W, Lother H
NUCLEIC ACIDS RES. 1995;23(21):4451-6.

Inhibition of CFU-C growth by VP-16 containing plasma samples obtained from patients after conditioning therapy for bone marrow transplantation
Krüger W, Berger C, Mross K, Bewermeier P, Pichlmeier U, Stockschläder M, Schleimer B, Zander A
BONE MARROW TRANSPL. 1995;15(1):9-15.

Experience with liposomal Amphotericin-B in 60 patients undergoing high-dose therapy and bone marrow or peripheral blood stem cell transplantation.
Krüger W, Stockschläder M, Rüssmann B, Berger C, Hoffknecht M, Sobottka I, Kohlschütter B, Kroschke G, Kröger N, Horstmann M
BRIT J HAEMATOL. 1995;91(3):684-690.

Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia
Stockschläder M, Hegewisch-Becker S, Krüger W, tom Dieck A, Mross K, Hoffknecht M, Berger C, Kohlschütter B, Martin H, Peters S
BONE MARROW TRANSPL. 1995;16(5):663-7.

[The structure of the hemodynamic reactions to isometric loading in relation to the initial arterial pressure level]
Lioznova E, Lioznov M
Fiziol Cheloveka. 1994;20(2):73-79.

Cellular Ca2+ ATPase activity in diabetes mellitus
Spieker C, Fischer S, Zierden E, Schlüter H, Tepel M, Zidek W
HORM METAB RES. 1994;26(11):544-7.

Timing of peripheral blood progenitor cell (PBPC) collections during recovery from chemotherapy supported by haematopoietic growth factor
Van Hoef M, Baumann I, Lange C, De Wynter E, Testa N, Howell A
LEUKEMIA. 1994;8(11):2020-1.

Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancer. Selection of the most acceptable regimen to induce maximal tumor response and investigation of the optimal time to collect peripheral blood progenitor cells for haematological rescue after high-dose consolidation chemotherapy
Van Hoef M, Baumann I, Lange C, Luft T, de Wynter E, Ranson M, Morgenstern G, Yvers A, Dexter T, Testa N
ANN ONCOL. 1994;5(3):217-24.

Rapid haematological recovery after high-dose consolidation chemotherapy with peripheral blood progenitor cells (PBPC) as sole source of support collected at a single apheresis
Van Hoef M, Ranson M, Morgenstern G, Baumann I, Lange C, de Wynter E, Testa N, Howell A
BONE MARROW TRANSPL. 1994;13(6):839-40.

Haemopoietic cells mobilised into the circulation by lenograstim as alternative to bone marrow for allogeneic transplants
Baumann I, Testa N, Lange C, de Wynter E, Luft T, Dexter T, van Hoef M, Howell A
LANCET. 1993;341(8841):369.

[Experience with using cefoperazone in cancer patients after bone marrow transplantation]
Afanas'ev B, Zubarevskaia L, Shmidt A, Zabelina T
Antibiot Khimioter. 1992;37(8):14-15.

Studies of the RB1 gene and the p53 gene in human osteosarcomas
Scholz R, Kabisch H, Weber B, Röser K, Delling G, Winkler K
PEDIATR HEMAT ONCOL. 1992;9(2):125-37.

Metolazone in der Behandlung fortgeschrittener therapieresistenter dilatativer Kardiomyopathie
Kröger N, Szuba J, Frenzel H
MED KLIN-INTENSIVMED. 1991;86(6):305-8, 332.

[The nature of the changes in the systemic hemodynamic parameters under the combined action of vasoactive substances]
Lioznov M, Tkachenko B
Fiziol Zh SSSR Im I M Sechenova. 1991;77(4):24-33.

Metolazone for severe dilated cardiomyopathy refractory to conventional therapy
Kröger N, Szuba J, Buhl C, Pompecki R, Frenzel H
LANCET. 1990;335(8696):1031-2.

[Changes in arterial pressure during the joint action of vasoactive substances with unidirectional effects]
Lioznov M, Tkachenko B
Biull Eksp Biol Med. 1990;109(3):222-224.

[Character of arterial pressure changes under combined action of pressor and depressor agents]
Lioznov M, Tkachenko B
Biull Eksp Biol Med. 1990;109(1):13-15.

Nachweis von Neuroblastomzellen im Knochenmark durch "Southern-Blot" und "In situ-Hybridisierung" mit Hilfe einer NMYC-DNS-Probe
Kabisch H, Heinsohn S, Milde-Langosch K, Löning T, Bartl S, Erttmann R, Landbeck G
MONATSSCHR KINDERH. 1987;135(4):210-213.

[Therapy of patients with myeloid leukemia with small doses of cytosine arabinoside]
Patterson D, Kravtsova V, Petrova E, Zabelina T, Balaian L
TERAPEVT ARKH. 1987;59(12):81-86.

[Cloning of hematopoietic cells of patients with different forms of hematopoietic dysplasia in agar (clinico-cultural correlations)]
Afanas'ev B, Kulibaba T, Zabelina T, Lukasheva T, Smirnova G
TERAPEVT ARKH. 1982;54(8):97-103.

Proliferation and maturation of hemopoietic cells in adult patients with different forms of acute leukemia and chronic myeloid leukemia in agar and liquid cultures.
Afanasiev B, Elstner E, Saidali M, Zabelina T
BLOOD TRANSFUS-ITALY. 1981;26:251-254.

[Cloning of hematopoietic cells from patients with different variants of leukemia in a double-layer agar system]
Almazov V, Afanas'ev B, Kulibaba T, Smirnova G, Zabelina T
TERAPEVT ARKH. 1981;53(9):110-115.

[Treatment of autoimmune thrombocytopenic purpura with vincristine]
Bueva O, Afanas'ev B, Zabelina T, Petrov M, Kuznetsova A
TERAPEVT ARKH. 1981;53(11):80-84.

[Colony-forming capacity of the bone marrow cells in acute agranulocytosis]
Afanas'ev B, Postriganeva T, Shishkov A, Zaritski A, Zabelina T
Probl Gematol Pereliv Krovi. 1980;25(7):19-23.

[Proliferation and maturation of the hematopoietic cells in myelocytic leukemia in the stage of blast crisis]
Afanas'ev B, Sa Dali M, Zaritski A, Zabelina T, Mikha Lova T
Probl Gematol Pereliv Krovi. 1980;25(4):15-21.

[Cyclophosphan and prednisolone immunosuppressant therapy of a patient with hypoplastic anemia]
Postriganeva T, Afanas'ev B, Zaritski A, Sa Dali M, Zabelina T
TERAPEVT ARKH. 1980;52(9):108-110.

[Granulomonocytopoietic precursor cells in chronic myeloid leukemia]
Zabelina T, Afanas'ev B, Zaritski A, Razorenov L, Evert A
TERAPEVT ARKH. 1980;52(9):78-82.

[Colony-stimulating activity of the plasma from hematologically healthy persons]
Zaritski A, Afanas'ev B, Zabelina T, Gol'dman E, Postriganeva T
Probl Gematol Pereliv Krovi. 1980;25(2):15-18.

[Bone marrow cell colony-forming capacity in persons with benign leukopenia]
Afanas'ev B, Zaritski A, Zabelina T, Postriganeva T
Probl Gematol Pereliv Krovi. 1979;24(9):29-32.

[Colony-forming capacity of bone marrow cells in patients with various neutropenic conditions: hypoplastic anemia]
Afanas'ev B, Zaritski A, Zabelina T, Postriganeva T
TERAPEVT ARKH. 1979;51(3):76-85.

[Colony-forming capacity of the bone marrow cells in B12- and folic acid-deficiency anemias]
Afanas'ev B, Zaritski A, Zabelina T, Sa Dali M, Postiganeva T
Probl Gematol Pereliv Krovi. 1979;24(5):13-16.

[Regulation of granulo- and monocytic precursor cells in myeloma disease]
Zaritski A, Afanas'ev B, Gol'daman E, Zabelina T, Dubova F
Probl Gematol Pereliv Krovi. 1979;24(6):11-16.

[Regulation of granulo- and monocytic cell precursors in chronic lympholeukemia]
Zaritski A, Afanas'ev B, Gol'dman E, Zabelina T, Dubova F
Probl Gematol Pereliv Krovi. 1979;24(4):19-24.

[Bone marrow cell colony-forming capacity in various neutropenic conditions. Liver cirrhosis]
Afanal'ev B, Zaritski A, Shishkov A, Zabelina T, Postriganeva T
TERAPEVT ARKH. 1978;50(10):108-111.

[Treatment of idiopathic thrombopenia with vincristine]
Afanas'ev B, Zabelina T, Petrov M, Zaritski A
TERAPEVT ARKH. 1978;50(5):60-67.

The colony-forming ability of bone marrow in patients with different neutropenic states.
Almazov V, Afanasiev B, Zaritsky A, Zabelina T
HAEMATOLOGICA. 1977;62(5):490-505.

[Colony-forming capacity of the bone marrow and blood cells in vitro in different forms of acute leukemia]
Zabelina T, Afanas'ev B, Zaritski A, Postriganeva T, Sa Dali M
TERAPEVT ARKH. 1977;49(8):53-59.

Letzte Aktualisierung aus dem FIS: 19.11.2024 - 23:32 Uhr